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RESUMEN 
 
Las células madre adultas tienen capacidad de autorrenovarse, y seguir siendo células 
madre, o bien continuar la vía de diferenciación para la que están programadas y, por lo 
tanto, producir uno o más tejidos maduros y plenamente diferenciados. Este fenómeno 
exige una compleja red molecular aún muy desconocida entre diferentes reguladores 
celulares que controlan el mantenimiento de ellas mismas, tal y como ocurre con las 
proteínas de Polycomb, especialmente Bmi1 y Ezh2.  
El gran interés de Ezh2 no sólo viene dado por su papel en el mantenimiento de células 
madre embrionarias, sino también porque Ezh2 está altamente expresado en numerosos 
cánceres humanos con mal pronóstico. Para comprender el papel de Ezh2 en la 
progresión de las neoplasias hematológicas, hemos generado modelos de ratón que 
pemiten la manipulación controlada de los niveles de expresión de Ezh2 in vivo. Hemos 
demonstrado que la histona methyltransfereasa Ezh2 tiene un papel clave en el control 
homeostático de las células madre hematopoyéticas (HSCs). Hemos encontrado que la 
activación selectiva de Ezh2 durante la auto-renovación de HSCs compromete 
gravemente la función hematopoyética, dando lugar a la aparición de desórdenes 
mieloproliferativos (MPD) con desenlace fatal, caracterizados por la expansión mieloide 
excesiva en la médula ósea y en el bazo, recuento elevado de glóbulos blancos y células 
mieloides maduras, y esplenomegalia.  
Debido al papel clave que tiene Bmi1 en la regulación de las HSCs, hemos estudiado 
sus consecuencias durante las etapas iniciales de la hematopoyesis en ratones adultos, 
pero eludiendo los mecanismos que inducen a la mortalidad temprana de ratones 
knockout convencionales para Bmi1. Para ello, hemos generado un modelo condicional 
de ratón para Bmi1, lo que permite inducir su deleción específica en el sistema 
hematopoyético. Nuestros resultados, tanto in vivo como in vitro, nos han permitido 
descifrar que Bmi1 regula directamente al factor de transcripción Ikaros, descrito 
extensivamente como una diana clave en la activación y maduración durante el linaje 
linfocitario, lo que explicaría que ratones delecionados condicionalmente para Bmi1 
sufren una importante expansión de progenitores linfoides cuya diferención y posterior 
maduración está totalmente bloqueada. A través de esta vía de señalización Bmi1-
Ikaros, hemos descrito que el número de HSCs está muy disminuido debido a un 
aumento en su capacidad de proliferación y en su capacidad de migración está 
igualmente afectada. 
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SUMMARY 
The hallmarks of adult stem cells are defined by their ability to both self-renew and 
differentiate into multiple lineages. This demands a complex molecular network poorly 
known among different cell-intrinsic regulators of self-renewal, like specific Polycomb 
proteins (Bmi1 and Ezh2), both absolutely required for the maintenance of certain stem 
cells. 
Understanding the role of Ezh2 in hematologic tumor progression requires the 
controlled manipulation of Ezh2 levels in vivo. Here we report that the histone 
methyltransferease Ezh2 appears to have a key role in controlling homeostasis of the 
haematopoietic stem cell compartment. By modulating Ezh2 expression in the 
haematopoietic system in vivo by intercrossing Ezh2 conditional gain-of-function mice 
with a haematopoietic-specific vav-Cre line, we found that self-renewing HSCs 
expressing Ezh2 lead to myeloidroliferative disorde (MPD). MPD was also observed in 
inducible Ezh2-KI-ER mice, in which we could control the timing of Ezh2 expression 
by injection with tamoxifen. Notably, targeted activation of Ezh2 in myeloid cells in the 
Ezh2-KI-M mice only mildly influences the homeostasis of the granulocytic lineage and 
never leads to MPD. 
To assess the specific interplay between the roles of Bmi1 in regulating HSC quiescence 
and blood-cell lineage commitment, circumventing and going beyond the mechanisms 
that induce early lethality in conventional Bmi1 knockout mice, we generated a 
conditional Bmi1 mutant mouse model. To gain insight into the role of Bmi1 at early 
stages of hematopoiesis in adult mice, we used a conditional deletion strategy. Our in 
vivo and in vitro results identify the DNA-transcription factor Ikaros as a critical 
downstream target of Bmi1, mediating its activation of lymphoid- lineage priming in the 
HSC pool, subsequently leading to increased cycling and decreased quiescence in 
HSCs, and more importantly, their migration capacity to the bone marrow is also 
impaired. Mice with germ-line deletion of Bmi1 exhibit similar rates of bone marrow 
hypocellularity and HSC loss, whereas specific deletion of Bmi1 in the hematopoietic 
system preserved this severe effect on the BM cellularity, allowing that the Bmi1-KO 
BM microenvironment was functional. Conditional deletion results in a significant and 
progressive expansion of lymphoid progenitors whose later differentiation into mature 
lymphoid cells is impaired. 
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Key of Abbreviations 
 
AML: Acute myeloid leukemia 
BM: Bone Marrow 
Bmi1: B lymphoma Mo-MLV insertion region 1 homolog 
CBX7: Chromobox homolog 7 
CDK: Cyclin-dependet-kinase 
CFU-GM: Colony formation unit – granulocyte/monocyte 
ChIP: Chromatin immunoprecipitation 
cKI: Conditional knock-in 
cKIT: Tyrosine-Protein Kinase Kit or CD117 
cKO: Conditional knock-out 
CLP: Common Lymphoid Progenitors 
CMP: Common Myeloid Progenitors 
CSC: Cancer stem cell 
DNMT: DNA-methyl-transferase 
ERT: Element response tamoxifen 
ESC: Embrionic stem cell 
EVI1: Ecotropic Virus Integration site 1 protein homolog 
Ezh2: Enhancer of Zeste 2 
FACS: Fluorescence-activated cell sorting 
GFP: Green Fluorescent Protein 
GM-CSF: Granulocyte/monocyte – colony stimulating factor 
GMP: Granulocyte/Monocyte Progenitors 
H&E: Hematoxylin and eosin 
H3K27me1,2,3: Mono-di-tri-Methylation of Histone 3 in Lysine 27 
HMT: Histone Methyl Transferase 
HSC: Hematopoietic Stem Cell 
IHC: Immunohistochemistry 
jARID: Jumonji/AT rich interactive domain 2 
lncRNA: Long-non-coding RNA 
LP: Lymphoid Progenitors 
L-S+K+: Lineage negative, Sca1 positive, cKit positive (LSK, refereed to HSC) 
LSC: Leukemic stem cell 
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LT-HSC: Long-Term Hematopoietic Stem Cell 
MDS: Myeloproliferative Disorder Syndrome 
MEP: Megakaryocyte/Erythrocyte Progenitor 
MP: Myeloid Progenitors 
MPD: Myeloproliferative disorder 
MPO: Myeloperoxidase 
MPP: Multipotent Progenitor 
NTRK3: Neurotrophic Tyrosine Kinase Receptor  type 3 
PB: Peripheral Blood 
PcG: Polycomb complex Group 
PRC1: Polycomb Repressive Complex 1 
PRC2: Polycomb Repressive Complex 2 
PRE: Polycomb response element 
Ring1A/B: Ring finger protein 1 A/B (sol called RNF1) 
ROS: Reactive oxygen specie 
SC: Stem cell 
SCA1: Lymphocyte Antigen 6A/E or Ly-6A/E 
SP: Side Population 
ST-HSC: Short-Term Hematopoietic Stem Cell 
TrxG: Trithorax group 
uH2AK119: Monoubiquitination of Histone 2A in Lysine 119 
VEGF: Vascular endothelial growth factor 
WBC: White blood cell 
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Resumen de la Introducción 
 
Desde el descubrimiento de que los efectos del ambiente (micro y macro) y 
demás factores externos tienen un efecto en la expresión interna del genoma 
repercutiendo en el envejecimiento, cáncer y mantenimiento de la homeostasis, 
diferenciación; estudios de cómo la nutrición, el tabaco, vivir en un clima u otro, 
han tratado de encontrar que molécula o mecanismo es responsable de 
conectar estos dos procesos. La epigenética trata de dar respuesta a esta 
cuestión. 
 
La epigenética es el estudio de los cambios estructurales y funcionales del 
genoma que no pueden ser explicados por cambios en la secuencia del DNA. 
En este sentido, estos cambios del genoma se dan desde el óvulo y su 
posterior diferenciación y desarrollo hasta la respuesta a un estímulo en un 
tejido adulto.  
 
Uno de los puntos más esperanzadores, es que a diferencia de los cambios en 
la secuencia de DNA que no pueden ser revertidos, los cambios epigenéticos si 
pueden ser revertidos. Estos cambios reversibles, son marcas en la estructura 
génica que producen la activación o el silenciamiento de regiones completas 
del genoma, decidiendo si esa región génica esté accesible a la maquinaria 
transcripcional o por el contrario se silencia. 
 
Unido a la epigenética como parte de un mecanismo reparador, el 
descubrimiento de las células madre y su uso y estudio en fenómenos como el 
envejecimiento, mantenimiento y reparación tisular y cáncer, hacen que el 
estudio de los factores epigenéticos en las células madre tenga aún más 
importancia y esperanza en el tratamiento de enfermedades, envejecimiento y 
cáncer. 
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Células madre hematopoyéticas 
 
Desde su descubrimiento en 1961, las células madre han cobrado cada vez 
más importancia en casi todos los tipos de investigación que se llevan a cabo 
en la actualidad. Entender mecanismos como el self-renewal, la diferenciación 
hacia un tipo celular y no otro, la proliferación o el mantenimiento de la 
stemness, abren un abanico de posibilidades para identificar diferentes 
mecanismos que soportan estas funciones. 
 
En nuestro campo de estudio nos centramos en las células madre 
hematopoyéticas (HSCs). Las HSCs son las células madre mejor estudiadas y 
se dividen en tres supoblaciones, las Long-Term-HSCs (LT-HSC), las Short-
Term-HSCs (ST-HSC) y los Progenitores-Multipotentes (MPP), las LT-HSC son 
consideradas como las verdaderas células madre en adultos, ya que son las 
únicas que pueden regenerarse así mismas y diferenciarse en el resto de 
células hematopoyéticas. Este pool de HSC da lugar a todas las células 
sanguíneas del cuerpo durante toda la vida de un organismo, mediante la 
diferenciación en tres líneas diferentes, la  línea linfoide, que da lugar a las 
células B y T principalmente, la línea mieloide que da lugar a los macrófagos, 
granulocitos y monocitos y la línea eritroide que da lugar a las plaquetas y los 
eritrocitos. 
 
Envejecimiento de células madre hematopoyéticas y cáncer 
 
Está bien documentado cuales son los cambios que se producen durante el 
envejecimiento normal en sistema hematopoyético, de una manera general los 
cambios que acontecen son un incremento en la población mielode y un 
descenso en la linfoide, reduciendo la capacidad inmune del organismo a 
patógenos externos. Estos cambios en las poblaciones celulares se deben a 
cambios en las células madre de las que preceden, así se han realizado 
estudios comparativos de las células madre hematopoyéticas jóvenes y 
adultos. Las diferencias que se encontraron en las células madre adultas 
fueron un defecto en la capacidad de migrar y anidar en médula ósea y una 
peor capacidad de regenerar por completo el sistema hematopoyético.  
Resumen de la Introducción 
 
 
 
El declive en las células madre hematopoyéticas con el envejecimiento se 
estudia también a nivel molecular, así varios investigaciones han mostrado 
como por ejemplo, supresores tumorales como Ink4ap16, p19ARF o p53, 
juegan un papel fundamental en el normal envejecimiento, incrementando la 
expresión de estos marcadores durante el envejecimiento. Estos marcadores 
protegen a las células contra en el daño celular provocando que aquellas 
células dañadas entre en apoptosis o senescencia, provocando el 
envejecimiento celular. Por otro lado, si el daño celular persiste o se incrementa 
mediante mutaciones en estos supresores tumorales, o la reactivación del ciclo 
celular o alteraciones epigenéticas, se incrementa probabilidad de que la célula 
sobreviva, se desregule y prolifere de forma irregular, dando lugar a fenómenos 
tumerogénicos. El estudio de todos estos factores que alteran el normal 
funcionamiento de las células madre hematopoyéticas durante el 
envejecimiento son de vital importancia tanto en descubrir cuales son las 
pautas y componentes que se activa o desactivan como para el posible 
tratamiento de enfermedades degenerativas o el cáncer.  
 
Complejos Polycomb y células madre 
 
Como hemos mencionado anteriormente, la epigenética regula el 
comportamiento de las células madre mediante el posicionamiento de las 
llamadas marcas epigenéticas represoras. Estas marcas son dispuestas por 
dos complejos epigenéticos (PcGs), el Complejo Represor de Polycomb 
(PRC1) y el Complejo Represor de Polycomb 2 (PRC2). PRC2 y su subunidad 
catalítica Ezh2 se encarga de la tri-metilización de la lisina 27 en la histona 3 
(H3K27me3) provocando el silenciamiento de esa zona cromosómica, esta 
marca es leída por el PRC1 que coloca la marca mono-ubiquitinizacion de la 
lisina 119 en la histona H2A (H2AK119Ub), provocando un mayor 
silenciamiento y compactación de la cromatina. En el caso de PRC1, su 
subunidad Bmi1 ha sido caracterizada como una de las principales dentro del 
núcleo de funcionamiento de PRC1. 
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Está bien caracterizado que tanto PRC1 como PRC2 son los responsables del 
silenciamiento de los supresores tumorales p16Ink4a y p19ARF en estadios 
jóvenes y que durante el envejecimiento, esta asociación se pierde, 
aumentando así los niveles de p16Ink4a y p19ARF. De esta misma manera, la 
sobre-expresión de Ezh2 y/o Bmi1, se ha observado en muchísimos tipos de 
cáncer, siendo incluso marcadores de pronóstico, agresividad o probabilidad de 
metástasis.  
 
Bmi1 en células madre hematopoyéticas 
 
Bmi1 forma parte del complejo represor 1 (PRC1), igualmente que para PRC2, 
este complejo esta formado por un gran número de subunidades y aunque 
Bmi1 no es el responsable de la actividad del complejo, se ha demostrado que 
juega un papel fundamental para que el complejo funcione correctamente. 
PRC1 reconoce la marca impuesta por PRC2 colocando la marca H2AK119ub 
y aumentado el silenciamiento y compactación cromosómica. 
 
En el caso de Bmi1, ratones knock-out si sobreviven y llegan a nacer, aunque 
mueren tras los primeros meses de vida. En estos ratones, se demostró que 
Bmi1 era fundamental para el mantenimiento de las células madre 
hematopoyéticas, provocando un defecto general en el sistema 
hematopoyético, y que podía ser parcialmente rescatado mediante la doble 
delección de Bmi1 y del locus Ink4a/ARF.  
 
Bmi1 está normalmente sobrexpresado en muchos tipos de cáncer. Sin 
embargo, para Bmi1 no se han descrito que mutaciones o perdidas de función 
que sean responsables de ningún tipo de cáncer, es más, se ha descrito que 
Bmi1 es esencial para el mantenimiento del pool de las células madre 
tumorales (al igual que las células madre sanas). 
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Ezh2 en células madre hematopoyéticas 
 
Ezh2 es uno de los genes mejor conservados a lo largo de la evolución, 
indicando que tiene un papel fundamental en las células. Ezh2 es una 
subunidad del complejo represor 2 (PRC2), siendo junto con Ezh1, el 
responsable de la actividad catalítica de PRC2. Como se ha mencionado 
anteriormente, la función principal de Ezh2 es la de poner la marca epigenética 
H3K27me3, esta marca provoca el silenciamiento de una región genómica, 
impidiendo el acceso a la maquinaria transcripcional. El responsable de esta 
actividad catalítica es el dominio SET de Ezh2, igualmente con un alto 
porcentaje de conservación a lo largo de la evolución. 
 
PRC2 es un complejo formado por múltiples subunidades, el núcleo principal es 
Ezh1, ezh2, Suz12 y Eed, pero se han descrito asociaciones temporales con 
otras proteínas como las DNA-metiltransferasas (DNMTs), jARID2, Sirt1 o RNA 
no codificantes. Estas asociaciones suelen ser específicas en el silenciamiento 
o regulación de determinados genes. 
 
La expresión de Ezh2 es normalmente alta en los primeros estadios de 
diferenciación, en células madre embrionarios y en las células madre en 
general, disminuyendo la expresión con el paso del tiempo (envejecimiento) y 
diferenciación), aunque en algunos tejidos adultos se sigue manteniendo una 
expresión elevada de Ezh2, normalmente asociados con tejidos que tienen una 
cierta capacidad proliferativa. En las células madre hematopoyéticas no se ha 
podido investigar a fondo el funcionamiento de ezh2 en ratones knock-out, ya 
que han resultado ser letales en estados embrionarios, existen algunos 
resultados con ratones knock-out condicionales, donde se delecciona el gen en 
un momento concreto tras el nacimiento. En algunos de estos estudios se ha 
mostrado el papel fundamental en el desarrollo de los linfocitos B, en el 
desarrollo de la piel o en el páncreas. Esta es una de las peculiaridades por las 
que se decidió generar un ratón con sobre-expresión de Ezh2. 
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En el caso de Ezh2, excepcionalmente se ha encontrado que mutaciones con 
perdidas de función provocan también leucemias, aunque en algunos casos se 
ha descrito un tipo de mutación que produce un aumento de la actividad 
metiltransferasa, equiparable a una sobreexpresión de Ezh2. 
 
Como resumen general, todos estos datos previos y los resultados obtenidos 
durante este periodo, dan una clara visión de que estos complejos represores 
han de ser regulados de una manera muy sensible, y que cualquier cambio 
tanto en la sobrexpresión como en la pérdida de expresión, provoca cambios 
importantes en muchas de las funciones de las células madre en el 
mantenimiento de la homeostasis, envejecimiento y cáncer. El poder estudiar 
este fino equilibrio mediante nuevos ratones transgénicos, nos pueden servir de 
herramienta para el estudio y tratamiento de muchas enfermedades, así como 
conocer mejor el uso de las células madre en terapia, una de las líneas con 
más proyección en estos últimos años. 
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INTRODUCTION 
 
Hematopoiesis is the lifelong process by which all the cells of the blood 
system are produced in a hierarchical manner from a small population of 
hematopoietic stem cells (HSCs), which reside in the bone marrow (BM) 
cavity in adult mammals (Orkin SH, 2008). HSCs give rise to progenitor cells 
that become increasingly lineage restricted and ultimately differentiate into all 
lineages of mature blood cells. As HSCs continually replenish cells that are 
lost or turned over, they must self-renew to maintain themselves over the 
lifetime of the organism. HSC self-renewal is experimentally defined as the 
capacity for long-term reconstitution of all blood lineages upon transplantation 
into a recipient (Ema H, 2006). However, the capacity to self-renew is by itself 
insufficient for lifelong maintenance of a functional HSC compartment, as the 
accumulation of damage in such long-lived cells can result in dysfunctional 
hematopoiesis including BM failure or leukemic transformation (Lane S.W., 
2010). Therefore, protection of the “stemness” network is essential to maintain 
a healthy HSC compartment during the lifetime of the organism. Among 
epigenetic regulators, the repressive histone modifications by the Polycomb-
group (PcG) complexes have been recognized as general regulators of HSC 
cellular fate decisions and are often found to be misregulated in human 
hematopoietic malignancies. 
 
HEMATOPOIETIC STEM CELLS 
 
The field of stem cell research has greatly expanded since the initial studies of 
Till and McCulloch, (Siminovitch L, 1964) and now includes stem cells that 
give rise to specific organs/tissues (collectively termed tissue-specific stem 
cells) and also embryonic stem cells which can give rise to every cell type in 
the adult body (Purton LE, 2007). A system of nomenclature has evolved to 
reflect the differentiation potential of different stem cell populations (table 1). 
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The blood system serves as a paradigm for understanding tissue stem cells, 
their biology, and involvement in aging, disease, and oncogenesis. Because 
mature blood cells are predominantly short lived, stem cells are required 
throughout life to replenish multilineage progenitors and the precursors 
committed to individual hematopoietic lineages. The hematopoietic stem cell 
(HSC) was the first stem cell to be identified and remains the best-studied 
tissue-specific stem cell. Isolation and characterization of the HSC has been 
facilitated by the development of adoptive transfer techniques, which afford a 
standard test for long-term self-renewal and multilineage potential. In these 
transplantation assays, bone marrow isolates are intravenously injected into 
conditioned recipient animals to evaluate their ability to reconstitute the blood. 
Such experiments have shown that a very small sub-population of the donor 
BM cells possessed two remarkable properties: (1) multipotency as the ability 
to differentiate into all functional blood cells, and (2) self-renewal as the ability 
to give rise to identical daughter HSCs without differentiation.  
 
Designation Differentiation potential implied by designation 
Examples of 
Stem/Progenitors 
with these 
Properties 
Toti-potent All embryonic and extraembryonic tissues Zygote 
Pluri-potent All embryonic tissues ICM, ES cell, iPS cell 
Multi-potent All lineages of tissue/organ HSC, NSC 
Oligo-potent Several but not all lineages of a tissue/organ CMP, CLP 
Uni-potent Single lineage of a tissue/organ Macrophage progenitor 
Table 1. Designations used to Define Differentiation Potential of a Cell Populations. 
Abbreviations used in Table 1: ICM: inner cell mass, ES: embryonic stem, iPS: induced 
pluripotent stem, HSC: hematopoietic stem cell, NSC: neural stem cell, CMP: common 
myeloid progenitor, CLP: common lymphoid progenitor 
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In 1988, the initial prospective purification of HSCs from mouse BM was 
achieved utilizing the relatively new technologies of multi-color fluorescence-
activated cell sorting (FACS) and monoclonal antibodies. In the mouse, 
repopulating activity is highly enriched in the fraction of bone marrow cells 
expressing the receptors c-kit and Sca-1, and lacking expression of 
membrane proteins specific to more differentiated blood lineages (LSK 
compartment) encompasses virtually all the repopulating activity of the bone 
marrow (Bryder D, 2006). This fraction represents approximately 0.05% of the 
mouse adult BM cells capable of transferring long-term reconstitution of the 
entire hematopoietic system (then defined as more than 3 months) when 
transplanted into lethally irradiated mice (Spangrude GJ., 1994). Since these 
initial studies, mouse HSCs have been more extensively purified by identifying 
and then utilizing additional cell-surface markers to distinguish them from 
other cells in BM; these included single cells that could self-renew and give 
long-term multilineage maturation. In the hematopoietic literature, the LSK 
compartment is sometimes divided into the long-term repopulating HSCs (LT-
HSCs), because they replenish the pool of blood cells by both maintaining the 
stem cells and allowing daughter cells to differentiate into the lymphoid, 
myeloid, and erythroid lineages. The daily replenishment of blood cells is 
achieved in large part by divisions and subsequent stepwise differentiation of 
cells descendants of LT-HSC pool, namely short term repopulating HSC (ST-
HSC), and slightly more committed hematopoietic progenitor cells (MPP-
HSC). These analyses have suggested a hierarchical structure in 
hematopoietic development in which multipotency is progressively restricted. 
HSCs initially give rise to the MPPs which no longer possess self-renewal 
ability yet keeping full-lineage differentiation potential. Further downstream, 
MPPs advance to oligopotent progenitors: 1) the common lymphoid progenitor 
(CLP) and 2) the common myeloid progenitor (CMP). Collectively these 
oligopotent progenitors then give rise to all the lineage-committed effector 
cells of the hematopoietic system e.g. CMPs give rise to 
megakaryocyte/erythrocyte progenitors (MEPs) and granulocyte/macrophage 
progenitors (GMPs) (figure 1). 
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Figure 1. The hierarchically primitive cells of the hematopoietic system. Long-Term 
hematopoietic stem cells (LT-HSC) maintain hematopoiesis by coordinating self-renewal, and 
production of short-term HSC (ST-HSC), and subsequently, the multipotent progenitors 
(MPP), which have an incredible capacity to divide and make other types of cells as they 
mature, although a limited ability to self-renew. Ultimately, this generates an array of mature 
blood cells with different functions: lymphoid blood cells (the B-cells; T-cells; natural killer or 
NK cells; plasma cells; dendritic cells and others), and erythroid and myeloid blood cells (the 
erythrocytes or red blood cells; megakaryocytes or platelet producing cells; granulocytes such 
as neutrophils, eosinophils, and basophils; and monocytes which make macrophages). The 
stem and progenitor cells can be purified to near-homogeneity by surface markers. For 
example, LT-HSCs express low levels of lineage markers, high levels of Sca1 and CD117/c-
KIT receptor, and low levels of CD34 (LSK CD34 lo). With limited renewal potential, the ST-
HSC pool has a similar surface immunophenotype to LT-HSC except that it has higher levels 
of CD34 (LSK CD34 hi). As ST-HSC in turn proliferates to form more differentiated MPP, they 
increase expression of another surface marker, FLK2 (LSK CD34 hi Flk2 hi). 
 
The relative quiescence of LT-HSCs pool protects their genomic integrity by 
reducing rounds of DNA replication and thus the probability of acquiring DNA 
damage that might compromise multilineage differentiation potential and/or 
render them malignant over time, though they appear to age with the host 
(Orkin SH, 2008). The rapid turnover of the hematopoietic system and the 
availability of advanced methods to study HSCs by different markers have led 
to this system being widely used as a model on stem cell functionality. It is 
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worthy to mention that although some functional aspects may be shared by all 
somatic stem cell fractions, the mechanisms of action are likely to differ 
between stem cell populations located in specific tissues (for example, 
intestine, muscle and bone marrow). 
 
SELF-RENEWAL REGULATORS: POLYCOMB GROUP (PcG) PROTEINS  
 
Epigenetics is commonly used to describe the chromatin-based events 
including DNA methylation, histone modifications, and chromatin structure, 
which regulate gene expression in a heritable manner. Modifications of DNA 
and histones can change chromatin structure and serve as specific sites for 
reader proteins that recruit additional chromatin-modifying proteins and 
enzymes (Bracken AP, 2009; Hansen KH, 2008). Epigenetic regulation allows 
cells to “remember” their gene expression profiles through subsequent cell 
divisions without any alterations to their DNA sequences (Jenuwein T, 2001). 
Epigenetic regulation is required not only for development, but also for tissue 
homeostasis, which is maintained via the self-renewal and differentiation of 
somatic stem cells. Accumulating evidence suggests that epigenetic 
regulators play critical roles in the maintenance of self-renewing HSCs. 
Among epigenetic regulators, the repressive histone modifications by the 
Polycomb-group (PcG) complexes have been recognized as general 
regulators in a broad range of biological processes including cell cycle control, 
genomic imprinting, X-inactivation, cell fate transitions, tissue homeostasis, 
and tumorigenesis (Bracken AP, 2006), (Sparmann A, 2006). First discovered 
in Drosophila, Polycomb group (PcG) proteins were found to be integral to the 
regulation of Hox genes and normal development (Lewis EB, 1978). In PcG-
mutant flies, Hox genes are expressed outside their normal spatial territories 
along the head-to-tail axis. This causes characteristic defects in body 
patterning, which are the hallmark phenotypes that define fly PcG proteins. 
However, the accumulation of PcG proteins at 100 chromosomal sites (Zink 
B, 1989) implies that they control many targets besides Hox genes. More 
recently, PcG proteins have gain much attention as modulators of stem cell 
differentiation in mammals (Bracken AP, 2009) (Pietersen AM, 2008). Thus, 
improved knowledge of how PcG proteins function has practical applications 
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for understanding development in mammals and for designing new methods 
to control the differentiation of stem cells for patient-specific therapies. 
 
The initial challenge in revealing PcG-mediated mechanisms of gene 
expression has been to identify PcG complexes and to determine what they 
do. Progress over the past decade has defined two main protein complexes, 
Polycomb repressive complex 1 (PRC1) and PRC2, with fundamental roles in 
PcG silencing. In mammals, there are two major complexes formed by PcG 
proteins: Polycomb Repressive Complex (PRC) 1 and 2. PRC2 contains three 
core subunits: Suz12, one of the Eed isoforms, and the histone 
methyltransferases Ezh1 and Ezh2, which catalyzes di- and tri-methylation of 
histone H3 at lysine 27 (H3K27me3). Canonical PRC1 contains four core 
subunits, Bmi1 or Mel18, Cbx, Phc, and Ring1A or Ring1B. PRC2 methylates 
histone H3 on Lys27 (H3K27), which is a central feature of PcG-silenced 
chromatin (table 2). PRC1 is commonly viewed as an important, direct 
executor of silencing at target genes. However, much about the basic PcG 
mechanisms remains unresolved. We still do not know precisely how PcG 
complexes are targeted to specific genes. Although H3K27 methylation is a 
key chromatin mark, there is ongoing debate about its molecular 
consequences. Most importantly, we do not yet have a clear description of 
how PcG complexes impede transcription. 
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Table 2. Principcal components of the Polycomb Group Complexes and their hematopoietic 
defects in mutant mice. Adapted from Takaaki Konuma, (Konuma T, 2012) 
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An important emerging theme is that there are multiple versions of PRC1 and 
PRC2, with mounting evidence that alternative subunit compositions confer 
distinct functions. This is especially relevant in mammalian systems, in which 
many individual subunits are encoded by multicopy PcG genes. PRC1 and 
PRC2 are therefore best viewed as two families of related PcG complexes 
rather than as single biochemical entities. Importantly, this diversity of form is 
accompanied by diversity of function: recent findings reveal molecular roles 
for PRC2 besides H3K27 methylation, and PRC1 family members are 
similarly implicated in both catalytic and non-catalytic functions. This diversity 
also poses technical challenges in dissecting PcG mechanisms. For example, 
subunit knockout tests yield outcomes that are difficult to attribute to particular 
variants among related PcG complexes that each contain the target protein.  
 
Loss of PRC2 activity results in embryonic lethality in mice, whereas 
inactivation of PRC1 generally results in less severe phenotypes that manifest 
later in development (table 2). These phenotypic differences, however, 
probably reflect the high degree of overlap in the function of PcG homologs 
and not their degree of importance during development (Leeb M, 2010). 
Consistent with this, the PRC1 component Ring1B, an E3 ubiquitin ligase, is 
essential for gastrulation during mouse development (Voncken JW, 2003). 
Thus, the precise mechanisms by which PcG proteins function in vivo have 
been difficult to dissect given their deleterious phenotypes.  
 
PRC1 family complexes and activities 
 
Genetic and biochemical studies imply that the proteins in PRC1 family 
complexes act as key engines for transcriptional silencing (Schwartz YB, 
2007), (Schuettengruber B, 2007), (Müller J, 2009). PRC1 silencing 
mechanisms are not yet fully understood and might include direct repression 
of the transcription machinery, regulation of chromatin structure and/or effects 
on higher-order nuclear structures (figure 2). There is significant diversity 
among complexes of the PRC1 family, especially in mammals. This diversity 
derives in part from the existence of multiple paralogues of each PcG gene, 
creating various possible combinations of core subunits. Additional diversity is 
Introduction 
 
 
20 
generated by the association of some PRC1 proteins with different core 
partners to create complexes with fundamentally different composition. The 
members of the PRC1 family execute gene silencing by blocking to the 
binding of key transcription factors or RNA polymerase at promoter and/or 
enhancer regions, or blocking to transcriptional initiation or elongation. 
Several studies imply that PRC1 family proteins and transcription factors can 
bind target genes at the same time (Breiling A, 2001), (Dellino GI, 2004), 
(Papp B, 2006), (Lee TI, 2006), (Bracken AP, 2006). There are hundreds of 
genes targeted by PcG complexes and silencing mechanisms may not be 
identical on all targets. 
 
Figure 2. Activity from the principal PRCs unit. 
 
Over the last decade, many studies utilizing knockout mice deficient for 
different subunits of PRC1 revealed the critical roles that each PRC1 gene 
plays in HSCs and their progeny cells (Iwama A, 2005), (Konuma T, 2012). 
Among the PRC1 genes in hematopoiesis, the role of the PcG gene Bmi1 has 
been best characterized. Loss of function of Bmi1 in mice (Berns A, 1994) has 
demonstrated its involvement in the self-renewal of hematopoietic, intestinal, 
and neuronal cells (Molofsky AV, 2003; Sangiorgi E, 2008). This germ-line 
Bmi1 deletion leads to hematopoietic defects, mild skeletal transformation, 
and neurological abnormalities (severe ataxia and seizures). These findings 
suggest that Bmi1 has a role in the regulation of HSCs; however, further 
analysis of Bmi1 in the adult hematopoietic system has been hampered 
because of the early lethality of Bmi1 mutant mice (Berns A, 1994). Although 
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Bmi1-deficient mice do not show defects in fetal liver hematopoiesis, they 
show severe postnatal pancytopenia due to progressive depletion of HSCs. In 
the absence of Bmi1, HSCs fail to self-renew in the long term, even though 
short-term reconstitution capacity is preserved (Lessard J, 2003), (Park IK, 
2003). Bmi1 directly binds to the promoter of the cyclin dependent kinase 
(CDK) inhibitor gene, p16Ink4a and the tumor suppressor gene, p19Arf 
together with other PRC1 components and represses their transcription. In 
Bmi1-deficient mice, expression of p16Ink4a and p19Arf is markedly de-
repressed in HSCs, restricting the proliferative capacity of HSCs and their 
progeny. Notably, deletion of both p16Ink4a and p19Arf in Bmi1-deficient mice 
substantially restores the defective self-renewal capacity of HSCs. These 
findings define p16Ink4a and p19Arf genes as important Bmi1 targets in HSCs 
(Park IK, 2003), (Oguro H, 2006). Bmi1 also regulates mitochondrial function 
by regulating the expression of a number of genes relevant to mitochondrial 
function and ROS generation. Bmi1-deficient cells have impaired 
mitochondrial function, which causes a marked increase in the intracellular 
levels of ROS and subsequent activation of DNA damage response (Liu J, 
2009). Antioxidant treatment or genetic depletion of Chk2 can rescue impaired 
proliferation of progenitors and lymphocytes, but not the long-term 
reconstitution capacity of HSCs in Bmi1-deficient mice. Taken together, these 
reports show that Bmi1 regulates HSC self-renewal, at least in part by 
repressing the expression of p16Ink4a and p19Arf , and by maintaining normal 
mitochondrial function.  
 
Since PcG proteins cannot bind specific DNA motifs, a key mechanistic 
question concerns how the Polycomb member Bmi1 is recruited to and 
displaced from target genes. A recent study, using Bmi1-deficient HSCs in an 
Ink4a/Arf null genetic background (Bmi1-/-Ink4a-Arf-/-), established that Bmi1 
keeps HSC differentiation programs by repressing a cohort of hematopoietic 
developmental regulator genes via bivalent chromatin domains (Konuma T, 
2012). However, the severe effect of the early blockade of hematopoietic 
development in germ-line Bmi1-deleted animals precluded detailed analysis of 
the mechanisms underlying the lack of primitive HSCs or an assessment of 
Bm1 function in more differentiated hematopoietic lineages.  
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Other PcG PRC1 components are also studied for their role in adult HSC 
regulation, although less intensively (table 2). Inactivation of Ring1a and 
Ring1b in mice showed distinct phenotypes. Ring1a−/− mice are fertile but 
show a number of minor skeletal abnormalities along the anterior-posterior 
axis (del Mar Lorente M, 2000), whereas Ring1b−/− mice showed defective 
gastrulation and were embryonic lethal (Voncken JW, 2003). In the 
hematopoietic system, conditional deletion of Ring1b resulted in 
hypocellularity of the bone marrow. Ring1b was found to specifically restrict 
the proliferation of progenitors and it paradoxically promoted proliferation of 
their maturing progeny. Thus, Ring1b showed to have dual functions in the 
regulation of hematopoietic cell turnover depending on the maturational stage 
of cell differentiation by both targeting cell cycle activators (cyclin D2 and 
cdc6) and inhibitors (p16Ink4a), (Calés C, 2008). PRC1 member Rae28 
(Phc1, Edr1, Mph1) is the only member of the Phc family that has been 
studied for its role in hematopoietic stem cells. During embryonic 
development, the number of HSCs in fetal liver progressively declines in 
Rae28-deficient mice (Ohta H, 2002). Rae28 showed to be essential for 
effective HSC self-renewal and Rae28−/− stem cells were unable to 
reconstitute the hematopoietic compartment upon serial transplantation 
experiments (Kim JY, 2004).  
 
At present, the Cbx family has been the least studied PcG PRC1 member with 
respect to their role in HSCs (table 2). The Cbx family of proteins comprises 
Cbx2, Cbx4, Cbx6, Cbx7 and Cbx8, and all can bind to H3K27me3 marks 
through their N-terminal chromodomain. Cbx2−/− mice showed normal 
numbers of HSCs in fetal liver and these HSCs were fully functional even after 
successive serial transplantations (Iwama et al., 2004). Although no gross 
abnormalities on fetal liver HSC number and function was observed, 4-week-
old Cbx2−/− mice showed several lymphocyte abnormalities (Coré N, 1997). 
By means of in-vitro proliferation assay using thymidine incorporation, Cbx2 
appeared to be required for T cell precursor proliferation (Coré N, 1997). This 
is further supported by the observation that Cbx2 is specifically present in 
PRC1 complexes in lymphocytes but not in HSCs (Kato Y, 2007). This 
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suggests that the PRC1 complexes in HSCs have a unique composition that 
includes another Cbx member that can compensate for Cbx2. However, this 
particular Cbx protein has not yet been identified since studies on the role of 
Cbx4, Cbx6, Cbx7 and Cbx8 in HSC regulation are so far lacking.  
 
Functions of PRC2 and H3K27me3 
 
PRC2 has four core subunits (figure 2, 3) and its signature activity is to 
methylate H3K27 (Cao R, 2002), (Kuzmichev A, 2002), adding up to three 
methyl groups to this target Lys residue. Trimethylated H3K27 (H3K27me3) is 
thought to be the main form of H3K27 that functions in PcG silencing because 
its genome-wide distribution tracks with PcG complexes (Schwartz YB, 2006), 
(Boyer LA, 2006), (Lee TI, 2006), whereas H3K27me and H3K27me2 seem to 
be more abundant and widespread. Although H3K27 trimethylation is viewed 
as crucial, recent studies also emphasize functions of PRC2 beyond this 
enzymatic activity. 
 
In mammals, two related genes encode Ezh1 and Ezh2. Furthermore, 
alternative translation start sites can produce four distinct isoforms of Eed 
(Kuzmichev A, 2004). Together, these multiple options yield a family of related 
mammalian PRC2 complexes (figure 3). Intriguingly, PRC2 containing certain 
EED isoforms can methylate the linker histone H1 in addition to H3K27 in vitro 
(Kuzmichev A, 2005). H1 methylation occurs in vivo (Trojer P, 2009), but its 
potential role in PcG silencing has yet to be addressed. 
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Figure 3. Different components of PRC2 describes with permanent or temporal interactions. 
 
Recent studies reveal major differences between PRC2 variants containing 
Ezh2 and those containing Ezh1. Whereas Ezh2 is highly expressed during 
embryogenesis and in proliferating cells, Ezh1 predominates in adult tissues 
and non-dividing cells (Bracken AP, 2003), (Margueron R, 2008), (Shen X, 
2008). There are striking biochemical differences: PRC2–Ezh1 has much less 
methyltransferase activity than PRC2–Ezh2, but it can compact 
polynucleosomes, whereas PRC2–Ezh2 cannot (Margueron R, 2008). 
Correspondingly, PRC2–Ezh1 can repress transcription from chromatinized 
templates in vitro, whereas PRC2–Ezh2 cannot. Thus, PRC2 seems to shift 
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from catalytic towards non-catalytic mechanisms when Ezh1 replaces Ezh2. 
Remarkably, this shift occurs despite Ezh1 and Ezh2 being 65% identical and 
partnered with the same core subunits. These findings also raise questions 
about in vivo PRC2 functions, such as in D. melanogaster, which has just one 
E(z) gene.  
 
Role of PRC2 genes in hematopoiesis 
 
Contrary to studies of PRC1, there have been relatively few reports detailing 
the role of PRC2 in HSCs. Heterozygosity for an Eed null allele causes 
myeloproliferative and lymphoproliferative disease in mice. A hypomorphic 
mutation of Suz12 and heterozygosity for an Ezh2 null allele mildly but 
significantly ameliorate the HSC defects and reduced platelet numbers in 
mice that lack the thrombopoietin (TPO) receptor (Majewski IJ, 2008). These 
findings evoke the possibility that PRC2 restricts HSC/progenitor activity. 
However, it has been reported recently that the complete loss of Eed 
significantly prolongs survival of leukemic mice and markedly reduces 
transplantability of leukemic cells into secondary recipients in the MLL-AF9 
leukemic fusion protein-induced murine leukemia model (Majewski IJ, 2008), 
(Neff T, 2012). Importantly, Eed-deficient MLL-AF9 leukemic cells show 
complete loss of H3K27me3. These findings clearly indicate that PRC2 is 
required for the maintenance of the self-renewal capacity of leukemic stem 
cells. Although the effect of loss of Eed in HSCs has not been reported, these 
findings also suggest an essential role of PRC2 in HSCs as well.  
 
In contrast, absence of Ezh2 appears not to impair adult hematopoiesis, 
although it causes severe defects in lymphoid differentiation (Su IH, 2005), 
(Mochizuki-Kashio M, 2011). In adult BM, the self-renewal capacity of Ezh2-
deficient HSCs is not compromised and the H3K27me3 is retained at 
significant levels even in the absence of Ezh2, possibly due to 
complementation by Ezh1. This is also the case in the MLL-AF9-induced 
leukemia model in mice. Ezh2 is not strictly required for the self-renewal of 
MLL-AF9 leukemia, but augments leukemogenicity, in part by reinforcing 
differentiation blockage (Tanaka S, 2012).  
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Accumulating evidence has uncovered a broad range of target genes of the 
PcG proteins that include both growth-promoting and growth-restricting 
genes. Thus, the PcG proteins fine-tune the growth of hematopoietic cells in 
both a positive and negative manner to maintain hematopoietic homeostasis. 
The balance between the opposing target genes is critical, and it may be 
altered depending on the dosage of PcG proteins and concomitant gene 
mutations in pathological settings. Indeed, inactivating mutations of EZH2 
have been identified in patients with MDS and MPN, showing that PcG genes 
also have a tumor suppressor function (Ernst T, 2010), (Nikoloski G, 2010b). 
The deregulated balance between the opposing PcG targets could account for 
the tumor suppressor function of PRC2 observed in human MDS and MPN. 
Although loss-of-function mutations in PRC1 genes have never been reported 
in a clinical setting, mutations in the PRC2 genes have been identified in a 
growing number of hematological malignancies, including acute lymphoblastic 
leukemia (ALL) (Sauvageau M, 2010).  
 
PcG proteins and cancer 
 
The PcG proteins are essential for the maintenance of both normal and 
cancer stem cell populations (Lessard J, 2003), (Molofsky AV, 2003), (Park, 
2004). This is partly attributed to their ability to bind to and repress the tumour 
suppressors p16Ink4a, p19Arf and p15Ink4b. p16Ink4a and p15Ink4b function 
upstream in the RB pathway, and ARF functions upstream in the p53 pathway 
(Gil J, 2006), (Anisimov VN, 2003). In addition to frequent genetic alterations, 
this locus is often epigenetically silenced by DNA methylation in cancer, and 
the PcG proteins have been proposed to contribute to this (Bracken AP, 
2007). Many additional PcG target genes accumulate DNA methylation on 
their promoters in cancer, such as Wilm's tumour 1 (Wt1), retinoic acid 
receptor (RARB), kruppel-like factor 4(Klf4), inhibitor of DNA binding 4 (Id4), 
Gata binding protein 3 (Gata3) chromodomain helicase DNA binding protein 5 
(Chd5) and PU.1 (also known as SPI1) (Bracken AP, 2006). The reports that 
enhancer of zeste homologue 2 (Ezh2) and chromobox homologue 7 (Cbx7) 
can physically associate with DNA methyltransferases (DNMTs) suggest a 
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mechanism whereby the PcG proteins directly contribute to the altered DNA 
methylation profiles that are observed in multiple cancer types (Mohammad 
HP, 2009). In fact, PcG target genes are as much as 12 times as likely to be 
aberrantly silenced by DNA methylation in cancer as non-PcG target genes 
(Ohm JE, 2007) (Ben-Porath I, 2008), (Schlesinger Y, 2007) and poorly 
differentiated and aggressive human tumours show preferential repression of 
PcG target genes (Ben-Porath I, 2008). Taken together, these results suggest 
a possible scenario in which PcG proteins and DNA methylating enzymes 
(such as DNMTs) cooperate to aberrantly silence pro-differentiation and anti-
proliferative genes, which leads to the accumulation of a population of cells 
unable to respond to differentiation signals. It is thought that the consequent 
block of differentiation may allow these tumour-initiating cells to linger and 
accumulate the additional epigenetic and/or genetic alterations necessary to 
develop into a tumour. 
 
However, the aberrant silencing of PcG target genes that is observed in many 
cancer types Ezh2 and BMI1 become aberrantly upregulated, leading to the 
progressive recruitment of DNMTs to PcG target genes, a switch to a more 
permanent transcriptional silencing and the generation of tumour-initiating 
cells. Supporting evidence for this hypothesis includes the fact that several 
PcG proteins are highly expressed in cancer (Sparmann A, 2006). For 
example, BMI1 is amplified and overexpressed in B cell lymphoma and 
functions as an oncogene that cooperates with Myc in a mouse model of 
lymphoma (Sauvageau M, 2010). Similarly, suppressor of zeste 12 
homologue (Suz12) is translocated in endometrial cancer (Koontz JI, 2001), 
and Ezh2 is amplified and highly expressed in many tumour types 
(Sauvageau M, 2010). Potentially contributing to these increased Ezh2 levels, 
the microRNA miR-101 has recently been reported to directly target Ezh2 and 
is itself deleted in some cancers (Varambally S, 2002). However, despite the 
functional evidence for a role of PcG proteins, particularly Bmi1, in the 
development of cancer, the higher levels of these proteins frequently 
observed in tumours could partly be a consequence of the high proportion of 
proliferating and/or 'stem-like' cells in tumours. For example, BMI1 has been 
reported to be highly expressed in normal stem cells (Raaphorst FM, 2001) 
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and Ezh2 expression correlates with proliferation rate as it is controlled by the 
RB–E2F pathway (Bracken AP, 2003). Therefore, an alternative and 
complementary hypothesis in which PcG proteins could choose the 
deregulation of factors that are required for their association to target genes in 
cancer, hypothesis that correlates with the fact of deregulation of these factors 
directly contributes to the aberrant modulation of transcriptional programmes 
observed in many cancers. 
 
The extraordinary interest of Ezh2-mediated methyltransferase activity is not 
only how the Ezh2-mediated H3K27me3 chromatin-mark is essential for 
maintaining stem cell identity and silencing of differentiation genes, but also 
how its deregulation contributes to cancer (Ben-Porath I, 2008); (Ohm JE, 
2007); (Widschwendter M, 2007); (Schlesinger Y, 2007). Hence, considerable 
attention is currently focused on studies with human tumors, wherein Ezh2 is 
often over-expressed in a wide variety of cancerous tissue types, including 
breast, and prostate cancer, with the highest Ezh2 levels correlating with 
advance stages of tumor progression and poor prognosis (Martin-Perez D, 
2010). More evidences of this oncogenic activity of Ezh2 has been confirmed 
in myeloproliferative disorders (MDS) (Xu F, 2010), and in acute myeloid 
leukemia (AML) (Paul TA, 2010). In contrast of its expected oncogenic role, 
somatic mutations of Ezh2 have been found in a cohort of patients diagnosed 
with both myeloid disorders and in subtypes of lymphomas, indicating that 
Ezh2 acts as a tumor suppressor (Ernst T, 2010; Morin RD, 2010; Nikoloski 
G, 2010a). Therefore, these data indicate both the increase and decrease of 
Ezh2-mediated H3K37me3 may cause cancer, opening the need of 
understanding the role of Ezh2 methyltransferase activity in the tumor 
progression in vivo. Here, we demonstrate that the fine-tuning of Ezh2 
expression in hematopoietic system by different mouse models conducts 
myeloproliferative disease arising from hematopoietic stem cells (HSCs), 
providing unprecedented insights into its methyltransferase action in the 
hematopoietic malignancies. 
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In summary, PcG proteins, are essential for self-renewal and proliferative 
potential, which are crucial for the maintenance of stemness, acting as a 
critical failsafe mechanism against loss of stem cells in response to 
senescence signals. In turn, Bmi1 and Ezh2 must be finely-regulated to 
prevent uncontrolled replicative expansion and tumour induction, both 
increase and decrease of expression can promote tumour. Despite the 
importance of PcG proteins, we are only beginning to unravel how these 
master regulators are themselves regulated to achieve an appropriate 
balance between ensuring stem cell longevity and preventing tumorigenesis 
(figure 4). Furthermore, the activities of PcG and trxG complexes toward 
nonhistone substrates have not been investigated in detail. 
 
Figure. 4. Fine-tuning regulating of stem cells and possibilities to promote cancer. Adapted 
from (Bracken AP, 2009). TF: Different transcription factors. 
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En base a los antecedentes del tema, el objetivo de este trabajo es valorar el 
papel regulador de ciertos miembros del completo de Polycomb, Bmi1 y 
Ezh2, en relación con la auto-renovación, proliferación y envejecimiento de 
las células madre hematopoyéticas (HSCs), mediante dos aproximaciones:  
 
i) evaluaremos el impacto y consecuencias funcionales de la 
sobreexpresión de Ezh2, lo que conlleva una ganancia de la marca 
epigenética H3K27me3, de forma controlada sobre el sistema 
hematopoyético. Para ello, se generaron y caracterizaron ratones 
condicionales knock-in para Ezh2.  
 
ii) estudiaremos la auto-renovación y envejecimiento de HCSs de 
ratones inactivados condicionalmente para Bmi1, específicamente 
en el sistema hematopoyético. Para ello, se generaron y 
caracterizaron ratones con pérdida de función para dicho gen. 
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Capítulo 1. La sobreexpresión de la histona-metiltransferasa Ezh2 en 
células madre hematopoyéticas causa desórdenes mieloproliferativos. 
 
El gran interés de Ezh2 no sólo viene dado por su papel en el mantenimiento 
de células madre embrionarias, sino también porque Ezh2 está altamente 
expresado en numerosos cánceres humanos con mal pronóstico. Para 
comprender el papel de Ezh2 en la progresión de las neoplasias 
hematológicas, hemos generado modelos de ratón que permiten la 
manipulación controlada de los niveles de expresión de Ezh2 in vivo. Hemos 
demostrado que la histona-metiltransferasa Ezh2 tiene un papel clave en el 
control homeostático de las células madre hematopoyéticas (HSCs). Hemos 
encontrado que la activación selectiva de Ezh2 durante la auto-renovación de 
células madre hematopoyéticas (HSCs) compromete gravemente la función 
hematopoyética, dando lugar a la aparición de desórdenes mieloproliferativos 
(MPD) con desenlace fatal, caracterizados por la expansión mieloide excesiva 
en la médula ósea y en el bazo, recuento elevado de glóbulos blancos y células 
mieloides maduras, y esplenomegalia.  
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Recent evidence shows increased and decreased expression of Ezh2 in cancer, suggesting a 
dual role as an oncogene or tumour suppressor. To investigate the mechanism by which Ezh2-
mediated H3K27 methylation leads to cancer, we generated conditional Ezh2 knock-in (Ezh2-KI) 
mice. Here we show that induced Ezh2 haematopoietic expression increases the number and 
proliferation of repopulating haematopoietic stem cells. Ezh2-KI mice develop myeloproliferative 
disorder, featuring excessive myeloid expansion in bone marrow and spleen, leukocytosis and 
splenomegaly. Competitive and serial transplantations demonstrate progressive myeloid 
commitment of Ezh2-KI haematopoietic stem cells. Transplanted self-renewing haematopoietic 
stem cells from Ezh2-KI mice induce myeloproliferative disorder, suggesting that the Ezh2 gain-
of-function arises in the haematopoietic stem cell pool, and not at later stages of myelopoiesis. 
At the molecular level, Ezh2 regulates haematopoietic stem cell-specific genes such as 
Evi-1 and ntrk3, aberrantly found in haematologic malignancies. These results demonstrate a 
stem cell-specific Ezh2 oncogenic role in myeloid disorders, and suggest possible therapeutic 
applications in Ezh2-related haematological malignancies. 
1 Stem Cell Aging Group, Spanish National Cardiovascular Research Center (CNIC), E-28029 Madrid, Spain. 2 Cellomic Unit, Spanish National 
Cardiovascular Research Center (CNIC), E-28029 Madrid, Spain. 3 Animal Unit, Spanish National Cardiovascular Research Center (CNIC), E-28029 
Madrid, Spain. 4 Genomics Unit, Spanish National Cancer Research Center (CNIO), E-28029 Madrid, Spain. Correspondence and requests for materials 
should be addressed to S.G. (email: sgonzalez@cnic.es). 
Ectopic expression of the histone 
methyltransferase Ezh2 in haematopoietic stem 
cells causes myeloproliferative disease
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Haematopoiesis is initiated by a small population of multipo-tent long-term haematopoietic stem cells (LT-HSCs) present in bone marrow that self-renew to maintain the quiescent 
HSC pool. On activation, LT-HSCs give rise to short-term HSCs 
(ST-HSCs), which further mature into the multipotent progenitors 
(MPP) that can differentiate to produce terminally differentiated 
haematopoietic cells1.
Among the key epigenetic repressors required for the mainte-
nance of transcriptional silencing in stem cells are the Polycomb 
group (PcG) proteins. PcG proteins are involved in regulating 
embryonic development, stem cell renewal and tumorigenesis2. PcG 
proteins exist as three multiprotein complexes: Polycomb repressive 
complexes (PRC) 1 and 2, and pleiohomeotic repressive complex3. 
PRC1 monoubiquitylates Lys 119 of histone H2A (H2AK119Ub) via 
RING1A and RING1B, whereas the catalytic component of PRC2, 
Ezh2, methylates lysine-27 of histone H3 (H3K27me2/3) in coop-
eration with other PRC2 components, such as Suz12 and Eed.
Ezh2 has attracted intense interest not only because of its role 
in maintaining stemness, but also because its deregulation con-
tributes to cancer4,5. Ezh2 is highly expressed in numerous human 
cancers, including breast and prostate, with the highest Ezh2 levels 
correlating with advanced stages of tumour progression and poor 
prognosis6. Moreover, mutation of Ezh2 Y641 has been described in 
lymphomas7 and results in Ezh2 gain-of-function8,9. Oncogenic 
activity of Ezh2 has also been described in myelodysplastic syn-
dromes10 and in acute myeloid leukaemia11, where it has been identi-
fied as a potential drug target12. However, acquired Ezh2 mutations 
in myeloid neoplasms have also been found, indicating that Ezh2 may 
act as a tumour suppressor13,14. Thus, increases and decreases in the 
H3K27 methylation activity of Ezh2 may both lead to cancer.
Understanding the role of Ezh2 in haematologic tumour pro-
gression requires the controlled manipulation of Ezh2 levels in vivo. 
In the present study, we generated mouse models that allow gain-of-
function of Ezh2 in the haematopoietic system. Activation of Ezh2 
expression specifically in self-renewing HSCs alters gene expres-
sion programs and severely compromises haematopoietic function, 
leading to the development of myeloproliferative disease.
Results
Expression of Ezh2 affects the HSC populations. To investigate 
the effect of increased Ezh2-mediated H3K27 methylation in vivo, 
we generated conditional knock-in Ezh2fl/fl mice (cki Ezh2fl/fl) 
by targeting a conditional construct encoding Ezh2 cDNA to the 
genomic ROSA26 locus (Supplementary Fig. S1a). To induce Ezh2 
in the haematopoietic system, targeted transgenic ckiEzh2fl/fl mice 
were bred with vav-Cre transgenic mice expressing Cre recombinase 
in haematopoietic cells15 (hereafter referred to as Ezh2-KI and 
control) (Supplementary Fig. S1b). In Ezh2-KI mice, Ezh2 messenger 
RNA levels were 2–3 fold higher in thymus and in spleen (P < 0.05), 
and fourfold higher (P < 0.05) in bone marrow (BM) compared 
with control littermates (Supplementary Fig. S2a). As expected, 
increased Ezh2 protein levels were not only detected in spleen 
and LSKs from Ezh2-KI mice, but also correlated with increased 
H3K27me3 levels (Supplementary Fig. S2b).
To test whether adverse effects of Cre activity contribute to the 
phenotype of transgenic Ezh2-KI mice, we intercrossed mice carry-
ing the R26R-GFP reporter with vavCretg/ +  mice (Supplementary 
Fig. S3a,b). We detected green fluorescent protein (GFP) expression 
in LSKs, as well as in other haematopoietic fractions of R26R/Cre +  
mice (Supplementary Fig. S3c), consistently with previous studies 
using transgenic mice driving Cre expression from vav promoter15–17. 
Moreover, the total numbers of white blood cells (WBC), lym-
phocytes, monocytes, granulocytes, platelets and red blood cells 
were comparable between the two genotypes (Supplementary 
Fig. S3d). Together, these results indicate that Cre expression from 
the vav promoter does not of itself influence phenotype.
To investigate the potential role of Ezh2 in regulating primitive 
haematopoietic cell function, we determined the haematopoietic 
subpopulation profile in BM. Compared with controls, BM of Ezh2-
KI mice contained a significantly higher frequency and absolute 
number of long-term repopulating HSCs (LT-HSC; P < 0.05) and 
short-term HSCs (ST-HSC; P < 0.05), whereas this increase was 
exacerbated in aged mice (50-week-old; P < 0.05; Supplementary 
Fig. S4a). In contrast, the multipotent progenitor fraction (MPP) 
was proportionately and absolutely smaller (Fig. 1a,b). As the total 
number of mononuclear cells per femur was similar in the two 
genotypes (Supplementary Fig. S2c), these data indicate an increase 
in the absolute number of repopulating HSCs in targeted transgenic 
Ezh2-KI mice.
Ezh2 contributes to the self-renewing HSC maintenance. To 
identify how Ezh2 maintains the stem cell compartment, we first 
analysed the cell-cycle frequency of Ezh2-KI primitive HSCs over 
48 h. The percentage of BrdU-incorporating LT- and ST-HSCs was 
higher in Ezh2-KI mice than in counterpart controls (Fig. 1c). We 
also examined the cell-cycle status of the LSKCD34 −  subpopulation 
and observed increased numbers of Pyrorin Ylow cells, indicating 
a higher abundance of quiescent HSCs in Ezh2-KI mice (P < 0.05; 
Fig. 1d). Analysis of LSK cells for the side population (SP) pheno-
type, a marker of quiescent HSCs in adult BM18, also revealed a 
twofold increase in LSK-SP cells in Ezh2-KI mice (P = 0.04; Fig. 1e). 
Examination of the annexinV + /DAPI −  population showed that the 
number of apoptotic LT- and ST-HSCs was lower in Ezh2-KI mice 
than in controls (P < 0.05), whereas the number of apoptotic MPP 
cells was higher in the knock-in mice (P = 0.04) (Fig. 1f). These data 
suggest that Ezh2 increases the pool of quiescent HSCs, by favour-
ing their cell cycling and reducing apoptosis, while having opposite 
effects on the MPP pool.
Ezh2-KI mice aberrantly prime to produce mature myeloid cells. 
Analysis of GFP status in myeloid progenitor subpopulations of Ezh2-
KI mice revealed a significant expansion only in the GMP popula-
tion (94.5% of cells GFP + ; P < 0.001; Fig. 1g); and again this decrease 
was exacerbated in aged Ezh2-KI animals (P < 0.001; Supplementary 
Fig. S4a). This population accounted for almost all of the increased 
numbers of myeloid progenitors (MP), with the numbers of common 
myeloid progenitor (CMP) and myeloid erythroid progenitor (MEP) 
remaining similar to control animals (Fig. 1a,g). Notably, Ezh2-KI 
mice showed a lower frequency of common lymphoid progenitors 
(CLP) than control animals (Fig. 1g). BrdU incorporation experi-
ments revealed that GMPs from Ezh2-KI mice were more prolifera-
tive than their counterpart controls (P = 0.04), whereas CMP and 
MEP cells showed little difference between genotypes (Fig. 2a).
To quantify the recombination rate in myeloid progenitors, 
we generated CFU–GM colonies in methylcellulose medium. 
Ezh2-positive colonies were hypersensitive to GM–CSF (Fig. 2b; 
data not shown), consistent with cell-autonomous signaling 
in Ezh2-expressing haematopoietic cells. The BM of Ezh2-KI 
mice also showed a marked presence of mature myeloid cells 
(Mac-1 + /Gr-1low and Mac-1 + /Gr-1 + ) in both young and adult-
mutant animals (P < 0.05; Fig. 2c). Immunohistochemistry (IHC) 
using anti-myeloperoxidase (MPO) antibodies effectively high-
lighted granulocytic cells and some monocytes, whereas immu-
nostaining for myeloid cells (Mac-1) and macrophages (F4-80) 
demonstrated an excess of monocytes and macrophages relative 
to the controls (Fig. 2d). Corroborating the flow cytometric analy-
sis, BM sections immunostained with myeloid-specific markers 
showed that Ezh2-KI BM was dominated by myeloid cells (Fig. 2d). 
These increases in primitive haematopoietic cell populations 
and later stage myeloid progenitors suggest that Ezh2 overex-
pression promotes expansion both of HSCs and of the myeloid 
lineage.
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To test the homing capacity of haematopoietic progenitors in 
Ezh2-KI mice, we transplanted lineage-negative CD45.2 +  cells into 
lethally irradiated wild-type (CD45.1 + ) mice. Homing of donor 
cells to BM of recipient animals was assessed by expression of 
CD45.2. Cells from Ezh2-KI mice homed to the BM of recipient 
mice at a higher frequency than cells from control mice (P < 0.05; 
Supplementary Fig. S4c). Together, these data indicate that the 
proliferative haematopoietic progenitors from Ezh2-KI mice are 
constitutively mobilized and favour rapid expansion of the myeloid 
lineage to mature myeloid cells.
Ezh2 expression induces myeloid-proliferative disorder. Analy-
sis of peripheral blood (PB) cell counts in young Ezh2-KI mice 
(10-week-old) revealed prominent increases relative to controls of 
circulating granulocytes (P < 0.001). and monocytes relative to con-
trols (P < 0.05) (Fig. 2e; Supplementary Fig. S4d). These increases 
were exacerbated in adult mice (30-week-old; P < 0.001; Fig. 2e) 
and sustained in aged animals (50-weeks-old; P < 0.001; Fig. 2e). 
White blood cell, lymphocyte, erythrocyte and platelet counts were 
normal in young animals (Fig. 2e; Supplementary Fig. S4d). 
However, over time, adult Ezh2-KI mice strikingly increased these 
differences in WBC and platelets counts (P < 0.001; Fig. 2e; Supple-
mentary Fig. S4d). Flow cytometry analysis revealed similar frequen-
cies of B and T lymphocytes in the two genotypes (Fig. 2f), whereas 
the granulocyte and macrophage populations were threefold greater 
in Ezh2-KI animals, and mature myeloid cells (Mac-1 + /Gr-1low and 
Mac-1 + /Gr-1 + ) were also significantly increased (P < 0.05; Fig. 2f). 
Ezh2-KI mice showed a marked splenomegaly, and it was reflected 
in an increased proportion of mature myeloid cells (Mac-1 + /Gr-
1 + ; F4-80 and Ly6G) (P < 0.05) (Fig. 3a–d), whereas an increased 
number of CLPs detected in spleen could not be accounted for 
by the fraction of lymphoid cells (Supplementary Fig. S4e). The 
enlarged spleens of Ezh2-KI mice contained abnormally high 
numbers of cells with the phenotypic characteristics of LSKs, 
CLPs and GMPs (Fig. 3e), providing further evidence of increased 
mobilization of progenitors and extramedullar haematopoiesis. 
Immunohistochemical staining of spleen sections with myeloid-
specific markers (MPO, F4-80 and Mac-1) corroborated the 
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Figure 1 | Ezh2 gain-of-function in the haematopoietic lineage alters the HSC population profile in BM. (a) Representative FACs profiles of Bm cells 
from Ezh2-KI mice and control littermates. FACs plots were gated on the L − s + K +  (LsK) supopulation (blue gate), which was subclassified for expression 
of CD34 and CD135 to give the percentages of mPPs, and LT- and sT-HsCs. The CLP fraction was gated on LKlowslowCD127 +  (green gate) expression. 
mP (red gate) were subclassified into CmP, GmP and mEP based on LKhighsnegCD16/32 and CD34 expression. At least six mice per genotype were 
tested, over at least two separate experiments. numbers indicate percentages of the total nucleated Bm cell population, except for the subclassification of 
LsK cells, where numbers indicate the percentage of the LsK subpopulation. (b) Absolute numbers per femur of the LT, sT and mPP primitive populations  
described in (a). Values are means ± s.d. (n = 12; *P < 0.05). (c) Proliferation activity of LT, sT and mPP populations measured by in vivo Brdu incorporation 
over 48 h. Values are means ± s.d. (n = 10, *P < 0.05). (d) FACs analysis of LsKCD34 −  cells in the quiescent G0 phase of the cell cycle. Representative plots 
show Hoechst 33342 and PyroninY staining in control and Ezh2-KI mice. numbers indicate the percentage of cells in G0 from at least three independent  
experiments (P < 0.05). (e) sP in LsK populations from control and Ezh2-KI mice, identified by Hoechst 33342 staining and the use of blue and red filters. 
numbers indicate the percentage of sP cells from three independent experiments. (f) AnnexinV-DAPI analysis of the percentage of early apoptotic cells in 
the LsK subpopulations. Values are means ± s.d. (*P < 0.05; n = 6). (g) Left: absolute numbers per femur of the CLP, CmP, mEP and GmP subpopulations 
(as described in Fig. 1a) in Bm from control and Ezh2-KI mice. Values are means ± s.d. (n = 10, **P < 0.001). Right: representative FACs plots showing 
GFP expression in the total CLP and GmP subpopulations of Ezh2-KI and control mice. numbers are the percentages of GFP +  cells from at least three 
independent experiments. The statistical significance of differences was measured by unpaired two-tailed student’s t-test: *P < 0.05, **P < 0.001.
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hyperproliferation of myeloid cells already detected by fluorescence-
activated cell sorting (FACS) analysis (Fig. 3f). Furthermore, Ezh2 
and Ki-67 immunostaining of splenic sections revealed an increase 
in the numbers Ezh2 expressing and proliferating (Ki-67 + ) cells in 
Ezh2-KI animals, both in red pulp and lymphoid follicles (Fig. 3f). 
Together, by modulating Ezh2 expression in the haematopoietic 
system in vivo by intercrossing Ezh2 conditional gain-of-function 
mice with a haematopoietic-specific vav-Cre line, we found that 
self-renewing HSCs expressing Ezh2 leads to fatal myeloprolifera-
tive disorder (MPD) (Fig. 3g).
Comparable in vivo and in vitro phenotypes were seen using a 
second model system in which Ezh2 was overexpressed using the 
tamoxifen-inducible Rosa26Cre-ERT2 mice19 (hereafter termed 
Ezh2-KI-ER) (Supplementary Fig. S5a-g). Together, these results 
show that inducible Ezh2 gain-of-function induces the proliferation 
of haematopoietic progenitors and initiates a myeloproliferative 
disease similar to that observed in constitutive Ezh2-KI mice.
Myeloid-restricted Ezh2 expression does not generate MPD. To 
identify the developmental stage at which activation of Ezh2 leads to 
MPD, we crossed ckiEzh2fl/fl mice with mice bearing the lysozyme-
M Cre (LyzMCre) recombinase transgene20, allowing expression 
of Ezh2 in the myeloid lineage. More than 70% of granulocytes 
in 8-week-old Ezh2fl/fl/Cre-Mtg/ +  mice (Ezh2-KI-M) were GFP +  
(Supplementary Fig. S6a). Consistent with this, increased Ezh2 
expression was detected in a subset of myeloid progenitors and in 
macrophages, platelets, monocytes and significantly in granulocytes 
(P < 0.05) (Supplementary Fig. S6b). PB of control and Ezh2-KI-M 
mice contained comparable amounts of leukocytes, platelets, red 
blood cells and haemoglobin (Supplementary Fig. S6c). Numbers 
of GMPs and granulocytes were slightly higher in BM of Ezh2-KI-
M mice, but there was no significant expansion of the granulocytic 
population in spleen (Supplementary Fig. S6d,e). Moreover, rela-
tive numbers of myeloid cells did not increase further during the 
10-month observation period and animals did not develop MPD. 
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Figure 2 | Haematopoietic-specific transgenic Ezh2 expression induces myeloproliferation. (a) Proliferation activity of different myeloid progenitors 
(CmP, mEP and GmP) in Bm was assessed using Brdu incorporation in vivo over 48 h. Values are means ± s.d., n = 4. (b) Granulocyte–macrophage colony 
formation by Bm cells from young (10-week-old) and adult (30-week-old) control and Ezh2-KI mice. Data are the numbers of live colonies ( > 30 cells) 
formed after 12 day culture on methylcellulose supplemented with granulocyte–macrophage colony stimulating factor (Gm–CsF; 10 ng ml − 1). Values are 
means ± s.d. (n = 10, *P < 0.05). (c) Left: absolute numbers per femur of mature myeloid cell populations (mac-1/Gr-1) in Bm from control and Ezh2-KI 
mice. Values are means ± s.d. (n = 12, *P < 0.05). Right: representative FACs plots showing the percentages of mac-1 + /Gr-1low and mac-1 + /Gr-1 +  cells 
in Ezh2-KI and control animals from at least three independent experiments. (d) Histological and immunohistological characterization of Bm sections 
from Ezh2-KI and control mice with H&E (×40 magnification), anti-mPo (×200 magnification), anti-F4-80 (×100 magnification), anti-CD34 (×200 
magnification)and anti-mac1 (×100 magnification) antibodies. The bar indicates 100 µm. (e) PB counts of Ezh2-KI and control mice at 10-, 30- and 
50-week-old. PLT, platelets. Values are means ± s.d. (n = 8, *P < 0.05; **P < 0.001). (f) Representative FACs plots showing the percentages of lymphoid 
(CD3, CD4/CD8 and B220) and myeloid (mac-1/Gr-1, F4-80 and Ly6G) -positive cells in Ezh2-KI and control animals (mean ± s.d.; n = 8; *P < 0.05). The 
statistical significance of differences was measured by unpaired two-tailed student’s t-test: *P < 0.05, **P < 0.001.
ARTICLE 

nATuRE CommunICATIons | DoI: 10.1038/ncomms1623
nATuRE CommunICATIons | 3:623 | DoI: 10.1038/ncomms1623 | www.nature.com/naturecommunications
© 2012 Macmillan Publishers Limited. All rights reserved.
Therefore, targeted Ezh2 expression in the myeloid lineage does not 
induce MPD.
Ezh2 contributes to the repopulating ability of HSCs. The long-
term engraftment potential of haematopoietic cells is predomi-
nantly a property of LT-HSCs21. Given that Ezh2-KI mice pro-
duced more repopulating HSCs than controls, we investigated their 
reconstitution properties. BM cells from 8-week-old control and 
Ezh2-KI mice (CD45.2) were transplanted in competition (1:1 
and 1:10) with wild-type CD45.1 cells, and analysed 16 weeks after 
transplantation (Fig. 4a). Ezh2-KI donor cells, but not counter-
part controls, strikingly outcompeted CD45.1 +  competitor cells 
(P < 0.05) (Fig. 4b,c). This is probably due, in part, to the enrichment 
of stem cells in the Ezh2-KI donor population, but may also reflect 
the higher proliferation capacity of this population. BrdU incorpo-
ration at the end of the 16-week period confirmed that donor cells 
from Ezh2-KI mice cycled more rapidly than controls (Fig. 4d). This 
change in cell cycling by Ezh2 knock-in cells was consistent with the 
findings described in Figure 1c. Moreover, the recipients of Ezh2-
KI and controls showed no significant differences in the percentage 
of apoptotic cells in primitive BM populations (Fig. 4e). Therefore, 
the increase in stem-cell number and function in Ezh2-KI animals 
was associated with a combination of higher cycling activity and 
a lower frequency of cell death. Moreover, PB contained a signifi-
cantly higher fraction of white blood cells (Fig. 4f) and mature 
myeloid cells originating from Ezh2-KI donors (P < 0.001; Fig. 4g). 
In BM, Ezh2-KI cells made a bigger contribution to primitive (LSK) 
repopulating populations and to myeloid and lymphoid progenitors 
(Fig. 4h).
To exclude an effect of Ezh2 expression in the BM microenviron-
ment on adult haematopoiesis, we transplanted wild-type BM cells 
(CD45.1) into lethally irradiated Ezh2-KI or littermate control mice 
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Figure 3 | Ezh2 expression induces myeloid-proliferative disorder. (a) Photograph of spleen from Ezh2-KI and control mice (50-week-old), showing 
splenomegaly in Ezh2-KI animals. (b) spleen weight in Ezh2-KI and control mice. Values are means ± s.d. (n = 12, *P < 0.05). (c) Top: absolute numbers of 
macrophages (F4-80) and granulocytes (LY6G) in spleen from control and Ezh2-KI mice. Values are means ± s.d. (n = 12, *P < 0.05). Bottom: representative  
FACs plots showing the percentages of F4/80 and LY6G cells in the spleen from Ezh2-KI and control animals. (d) Left: absolute numbers of mature 
myeloid cell populations (mac-1/Gr-1) in spleen from control and Ezh2-KI mice. Values are means ± s.d. (n = 12, *P < 0.05). Right: representative FACs plots  
showing the percentages of mac-1 + /Gr-1low and mac-1 + /Gr-1 +  cells in the spleen from Ezh2-KI and control animals. (e) Absolute numbers of LsK, CLP 
and CmP populations in spleen from Ezh2-KI and control mice. Values are means ± s.d. (n = 12). (f) Histological and immunohistological characterization 
of spleen sections from Ezh2-KI and control mice with H&E (×40 magnification), and anti-Ezh2 (100× magnification), anti-Ki67 (×100 magnification), 
anti-mPo (×40 magnification), anti-F4-80 (×40 magnification), anti-CD34 (×40 magnification), and anti-mac1 (×40 magnification) antibodies. The bar 
indicates 100 µm. (g) Kaplan–meier survival plot showing survival rates for Ezh2-KI mice or littermate controls (*P < 0.001). The statistical significance of 
differences was measured by unpaired two-tailed student’s t-test: *P < 0.05, **P < 0.001.
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(CD45.2). Examination of PB and BM revealed no differences in 
engraftment between genotypes at all time points examined (Sup-
plementary Fig. S7a,b), indicating that the Ezh2-KI microenviron-
ment does not influence the engraftment of HSCs. Taken together, 
these results suggest that Ezh2-expressing repopulating HSC 
subpopulations are highly efficient at long-term repopulation, and 
give rise to significantly increased levels of mature myeloid cells in 
recipient animals.
Ectopic Ezh2 on BM cells is haematopoietic cell autonomous. 
To investigate the cell-intrinsic nature of the phenotypic defects of 
Ezh2-KI mice, we tested the ability of unfractioned Ezh2-KI BM 
cells to reproduce these defects in wild-type CD45.1 recipients. 
After secondary transplantation with Ezh2-KI BM cells, which 
yielded a high percentage of chimerism (Fig. 5a), lethally irradi-
ated recipient mice began to develop MPD, characterized at 10 
weeks by progressive enlargement of spleens (Fig. 5b) and increased 
numbers of monocytes (P < 0.001), platelets (P < 0.05), and granulo-
cytes (P < 0.05) (Table 1). This was followed at 16 weeks post trans-
plantation by substantial increases in total WBC counts (Fig. 5c). 
Moreover, second transplanted BM cells formed bigger and high 
colonies in in vitro colony-forming assays (Fig. 5d). FACS analy-
sis confirmed increased numbers myeloid cells (P < 0.05) originat-
ing from Ezh2-KI donor, and showed that lymphoid populations 
were unaffected (Fig. 5e). Thus, secondary recipient mice manifest a 
progressive MPD similar to that seen in the original Ezh2-KI 
donors. Strikingly, after the third transplant cycle, recipients of 
Ezh2-KI cells died by week 2–4 post transplant by developing 
aggressive MPD (P < 0.01; Fig. 5f), whereas recipients of control 
cells survived; lethally irradiated animals that did not receive BM 
transplant (n = 4) survived 10–14 days (data not shown). Lineage 
contribution analysis suggested that the effect of this third serial 
transplantation was primarily attributable to excess expansion of 
myeloid cells from secondary transplants Ezh2-KI BM cells, marked 
by elevated myeloid presence in BM and spleen of mature myeloid 
cells (Fig. 5g). To determine whether increased cytokine sensitiv-
ity in these tertiary transplanted animals also occurred at the level 
of stem cell/progenitors, LSK cells were cultured in the presence of 
IL-3. Tertiary-transplanted Ezh2-overexpressing cells were increased 
100-fold, compared with a 30-fold increase for wild-type cells (Sup-
plementary Fig. S7c), indicating that the accompanying myeloid 
differentiation induced by this cytokine was enhanced by Ezh2. 
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These results verify the cell-autonomous effect of Ezh2 on sensitiz-
ing HSCs/progenitors to cytokine-induced differentiation. Together, 
these data suggests that the effect of Ezh2 overexpression on HSCs is 
haematopoietic cell autonomous.
The MPD of Ezh2-KI mice is induced by Ezh2-KI HSCs. To iden-
tify which BM subpopulation is responsible for the transfer of MPD 
to secondary recipients, we injected lethally irradiated wild-type 
CD45.1. mice with highly purified subpopulations isolated from 
18-week-old Ezh2-KI mice. Injection of a mix of CMPs, GMPs 
and MEPs contributed less than 5% of circulating myeloid cells in 
primary recipients one month after transplantation, irrespective of 
Ezh2 expression (Fig. 6a). In contrast, injection of LT- and ST-HSCs 
from Ezh2-KI animals triggered mild-to-moderate myeloprolif-
eration (Fig. 6b), manifested by a marked increase in myeloid cell 
number in PB (Table 1), an effect also evidenced by increased WBC 
counts over time (Table 1). Thus LT- and ST-HSCs are uniquely 
able to transplant the MPD observed in primary Ezh2-KI donor 
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*P < 0.05). Left: representative FACs plots showing the percentages of mac-1 + /Gr-1low and mac-1 + /Gr-1 +  cells in Ezh2-KI and control animals (n = 4).  
The statistical significance of differences was measured by unpaired two-tailed student’s t-test: *P < 0.05, **P < 0.001.
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mice, indicating that the haematopoietic phenotype associated with 
Ezh2 expression is specifically induced by primitive haematopoietic 
populations. The transplantability of MPD, especially in recipients 
transplanted with LT- and ST-HSCs, supports the idea that the 
pathogenic effects of Ezh2-everexpressing cells are cell autonomous.
Regulation of HSC-maintenance genes by Ezh2. Given the broad 
role of PCR2 family proteins as chromatin repressors, we conducted 
a global gene expression analysis of Ezh2-expressing LSKs to iden-
tify the most direct targets of Ezh2. Analysis of gene arrays using 
stringent criteria identified a specific Ezh2 signature in Ezh2-KI 
LSK cells. The most significantly up- and down-regulated genes are 
depicted in Supplementary Figure S8a. A complete list of all differ-
entially regulated genes has been deposited in the Gene Expression 
Omnibus under accession no. GSE28369, and summarized as a heat 
map presentation in Supplementary Figure S8b. Enriched expres-
sion was observed for several genes encoding extracellular proteins 
implicated in HSC quiescence22, including biglycan (BGN)23 and 
angiopoietin 1 (ANGPT1)24, whereas NTRK3, important onco-
genic tyrosine kinase in haematologic malignancies25, was down-
regulated. We also observed significant Ezh2-mediated expression 
of master transcriptional regulators of HSC-specific genes26, for 
example, EVI-1, ATF4 and IKZF1, essential molecular markers in 
leukaemias27,28. In addition to its DNA-binding activity, EVI-1 can 
recruit proteins, including histone methyl transferases29, to generate 
complexes for transcriptional regulation. The differential expres-
sion of several of the genes enriched in Ezh2-expressing LSKs from 
Ezh2-KI mice was validated by quantitative RT–PCR (qRT–PCR) 
(Fig. 7a). qRT–PCR showed the same trend in Ezh2-KI LSK cells 
seen in array analysis, with increased expression of EVI-1, BGN, 
ANGPT1 and decreased expression of NTRK3, ATF4 and IKZF1.
To determine whether Ezh2 regulates the expression of genes 
selectively enriched in HSCs from Ezh2-KI mice, we performed 
chromatin immunoprecipitation (ChIP) assays. Ezh2 expression 
increased the amount of bound H3K27me3 in the promoter regions 
of NTRK3 and ATF4, but not the BGN and ANGPT1 promoters 
(Fig. 7b; Supplementary Fig. S9). Moreover, examination of the spe-
cific binding of Ezh2 by ChIP assay using Ezh2-specific antibodies 
detected site-specific binding of Ezh2 to the promoter regions of 
NTRK3 and ATF4 and the INK4/ARF locus30 in Ezh2-KI cells, but 
not to the BGN and ANGPT1 promoters (Fig. 7b; Supplementary 
Fig. S10). These studies revealed direct association of Ezh2 with 
NTRK3, ATF4 or INK4/ARF transcripts, whereas attenuated lev-
els of Ezh2 protein and the H3K27me3 mark associated with BGN  
or ANGPT1 may contribute to increased BGN and ANGPT1  
expression.
We next assessed whether the upregulated BGN and ANGPT1 
transcript expression in HSCs of Ezh2-KI mice resulted in changes 
in Polycomb-dependent histone modifications. As well as examining 
the level of the essential PRC1 member Bmi1, we examined the level 
of H2A ubiquitylation (H2A-ub), a histone modification mediated 
by PRC1 (ref. 31). The entire promoter regions of the downregulated 
NTRK3 and ATF4 genes in Ezh2-KI Lin −  cells were significantly 
enriched for the H2A-ub signal and Bmi1, showing that the signal 
was probably specific. In contrast, the H2A-ub signal and Bmi1 
were absent from the BGN and ANGPT1 promoters in Ezh2-KI 
Lin −  cells, suggesting that Ezh2 action likely requires the binding 
of Bmi1 (Fig. 7b).
To confirm the assembly of Ezh2, knockdown of Ezh2 reduced 
not only binding of Ezh2 and trimethylation of H3K27 at the 
promoter region of ARF4, but also Bmi1-binding and H2A ubiq-
uitylation signal (Supplementary Fig. S11). In contrast, Bmi1 and 
H2A-ub signals at the ANGPT1 promoter were not altered, sug-
gesting that Ezh2 is required for the binding of Bmi1. To further 
examine whether the DNA methylation status might account for 
the different expression states of the genes and differing effects of 
increasing Ezh2 levels, bisulfite sequencing detected minimal basal 
DNA methylation in the NTRK3 and ATF4 promoters of young 
Ezh2-KI LSKs cells (Supplementary Fig. S12), although this DNA 
Table 1 | Peripheral blood counts in recipients after secondary transplant at 10 weeks post transplant and in recipients  
4- and 12-week-post transplants with sorted LT/ST-HSCs.
secondary recipients 10 weeks after  transplant
Donor† WBC×103 ml − 1 LYM×103 ml − 1 MID×103 ml − 1 GRA×103 ml − 1 PTL×103 ml − 1 RBC×103 ml − 1
Control 8.43 ± 1.70 7.35 ± 0.43 0.17 ± 0.08** 0.68 ± 0.26* 470.17 ± 90.08* 10.48 ± 0.23
Ezh2-kl 7.90 ± 1.78 6.48 ± 1.36 0.34 ± 0.1 1.18 ± 0.35 687.12 ± 60.16 11.68 ± 0.55
Recipients after 4–12-week-post transplant of primary recipients
WBC×103 ml − 1 LYM×103 ml − 1 MID×103 ml − 1 GRA×103 ml − 1 PTL×103 ml − 1 RBC×103 ml − 1
Control‡ 7.32 ± 0.60 6.82 ± 0.41 0.14 ± 0.39 0.46 ± 0.31* 415.84 ± 24.37 13.26 ± 1.71
Ezh2-kl‡ 7.97 ± 0.98 6.98 ± 0.12 0.20 ± 0.53 0.84 ± 0.51 548.20 ± 21.53 10.74 ± 1.53
Control§ 6.53 ± 0.90* 7.02 ± 0.36 0.21 ± 0.09* 0.44 ± 0.27* 445.44 ± 20.34* 12.76 ± 1.25
Ezh2-kl§ 11.47 ± 0.79 7.57 ± 0.22 0.54 ± 0.43 1.44 ± 0.47 608.52 ± 24.62 11.34 ± 0.96
GRA, granulocytes; LYm, lymphocytes; mID, monocytes; PLT, platelets; RBC, red blood cells. Values are means ± s.d. (n=8). The statistical significance of differences was measured by unpaired two-
tailed student’s t-test: *P < 0.05, **P < 0.001.
†In secondary recipients 10 weeks post transplant.
‡4 weeks post transplant of primary recipients.
§12 weeks post transplant of primary recipients.
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Figure 6 | HSCs but not myeloid progenitors from Ezh2-KI mice induces 
MPD in recipient hosts. (a, b) subpopulation profiles in Bm (myeloid 
progenitors, mP) and PB (mature myeloid cells, mac-1 + /Gr-1 + ) of 
recipient mice transplanted with either (a) pooled myeloid progenitors 
(Lin − c-kit + sca-1 − ) or (b) LT/sT-HsCs from Ezh2-KI or control donors. 
Values are means ± s.d., n = 4 recipients per group. similar results were 
obtained in a second experiment.
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methylation was increased when aged Ezh2-KI cells were analysed 
(50-week-old) (Supplementary Fig. S13).
Together, these gene expression data strongly correlate with the 
haematopoietic phenotype of Ezh2-KI mice and indicate that regu-
lation of NTRK3 and ATF4 on Ezh2 overexpression in LSK cells may 
prime these primitive haematopoietic stem cells to generate MPD 
in these mice.
Discussion
Here we report that the histone methyltransferease Ezh2 appears 
to have a key role in controlling homeostasis of the haematopoietic 
stem cell compartment. By modulating Ezh2 expression in the hae-
matopoietic system in vivo by intercrossing Ezh2 conditional gain-
of-function mice with a haematopoietic-specific vav-Cre line, we 
found that self-renewing HSCs expressing Ezh2 lead to MPD32,33. 
MPD was also observed in inducible Ezh2-KI-ER mice, in which 
we could control the timing of Ezh2 expression by injection with 
tamoxifen. Notably, targeted activation of Ezh2 in myeloid cells in 
the Ezh2-KI-M mice only mildly influences the homeostasis of the 
granulocytic lineage and never leads to MPD.
The results presented here provide the first experimental demon-
stration of altered HSC function caused by overactive Ezh2 function, 
leading to MPD. Our mouse models of controlled Ezh2 expression 
indicate that haematological disorders induced by Ezh2 overex-
pression developed fatal MPD, characterized by excessive myeloid 
expansion in BM and spleen, elevated white blood cell counts 
and mature myeloid cells, and splenomegaly. Moreover, analysis 
of BM and spleen cells revealed heightened sensitivity of haemato-
poietic progenitor cells to cytokines in vitro. Taken together, these 
findings support a model in which Ezh2-mediated H3K27me3 
induces MPD.
Once Ezh2 protein has enacted its direct repressive effect through 
H3K27 methylation, full repression seems to require the subsequent 
action of other Polycomb members, as others have reported31. Our 
results, while validating only a small proportion of Ezh2-regulated 
transcripts, shed light on this matter, and contrast the binding of 
Ezh2 and Bmi1 to upregulated BGN and ANGPT1 genes. The action 
of Ezh2 might involve the action of other chromatin targets, such 
that activation or repression of a gene program by histone meth-
ylation closely synchronizes with other epigenetic adjustments, 
enabling fine regulation of cell specification processes. These data 
provide a starting point for further studies to uncover the under-
lying mechanisms of Ezh2-mediated haematopoiesis and probably 
leukaemogenesis.
Recent studies have demonstrated that Ezh2 can bind to DNA 
methyltransferases, which can result in DNA methylation34, and 
that H3K27 methylation is prerequisite for de novo methylation5,34. 
Thus, oncogenic Ezh2 action marks genes that are prone to cancer-
specific DNA methylation35,36. In cancer risk states, with abnormal 
regulation of tissue renewal, such tight transcriptional repression 
may favour the abnormal expansion of stem and progenitor cell 
populations37. This expansion may, in turn, select mutations in 
oncogenic genes, helping to promote abnormal growth and pro-
gression to invasiveness and malignancy38. Consistent with this 
idea, mutations in genes involved in the epigenetic regulators have 
recently been documented. Inactivating mutations for Ezh2 have 
been found in a large cohort of myeloid neoplasms and lympho-
mas7,13,14,39, although follow-up studies have revealed that several 
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of those mutations actually lead to increased levels of H3K27me3 
(refs 8, 9). The question now is whether or not these mutations 
are critical drivers of the underlying myeloproliferative process or 
if some of the mutations are simply markers of cancer-associated 
genomic instability. Larger studies, incorporating detailed analy-
ses, will be needed to further clarify the spectrum and frequency 
of mutations, the functional consequences of these mutations, the 
degree of genotypic overlap, and their clinical significance, particu-
larly in predicting outcomes for available therapies.
Our working model proposes a molecular progression during 
tumorigenesis that starts with abnormal expansion of Ezh2-express-
ing haematopoietic stem or myeloid progenitor cell compartments, 
in which genes such as ATF4 and NTRK3 undergo Ezh2-mediated 
gene silencing associated with progressive DNA methylation of 
their promoter CpG islands. In early stage cancer, with abnormal 
expansion of stem and progenitor cell populations, such epigenetic 
changes might result in mutations that affect expression or func-
tion of essential DNA methyltransferases, such as Ezh2 or other 
epigenetically relevant proteins, compounding the cancer-associ-
ated genomic instability40. Identification of cellular pools with the 
capacity to start the neoplastic transformation underlying MPD 
could allow a more rational classification and prognosis of disease 
and, eventually, the development of targeted therapy. In general, 
mouse models of MPD41,42 have had limited success in recogniz-
ing the MPD-initiating cell population because of complexity in 
transplanting and reproducing the consequences of the primary 
disease43–45. Our results show that at least two distinct cellular 
subfractions, the Ezh2-KI LT- and ST-HSCs, are essential for MPD 
pathogenesis. The identification of Ezh2-activated LT- and ST-HSCs 
as potential leukaemic stem cells (LSCs) for the Ezh2-induced MPD 
lends further support to the notion that leukaemias and cancers 
may be sustained by rare LSCs or cancer stem cells46 (Supplemen-
tary Fig. S14). Because the only self-renewing capacity is sustained 
by the HSCs, we expect that only clones of Ezh2-expressing HSCs 
can induce and accumulate the epigenetic changes required for the 
progression and development to leukaemia. Future investigation 
of the stem cell-specific oncogenic role of Ezh2 in myeloid disor-
ders should therefore provide a better molecular understanding of 
Ezh2-expressing HSCs acting with LSC functions.
Methods
Mice. The generation of cki-Ezh2fl/ +  mice, carrying the conditional ROSA26-Ezh2 
allele, is described in Supplementary Information. The vav-Cre, Rosa26Cre-ERT2 
and LyzM-Cre mouse lines, which were crossed with cki-Ezh2fl/fl to generate 
Ezh2-KI (Ezh2fl/fl/vavCretg/ + ), Ezh2-KI-ER (Ezh2fl/fl/Cre-ERtg/tg) and Ezh2-KI-M 
(Ezh2fl/fl/LyzMCretg/ + ) mice, respectively, were all generated after backcrossing 
two generations to C57BL/6. In addition, R26R reporter mice were crossed with 
Ezh2 + / + -Cretg/ +  to generate R26R/Cre +  and R26R/Cre − . All genotyping prim-
ers are listed in Supplementary Table S1. In Ezh2-KI-ER mice, Cre was induced 
by injections on 5 consecutive days of 1 mg tamoxifen (Sigma) in corn coil. PB 
samples (~50 µl) were collected by tail bleeding into tubes containing EDTA, 
and white blood cells, lymphocytes, monocytes, platelets and granulocytes were 
counted using a Hemavet 950FS cell counter (Drew Scientific). Wild-type C57BL/6 
(CD45.2 + ) and C57BL6/SJL (CD45.1 + ) mice were purchased from The Jackson 
Laboratory. Ezh2-KI, Ezh2-KI-ER and Ezh2-KI-M mice were all on the C57BL/6, 
CD45.2 background, and were bred in-house. All mice were maintained in a 
pathogen-free environment, and were provided with standard care and nutrition 
according to institutional guidelines and animal study proposals approved by  
the CNIC.
Transplantation assays. Cells were transplanted into the congenic CD45.1 + . 
B6.SJL mouse strain and monitored for the presence of CD45.2 +  donor-derived 
cells. For competitive transplants, 5×105 BM cells from individual Ezh2-KI or 
littermate mice (CD45.2) were transplanted together with 5×105 competitor cells 
(CD45.1) lethally irradiated (10Gy) 8-week-old B6.SJL mice (CD45.1). Repopula-
tion was assessed at 16 weeks by FACS analysis of PB and BM. Noncompetitive se-
rial transplants were initiated by transplanting 2×106 whole BM cells pooled from 
three control or Ezh2-KI donors (CD45.2) into each irradiated recipient (CD45.1). 
Secondary and tertiary transplants were performed after a 10-week engraftment 
period by pooling whole BM cells from 2 reconstituted recipients and transplant-
ing 2×106 of these cells into new groups of 8 irradiated CD45.1 recipients. PB cells 
were obtained by tail vein nicking 10 or 16 weeks post transplantation. For homing 
assays, 5×106 CD45.2 cells from BM of individual Ezh2-KI and littermate mice 
were transplanted into lethally irradiated B6.SJL mice (CD45.1). BM cells were 
collected after 24 h and analysed by FACS.
Flow cytometry and cell sorting. Flow cytometry was performed as described47. 
Single-cell suspensions were prepared from BM, PB or spleen, and red cells were 
lysed with ACK buffer (NH4Cl/KHCO3). Cells were analysed with a cocktail of 
biotinylated anti-mouse antibodies to Ly-6G, F4-80, CD3var epsilon, CD4, CD8a 
(Ly-2) and B220 (CD45R) (558451; BD Biosciences; according to the manufactur-
er’s instructions). Cells were detected and sorted using streptavidin conjugated to 
Alexa647, APC/Alexa750, Q-dot605, 405 (Invitrogen), or R/PE (BD Biosciences) 
(these antibodies were used at 1:100). Directly conjugated antibodies used were as 
follows: cKit-PerCP/Cy5.5, cKit-PE, cKit-APC (CD117) and Flk2-PE (CD135) (BD 
Biosciences); Sca1-PE/Cy7, Sca1-APC and Sca1-PE (Ly 6A/E, Caltag); Ki-67-APC 
and Ki-67-Alexa647; and CD34-Alexa647, CD127-PE and CD16/32-Alexa700 
(these antibodies were used at 1:100). PB cell counts were obtained by tail vein 
nicking, red blood cells were lysed with NH4Cl, and the remaining cells were 
stained with either APC-anti-CD45.2 (eBioscience) and PE/Cy5.5-anti-CD45.1 
(eBioscience) and the following lineage surface markers: CD3e-Biotin-ST-405, 
PE-anti-CD4 (GK1.5), APC-anti-CD8 (53-6.7) for T cells; Alexa647 anti-B220 
(RA3-6B2; eBioscience) for B cells; F4/80-PB for monocytes; and PE-anti-Gr-1 
granulocytes (51-01212J; BD Biosciences) (these antibodies were used at 1:100).
Cell-cycle analysis. BrdU incorporation was analysed with the APC-BrdU Flow 
Kit (BD Biosciences). BM was assayed 48 h after a single intraperitoneal injection 
of BrdU (100 µl of a 10 mg ml − 1 solution). Surface staining for lineage markers was 
performed as above with antibodies to Lin-APC-Alexa750, Sca1-Biotin-Qdot605, 
cKit-PerCP/Cy5.5, CD135-APC and CD34-FITC (GFP is lost after fixing; data 
not shown). For the apoptosis assay, BM cells were stained with lineage, stem 
and progenitor markers, followed by staining with DAPI (Molecular Probes) and 
AnnexinV–APC (BD Biosciences). To detect quiescent HSCs, unmanipulated BM 
cells were incubated with 10 µg ml − 1 Hoechst 33342 for 90 min at 37 °C. Cells were 
washed and stained with antibodies against cKit, Sca1 and Lin. The cells were fixed 
in 5% PFA and incubated with the RNA dye Pyronin Y (PY, 1 µg ml − 1) before flow 
cytometry. The proportion of cells in G0 (PYlow Hoechstlow) was measured in the 
LK + S + CD34low-gated populations.
Gene expression and qRT–PCR. Total RNA was isolated from PB, BM, spleen 
and other tissues with the Trizol reagent (Invitrogen), and treated essentially as 
described48, using the primers listed in Supplementary Table S2. Gene expression 
analysis is described in Supplementary Information.
Chromatin immunoprecipitation assays. ChIP was performed essentially as 
described48. Antibodies for immunoprecipitation were rabbit polyclonals to 
H3K27me3, H3K9me3, H2Aub1, IgM, Ezh2 and H3K4me3 (all from Upstate; 
1:2,500). DNA from precipitated complexes was amplified by RT–PCR, performed 
in triplicate with multiple dilutions, using the primers listed in Supplementary 
Table S3. For retroviral transduction of short hairpin RNAs, Ezh2 targeting short 
interfering RNA (Dharmacon D-00210-01 and D-004218-01) and non-target-
ing controls were cloned into the pSuper vector (OligoEngine). LSK cells (5×105) 
isolated from Ezh2-KI and control mice were infected with shEzh2 or control 
retrovirus (at least 106 cfu ml − 1) by spinoculation (at 1,600×g and 37°C). After 24 h 
culture in medium containing 10 ng ml − 1 IL-3, 10 ng ml − 1 IL-6, and 100 ng ml − 1 
stem cell factor, a second round of spinoculation was performed, followed by 
culture for an additional 24 h.
Colony assays. Lin negative cells (104) from BM of both genotypes were plated in 
1.3%. methylcellulose (H4100, Stem Cell Technologies) supplemented with 30% 
FBS, 10% detoxified BSA (Stem Cell), 200 mM nonessential amino acids, 200 mM 
L-glutamine, 10 U ml − 1 penicillin G, 10 µg ml − 1 streptomycin, 100 M 2-ME 
(Sigma), 50 µg ml − 1 ascorbic acid (Sigma), 20 ng ml − 1 IL-6, 20 ng ml − 1 mSCF, 
10 ng ml − 1 mIL-11, 20 ng ml − 1 mIL-3, 10 ng ml − 1 mTPO, 10 ng ml − 1 hG-CSF 
and 1 U ml − 1 hEPO (Amgen). All supplements and media were purchased from 
Invitrogen and cytokines from R&D Systems, except where indicated. Primitive 
erythroid colonies were scored after 3–4 days in culture. All other colony types 
were scored after 7–8 days in culture. To assay formation of granulocyte–macro-
phage colonies (CFU–GM), nucleated BM cells (1×105) were plated in triplicate on 
methylcellulose (MethoCult, Stem Cell) supplemented with granulocyte–macro-
phage colony stimulating factor (GM–CSF) and IL-3, at the indicated concentra-
tions. Colonies ( > 30 cells) were scored blindly after 12 days, using an inverted 
microscope.
Protein analysis and immunohistochemistry. Immunoblots were performed  
essentially as described49. Mouse Ezh2 was detected with monoclonal antibody AC22  
(Cell Signaling), H3K27me3 with rabbit polyclonal antibody (Upstate) and β-actin 
with monoclonal antibody AC-15 (Sigma). Secondary antibody was HRP-linked 
anti-mouse IgG (DAKO). Signals were detected by enhanced chemiluminescence 
(GE Lifesicences). For histopathology, femurs were fixed in formaldehyde, decalci-
fied and paraffin embedded. Spleens were treated similarly, with the omission of 
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decalcification. Sections (4.5 µm) were cut and stained with haematoxylin and 
eosin (H&E) or processed for IHC. Sections for IHC were staining with antibod-
ies to Ezh2 (AC22; Cell Signaling; 1:1,000), F4-80 (T-2006; BMA Biomedicals; 
1:1,000), Mac-1 (ab63317, ABCAM; 1:2,000), CD34 (ab8158; ABCAM; 1:2,000), 
MPO (A0398; DAKO; 1:1,500) and Ki67 (0003110QD; Master Diagnostica; 1: 500). 
Samples were then incubated with biotinylated anti-mouse IgG followed by  
avidin-biotin peroxidase complexes (Vector Lab).
Statistical methods. All data are expressed as the mean ± s.d. The statistical 
significance of differences was measured by unpaired two-tailed Student’s t-test; 
*P < 0.05, or **P < 0.001. 
References
1. Akala, O. O. & Clarke, M. F. Hematopoietic stem cell self-renewal. Curr. Opin. 
Genet. Dev. 16, 496–501 (2006).
2. Bracken, A. P. & Helin, K. Polycomb group proteins: navigators of lineage 
pathways led astray in cancer. Nat. Rev. Cancer 9, 773–784 (2009).
3. Margueron, R. & Reinberg, D. The Polycomb complex PRC2 and its mark in 
life. Nature 469, 343–349 (2011).
4. Ben-Porath, I. et al. An embryonic stem cell-like gene expression signature in 
poorly differentiated aggressive human tumors. Nat. Genet. 40, 499–507 (2008).
5. Schlesinger, Y. et al. Polycomb-mediated methylation on Lys27 of histone H3 
pre-marks genes for de novo methylation in cancer. Nat. Genet. 39, 232–236 (2007).
6. Martin-Perez, D., Piris, M. A. & Sanchez-Beato, M. Polycomb proteins in 
hematologic malignancies. Blood 116, 5465–5475 (2010).
7. Morin, R. D. et al. Somatic mutations altering EZH2 (Tyr641) in follicular 
and diffuse large B-cell lymphomas of germinal-center origin. Nat. Genet. 42, 
181–185 (2010).
8. Sneeringer, C. J. et al. Coordinated activities of wild-type plus mutant 
EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone 
H3 (H3K27) in human B-cell lymphomas. Proc. Natl Acad. Sci. U S A 107, 
20980–20985 (2011).
9. Yap, D. B. et al. Somatic mutations at EZH2 Y641 act dominantly through a 
mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 
trimethylation. Blood 117, 2451–2459 (2010).
10. Xu, F. et al. Overexpression of the EZH2, RING1 and BMI1 genes is common 
in myelodysplastic syndromes: relation to adverse epigenetic alteration and 
poor prognostic scoring. Ann. Hematol. 90, 643–653 (2010).
11. Paul, T. A. et al. Signatures of polycomb repression and reduced H3K4 
trimethylation are associated with p15INK4b DNA methylation in AML. Blood 
115, 3098–3108 (2010).
12. Fiskus, W. et al. Combined epigenetic therapy with the histone 
methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone 
deacetylase inhibitor panobinostat against human AML cells. Blood 114, 
2733–2743 (2009).
13. Nikoloski, G. et al. Somatic mutations of the histone methyltransferase gene 
EZH2 in myelodysplastic syndromes. Nat. Genet. 42, 665–667 (2010).
14. Ernst, T. et al. Inactivating mutations of the histone methyltransferase gene 
EZH2 in myeloid disorders. Nat. Genet. 42, 722–726 (2010).
15. de Boer, J. et al. Transgenic mice with hematopoietic and lymphoid specific 
expression of Cre. Eur. J. Immunol. 33, 314–325 (2003).
16. Croker, B. A. et al. SOCS3 is a critical physiological negative regulator of G-CSF 
signaling and emergency granulopoiesis. Immunity 20, 153–165 (2004).
17. Ogilvy, S. et al. Promoter elements of vav drive transgene expression in vivo 
throughout the hematopoietic compartment. Blood 94, 1855–1863 (1999).
18. Goodell, M. A. et al. Isolation and functional properties of murine hematopoietic 
stem cells that are replicating in vivo. J. Exp. Med. 183, 1797–1806 (1996).
19. Ventura, A. et al. Restoration of p53 function leads to tumour regression  
in vivo. Nature 445, 661–665 (2007).
20. Clausen, B. E. et al. Conditional gene targeting in macrophages and 
granulocytes using LysMcre mice. Transgenic Res. 8, 265–277 (1999).
21. Passegue, E. et al. Global analysis of proliferation and cell cycle gene expression 
in the regulation of hematopoietic stem and progenitor cell fates. J. Exp. Med. 
202, 1599–1611 (2005).
22. Ashburner, M. et al. Gene ontology: tool for the unification of biology. The 
gene ontology consortium. Nat. Genet. 25, 25–29 (2000).
23. Kiel, M. J., Radice, G. L. & Morrison, S. J. Lack of evidence that hematopoietic 
stem cells depend on N-cadherin-mediated adhesion to osteoblasts for their 
maintenance. Cell Stem Cell 1, 204–217 (2007).
24. Arai, F. et al. Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell 
quiescence in the bone marrow niche. Cell 118, 149–161 (2004).
25. Tam, W. F. et al. Id1 is a common downstream target of oncogenic tyrosine 
kinases in leukemic cells. Blood 112, 1981–1992 (2008).
26. Forsberg, E. C. et al. Molecular signatures of quiescent, mobilized and 
leukemia-initiating hematopoietic stem cells. PLoS One 5, e8785 (2010).
27. Buonamici, S. et al. EVI1 induces myelodysplastic syndrome in mice. J. Clin. 
Invest. 114, 713–719 (2004).
28. Goyama, S. et al. Evi-1 is a critical regulator for hematopoietic stem cells and 
transformed leukemic cells. Cell Stem Cell 3, 207–220 (2008).
29. Goyama, S. et al. EVI-1 interacts with histone methyltransferases SUV39H1 
and G9a for transcriptional repression and bone marrow immortalization. 
Leukemia 24, 81–88 (2010).
30. Bracken, A. P. et al. The Polycomb group proteins bind throughout the INK4A-
ARF locus and are disassociated in senescent cells. Genes Dev. 21, 525–530 (2007).
31. Sauvageau, M. & Sauvageau, G. Polycomb group proteins: multi-faceted 
regulators of somatic stem cells and cancer. Cell Stem Cell 7, 299–313 (2010).
32. Tefferi, A. & Gilliland, D. G. Oncogenes in myeloproliferative disorders. Cell 
Cycle 6, 550–566 (2007).
33. Kogan, S. C. et al. Bethesda proposals for classification of nonlymphoid 
hematopoietic neoplasms in mice. Blood 100, 238–245 (2002).
34. Vire, E. et al. The Polycomb group protein EZH2 directly controls DNA 
methylation. Nature 439, 871–874 (2006).
35. Ohm, J. E. et al. A stem cell-like chromatin pattern may predispose tumor 
suppressor genes to DNA hypermethylation and heritable silencing. Nat. Genet. 
39, 237–242 (2007).
36. Widschwendter, M. et al. Epigenetic stem cell signature in cancer. Nat. Genet. 
39, 157–158 (2007).
37. Coussens, L. M. & Werb, Z. Inflammation and cancer. Nature 420, 860–867 
(2002).
38. Jones, P. A. & Baylin, S. B. The epigenomics of cancer. Cell 128, 683–692 (2007).
39. Bejar, R. et al. Clinical effect of point mutations in myelodysplastic syndromes. 
N. Engl. J. Med. 364, 2496–2506 (2011).
40. Lund, A. H. & van Lohuizen, M. Polycomb complexes and silencing 
mechanisms. Curr. Opin. Cell Biol. 16, 239–246 (2004).
41. Passegue, E. & Wagers, A. J. Regulating quiescence: new insights into 
hematopoietic stem cell biology. Dev. Cell 10, 415–417 (2006).
42. Li, Q. et al. Hematopoiesis and leukemogenesis in mice expressing oncogenic 
NrasG12D from the endogenous locus. Blood 117, 2022–2032 (2011).
43. Cleary, M. L. Regulating the leukaemia stem cell. Best Pract. Res. Clin. 
Haematol. 22, 483–487 (2009).
44. Braun, B. S. et al. Somatic activation of oncogenic Kras in hematopoietic cells 
initiates a rapidly fatal myeloproliferative disorder. Proc. Natl Acad. Sci. U S A 
101, 597–602 (2004).
45. Mullally, A. et al. Physiological Jak2V617F expression causes a lethal 
myeloproliferative neoplasm with differential effects on hematopoietic stem 
and progenitor cells. Cancer Cell 17, 584–596 (2010).
46. Warr, M. R., Pietras, E. M. & Passegue, E. Mechanisms controlling 
hematopoietic stem cell functions during normal hematopoiesis and 
hematological malignancies. Wiley Interdiscip. Rev. Syst. Biol. Med. 3, 681–701 
(2011).
47. Herrera-Merchan, A. et al. miR-33-mediated downregulation of p53 controls 
hematopoietic stem cell self-renewal. Cell Cycle 9, 3277–3285 (2010).
48. Gonzalez, S., Pisano, D. G. & Serrano, M. Mechanistic principles of chromatin 
remodeling guided by siRNAs and miRNAs. Cell Cycle 7, 2601–2608 (2008).
49. Gonzalez, S. et al. Oncogenic activity of Cdc6 through repression of the INK4/
ARF locus. Nature 440, 702–706 (2006).
Acknowledgements
We are grateful to Giovanna Giovinazzo, Luis-Miguel Criado, Maria Montoya and their 
teams (CNIC) for technical support. We also thank Simon Bartlett (CNIC) for English 
editing, Dr Serrano for helpful discussion, and Purificacion Arribas for her wonderful 
technical assistance. S. Gonzalez is funded by the Human Frontiers Science Program 
Organization, the Spanish Ministries of Science and Innovation (SAF2010-15386) 
and Health (FIS PI06/0627) The CNIC is supported by the Ministry of Science and 
Innovation and the Pro-CNIC Foundation.
Author contributions
A.H-M. performed most of the experiments, contributed to data analysis, and discussion 
of the paper. L.A. helps with technical issues regarding gene expression assays. J.M.L. 
supervised the cytometric analyses. A.M. performed all pathological analyses. O.D. 
designed and supervised the gene expression data. S.G. designed and supervised the 
study, secured funding, analysed the data and wrote the paper. All authors discussed the 
results and commented on the paper.
Additional information
Accession codes: The microarray data have been deposited in the Gene Expression 
Omnibus under accession code GSE28369.
Supplementary Information accompanies this paper at http://www.nature.com/
naturecommunications
Competing financial interests: The authors declare no competing financial interests.
Reprints and permission information is available online at http://npg.nature.com/
reprintsandpermissions/
How to cite this article: Herrera-Merchan, A. et al. Ectopic expression of the histone 
methyltransferase Ezh2 in haematopoietic stem cells causes myeloproliferative disease. 
Nat. Commun. 3:623 doi: 10.1038/ncomms1623 (2012).
Oncogenic Ezh2 induces MPD   
Herrera-Merchan et al. resubmitted to Nature Communications (2011)    1 
SUPPLEMENTARY INFORMATION  
  
Ectopic expression of the histone methyltransferase Ezh2 in 
hematopoietic stem cells causes myeloproliferative disease  
Herrera-Merchan, A., Arranz, L., Ligos, J.M., de Molina, A., Dominguez, O., and 
Gonzalez, S.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Oncogenic Ezh2 induces MPD   
Herrera-Merchan et al. resubmitted to Nature Communications (2011)    2 
Supplementary Figures and Legends 
 
Supplementary Figure S1. Hematopoietic-specific transgenic Ezh2 expression.  
a, Strategy used to conditionally target Ezh2 to the ROSA26 locus (cki-Ezh2fl/fl). A floxed 
transcriptional stop cassette was upstream of the murine Ezh2 cDNA, which was linked 
via an internal ribosomal entry sequence (IRES) to a GFP gene (see details in 
Supplemental Experimental Procedures). Southern blot analysis of EcoRV-digested 
genomic DNA with the indicated probe was done according to standard protocols.  
b, Experimental scheme (left) used for crossing cki-Ezh2fl/fl mice with vav-Cretg/+ 
transgenic mice. Genomic PCR analysis (right) of Ezh2-KI (Ezh2fl/fl-Cretg/+), Ezh2fl/+-
Cretg/+, and control (Ezh2fl/fl-Cre+/+) alleles from the indicated mice. Primers of 
genotyping are listed in Table S1. 
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Supplementary Figure S2. Characterization of the hematopoietic system in the Ezh2-
KI mice.  
a, Expression of total Ezh2 mRNA was measured in total BM cells, in sorted LSK 
subpopulation, thymus, spleen, and brain from control and Ezh2-KI mice by qRT-PCR 
analysis. Results have been standardized for b-actin levels and are expressed as fold-
induction (means ±SD; n=12, * p<0.05) compared to the control levels.  
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b, Western blots using anti-Ezh2, anti-H3K27me3, and anti-βactin antibodies show the 
corresponding levels of Ezh2, H3K27me3, and β-actin in the indicated cellular fractions, 
respectively, of Ezh2-KI and control mice. 
c, Total BM cellularity (femurs) within of the control and Ezh2-KI mice. Data are 
expressed as means ± SD, n = 8 per genotype. 
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Supplementary Figure S3. Specific expression of Cre recombinase by the vavCre 
transgene.  
a, Strategy used to generate R26R/Cre+ and R26R/Cre- mice. vavCretg/+ mice were 
intercrossed with R26 reporter (R26R; loxP-stop-loxP-GFP) mice, and GFP activity in 
adult tissues was used as an indicator of Cre-mediated deletion. A floxed transcriptional 
stop cassette was upstream of an internal ribosomal entry sequence (IRES) to a GFP 
gene.  
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b, Experimental scheme used for crossing cki-Ezh2fl/fl mice with vav-Cretg/+ transgenic 
mice. Genomic PCR analysis (right) of Ezh2-KI (Ezh2fl/fl-Cretg/+), Ezh2fl/+-Cretg/+, and 
control (Ezh2fl/fl-Cre+/+) alleles (hereafter referred to as R26R/Cre+ and R26R/Cre-, 
respectively) from the indicated mice.  
c, Representative FACS plots showing GFP expression in the total LSK subpopulations, 
thymocytes, brain cells, and hepatocytes of R26R/Cre+ and R26R/Cre- mice. Numbers are 
the percentages of GFP+ cells from at least three independent experiments. 
d, Analysis of peripheral blood counts in both R26R/Cre+ and R26R/Cre- mice depicted 
the absolute numbers of white blood cells (WBC), lymphocytes (LYM), monocytes 
(MID), granulocytes (GRA), platelets (PLT), and red blood cells (RBC). Values are 
means ± SD (n = 4). 
 
Oncogenic Ezh2 induces MPD   
Herrera-Merchan et al. resubmitted to Nature Communications (2011)    7 
Supplementary Figure S4. Consequences of aged Ezh2-KI and control in the BM 
populations.   
a, Left: Representative FACs profiles of bone marrow (BM) cells from aged Ezh2-KI 
mice and control littermates (50-week-old). LSK supopulation was subclassified for 
expression of CD34 and CD135 to give the percentages of MPPs and long-term (LT) and 
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short-term (ST) HSCs, and for expression of CD16/32 and CD34 to give the percentages 
of common myeloid progenitors (CMP), granulocytic macrophage progenitors (GMP) 
and megakaryocytic-erythroid progenitors (MEP). At least ten mice per genotype were 
tested, over at least two separate experiments. Numbers indicate percentages of the total 
nucleated BM cell population. Right: Absolute numbers per femur of the LT, ST, MPP, 
CMP, GMP, and MEP primitive populations described above. Values are means ± SD 
(n=12, *p < 0.001). 
b, Bone marrow cells collected by tertiary serial transplanted animals from Ezh2-KI and 
control animals were immunostained with antibodies against CD45, Mac-1 and c-Kit. 
The SSCmedCD45high population was subfractioned according to c-Kit and Mac-1 
expression to determine Mac-1+/c-Kit+ blasts. At least five mice per genotype were 
tested. Numbers indicate percentages of the total Mac-1+/c-Kit+ cell population. 
c, Representative FACS plots of BM cells from control or Ezh2-KI donors (CD45.2) 24 h 
posttransplant into wild-type CD45.1 recipients. Data represent at least three independent 
experiments. 
d, Peripheral blood counts in 10-, 30- and 50-week-old Ezh2-KI and control mice. WBC, 
white blood cells; LYM, lymphocytes; MID, monocytes; GRA, granulocytes; PLT, 
platelets; RBC, red blood cells. Values are means ± SD (n = 8, * p<0.05; ** p<0.001). 
e, Average of total lymphoid populations (CD3, CD4, CD8, and B220) in the spleen of 
control and Ezh2-KI mice (mean ±SD; n=8, * p<0.05).  
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Supplementary Figure S5. Ezh2 expression induces myeloid-proliferative disorder.  
a, Expression of total Ezh2 mRNA was measured in the indicated cellular fractions from 
control and Ezh2-KI-ER mice after one month of tamoxifen induction by qRT-PCR 
analysis. Results have been standardized for β-actin levels and are expressed as fold-
induction (means ±SD; n=12, * p<0.05) compared to the control levels. 
b, Average of total numbers of CLP, CMP, MEP and GMP subpopulations within of the 
total BM cells in control or Ezh2-KI-ER BM cells, after four months of Cre induction. 
Values are means ± SD (n=8, *p<0.05). 
c, BM cells (2x104/ml) harvested from Ezh2-KI-ER and control littermates (n=3 per 
group) were assessed by myeloid colony assays 4 months after tamoxifen induction.  
d, Representative FACS plots of mature myeloid (Mac-1/Gr-1) cells in the spleen and 
BM of control and Ezh2-KI-ER mice 4 months after tamoxifen induction. Numbers 
indicate percentages of the total nucleated BM cell population. 
e, Total spleen weights from Ezh2-KI-ER and control mice. Values are means ± SD (n = 
7, *p<0.05). 
f, Analysis of peripheral blood counts in both Ezh2-KI-ER and control mice, after four 
and eight months of Cre induction, depicted the numbers of white blood cells (WBC), 
lymphocytes (LYM), monocytes (MID), granulocytes (GRA), platelets (PLT), and red 
blood cells (RBC). Values are means ± SD (n = 8, * p<0.05; ** p<0.001). 
g, Proliferation analysis of sorted CMP, MEP and GMP BM-subpopulations in control 
and Ezh2-KI-ER mice six weeks after Cre induction. Values are means ± SD, n = 7. 
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Supplementary Figure S6 Targeted Ezh2 expression in myeloid lineage is not 
sufficient for inducing MPD. 
a, Representative FACS plots showing GFP expression in the granulocyte fraction in 
Ezh2-KI-M and control mice. Numbers are the percentages of GFP+ cells from at least 
three independent experiments. 
b, Efficient expression of total Ezh2 mRNA in different BM subpopulations (MP, GMP, 
Gr-1, LSK) and brain cells from Ezh2-KI-M by qRT-PCR analysis. Results have been 
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standardized for β-actin levels and are expressed as fold-induction (means ±SD; n=12, * 
p<0.05) compared to the control levels within of the cellular fractions indicated. 
c, Analysis of peripheral blood counts in both Ezh2-KI-M and control mice depicted the 
absolute numbers of white blood cells (WBC), lymphocytes (LYM), monocytes (MID), 
granulocytes (GRA), and red blood cells (RBC). Values are means ± SD (n = 5). 
d, Average of total numbers of CLP, CMP, MEP and GMP subpopulations within of the 
total BM cells in control or Ezh2-KI-M BM cells. Values are means ± SD (n=8). 
e, Absolute numbers of the mature myeloid cells (Mac-1+/Gr-1low and Mac-1+/Gr-1+ 
cells) populations within of the total BM cells recovered per femur accounted in Ezh2-
KI-M and controls mice. Values are means ± SD (n=5). 
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Supplementary Figure S7. Ezh2 expression in the microenvironment does not cause 
PB or BM alterations. 
a-b, Average of chimerism in posttransplant recipients analyzed by the contribution of 
donor-derived (CD45.2) cells in PB (A) (WBC, white blood cells), and in BM for 
circulating CLP, CMP, MEP and GMP progenitors (B). Values are means ± SD (n = 8). 
c, BM cells (5x103/ml) from tertiary transplants with Ezh2-KI and wt mice were cultured 
in IL-3 (0 or 2 ng/ml). Total cells numbers were determined for each condition (means 
±SD; n=4, * p<0.05). 
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Supplementary Figure S8. Ezh2 signature from Ezh2-KI LSK cells.  
a, Top differentially regulated transcripts with corresponding SAM plots. Features 
colored red or green represent genes up- or downregulated, respectively.  
 
b, Heatmap representation of differential gene expression. Each column represents a 
pairwise comparison between control and Ezh2-KI mice. Rows represent individual 
genes. Conventional red-green expression data for all the differentially regulated genes 
for each array.  
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Supplementary Figure S9. Characterization of up- and down-regulated targets from 
Ezh2-KI LSK cells.  
a, Diagram illustrating the genomic context of BGN, NTRK3, ANGPT1, and ATF4 
promoter loci. The sequence comparison of human and mouse for the indicated genes 
using VISTA (VISualization Tool for Aligment)50 for estimating a larger portion of each 
promoter region. The figure shows the calculated percent identity over a window of 200-
nucleotides at each base pair. Regions amplified in the ChIP studies by site-specific 
quantitative PCR are indicated 1-3 promoter targeted regions and 4 as non-promoter 
amplified regions. Detection of regions of genomic sequences that are rich in the CpG 
pattern is indicated. 
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Supplementary Figure S10. Consequences of ectopic Ezh2 in regulating the 
INK4/ARF locus through modulation of histone modifications.  
a, ChIP analyses of Ezh2-KI lineage- cells in INK4/ARF promoter region, via 
H3K27me3, H3K4me4, Ezh2, Bmi1, and H2A-ub antibodies. Primer sets 1-3 indicated 
different locations into the promoter regions, and set 4 indicates non-promoter amplified 
regions (for sequences, please see51). Percentages of input DNA are shown as the means 
± SD for triplicate analyses (* p<0.05). 
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Supplementary Figure S11. Consequences of Ezh2 knockdown on the Ezh2 
signature.  
a, Expression of total EZH2, EVI-1, BGN, ANGPT1, NTRK3, and ATF4 mRNA was 
measured in sorted LSK subpopulation transduced with non-targeting control or shEzh2 
from control and Ezh2-KI mice by qRT-PCR analysis. Results have been standardized 
for b-actin levels and are expressed as difference of PCR cycles (means ±SD; n=4). 
 
b, ChIP analyses of Ezh2-KI lineage- cells treated with non-targeting control or shEzh2 in 
ANGPT1 and ATF4 promoter regions, via H3K27me3, H3K4me4, Ezh2, Bmi1, and 
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H2A-ub antibodies. Primer sets 1-3 indicated different locations into the promoter 
regions, and set 4 indicates non-promoter amplified regions. Percentages of input DNA 
are shown as the means ± SD for triplicate analyses (* p<0.05). 
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Supplementary Figure S12. Consequences of ectopic Ezh2 into the promoter DNA 
methylation over the time.   
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a, Abundance of methylated CpG dinucleotides regions, as indicated, were determined by 
bisulfite sequencing. We analyzed 9-16 clones per genotype (10-week-old). Yellow and 
blue represent the frequency of methylated and unmethylatedCpG dinucleotides, 
respectively. Grey corresponds to undetermined methylation. CpG, CpG position; U, 
unmethylated; M, methylated; NP, not present. 
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Supplementary Figure S13. Consequences of ectopic Ezh2 into the promoter DNA 
methylation over the time.   
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a, Abundance of methylated CpG dinucleotides regions, as indicated, were determined by 
bisulfite sequencing. We analyzed 9-16 clones per genotype (50-week-old). Yellow and 
blue represent the frequency of methylated and unmethylatedCpG dinucleotides, 
respectively. Grey corresponds to undetermined methylation. CpG, CpG position; U, 
unmethylated; M, methylated; NP, not present. 
 
Oncogenic Ezh2 induces MPD   
Herrera-Merchan et al. resubmitted to Nature Communications (2011)    23 
Supplementary Figure S14. Proposed model illustrating the consequences in the 
hematopoietic stem cell compartment in Ezh2-KI mice. In mice harboring stem cell 
activation of Ezh2, the presence of Ezh2 leads to increased numbers of LT-HSC, due to 
at least in part, to increased proliferation and/or blockade of apoptosis. Hence, Ezh2 
overexpression contributes to the control for the granulocytic lineage, leading to a vast 
expansion of GMP and mature granulocytes. We propose that the expanded population of 
LT-HSC is the LSC-like of the Ezh2-expressing MPD, e.g. the only population capable 
of transplanting the disease to recipient mice, while the expanded GMP and granulocyte 
populations provide the myeloproliferative features of the leukemia-like stem cell.  
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Supplementary Tables  
Supplementary Table S1: Primer sequences used for genotyping 
cki-Ezh2fl/fl mice 
FWwtROSA26 (A) (5-‘GGAGGGGAGTGTTGCAATACC-3’) 
RVwtROSA26 (B) (5’-ACACCAGGTTAGCCTTTAAGCC-3’) 
FwtgEZH2 (C) (5’- CACCATGGGCCAGACTGGGAAG-3’) 
RVtgEZH2 (D) (5’-TGTATCCTCCGCTGCTTCCACTCT-3’) 
RVpostCRE (E) (5’ – TGTACTCTGATTTTACACGC -3’) 
 
vav-Cre mice 
FWintposControl (5’ – CTAGGCCACAGAATTGAAAGATCT – 3’) 
RVintposControl (5’ - GTAGGTGGAAATTCTAGCATCATCC – 3’) 
FWVAVcre (5’ - AGATGCCAGGACATCAGGAACCTG -3’) 
RVVAVcre (5’ – ATCAGCCACACCAGACACAGAGATC -3’) 
 
Rosa26Cre-ERT2 mice 
FWRNA3 (5’ – CAGTACACATACAGACTTTTGG -3’) 
RVPOL3 (5’ – GAGCGAACAGGGCGAAGAGC – 3’) 
RVERT2 (5’ – TCCATGGAGCACCCAGTGAA – 3’) 
 
LyzM-Cre mice 
FWMcre (5’ - GCGGTCTGGCAGTAAAAACTATC – 3’) 
RVMcre (5’ - GTGAAACAGCATTGCTGTCACTT 3’) 
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Supplementary Methods  
Generation of conditional knock-in Ezh2 (cki-Ezh2fl/fl) mice. For generation of mice 
carrying the conditional ROSA26-Ezh2 allele cki-Ezh2fl/+ was generated using the 
gateway-compatible ROSA26 locus targeting vector as previously described52. The 
pROSA26-Ezh2 DNA construct used to conditionally target Ezh2 to the ROSA26 locus 
consists of the full length mouse Ezh2 cDNA cloned between two homology region 
corresponding to the ROSA26 locus, downstream of a splice acceptor (SA) site and 
floxed transcriptional stop sequence and upstream of an IRES-EGFP-pA reporter 
sequence (see Supplementary Figure S1A). 20 μg of linearized target vector was 
electroporated into 107 R1 mouse ES cells using 500 μF and 250 V settings on Gene 
Pulser (Bio-Rad). After 24 h, the cells were selected for neomycin resistance in G418 
(170 μg/ml) for 8 days. The neomycine resistant colonies were picked, expanded and 
split in 96-well plates. To detect targeting of the ROSA26 locus, genomic DNA was 
isolated from the ES cells, digested with EcoRV and the fragments separated on 0.7% 
agarose gel. Southern blotting was performed using a 5’ external probe53 and sequential 
washes at conditions of 2X SSC/0.1% SDS at room temperature for 10 min, and three 
times 0.1X SSC/0.1%SDS at 65 degrees for 5 min. Germline transmitting chimeric males 
were crossed with outbred ICR females and the offspring was genotyped by Southern 
blotting for 5’ integration and single-copy insertion as described52 as above using 10 μg 
genomic DNA extracted from mouse tail biopsies. Further genotyping, a PCR-based 
strategy was developed to distinguish between the floxed targeted allele and the Cre-
excised allele of Ezh2 transgen (primers are listed in Supplemental Table I).  
 
Gene expression assays. Gene expression assays were performed using Whole Mouse 
Gene Expression Microarray from Agilent (60K format) with labeled RNAs isolated 
from control and Ezh2-KI LSK cells. Raw data will be available for download from Gene 
Expression Omnibus (http://ncbi.nlm.nih.gov/geo/, accession number GSE28369). The 
Agilent data were analyzed using the Ingenuity Pathways Analysis program 
(www.ingenuity.com); to identify the pathways that met the < or > 2-fold change cutoff 
and were associated with a canonical pathway in the Ingenuity Pathways Knowledge base 
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were considered for the analysis. The significance of the association between the data set 
and the identified canonical pathway was measured in 2 ways: (1) Benjamini-Hochberg 
multiple testing correction enables to control the error rate in analysis results and focus in 
on the most significant biological entities. It provides with a “corrected p-value” that 
takes into account the number of measures. A standard threshold is the corrected p-value 
<0.05 (equivalent to a False Discovery Rate (FDR) of 5%). (2) Fischer's exact test, to 
calculate a p value determining the probability that the association between the genes in 
the data set and the canonical pathway is explained by chance alone. 
 
Chromatin Immunoprecipitation Assays (ChIP). For retroviral transduction of Ezh2-
knockdown shRNAs (shEzh2), Ezh2 targeting siRNA (Dharmacon D-00210-01 and D-
004218-01) and non-targeting controls were cloned into the pSuper vector (OligoEngine). 
LSK cells (5 x105) isolated from Ezh2-KI and control mice were infected with shEzh2 
retroviruses (at least 106 cfu/ml) by spinoculation (at 1,600 × g and at 37°C). Following 
24 h of culture in medium containing 10 ng/ml IL-3, 10 ng/ml IL-6, and 100 ng/ml stem 
cell factor, a second round of spinoculation was performed, followed by an additional 24 
hours of culture.  
 
Bisulfite sequencing. Genomic DNA was extracted from Ezh2-KI and control LSKs; 1 
ugr of DNA was bisulfite modified as standard protocols and abundance of methylated 
CpG dinucleotides regions were analyzed (primer sequences are available upon request). 
Results were analyzed with BiQ Analyzer Software for DNA methylation analysis 
(Applied Biosystem Software Community Program).  
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Resultados 
 
 
Capítulo 2. Bmi1 es esencial en la regulación linfocitaria mediada por 
Ikaros en las células madre hematopoyéticas. 
 
Debido al papel clave que tiene Bmi1 en la regulación de las células madre 
hematopoyéticas (HSCs), nos proponemos sus consecuencias durante las 
etapas iniciales de la hematopoyesis en ratones adultos, pero eludiendo los 
mecanismos que inducen a la mortalidad temprana de ratones knock-out 
convencionales para Bmi1. Para ello, hemos generado un modelo condicional 
de ratón para Bmi1, lo que permite inducir su delección específica en el sistema 
hematopoyético. Nuestros resultados, tanto in vivo como in vitro, nos han 
permitido descifrar que Bmi1 regula directamente al factor de transcripción 
Ikaros, descrito extensivamente como una diana clave en la activación y 
maduración durante el linaje linfocitario, lo que explicaría que ratones 
deleccionados condicionalmente para Bmi1 sufren una importante expansión 
de progenitores linfoides cuya diferenciación y posterior maduración está 
totalmente bloqueada. A través de esta vía de señalización Bmi1-Ikaros, hemos 
descrito que el número de células madre hematopoyéticas (HSCs) está muy 
disminuido debido a un aumento en su capacidad de proliferación y en su 
capacidad de migración está igualmente afectada.   
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Introduction
The hematopoietic system is the best-studied example of the hier-
archical development of a tissue from a small number of relatively 
quiescent stem cells. Hematopoietic stem cells (HSCs) give rise to 
progenitors that proliferate and differentiate, and then progress 
to mature blood cells produced in the billions each day.1 The 
program for maintaining quiescence must involve dedicated 
regulatory genes;2,3 but although the phenotypic and functional 
properties of HSCs have been extensively characterized, we have 
only just begun to understand how HSC quiescence is regulated 
to subsequent hematopoietic lineage-specific commitments.
Important regulators of HSC maintenance include mem-
bers of the Polycomb group (PcG).4 PcG proteins assemble into 
discrete chromatin-associated complexes that ensure the stable 
inheritance of gene-expression status through cell division.5 
PcG proteins form two gene-repressive complexes; together with 
Polycomb repressive complex 2 (PRC2), which trimethylates 
histone H3 at the K27 residue, Polycomb repressive complex 1 
(PCR1) induces robust chromatin silencing through ubiquitina-
tion of histone H2A at the K119 residue, thereby impeding RNA 
polymerase II elongation to allow stable maintenance of gene 
repression.
The PCR1 complex component Bmi1 is a proto-oncogene that 
regulates chromatin structure by recruiting epigenetic regulators 
to specific loci.6-8 Loss of function of Bmi1 in mice9 has dem-
onstrated its involvement in the self-renewal of hematopoietic, 
preservation of hematopoietic hierarchy requires a constant and reciprocal interplay between chromatin-specific 
epigenetic regulators and lineage-modifying transcription factors. the polycomb member Bmi1 is a key factor in 
hematopoietic stem cell (hsC) maintenance, but its specific physiological role in subsequent hematopoietic lineage-
specific commitments is unclear. here, we generated conditional Bmi1 knockout (Bmi1-Ko) mice. selective ablation 
of Bmi1 in the hematopoietic system induced extensive upregulation of Ikaros, and concomitant Ikaros-dependent 
lymphoid-lineage transcriptional priming, which is marked by their loss of h2a ubiquitination and increased h3K4 
trimethylation in Bmi1-Ko long-term hsCs (Lt-hsCs). Removal of Ikaros in Bmi1-null Lt-hsCs significantly diminished the 
hematopoietic defects seen in conditional Bmi1-Ko mice. these alterations resulted in recovering the Bmi1-Ko exhausted 
quiescent stem-cell pool, whereas the block in Bmi1-Ko lymphoid-progenitor differentiation was rescued, allowing the 
development of mature lymphoid cells. together, our results indicate that Ikaros is a critical Bmi1 target in vivo that 
promotes premature lineage specification of hsCs.
Bmi1 is critical to prevent Ikaros-mediated 
lymphoid priming in hematopoietic stem cells
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intestinal and neuronal cells.10-12 This germ-line Bmi1 deletion 
leads to hematopoietic defects, mild skeletal transformation and 
neurological abnormalities (severe ataxia and seizures), surviving 
after birth, although half die before the weaning period.9 These 
findings suggest that Bmi1 has an important role in the regu-
lation of HSCs; however, further analysis of Bmi1 in the adult 
hematopoietic system has been hampered because of the early 
lethality of Bmi1 mutant mice.
The capacity of Bmi1 to maintain self-renewal in various 
stem-cell populations depends largely on the silencing of one of its 
targets, the Cdkn2a locus, which encodes the tumor suppressors 
p16INK4a and ARF. Moreover, defects associated with germ-line 
Bmi1 absence can be partially rescued by codeletion of p16INK4a/
ARF locus.13-17 Recent evidence suggests the involvement of other 
Bmi1 target genes in stem cell functions. For example, Bmi1-/- 
leukemia cell lines lacking expression of p16INK4a and ARF still 
require ectopic expression of Bmi1 to generate leukemia in vivo.18 
Moreover, Bmi1 regulates the repopulating activity of HSCs in 
p16INK4a/ARF-independent manner through interaction with the 
E4 transcription factor 1 (E4F1), an atypical p53 E3 ubiquitin 
ligase.19,20
During hematopoiesis, lineage commitment and differen-
tiation are coordinated by activation and repression of specific 
transcription factor networks that associate with PcG proteins 
at gene regulatory regions.21 A key regulator of the development 
of the adaptive immune system is the zinc finger DNA binding 
factor Ikaros (Ikzf1), whose main role is to reciprocally regulate 
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correlated with decreased levels of methylation on lysine 9 of his-
tone H3 (H3K9me3), an epigenetic mark imposed by Polycomb 
complex as a direct executor of silencing at target genes27 (Fig. 
1D). As expected, the decreased Bmi1 levels correlated inversely 
with increased levels of p16INK4a, ARF and p15INK4b (p < 0.001); but 
we did not detect compensatory increases in other PcG proteins 
such as Ezh1 and Suz12 (Fig. 1C and data not show).
Bmi1 deletion augments cycling LT-HSCs, exhausting the 
quiescence stem cell pool. To assess the specific interplay of Bmi1 
in regulating HSC quiescence and blood-cell lineage commit-
ment in adult animals, we started to investigate how the specific 
loss of Bmi1 in the hematopoietic system regulate the hemato-
poietic subpopulation profile in BM cells. Young adult Bmi1-KO 
animals (8-week-old) had significantly smaller (p < 0.05) pools 
of HSC-enriched LSKs (lineage negative, Sca-1 positive and 
cKit positive; L-S+K+), and this decrease was exacerbated in aged 
mice (20-week-old; p < 0.001; Fig. 2A), as also noted previously 
by others.10 However, when the total numbers of BM cells were 
taken into account, we surprisingly observed a slight decrease in 
the BM cellularity of young Bmi1-KO animals, whereas aged 
mice increased these differences (Fig. 2B). Analysis of subfrac-
tions of the LSK population in young Bmi1-KO mice showed sig-
nificantly lower frequencies (p < 0.001) and absolute numbers (p 
< 0.001) of all three primitive LSK populations: long-term HSCs 
(LT-HSC; LSK CD34lowFlk-2low), short-term repopulating HSCs 
(ST-HSC; LSK CD34lowFlk-2high), and multipotent progenitors 
(MPP; LSK CD34highFlk-2high);28-30 and again this decrease was 
exacerbated in aged KO animals (p < 0.001; Fig. 2A). We next 
tested the functional capacity of fractioned Bmi1-KO LSK cells, 
and consistent with the findings obtained for the prior germ-line 
Bmi1 mutant mice,10 they were unable to rescue irradiated hosts 
under conditions supported by Bmi1-WT littermate BM donors 
(p < 0.0001; Fig. 2C). Furthermore, BM chimeras were gener-
ated by transplantation of up to 5 x 105 viable LSK cells from 
8-week-old Bmi1-KO or control animals (CD45.2) together with 
5 x 105 wild-type BM competitor cells (CD45.1) into lethally-
irradiated recipients (CD45.1). Animals injected with Bmi1-KO 
LSK cells failed to yield any significant donor contribution either 
at 4 weeks post transplantation (Fig. 2D) or as late as 16 weeks 
(data not shown). Thus, our Bmi1-KO mouse model corroborate 
that Bmi1 might be required for self-renewal of adult HSCs.10
To go further on the inability of Bmi1-KO LSK to compete 
with wild-type cells in transplantation experiments, as well 
as their disappearance from the BM, we wonder whether that 
cells undergo either programmed cell death or growth arrest in 
response to Bmi1 deletion. Thus, we assessed Annexin V and 
Hoechst staining of LSK cells. As shown in Figure 2E, we found 
no significant difference between both genotypes. Surprisingly, 
examination of the cell cycle status by BrdU-incorporation 
showed that Bmi1-KO LT-HSCs and ST-HSCs/MPPs popula-
tions cycled more rapidly than corresponding controls when nor-
malized by total numbers (p < 0.05; Fig. 2F). Moreover, pyrorin 
Y staining of LSK CD34low cells showed significant diminution 
of quiescent (G
0
) HSCs in Bmi1-KO mice (p < 0.05), although 
high proportion of cycling LSKCD34low/negative in S phase (p < 
0.05; Fig. 2G). Therefore, the first defect observed in Bmi1-KO 
the priming of lymphoid and myeloid transcriptional programs 
in HSCs through chromatin-based mechanisms. Ikaros also 
represses the stem cell transcriptional program as well as dispa-
rate transcriptional programs downstream of the HSC.22-24
Since PcG proteins cannot bind specific DNA motifs, a key 
mechanistic question concerns how the Bmi1 Polycomb mem-
ber is recruited to and displaced from target genes during HSCs 
self-renewal and further lineage specification. A recent study, 
using Bmi1-deficient HSCs in an Ink4a/ARF null genetic back-
ground (Bmi1-/-Ink4a-ARF-/-), established that Bmi1 keeps HSC 
differentiation programs by repressing a cohort of hematopoietic 
developmental regulator genes via bivalent chromatin domains.25 
However, the severe effect of the early blockade of hematopoi-
etic development in germ-line Bmi1-deleted animals precluded 
detailed analysis of the mechanisms underlying the lack of primi-
tive HSCs or an assessment of Bm1 function in more differenti-
ated hematopoietic lineages.
To assess the specific interplay between the roles of Bmi1 in 
regulating HSC quiescence and blood-cell lineage commitment, 
circumventing and going beyond the mechanisms that induce 
early lethality in conventional Bmi1 knockout mice,9 we gener-
ated a conditional Bmi1 mutant mouse model. Our results show 
that deletion of Bmi1 expression specifically in self-renewing 
HSCs controls Ikaros-dependent gene expression programs in 
the lymphoid lineage, and subsequently compromises hemato-
poietic function.
Results
Conditional loss-of-function of the Bmi1 allele. To assess the 
specific physiological role of Bmi1 in adult hematopoiesis, we 
developed a mouse model in which Bmi1 can be inactivated in 
specific lineages to provide a model system in which such func-
tions could be studied in more detail. To create the conditional 
knockout allele of Bmi1, we generated a conditional knockout 
allele of Bmi1 by inserting loxP sites flanking exon 2. Deletion 
of exon 2 introduced a frameshift and subsequent termination 
mutation, effectively deleting Bmi1 expression (Fig. 1A). Germ-
line transmission was confirmed by DNA gel blot analysis of tail 
DNA (Fig. 1A). Heterozygous conditional Bmi1 mutant mice 
were obtained at the expected frequency, and crosses produced 
mice homozygous for conditional loss of Bmi1 (ckoBmi1fl/fl). 
To induce specific Bmi1 deletion in the hematopoietic system, 
we then crossed ckoBmi1fl/fl mice with vavCre transgenic mice, 
which express Cre recombinase in hematopoietic cells.26 This 
generated Bmi1fl/fl-vavCretg/+ knockout and Bmi1fl/fl-vavCre+/+ 
wild-type mice (hereafter referred to as Bmi1-KO and Bmi1-WT, 
respectively). Hematopoietic Bmi1-KO mice were born at 
expected Mendelian frequency and were fertile, although 93% 
died within 24–26 weeks, whereas Bmi1-WT counterparts had a 
normal lifespan (p < 0.0001; Fig. 1B). In Bmi1-KO mice, Bmi1 
mRNA levels were 4–5-fold lower than in Bmi1-WT littermates 
in thymus and spleen (p < 0.001), and 4-fold lower (p < 0.001) in 
bone marrow (BM) (Fig. 1C), demonstrating efficient Bmi1 dele-
tion in adult animals (6–8 weeks). Decreased Bmi1 protein levels 
were detected in spleen and BM cells of Bmi1-KO mice, and this 
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Bmi1-KO BM microenvironment is unaffected. The BM 
microenvironment in germ-line Bmi1-null mice appeared 
severely defective in supporting hematopoiesis.16 To further con-
siderer whether microenvironmental alterations in Bmi1-KO 
mice are responsible for the Bmi1-KO engraftment defects, we 
HSCs is the failure to maintain quiescence, followed thereafter 
by an increased number of cycling repopulating LT-HSCs. These 
data suggest that the depletion of HSCs upon specific Bmi1 loss 
is due to their failure to self-renew and maintain a noncycling 
population of HSCs.
Figure 1. Conditional inactivation of Bmi1. (a) Left: schematic representation of part of the Bmi1 genomic locus and the Bmi1-targeted locus before 
and after Cre-mediated recominbination are shown. the arrows correspond to the loxP sequences. the size of the expected restriction enzyme-
digested DNa fragments that were recognized by probe 5’ are shown. h, hindIII; neo/tk, pGK-neo/hsV-thymidine kinase positive selection cassette; 
Right: Genomic DNa isolated from es cells was digested with hindIII and analyzed by DNa gel blot analysis, according to standard protocols. Genomic 
pCR analysis using both tail and blood cells from the indicated mice. (B) Kaplan-Meier survival plot showing survival rates for Bmi1-Ko mice or lit-
termate controls (***p < 0.001). (C) expression of total Bmi1, p16INK4a, ARF and p15INK4b mRNa was measured in total BM, thymus, spleen, liver and brain 
cells from control and Bmi1-Ko mice by qRt-pCR analysis. Results have been standardized for βactin levels and are expressed as fold-induction (means 
± sD; n = 12, **p < 0.001) compared with the control levels. (D) protein gel blots using anti-Bmi1, anti-h3K9me3 and anti-βactin antibodies show the 
corresponding levels of Bmi1 and h3K9me3 of Bmi1-Ko and control mice, in the indicated cellular fractions, respectively.
©2011 Landes Bioscience.
Do not distribute.
4 Cell Cycle Volume 11 Issue 1
femurs and their BM cell counts demonstrated that Bmi1-KO 
BM microenvironment is not defective in supporting the BM 
repopulation by wild-type HSCs (Fig. 3B). Together, these data 
revealed that specific Bmi1-deficient HSCs likely play a negligible 
role of the Bmi1-KO niche in affecting hematopoietic stem cell 
homeostasis, whereas that germ-line Bmi1 deletion,16 affecting the 
whole BM, what includes neighboring non-hematopoietic cells, 
could explain the severe defects in the BM microenvironment.
transplanted wild-type BM cells (CD45.1) into lethally irradi-
ated young Bmi1-KO or Bmi1-WT littermates (CD45.2). After 
8 weeks, donor contribution to lymphoid progenitors slightly 
declined in BM cells, as well as lymphocytes in PB, without 
affecting peripheral blood myeloid cells (Fig. 3A). The hemato-
poietic-specific Bmi1-deficient microenvironment thus appears 
to be able to support the differentiation of both mature lymphoid 
and myeloid cells. In fact, the histological analysis of recipients’ 
Figure 2. For figure legend, see page 5.
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Homing defects in Bmi1-KO progenitors. We next investi-
gated whether the progressive cell loss in the BM of Bmi1-KO 
adult animals affected to the lineage-committed progenitors. We 
found that the absolute number of myeloid progenitor popula-
tion (MP; L-S-K+) showed 2-fold reductions, with a concomitant 
reduction of myeloid and erythroid colony frequencies (p < 0.05; 
Fig. 4A and B). Most striking was a significant and progressive, 
increase in the frequency and absolute numbers (p < 0.05) of 
the immunophenotypic common lymphoid fraction (CLP; Lin-
KitlowSca1lowCD127+) in young and increased in aged Bmi1-KO 
mice, compared with Bmi1-WT animals (p < 0.05; Fig. 4A). In 
contrast, the lymphoid colony frequency was reduced 4-fold in 
Bmi1-KO bone marrow (p < 0.001; Fig. 4B), which does not 
account for the increased numbers of these cells. Further analysis 
of the cell cycle in CLPs revealed a significant increase in the pro-
portion of cells in S/G
2
/M phase when Bmi1 is absent, indicat-
ing that the increased size of this pool is likely due to enhanced 
proliferation (p < 0.05, Fig. 4C). Importantly, we observed no 
significant difference in the frequency of AnnexinV+/Hoechst- 
cells within this progenitor-containing population (Fig. 4D). 
To further check the functional ability of Bmi1-KO CLPs, 
highly-purified CLP subpopulations isolated from 8-week-old 
Bmi1-KO mice were injected into sublethally-irradiated NOD-
SCID (CD45.1) mice. Injection of Bmi1-KO CLPs contributed 
less than 16% of circulating lymphoid cells in primary recipients 
two months after transplantation (p < 0.05; Fig. 4E). These data 
suggest that Bmi1 is required to maintain the quiescence of the 
HSC-enriched bone marrow population, which likely causes a 
compensatory increased of unfunctional CLP numbers.
To test the homing capacity of Bmi1-KO hematopoietic pro-
genitors, we transplanted lineage-negative CD45.2+ cells into 
lethally-irradiated wild-type (CD45.1+) mice. Homing of donor 
cells to bone marrow of recipient animals was assessed by CD45.2 
expression after 24 h. Cells from Bmi1-KO mice homed to the 
BM of recipient mice at a significant lower frequency than cells 
from control mice (p < 0.05; Fig. 4F). This data suggest that the 
HSC defect in Bmi1-KO BM is likely to be the result of defective 
HSC migration to the bone marrow.
Bmi1 deficiency impairs lymphoid differentiation. Given the 
observed differences in primitive subpopulations in Bmi1-KO 
Figure 2 (See opposite page). Loss of quiescent hsCs by high proliferation upon Bmi1 deletion. (a) Representative FaCs profiles of bone marrow 
(BM) L-s+K+ (lineage-, sca1+, cKit+; LsK) cells from Bmi1-Ko mice and Bmi1-Wt control littermates with 8–10-week-old and 20–22-week-old. BM cells were 
immunostained with antibodies against hematopoietic lineage markers, sca1 and cKit. Numbers indicate percentage of total nucleated BM cells. FaCs 
plots of LsK cells were gated for CD34 and CD135 expression to obtain percentages of long-term (Lt) and short-term (st) hematopoietic stem cells 
(hsC) and multipotent progenitors (Mpp). Numbers indicate percentage of the LsK population. Column figures show absolute numbers of LsK, Lt, st 
and Mpp per femur, where values are the means ± sD (n = 6, ***p < 0.001, *p < 0.05). (B) total BM cellularity (femurs) within of the control and Bmi1-
Ko mice. Data are expressed as means ± sD, n = 6 per genotype. (C) Kaplan-Meier survival plot showing survival rates for primary recipients of BM 
originating from Bmi1-Ko mice or littermate controls (n = 18, ***p < 0.0001). (D) Right: scheme of the competitive repopulation assay. at 4 weeks post-
transplant, peripheral blood (pB) cells were analyzed for donor-derived (CD45.2) contribution. Left: average chimerism in posttransplant recipients 
analyzed by the contribution of donor-derived lymphoid (B220, CD3) and myeloid (CD11b) cells under CD45.2 expression. FaCs plots show a represen-
tative experiment. the bar graph shows the percentages (mean ± sD) of the indicated populations in pB 4 weeks posttransplant (n = 6). (e) annexinV-
hoechst analysis of the percentage of early apoptotic cells in the LsK subpopulation. Values are means ± sD (n = 8). (F) proliferation rate of BM Lt-hsC 
and st-hsC/Mpp populations measured by in vivo BrdU incorporation over 24 h. Representative FaCs plots show percentage of the LsKCD34- popula-
tion. Column figures show proliferation rate (%), where values are the means ± sD (n = 6, *p < 0.05). (G) analysis of BM LsK cell quiescence (G0 phase of 
the cell cycle) by pyroninY staining followed by FaCs. Representative plots show hoechst 33,342 (measured of DNa content) and pyronin Y (RNa con-
tent) incorporated by the BM LsKCD34-population of Bmi1-Wt and Bmi1-Ko mice. Representative FaCs plots show the percentage of LsKCD34- cells in 
G0, G1, s and G2/M, where values are the means ± sD (n = 6, *p < 0.05).
mice, we next analyzed whether specific Bmi1 deletion affected 
adult hematopoiesis in vivo. Peripheral blood (PB) cell counts 
and flow cytometry analysis of PB, spleen and thymus in young 
Bmi1-KO animals revealed a marked and significant loss of B 
and T lymphocytes (p < 0.05), and a slight decrease in myeloid 
cells (Fig. 5A–C), consistent with reported findings in germ-
line Bmi1 mutant mice.9 The differences in the levels of mature 
lymphoid and myeloid cells compared with Bmi1-WT litter-
mates reached statistical significance in older Bmi1-KO mice (p 
< 0.001; Fig. 5A). Spleens and thymus of Bmi1-KO animals were 
~4-fold smaller than those of their control littermates (p < 0.05; 
Fig. 5B and C), reflecting a reduced proportion of mature lym-
phoid cells (p < 0.05; Fig. 5B and C). Histopathological analysis 
of different aged Bmi1-KO (22-week-old) tissues was consis-
tent with the phenotype described above (Fig. 5D; left parts). 
Hematoxylin and eosin staining of Bmi1-KO sections showed 
severe femoral bone marrow hypoplasia, marked thymus atrophy 
with loss of cortico-medullar differentiation, manifest white and 
red pulp hypoplasia and absence of germinal centers in spleen and 
reduced size of periarteriolar lymphoid sheaths (PALS), accom-
panied in all cases by depletion of lymphoid cells. In contrast, 
littermate control mice had normal BM, high thymic cellularity, 
well-developed cortical and medullary thymic regions, and nor-
mal spleen architecture with regular white and red pulp zones. 
Brain, heart and lung showed no pathologic changes (Fig. S1A). 
On Bmi1-KO sections, all hematopoietic cells except megakary-
ocytes stained positively for the proliferation marker K
i
-67, and 
many cells in the red pulp were also K
i
-67-positive, whereas only 
a few scattered K
i
-67-positive cells were detected in the white 
pulp (Fig. 5D; middle parts). Immunohistochemical staining 
for Bmi1 confirmed normal expression in Bmi1-WT controls in 
all tissues and the absence of staining in Bmi1-KO lymphoid 
tissues (Fig. 5D; right parts). No significant differences in Bmi1 
staining were observed in non-lymphoid tissues, and the absence 
of Bmi1 expression in hematopoietic cells contrasted sharply 
with positive Bmi1 staining in cells of the fibrovascular stroma 
(sinusoid endothelial cells, adipocytes, fibroblasts) in BM sec-
tions of Bmi1-KO mice, data correlated with the slight Bmi1 
protein levels detected for BM cells in the Bmi1-KO animals 
(Fig. 1D).
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of both early and mature lymphoid priming, we chosen Ikzf1, 
Dntt, Ebf1, Lef1, Vprep1, CD19, B220 and Igll1 genes, checked 
RT-PCR, and some by FACS3,32 (Fig. 6B and C). These genes 
showed the same trend by qRT-PCR in the absence of Bmi1 as 
seen in the array analysis. To determine whether Bmi1 regulates 
the expression of the genes selectively enriched in HSCs from 
Bmi1-KO mice, we conducted chromatin immunoprecipitation 
Comparable in vivo phenotypes were 
generated in a second model system 
in which Bmi1 alleles were deleted in 
tamoxifen-inducible Rosa26Cre-ERT2 
mice31 (Fig. S2). Tamoxifen-induced 
Cre expression in 4-week-old ckoB-
mi1fl/fl/Cre-ERtg/tg mice (Bmi1-KO-ER 
mice) supported significant Bmi1 dele-
tion (Fig. S2A). Four months after Cre 
induction, numbers of primitive HSCs 
were lower in the BM of Bmi1-KO-ER 
mice than in controls, with a significant 
increase in CLPs (p < 0.05) (Fig. S2B). 
This was accompanied by lower numbers 
of PB lymphocytes (p < 0.05), but not 
myeloid cells (Fig. S2C), as well as lower 
spleen mass (Fig. S2D). Moreover, the 
LSK population in Bmi1-KO-ER BM 
was significantly more proliferative than 
the equivalent populations in control 
animals (Fig. S2E). This phenotype was 
associated with death of Bmi1-KO-ER 
animals at 28–32 weeks, whereas Bmi1-
WT-ER mice showed normal survival 
(p < 0.05). Together, the contribution 
of Bmi1-KO-ER HSCs to the lymphoid 
lineage was most significantly affected as 
opposed to the myeloid lineages.
Bmi1 deletion induced upregula-
tion of Ikaros-dependent lymphoid-
lineage transcriptional priming. To 
investigate how Bmi1-null HSCs main-
tain a minimal quiescent state and tran-
siently re-enter the cell cycle to produce 
an excessive expansion of anomalous 
CLPs, we profiled gene expression in 
sorted, highly-enriched repopulating 
HSCs populations (LSK CD34low) iso-
lated from Bmi1-KO and control mice. 
The most significantly up and down-
regulated genes are shown in Figure 6A, 
and a complete list of all differentially-
regulated genes is included in Table S1. 
Analysis of gene arrays using stringent 
criteria identified a specific Bmi1 signa-
ture in Bmi1-KO primitive HSC cells. 
Strikingly, we identified specific activa-
tion of lymphoid-lineage transcriptional 
priming in Bmi1-KO HSC populations, 
including prominent lymphoid differentiation factors such as 
Ikzf1, Dntt, steril Igh transcripts, Ebf1, Flt3, Lef1, Cd19 and Il7r. 
To validate these findings and identify cells expressing Bmi1-KO 
HSC-associated transcripts, we analyzed HSC-enriched popu-
lations by qRT-PCR for HSC-associated transcripts previously 
shown to be correlated with the long-term reconstitution poten-
tial of HSCs, such as Mamdc2 and Mpl, and as representative 
Figure 3. Microenvironment of Bmi1-Ko does not cause pB or BM alterations. (a and B) average of 
chimerism in posttransplant recipients analyzed by the contribution of donor-derived (CD45.2) cells 
in pB (a) (WBC, white blood cells), and in BM for circulating CLp, CMp, Mep and GMp progenitors 
(B). Values are means ± sD (n = 9). (C) histological and immunostaining characterization of bone 
marrow, thymus and lymph nodes sections using h&e and anti-Ki67 antibodies, respectively, from 
Bmi1-Wt and Bmi1-Ko mice.
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genomic context into the promoter regions of Ikaros, CD19, Il7r, 
Lef1 and Clec1a. Bmi1 deletion decreased the amount of bound 
H2Aub1 mark in the promoter region of Ikaros, CD19, Il7r and 
(ChIP) assays on LSKs. Chromatin silencing mediated by Bmi1 
was examined by measuring ubiquitination of histone H2A at 
the K119 residue, and the presence of H3K4me3 in two different 
Figure 4. Functional impact of the Bmi1-loss on BM. (a) Right: absolute numbers per femur of the CLp and Mp subpopulations (as described in Fig. 
1a) in BM from control and Bmi1-Ko mice at different age (8-week-old and 20-week-old). Values are means ± sD (n = 12, *p < 0.05). Left: Representa-
tive FaCs plots of LsK cells were gated for CD127 expression to obtain percentages of common lymphoid progenitors (CLp) and myeloid progenitors 
(Mp). Numbers indicate percentage of the CLp and Mp population. Column figures show absolute numbers of CLp and Mp per femur, where values are 
the means ± sD (n = 6, *p < 0.05). (B) CFU-C assay using bone marrow cells prepared as indicated in Methods section. Cells from at least three donors 
per genotype were plated in triplicate and colonies were scored 7 d later. the graph represents the averages of total colonies from duplicate cultures. 
similar results were obtained with three different pairs of control and Bmi1-Ko mice. Megakaryocyte/erythroid colonies, Meg/e; burst formation unit-
erythroid, BFU-e; granulocyte colonies, G; macrophage colonies, M; granulocyte/macrophage colonies, GM; and granulocyte, erythroid, macrophage, 
megakaryocyte colonies, GeMM. (C) analysis of BM CLp cell cycle analysis by pyroninY staining followed by FaCs. Representative plots show hoechst 
33,342 (measured of DNa content) and pyronin Y (RNa content) incorporated by the BM CLp population of Bmi1-Wt and Bmi1-Ko mice. Representative 
FaCs plots show the percentage of CLp cells in G0, G1, s and G2/M, where values are the means ± sD (n = 7, *p < 0.05). (D) annexinV analysis of BM CLp 
cell apoptosis. Representative FaCs plots show the percentage of alive, early apoptotic and apoptotic cells in the CLp population. Column figures show 
the means ± sD (n = 3–4). (e) subpopulation profiles of B cells (B220; CD45.1/CD45.2) in peripheral blood of recipient mice transplanted with pooled 
lymphoid progenitors (LsKCD127) from Bmi1-Ko or control donors. Values are means ± sD, n = 5 recipients per group (*p < 0.05). similar results were 
obtained in a second experiment. (F) Representative FaCs plots of pB cells from control or Bmi1-Ko donors (CD45.2) 24 h posttransplant into wild-type 
CD45.1 recipients. Data represent at least three independent experiments. Column figures show percentage of donor-derived Bmi1-Ko or Bmi1-Wt 
(CD45.2) contribution, where values are the means ± sD (n = 5, **p < 0.05).
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Figure 5. For figure legend, see page 9.
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Discussion
Here, we demonstrate that self-renewal and multilineage differ-
entiation potential—the key properties of HSCs—are critically 
dependent on the epigenetic regulator Bmi1. To gain insight into 
the role of Bmi1 at early stages of hematopoiesis in adult mice, 
we used a conditional deletion strategy. Our in vivo and in vitro 
results identify the DNA-transcription factor Ikaros as a criti-
cal downstream target of Bmi1, mediating its activation of lym-
phoid-lineage priming in the HSC pool, subsequently leading to 
increased cycling and decreased quiescence in HSCs, and more 
importantly, their migration capacity to the bone marrow is also 
impaired. Mice with germ-line deletion of Bmi1 exhibit similar 
rates of bone marrow hypocellularity and HSC loss,9 whereas spe-
cific deletion of Bmi1 in the hematopoietic system preserved this 
severe effect on the BM cellularity, allowing that the Bmi1-KO 
BM microenvironment was functional. Conditional deletion 
results in a significant and progressive expansion of lymphoid 
progenitors whose later differentiation into mature lymphoid 
cells is impaired. Together, this establishes for the first time, to 
our knowledge, a connection between Bmi1-mediated silencing 
and Ikaros-dependent lineage specification of primitive hemato-
poietic stem cells, and shows that Bmi1-mediated transcriptional 
repression is not only crucial for the regulation of the quiescent 
stem-cell pool, but also controls the expression of critical lym-
phoid-lineage priming genes in the HSC pool. Recent evidence 
demonstrates that in a INK4/ARF-null background Bmi1 is 
required to reinforce bivalent domains at the promoters of hema-
topoietic lineage-determining factors such as Pax5 and Ebf1,25 
providing further support for its key role in hematopoietic lineage 
decisions.
The ability of somatic stem cells to self-renew and differ-
entiate into downstream lineages is dependent on specialized 
epigenetic factors that control stem-cell-specific genes and key 
differentiation factors. The molecular studies described here 
reveal a dual role for the epigenetic regulator Bmi1 in stem-cell 
maintenance and the multilineage differentiation of the early 
hematopoietic hierarchy. Shortly after conditional inactivation of 
Bmi1, the numbers of cells with a repopulating LT-HSC-specific 
cell surface phenotype was reduced by 5-fold, accompanied by 
a reciprocal increase in the numbers of dividing cells, provok-
ing a decrease in the quiescent cell population in this compart-
ment. Given that the apoptosis rate is not decreased, this change 
is likely due to an accelerated cycling rate, with a concomitant 
defect of homing capacity of Bmi1-KO hematopoietic progeni-
tors. The maintenance of HSC activity can be compromised by 
Lef1, whereas the binding of H3K4me3 was increased, suggesting 
the Bmi1-specific effect on these genes (Fig. 6D). Thus, given 
that lymphoid-lineage transcriptional priming is dependent on 
Ikaros,32 and that most of the upregulated factors in the absence 
of Bmi1 are known effectors of Ikaros-dependent lymphoid 
priming, we suggest that the priming and establishment of lym-
phoid-lineage potential in HSCs requires the direct regulation by 
Bmi1 of Ikaros-dependent activation of a cascade of lymphoid 
gene expression.
Maintenance of lymphoid potential is dependent on Bmi1. 
We further pursued the molecular mechanism underlying Bmi1-
dependent Ikaros-lymphoid potential in Bmi1-KO HSCs. Bone 
marrow cells were harvested from Bmi1-WT (Ly5.2) or Bmi1-KO 
(Ly5.2) mice, sorted into LSK pools and then transduced with 
retrovirus producing specific Ikaros-downregulated miR-92,33 
or control empty MSCV-based retrovirus (referred as vector). 
Appropriate processing of miR-92 in transduced LSK cells led to 
a 50–55% reduction in Ikaros mRNA expression (Fig. 7A). We 
also observed changes in the expression of previously described 
Ikaros target genes in HSCs, such as Dntt, Igh6 and Lef1,24 (Fig. 
7A). Transduced cells were then transplanted into lethally irra-
diated recipients B6.SJL recipient mice (CD45.1) along with a 
constant dose of competitor marrow cells (CD45.1). Remarkably, 
flow cytometric analysis of PB in stably-engrafted chimeric mice 
showed significant higher levels of donor-derived (CD45.2) LSK 
cells in hosts injected with miR-92-overexpressing Bmi1-KO cells 
than in animals receiving miR-Control-overexpressing Bmi1-KO 
cells (p < 0.05; Fig. 7B). This effect was specific to miR-92, 
since neither control retrovirus nor retroviruses expressing unre-
lated miR-207 significantly affected engraftment levels (data not 
shown). The increased repopulating capacity of miR-92-express-
ing Bmi1-KO LSK cells increased one-month survival of recipients 
from 0% (four of four dead) to 30% (five of 15 alive), accompa-
nied by a marked increase in lymphoid cell number in PB with no 
changes in granulocyte and macrophage populations, as well as 
the proportion of LSK cells (Fig. 7C). Moreover, recipient mice 
transplanted with Bmi1-KO LSKs expressing control miRNA 
manifested severe hematopoietic defects similar to those seen in 
the original Bmi1-KO donors and died rapidly (Fig. 7B). Thus, 
the expression of miR-92 into Bmi1-KO LSKs resulted in recov-
ering the Bmi1-KO exhausted quiescent stem-cell pool, while the 
block in Bmi1-KO lymphoid-progenitor differentiation was res-
cued, allowing the development of mature lymphoid cells. Taken 
together, these results suggest that Bmi1 is not only indispensable 
for proliferation and maintenance of adult BM HSCs, but also for 
the maintenance of lymphoid-lineage potential in HSCs.
Figure 5 (See opposite page). Lymphoid differentiation defects in Bmi1-Ko hematopoiesis. (a) peripheral blood counts in 8–10-week-old and 
20–22-week-old Bmi1-Ko, and control mice. WBC, white blood cells; LYM, lymphocytes; MID, monocytes; GRa, granulocytes; RBC, red blood cells; pLt, 
platelets. Values are means ± sD (n = 8). (B) Left: Representative FaCs plots showing the percentages of B220 positive cells in the spleen Bmi1-Ko and 
control animals. FaCs plots show a representative experiment. Right: photograph of spleens from Bmi1-Ko and Bmi1-Wt mice. absolute numbers per 
femur of mature lymphoid (B220) and spleen cell populations in the spleen Bmi1-Ko and control mice. Values are means ± sD (n = 11, *p < 0.5). (C) Left: 
Representative FaCs plots showing the percentages of CD4, CD4CD8 and CD8 positive cells in the thymus Bmi1-Ko and control animals. FaCs plots 
show a representative experiment. Right: photograph of thymus from Bmi1-Ko and Bmi1-Wt mice. absolute numbers per femur of mature lymphoid 
(CD4, CD4CD8 and CD8) and thymus cell populations in the thymus Bmi1-Ko and control mice. Values are means ± sD (n = 11, *p < 0.5). (D) histological 
and immunostaining characterization of bone marrow, spleen and thymus sections from Bmi1-Ko mice and Bmi1-Wt control littermates, using hema-
toxylin and eosin stain (h&e), and anti-KI67 and anti-Bmi1 antibodies.
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Figure 6. For figure legend, see page 11.
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Figure 6 (See opposite page). Bmi1 signature from Bmi1-Ko LsKCD34low cells. (a) top differentially up and downregulated transcripts. (B) expres-
sion of total Ikzf1, Dntt, Ebf1, Flt3, Lef1, Vprep1, Igll1, Mamdc2, Mpl, Bmi1, Clec1a and Il7d mRNa was measured in sorted LsK CD34low subpopulation from 
control and Bmi1-Ko mice by qRt-pCR analysis. Results have been standardized for βactin levels and are expressed as difference of pCR cycles (means 
± sD; n = 6). (C) Representative FaCs histograms of B cell-related antigen membrane expression in BM LsK CD34low cells from Bmi1-Ko mice and Bmi1-
Wt animals. (D) ChIp analyses of control and Bmi1-Ko LsK cells in two different genomic context into the promoter regions of Ikzf1, CD19, Lef1, Clec1a 
and Il7R genes (1 and 2 referred to proximal or distal promoter region to the starting codon), and p73 control promoter region (control), via h2aub1 or 
h3K4me4 antibodies. percentages of input DNa are shown as the means ± sD for triplicate analyses (*p < 0.5).
both by cell cycle blockade, preventing self-renewing divisions, 
or by cell cycle activation, leading to exhaustion of the HSC 
pool. Similar effects have been reported in studies of compo-
nents of the cell cycle machinery that modulate HSC activity. 
Increased expression of the cell cycle inhibitors p16Ink4A, p19Ink4D 
or p18Ink4C has an adverse effect on HSC self-renewal, presum-
ably by restricting entry into the cell cycle.10,16,34 Loss of the cell 
cycle inhibitor p21Cip1/Waf1 has a similar negative effect on HSC 
self-renewal, but this time by allowing increased cycling that 
promotes HSC exhaustion.35,36
Significantly, the expansion and differentiation properties of 
Bmi1-KO mutant HSCs and their progeny are cell-intrinsic and 
are not dependent on a mutant environment. Moreover, exami-
nation of gene expression in Bmi1-KO mutant HSCs revealed 
essential changes in the expression of genes associated with self-
renewal and lineage priming, indicating a pivotal role of Bmi1 in 
their regulation. Bmi1 thus provides the hematopoietic system 
with immune cell capabilities as well as with an extensive regen-
erative capacity. In the future, studies on Bmi1 HSC-specific tar-
gets may provide a comprehensive view of the pathways that act 
in concert to ensure a life-long supply of HSCs.
Bmi1-dependent regulation of Ikaros reflects the fact that 
these are two of the most frequently disrupted pathways in several 
leukemias. Impaired Ikaros activity is associated with the devel-
opment of infant T-cell acute lymphoblastic leukemia (ALL), 
adult B cell ALL, myelodysplastic syndrome, acute myeloid leu-
kemia and adult and juvenile chronic myelogenous leukemia.37 
Recently, the deletion of Ikaros has been demonstrated in more 
than 30% of childhood leukemias, and the complete absence of 
Ikaros was observed in more than 80% of patients with Bcr-Abl-
positive acute lymphoblastic leukemia.38 These studies establish 
Ikaros as a key regulator of hematopoiesis and a major tumor 
suppressor whose loss of function is associated with the malig-
nant transformation of hematopoietic cells. The first evidence 
for a possible involvement of Bmi1 in the development of hema-
tological malignancies came from mouse models in which Bmi1 
was identified as a cooperating factor with c-Myc in the induc-
tion of B-cell lymphomagenesis.39 Lessard and Sauvageau18 later 
demonstrated that Bmi1 not only determines the proliferative 
capacity of normal stem cells, but also of leukemic stem cells. 
Over the past decades, leukemia has come to be regarded as a 
multistep process in which a number of epigenetic events are 
required in order to induce overt leukemia. To date, it has not 
been demonstrated that expression of Bmi1 alone is sufficient 
to induce leukemia. However, various lines of evidence sug-
gest that Bmi1 might act as an important collaborating factor 
to the transformation process. Our results indicate that Bmi1 
appears to underlie the self-renewing and multilineage poten-
tial of stem cells and their immediate progeny by controlling 
Ikaros-dependent lineage specification. These observations leave 
open the possibility that oncogenic Bmi1 overexpression might 
contribute to the development of leukemia through downregula-
tion of the Ikaros.
The defining properties of somatic stem cells are their abil-
ity to self-renew and to progress through available differentiation 
pathways; and these properties are critical for the life-long tissue 
integrity of multicellular organisms.40 A balance between stem-
cell quiescence and activation is required to sustain the stem-cell 
pool and to provide adequate numbers of mature cells to meet 
normal homeostatic demands. Both the self-renewal and differ-
entiation properties of stem cells can be altered dramatically in 
order to meet demands imposed by stress conditions. Our analy-
sis reveals that Bmi1 is indispensable for the correct functioning 
and differentiation ability of adult HSCs. The demonstration 
that Bmi1 regulates the hematopoietic lineage-determining gene 
Ikaros to enable correct differentiation of the lymphoid lineage 
provides important insight into how Polycomb controls normal 
stem-cell functions.
Materials and Methods
Mice. The cko-Bmi1fl/+ mice were generated by introducing the 
targeting vector into R1 embryonic stem cells. Chimeric mice 
raised by aggregation were crossed to the C57BL/6 background 
in at least 6 generations. The excision of Bmi1 DNA, the loss 
of Bmi1 RNA, and the loss of Bmi1 protein were confirmed by 
DNA gel blotting, western blotting, PCR and sequence analysis, 
according to standard protocols. The vav-Cre and Rosa26Cre-
ERT2 mouse lines were maintain after backcrossing over two gen-
erations to C57BL/6, and were crossed with cko-Bmi1fl/fl mice 
to generate Bmi1-KO (Bmi1fl/fl/vavCretg/+), Bmi1-Wt (Bmi1fl/fl/
vavCre+/+), Bmi1-KO-ER (Bmi1fl/fl/Cre-ERtg/tg) and Bmi1-Wt-ER 
(Bmi1+/+/Cre-ERtg/tg) mice. All genotyping primers are available 
under request. In Bmi1-KO-ER and Bmi1-Wt-ER mice, Cre was 
induced by injections on five consecutive days with 1 mg tamoxi-
fen (Sigma) in corn coil. Peripheral blood samples (~50 μL) were 
collected by tail bleeding into tubes containing EDTA. Wild-type 
C57BL/6 (CD45.2+), NOD-SCID and C57BL6/SJL (CD45.1+) 
mice were purchased from The Jackson Laboratory. Bmi1-KO, 
Bmi1-Wt, Bmi1-KO-ER and Bmi1-Wt-ER mice were all on the 
C57BL/6, CD45.2 background, and were bred in-house. All 
mice were maintained in a pathogen-free environment, and were 
provided with standard care and nutrition according to institu-
tional guidelines. All animal study proposals were approved by 
the CNIC.
Transplantation assays. Cells were transplanted into the con-
genic CD45.1+ B6.SJL mouse strain and hosts were monitored 
for the presence of CD45.2+ donor-derived cells. For competitive 
©2011 Landes Bioscience.
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lineage-negative 2 x 106 cells from BM (CD45.2) and were 
injected into CD45.1+ B6.SJL mice, and recipient mice were sacri-
ficed 24 h later. For retroviral transduction of miRNAs, LSK cells 
(5 x 105) isolated from Bmi1-KO and control mice were infected 
with miRNA retroviruses (at least 106 cfu/ml) by spinoculation 
(at 1,600x g and at 37°C). Following 24 h of culture in medium 
containing 10 ng/ml IL-3, 10 ng/ml IL-6 and 100 ng/ml stem cell 
factor, a second round of spinoculation was performed, followed 
transplants, 5 x 105 BM cells from individual Bmi1-KO or lit-
termate mice (CD45.2) were transplanted together with 5 x 105 
competitor cells (CD45.1) into lethally-irradiated (10 Gy) 8-week-
old B6.SJL mice (CD45.1). Repopulation was assessed at 4 and 16 
weeks by FACS analysis of PB. Noncompetitive serial transplants 
were initiated by transplanting 2 x 106 whole BM cells pooled 
from three control or Bmi1-KO donors (CD45.2) into each irra-
diated recipient (CD45.1). For homing experiments, we isolated 
Figure 7. effect of miR-92 on the self-renewal capacity of Bmi1-Ko hsCs. (a) Relative normalized expression levels of both Ikaros, Dntt and Lef1 
transcripts in FaCs-purified Bmi1-Wt, Bmi1-Ko LsK cells transduced with miR-92 and Control vector. Data shown are the mean percentage (±sD) (p < 
0.05, n = 5). (B) Competitive repopulationg capacity of Bmi1-Ko and Bmi1-Wt LsK cells transduced with miR-92 or vector. Lethally irradiated recipient 
mice (CD45.1) were transplanted with the indicated numbers of cells from Bmi1-Ko and Bmi1-Wt mice (CD45.2) and competitor cells (CD45.1). percent 
chimerism of donor cells 4 and 12 weeks after transplantation and survival of transplanted recipients are presented as mean ± sD (p < 0.05). (C) FaCs 
analysis of the contribution of donor-derived cells to the mature lymphoid and myeloid lineages (LYM, lymphocytes; MID, monocytes; GRa, granu-
locytes) in pB and LsK in BM of transplant recipients. the bar graph shows the percentages (mean ± sD) of the indicated populations in pB 16 weeks 
posttransplant (n = 5).
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precipitated complexes was amplified by RT-PCR. RT-PCR 
amplifications were performed in triplicate with multiple dilu-
tions, using the list of primers available under request.
Colony assays. Lin negative cells (104) from BM of both 
genotypes were plated in 1.3% methylcellulose (H4100, Stem 
Cell Technologies) supplemented with 30% FBS, 10% detoxi-
fied BSA (Stem Cell Technologies), 200 mM nonessential amino 
acids, 200 mM L-glutamine, 10 U/ml penicillin G, 10 μg/ml 
streptomycin, 100 M 2-ME (Sigma), 50 μg/ml ascorbic acid 
(Sigma), 20 ng/ml IL-6, 20 ng/ml mSCF, 10 ng/ml mIL-11, 20 
ng/ml mIL-3, 10 ng/ml mTPO, 10 ng/ml hG-CSF and 1 U/
ml hEPO (Amgen). All supplements and media were purchased 
from Invitrogen and cytokines from R&D Systems, except where 
indicated. Primitive erythroid colonies were scored after 3–4 d in 
culture. All other colony types were scored after 7–8 d in culture.
Protein analysis and immunohistochemistry. Immunoblots 
were performed as described in reference 43. Bmi1 was detected 
with monoclonal antibody F6 (Millipore), H3K9me3 with a rab-
bit polyclonal antibody (Upstate); and β-actin with monoclonal 
antibody AC-15 (Sigma). Secondary antibody was HRP-linked 
anti-mouse IgG (DAKO). Signals were detected by enhanced 
chemiluminescence (GE Lifesciences). For histopathology, 
femurs were fixed in formaldehyde, decalcified and paraffin 
embedded. Spleens were treated similarly, with the omission of 
decalcification. Sections (4.5 μm) were cut and stained with 
hematoxylin and eosin (H&E) or processed for immunohisto-
chemistry (IHC). Sections for IHC were stained with anti-Bmi1 
(F-6, Millipore) and anti-K
i
67 (Ab-2; Neo-Markers). Samples 
were then incubated with biotinylated anti-mouse IgG followed 
by development with avidin-biotin peroxidase complexes (Vector 
Lab.).
Statistical analysis. All data are expressed as the mean ± 
SD. The statistical significance of differences was measured by 
unpaired 2-tailed Student t-test; *p < 0.05 or **p < 0.001.
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by an additional 24 h of culture. Then 2.5 x 104 infected cells were 
mixed with 4 x 105 “supportive” B6/SJL bone marrow cells and 
injected, via the retro-orbital route, into lethally irradiated B6.SJL 
(11 Gy) recipient mice. Peripheral blood cell counts were obtained 
by tail vein nicking 4 and 12 weeks post-transplantation.
Flow cytometry and cell sorting. Flow cytometry was per-
formed as described in reference 41. Single-cell suspensions 
were prepared from BM, PB or spleen, and red cells were lysed 
with ACK buffer (NH
4
Cl/KHCO
3
). Cells were analyzed with 
a cocktail of biotinylated anti-mouse antibodies to Gr-1 (Ly-
6G), F4–80, CD3var epsilon, CD4, CD8a (Ly-2) and B220 
(CD45R) (BD Biosciences). Cells were detected and sorted 
using streptavidin conjugated to Alexa647, APC/Alexa750, 
Q-dot605, 405 (Invitrogen), or R/PE (BD Biosciences). 
Directly conjugated antibodies used were as follows: cKit-
PerCP/Cy5.5, cKit-PE, cKit-APC (CD117) and Flk2-PE 
(CD135) (BD Biosciences); Sca1-PE/Cy7, Sca1-APC, Sca1-PE 
(Ly 6A/E, Caltag); and CD34-Alexa647, CD127-PE and 
CD16/32-Alexa700. For PB cell counts, PB was obtained by 
tail vein nicking, red blood cells were lysed with NH
4
Cl, and 
the remaining cells were stained with either APC-anti-CD45.2 
(eBioscience) or PE/Cy5.5-anti-CD45.1 (eBioscience), and 
the following lineage surface markers: CD3e-Biotin-ST-405, 
PE-anti-CD4 (GK1.5) and APC-anti-CD8 (53-6.7) for T 
cells; Alexa647 anti-B220 (RA3-6B2; eBioscience) for B cells; 
F4/80-PB for monocytes; and PE-anti-Gr-1 for granulocytes 
(RB6-8C5; eBioscience).
Cell cycle analysis. BrdU incorporation was analyzed with 
the APC-BrdU Flow Kit (BD Biosciences). BM was assayed 48 
h after a single intraperitoneal injection of BrdU (100 μl of a 
10 mg/ml solution). Surface staining for lineage markers was 
performed as above with antibodies to Lin-APC-Alexa750, 
Sca1-Biotin-Qdot605, cKit-PerCP/Cy5.5, CD135-APC and 
CD34-FITC (GFP is lost after fixing; data not shown). For the 
apoptosis assay, BM cells were stained with lineage, stem and pro-
genitor markers, followed by staining with Hoechst 33,342 and 
AnnexinV-APC (BD Biosciences). To detect quiescent HSCs, 
unmanipulated BM cells were incubated with 10 ug/ml Hoechst 
33,342 for 90 min at 37°C. Cells were washed and stained with 
antibodies against to c-Kit, Sca1 and Lin. The cells were fixed 
in 5% PFA, and incubated with the RNA dye pyronin Y (PY, 1 
μg/ml), prior to flow cytometry. The proportion of cells in G
0
 
(PYlow, Hoechstlow) was measured in the LK+S+CD34low or CLP 
gated populations.
Gene expression and qRT-PCR. Total RNA was isolated from 
peripheral blood, bone marrow, spleen, and other tissues with 
Trizol reagent (Invitrogen), and treated essentially as described 
in reference 42, using the list of primers available under request. 
Gene expression assays were performed using Whole Mouse Gene 
Expression Microarray from Agilent (60K format) with labeled 
RNAs isolated from control and Bmi1-KO LSK CD34low cells.
Chromatin immunoprecipitation assays (ChIP). ChIP assay 
was conducted as described in reference 42. The antibodies used 
for the immunoprecipitation were rabbit polyclonal antibody 
to H3K9me3 (Upstate) and H2Aub1 (Upstate). DNA from 
©2011 Landes Bioscience.
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Up- and down-regulated genes after gene expression array of Bmi1KO and Bmi1-Wt LSKs
p-value regulation Log FC Gene Symbol Description
0.002413675 up 5.8585963 Arx Mus musculus aristaless related homeobox (Arx), mRNA [NM 007492]
0.015421712 up 5.7851224 Cdkn2b Mus musculus cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4) (Cdkn2b), mRNA [NM 007670]
0.002012937 up 5.262425 Lin28b Mus musculus lin-28 homolog B (C. elegans) (Lin28b), mRNA [NM 001031772]
0.0025569 up 5.0162206 Clcnka Mus musculus chloride channel Ka (Clcnka), transcript variant 1, mRNA [NM 024412]
4.64E-04 up 4.737923 Cdkn2a Mus musculus cyclin-dependent kinase inhibitor 2A (Cdkn2a), transcript variant 1, mRNA [NM 009877]
0.013426268 up 4.585672 Igll1 Mus musculus immunoglobulin lambda-like polypeptide 1 (Igll1), mRNA [NM 001190325]
0.018433852 up 4.526715 Gm11538 PREDICTED: Mus musculus hypothetical gene supported by AK078606 (LOC432593), mRNA [XM 992767]
0.006021795 up 4.433409 Stfa1 Mus musculus stefin A1 (Stfa1), mRNA [NM 001082543]
0.003962773 up 4.295573 Clcnka Mus musculus chloride channel Ka (Clcnka), transcript variant 1, mRNA [NM 024412]
2.22E-04 up 4.2922173 lincRNA:chr13:83867711-83878140 forward strand
0.001427625 up 4.2718415 lincRNA:chr5:23195569-23218551 reverse strand
0.027658071 up 4.1983514 Pyhin1 Mus musculus pyrin and HIN domain family, member 1 (Pyhin1), mRNA [NM 175026]
7.95E-04 up 4.0735803 lincRNA:chr5:23195569-23218551 reverse strand
0.007931581 up 4.069818 Plch1 Mus musculus phospholipase C, eta 1 (Plch1), transcript variant 3, mRNA [NM 001177732]
0.002168057 up 4.029996 Hoxb13 Mus musculus homeobox B13 (Hoxb13), mRNA [NM 008267]
0.022504333 up 4.0221624 Gfra2 Mus musculus glial cell line derived neurotrophic factor family receptor alpha 2 (Gfra2), mRNA [NM 008115]
0.02215391 up 3.976971 Epha2 Mus musculus Eph receptor A2 (Epha2), mRNA [NM 010139]
0.001421025 up 3.770875 D630023F18Rik Mus musculus RIKEN cDNA D630023F18 gene (D630023F18Rik), mRNA [NM 175293]
1.22E-04 up 3.6461346 apoptosis-inducing, TAF9-like domain 1 Gene [Source:MGI (curated);Acc:MGI:1917178] [ENSMUST00000105696]
0.006405056 up 3.6457393 Phlda3 Mus musculus pleckstrin homology-like domain, family A, member 3 (Phlda3), mRNA [NM 013750]
0.006691692 up 3.6302764 Tnfsf4 Mus musculus tumor necrosis factor (ligand) superfamily, member 4 (Tnfsf4), mRNA [NM 009452]
0.013638584 up 3.6122234 lincRNA:chr13:83867711-83878140 reverse strand
0.011434931 up 3.6004167 C78205 H3039E03-3 NIA Mouse 15K cDNA Clone Set Mus musculus cDNA clone H3039E03 3', mRNA sequence [BG066149]
0.001404315 up 3.5680268 D10Ertd755e Mus musculus 3 days neonate thymus cDNA, RIKEN full-length enriched library, clone:A630024B09 product:unclassifiable, full insert sequence. [AK080282]
0.001097191 up 3.5558367 lincRNA:chr13:83867711-83878140 forward strand
3.20E-04 up 3.5527246 Cdkn2a Mus musculus cyclin-dependent kinase inhibitor 2A (Cdkn2a), transcript variant 1, mRNA [NM 009877]
0.031731054 up 3.5280457 Clic6 Mus musculus chloride intracellular channel 6 (Clic6), mRNA [NM 172469]
8.25E-04 up 3.508087 lincRNA:chr5:23195569-23218551 reverse strand
0.002849302 up 3.4987 lincRNA:chr13:83867711-83878140 forward strand
0.043334544 up 3.3937654 9630023C09Rik Mus musculus 13 days embryo heart cDNA, RIKEN full-length enriched library, clone:D330021P03 product:unclassifiable, full insert sequence. [AK084616]
0.005050978 up 3.3839145 BC100530 Mus musculus cDNA sequence BC100530 (BC100530), mRNA [NM 001082546]
0.005314171 up 3.3328922 Prok2 Mus musculus prokineticin 2 (Prok2), transcript variant 1, mRNA [NM 015768]
0.00820932 up 3.2257006 Ikzf1 Mus musculus IKAROS family zinc finger 1 (Ikzf1), transcript variant 1, mRNA [NM 001025597]
0.022068538 up 3.1736734 Vpreb1 Mus musculus pre-B lymphocyte gene 1 (Vpreb1), mRNA [NM 016982]
0.010067336 up 3.168111 Zfhx4 Mus musculus zinc finger homeodomain 4 (Zfhx4), mRNA [NM 030708]
0.049175926 up 3.1417007 LOC100048309 PREDICTED: Mus musculus similar to interferon activated gene 204 (LOC100048309), mRNA [XM 001479990]
1.76E-04 up 3.14116 lincRNA:chr13:83867711-83878140 forward strand
0.003609206 up 3.1112828 lincRNA:chr4:89048647-89066563 forward strand
0.029265838 up 3.0813894 RIKEN cDNA C130071C03 gene Gene [Source:MGI Symbol;Acc:MGI:2443574] [ENSMUST00000052354]
8.17E-05 up 3.0812447 Flt3 Mus musculus Flt3 interacting zinc finger protein 1 (Fiz1), transcript variant 2, mRNA [NM 011813]
6.79E-04 up 3.062433 BC023969 Mus musculus lung RCB-0558 LLC cDNA, RIKEN full-length enriched library, clone:G730014H17 product:unclassifiable, full insert sequence. [AK144629]
0.007518976 up 3.0385137 lincRNA:chr4:149383134-149451259 forward strand
6.02E-05 up 3.0262845 lincRNA:chr4:89088538-89130181 forward strand
0.002991234 up 3.024258 lincRNA:chr15:61984389-62102500 forward strand
0.011747978 up 2.973618 lincRNA:chr4:149445201-149445902 forward strand
0.013758143 up 2.948943 LOC545383 PREDICTED: Mus musculus similar to pyrin and HIN domain family, member 1 beta 1 isoform (LOC545383), mRNA [XM 619699]
0.02693097 up 2.931482 Elavl4 Mus musculus ELAV (embryonic lethal, abnormal vision, Drosophila)-like 4 (Hu antigen D) (Elavl4), transcript variant 1, mRNA [NM 010488]
0.0049136 up 2.9181411 lincRNA:chr4:146345650-146356650 reverse strand
0.020056263 up 2.8706577 Tmem108 Mus musculus transmembrane protein 108 (Tmem108), mRNA [NM 178638]
0.02208222 up 2.8355267 lincRNA:chr10:118385588-118439338 forward strand
0.011960508 up 2.8284323 Cdkn2b Mus musculus cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4) (Cdkn2b), mRNA [NM 007670]
0.028392114 up 2.807507 lincRNA:chr4:89088538-89130181 forward strand
0.038660042 up 2.8042657 Ebf1 Mus musculus early B-cell factor 1 (Ebf1), mRNA [NM 007897]
9.00E-04 up 2.8041775 Masp2 Mus musculus mannan-binding lectin serine peptidase 2 (Masp2), transcript variant 2, mRNA [NM 010767]
0.001060409 up 2.7999675 Gm5158 Mus musculus predicted gene 5158 (Gm5158), mRNA [NM 001081372]
0.002744216 up 2.7961228 Dntt Mus musculus deoxynucleotidyltransferase, terminal (Dntt), transcript variant 1, mRNA [NM 009345]
0.018459236 up 2.7919633 lincRNA:chr13:83867711-83878140 reverse strand
0.018437872 up 2.7153373 Pmaip1 Mus musculus phorbol-12-myristate-13-acetate-induced protein 1 (Pmaip1), mRNA [NM 021451]
2.41E-04 up 2.6655455 Xlr3a Mus musculus X-linked lymphocyte-regulated 3A (Xlr3a), mRNA [NM 001110784]
0.021867774 up 2.6297553 Bves Mus musculus blood vessel epicardial substance (Bves), mRNA [NM 024285]
9.95E-04 up 2.6295676 lincRNA:chr5:23195569-23218551 reverse strand
0.032225907 up 2.603478 Lrrc7 Mus musculus leucine rich repeat containing 7 (Lrrc7), mRNA [NM 001081358]
0.011553384 up 2.5885317 Lef1 Mus musculus stefin A3 (Stfa3), mRNA [NM 025288]
0.030341888 up 2.5764632 Foxa1 Mus musculus forkhead box A1 (Foxa1), mRNA [NM 008259]
2.69E-06 up 2.5732212 Cttnbp2 Mus musculus cortactin binding protein 2 (Cttnbp2), mRNA [NM 080285]
0.001951857 up 2.5625637 Nov Mus musculus nephroblastoma overexpressed gene (Nov), mRNA [NM 010930]
0.030980032 up 2.5608296 Gm16223 predicted gene 16223 Gene [Source:MGI Symbol;Acc:MGI:3648966] [ENSMUST00000087332]
0.030329121 up 2.549822 Raet1c Mus musculus retinoic acid early transcript gamma (Raet1c), mRNA [NM 009018]
0.018569076 up 2.5450966 Eda2r Mus musculus ectodysplasin A2 receptor (Eda2r), transcript variant 3, mRNA [NM 001161433]
0.003738005 up 2.540359 LOC100045246 PREDICTED: Mus musculus hypothetical protein LOC100045246 (LOC100045246), mRNA [XM 001474040]
0.020347808 up 2.53586 Twist1 Mus musculus twist homolog 1 (Drosophila) (Twist1), mRNA [NM 011658]
0.004121066 up 2.531892 lincRNA:chr4:149383134-149451259 reverse strand
0.018020714 up 2.5295377 Hoxc9 Mus musculus homeobox C9 (Hoxc9), mRNA [NM 008272]
0.004271506 up 2.5224874 Hoxc4 Mus musculus homeobox C4 (Hoxc4), mRNA [NM 013553]
0.029216582 up 2.5133688 Ccdc135 Mus musculus coiled-coil domain containing 135 (Ccdc135), mRNA [NM 001042715]
0.026941333 up 2.510959 Bfsp2 Mus musculus beaded filament structural protein 2, phakinin (Bfsp2), mRNA [NM 001002896]
0.012047506 up 2.508404 lincRNA:chr4:131903928-131909578 reverse strand
1.66E-04 up 2.487734 lincRNA:chr2:79521628-79521871 forward strand
0.050819114 up 2.4737918 lincRNA:chr8:94841965-94881130 reverse strand
0.043429747 up 2.463888 lincRNA:chr11:97457180-97487074 reverse strand
0.029876256 up 2.4599247 Bst1 Mus musculus bone marrow stromal cell antigen 1 (Bst1), mRNA [NM 009763]
0.014317071 up 2.4578936 Nid1 Mus musculus nidogen 1 (Nid1), mRNA [NM 010917]
0.038542822 up 2.45702 lincRNA:chr8:124364048-124365705 forward strand
0.004268271 up 2.4305408 Eda2r Mus musculus ectodysplasin A2 receptor (Eda2r), transcript variant 2, mRNA [NM 175540]
0.033804715 up 2.4156613 lincRNA:chr8:94849929-94870274 reverse strand
0.035984877 up 2.4139469 Alpl Mus musculus alkaline phosphatase, liver/bone/kidney (Alpl), mRNA [NM 007431]
0.007011542 up 2.4101832 lincRNA:chr15:62007025-62090191 forward strand
0.035060883 up 2.4096787 lincRNA:chr4:89048647-89066563 forward strand
0.023616847 up 2.3952322 Rgs8 Mus musculus regulator of G-protein signaling 8 (Rgs8), mRNA [NM 026380]
0.044057455 up 2.3860893 lincRNA:chr1:183832694-183834125 reverse strand
0.006223039 up 2.381642 Mab21l2 Mus musculus mab-21-like 2 (C. elegans) (Mab21l2), mRNA [NM 011839]
0.026503311 up 2.3627737 lincRNA:chr1:183783306-183834531 forward strand
0.02219241 up 2.3617055 Id1 Mus musculus inhibitor of DNA binding 1 (Id1), mRNA [NM 010495]
0.028324647 up 2.3482563 Dmrt2 Mus musculus doublesex and mab-3 related transcription factor 2 (Dmrt2), mRNA [NM 145831]
0.025912706 up 2.3341444 lincRNA:chr11:97457180-97487074 reverse strand
0.005176142 up 2.3301463 Kcnmb2 Mus musculus potassium large conductance calcium-activated channel, subfamily M, beta member 2 (Kcnmb2), mRNA [NM 028231]
0.04947291 up 2.2782183 Novel KRAB box containing protein Fragment  [Source:UniProtKB/TrEMBL;Acc:A2A8V6] [ENSMUST00000105735]
0.01967821 up 2.275977 lincRNA:chr1:183783306-183834531 forward strand
0.040370487 up 2.266877 Vpreb3 Mus musculus pre-B lymphocyte gene 3 (Vpreb3), mRNA [NM 009514]
0.00496089 up 2.2581327 lincRNA:chr15:62046023-62082530 forward strand
0.045204986 up 2.255811 Olfr1406 Mus musculus olfactory receptor 1406 (Olfr1406), mRNA [NM 146763]
0.014288977 up 2.2535565 lincRNA:chr1:183783306-183834531 forward strand
0.009447477 up 2.2489183 lincRNA:chr15:61984389-62102500 reverse strand
0.002721369 up 2.2317123 Gm13138 Mus musculus predicted gene 13138 (Gm13138), mRNA [NM 001177767]
0.017985502 up 2.2198927 Sulf2 Mus musculus sulfatase 2 (Sulf2), mRNA [NM 028072]
0.021522632 up 2.2023892 Cdkn1a Mus musculus cyclin-dependent kinase inhibitor 1A (P21) (Cdkn1a), transcript variant 1, mRNA [NM 007669]
0.00190223 up 2.2019985 lincRNA:chr15:61984389-62102500 forward strand
9.70E-04 up 2.190272 lincRNA:chr5:23349978-23402028 reverse strand
0.01886237 up 2.188618 lincRNA:chr4:89032648-89133273 reverse strand
0.032024447 up 2.1828887 Cd19 Mus musculus CD19 antigen (Cd19), mRNA [NM 009844]
0.002695301 up 2.1816201 lincRNA:chr15:61984389-62102500 reverse strand
0.003888229 up 2.1644988 Pvt1 Mus musculus plasmacytoma variant translocation 1 (Pvt1), non-coding RNA [NR 003368]
0.04368935 up 2.1590192 Vpreb2 Mus musculus pre-B lymphocyte gene 2 (Vpreb2), mRNA [NM 016983]
0.013719983 up 2.1553497 9030617O03Rik Mus musculus RIKEN cDNA 9030617O03 gene (9030617O03Rik), mRNA [NM 145448]
0.014964627 up 2.128331 lincRNA:chr13:83867711-83878140 forward strand
0.015837358 up 2.1128645 lincRNA:chr1:183783306-183834531 forward strand
0.004300546 up 2.1033087 lincRNA:chr8:94841965-94881130 forward strand
0.033661228 up 2.0911357 Gm2170 PREDICTED: Mus musculus hypothetical protein LOC100039341 (LOC100039341), mRNA [XM 001472717]
4.54E-05 up 2.077703 Vmn1r82 Mus musculus vomeronasal 1 receptor 82 (Vmn1r82), mRNA [NM 134234]
0.00177322 up 2.077545 E230008N13Rik Mus musculus RIKEN cDNA E230008N13 gene (E230008N13Rik), mRNA [NM 198660]
0.0019269 up 2.0747178 lincRNA:chr2:174088550-174109425 forward strand
0.015146041 up 2.0651476 Raet1c Mus musculus retinoic acid early transcript gamma (Raet1c), mRNA [NM 009018]
0.002934482 up 2.0505428 lincRNA:chr15:61919018-61935580 reverse strand
0.012355769 up 2.046355 Enah Mus musculus enabled homolog (Drosophila) (Enah), transcript variant 1, mRNA [NM 010135]
0.001894736 up 2.033928 RIKEN cDNA B630019A10 gene Gene [Source:MGI Symbol;Acc:MGI:2443371] [ENSMUST00000089895]
0.004425025 up 2.0182278 lincRNA:chr15:61984389-62102500 reverse strand
0.026951892 up 2.0102627 Il7r Mus musculus interleukin 7 receptor (Il7r), mRNA [NM_008372]
0.01861088 up 1.9924378 lincRNA:chr15:61870759-61938796 forward strand
0.042189658 up 1.9921292 Blnk Mus musculus B-cell linker (Blnk), mRNA [NM 008528]
0.043413546 up 1.9876369 4933436C20Rik Mus musculus RIKEN cDNA 4933436C20 gene (4933436C20Rik), non-coding RNA [NR 033641]
p-value regulation Log FC Gene Symbol Description
9.47E-04 down -7.6614437 5830444B04Rik Mus musculus adult male thymus cDNA, RIKEN full-length enriched library, clone:5830444B04 product:unclassifiable, full insert sequence. [AK030886]
0.004402275 down -5.713364 Mus musculus clone 17 immunoglobulin kappa light chain mRNA, partial cds. [AY731702]
0.032606818 down -5.4194555 Mus musculus (clone 16-P) IgM chain mRNA, VDNJ3 region. [M26464]
0.004995796 down -5.2880983 Mcpt2 Mus musculus mast cell protease 2 (Mcpt2), mRNA [NM_008571]
8.58E-04 down -5.065015 Rab6b Mus musculus RAB6B, member RAS oncogene family (Rab6b), mRNA [NM_173781]
0.03601507 down -4.926181 Mouse mRNA for the V(kappa) region from an anti-phosphatidyl choline producing hybridoma (NC19-F5). [X53355]
6.08E-04 down -4.582318 C130078N14 Mus musculus 16 days embryo head cDNA, RIKEN full-length enriched library, clone:C130078N14 product:unclassifiable, full insert sequence. [AK081811]
0.023838092 down -4.5332212 predicted gene 5571 Gene [Source:MGI Symbol;Acc:MGI:3647784] [ENSMUST00000103316]
0.001308033 down -4.2685323 lincRNA:chr7:67111261-67120697 forward strand
5.61E-04 down -4.2530804 Il17d Mus musculus interleukin 17D (Il17d), mRNA [NM_145837]
0.009306158 down -4.1267815 lincRNA:chr2:154235540-154248551 forward strand
0.018896054 down -4.119893 Mus musculus monoclonal antibody FG1 to cardiolipin, Ig light chain variable region mRNA, partial cds. [U41438]
3.92E-04 down -4.0549808 Putative uncharacterized protein  [Source:UniProtKB/TrEMBL;Acc:Q3UGM7] [ENSMUST00000075769]
0.007021383 down -3.9776309 predicted gene 9740 Gene [Source:MGI Symbol;Acc:MGI:3815333] [ENSMUST00000103528]
0.005041947 down -3.9688983 Ig gamma-3 chain C region  [Source:UniProtKB/Swiss-Prot;Acc:P03987] [ENSMUST00000103422]
0.023135986 down -3.9102745 predicted gene 9740 Gene [Source:MGI Symbol;Acc:MGI:3815333] [ENSMUST00000103528]
0.002486393 down -3.780811 Fbxo44 Mus musculus F-box protein 44 (Fbxo44), transcript variant 1, mRNA [NM 173401]
0.005517062 down -3.7266123 Ig kappa chain V-V region MOPC 173B Precursor  [Source:UniProtKB/Swiss-Prot;Acc:P01641] [ENSMUST00000103308]
7.26E-04 down -3.689104 lincRNA:chr5:35893908-35896613 reverse strand
0.001522274 down -3.5410223 Klrb1c Mus musculus killer cell lectin-like receptor subfamily B member 1C (Klrb1c), transcript variant 2, mRNA [NM_008527]
9.49E-04 down -3.488835 6330545A04Rik RIKEN cDNA 6330545A04 gene Gene [Source:MGI Symbol;Acc:MGI:1923416] [ENSMUST00000105793]
0.019442813 down -3.428975 M.musculus mRNA for variable light chain. [X96756]
7.58E-05 down -3.4168222 Il1rapl2 Mus musculus interleukin 1 receptor accessory protein-like 2 (Il1rapl2), mRNA [NM_030688]
0.00510547 down -3.3926878 Gm10419 Mus musculus lung RCB-0558 LLC cDNA, RIKEN full-length enriched library, clone:G730014J15 product:hypothetical protein, full insert sequence. [AK165889]
0.039696265 down -3.3604255 Mus musculus rearranged immunoglobulin light chain variable region mRNA, partial cds. [U37911]
0.01087537 down -3.3359444 Setbp1 Mus musculus SET binding protein 1 (Setbp1), mRNA [NM_053099]
3.98E-04 down -3.3093147 LOC665353 PREDICTED: Mus musculus similar to spermiogenesis specific transcript on the Y 1 (LOC665353), misc RNA [XR_032990]
0.002070209 down -3.2951257 LOC631518 PREDICTED: Mus musculus similar to RGD1359202 protein (LOC631518), mRNA [XM_905362]
0.002926378 down -3.2593882 B3galt1 Mus musculus UDP-Gal:betaGlcNAc beta 1,3-galactosyltransferase, polypeptide 1 (B3galt1), mRNA [NM_020283]
0.001189202 down -3.2270238 lincRNA:chr19:21653968-21671718 forward strand
0.006001627 down -3.2252457 H2-T18 PREDICTED: Mus musculus histocompatibility 2, T region locus 18 (H2-T18), mRNA [XM_912024]
0.004778924 down -3.1781182 Clec1a Mus musculus C-type lectin domain family 1, member a (Clec1a), mRNA [NM_175526]
0.022805829 down -3.1611834 lincRNA:chr18:5162836-5165729 reverse strand
0.008810748 down -3.147753 Cyp26b1 Mus musculus cytochrome P450, family 26, subfamily b, polypeptide 1 (Cyp26b1), transcript variant 1, mRNA [NM_175475]
0.010102298 down -3.133514 Xkr6 Mus musculus X Kell blood group precursor related family member 6 homolog (Xkr6), mRNA [NM_173393]
0.03521478 down -3.1309357 lincRNA:chr2:75492010-75492464 forward strand
0.010182047 down -3.1277063 LOC630322 PREDICTED: Mus musculus similar to H4a-3 coding region (LOC630322), mRNA [XM_903449]
0.001670897 down -3.124043 lincRNA:chr5:23195569-23218551 reverse strand
0.006475207 down -3.1126535 Ripply3 Mus musculus ripply3 homolog (zebrafish) (Ripply3), mRNA [NM_133229]
0.027849007 down -3.1099658 Il20 Mus musculus interleukin 20 (Il20), mRNA [NM_021380]
0.00408834 down -3.0700576 Gm14461 Mus musculus predicted gene 14461 (Gm14461), mRNA [NM_177843]
0.034203794 down -3.0465045 lincRNA:chr3:70581406-70614856 reverse strand
7.55E-04 down -3.0427873 Maf avian musculoaponeurotic fibrosarcoma (v-maf) AS42 oncogene homolog Gene [Source:MGI (curated);Acc:MGI:96909] [ENSMUST00000069009]
0.039671656 down -3.0338292 Adam5 Mus musculus a disintegrin and metallopeptidase domain 5 (Adam5), mRNA [NM_007401]
0.024397673 down -3.0128407 Magi1 Mus musculus membrane associated guanylate kinase, WW and PDZ domain containing 1 (Magi1), transcript variant 4, mRNA [NM_001083321]
0.002069983 down -2.9615986 lincRNA:chr5:23195569-23218551 forward strand
4.86E-04 down -2.9522479 Olfr402 Mus musculus olfactory receptor 402 (Olfr402), mRNA [NM_146708]
0.003221461 down -2.9228995 lincRNA:chr5:23195569-23218551 reverse strand
1.54E-05 down -2.9165099 lincRNA:chr5:23195569-23218551 forward strand
0.003025823 down -2.9098823 C-type lectin domain family 9, member a Gene [Source:MGI (curated);Acc:MGI:2444608] [ENSMUST00000112077]
0.021585364 down -2.901179 Mus musculus JL1/1-10 rearranged immunoglobulin kappa chain variable region mRNA, partial cds. [AF316510]
2.08E-04 down -2.8856752 4930412D23Rik RIKEN cDNA 4930412D23 gene Gene [Source:MGI Symbol;Acc:MGI:1921184] [ENSMUST00000052500]
0.006530322 down -2.8795645 lincRNA:chr3:70581406-70614856 forward strand
0.006377236 down -2.8636053 lincRNA:chr18:5813291-5813708 reverse strand
0.008362956 down -2.8594446 lincRNA:chr1:58443698-58449898 forward strand
0.003741361 down -2.8356378 1700022P22Rik Mus musculus RIKEN cDNA 1700022P22 gene (1700022P22Rik), mRNA [NM_029336]
0.02486092 down -2.8323283 PREDICTED: Mus musculus similar to H2b-3 coding region (LOC630348), mRNA [XM_903476]
0.008915771 down -2.8255765 lincRNA:chr13:56286339-56298089 forward strand
7.03E-04 down -2.8062608 lincRNA:chr6:93029101-93031007 forward strand
0.02591643 down -2.7976701 Runx1t1 Mus musculus runt-related transcription factor 1; translocated to, 1 (cyclin D-related) (Runx1t1), transcript variant 3, mRNA [NM_009822]
0.020206293 down -2.7455828 LOC100046053 PREDICTED: Mus musculus hypothetical protein LOC100046053, transcript variant 1 (LOC100046053), mRNA [XM_001475940]
0.011130138 down -2.7345083 Dppa5b PREDICTED: Mus musculus similar to developmental pluripotency associated 5 (LOC666367), mRNA [XM_983385]
0.0422615 down -2.7337208 Dhh Mus musculus desert hedgehog (Dhh), mRNA [NM_007857]
0.00169765 down -2.7098627 Fbxo44 Mus musculus F-box protein 44 (Fbxo44), transcript variant 1, mRNA [NM 173401]
0.032793086 down -2.6884117 RAR-related orphan receptor alpha Gene [Source:MGI (curated);Acc:MGI:104661] [ENSMUST00000064920]
3.81E-04 down -2.6864197 Putative uncharacterized protein  [Source:UniProtKB/TrEMBL;Acc:Q8C7F8] [ENSMUST00000069111]
0.017106814 down -2.6823 Sprr2d Mus musculus small proline-rich protein 2D (Sprr2d), mRNA [NM_011470]
0.019260712 down -2.6734889 2200002J24Rik Mus musculus RIKEN cDNA 2200002J24 gene (2200002J24Rik), mRNA [NM_026961]
0.002777776 down -2.6687574 LOC632297 UDP glucuronosyltransferase 1 family, polypeptide A6A Gene [Source:MGI (curated);Acc:MGI:2137698] [ENSMUST00000113139]
0.016608866 down -2.6586192 lincRNA:chr11:112898724-113062945 reverse strand
0.022540202 down -2.6520731 lincRNA:chr4:142937279-142937669 reverse strand
0.010077867 down -2.6496277 lincRNA:chr5:31883451-31884082 forward strand
0.006168686 down -2.646963 Clec12b Mus musculus C-type lectin domain family 12, member B (Clec12b), mRNA [NM_027709]
0.029021248 down -2.6469362 Tspyl5 Mus musculus testis-specific protein, Y-encoded-like 5 (Tspyl5), mRNA [NM_001085421]
0.00440361 down -2.6404247 lincRNA:chr5:23195569-23218551 forward strand
0.022119857 down -2.6364431 H2-Aa Mus musculus histocompatibility 2, class II antigen A, alpha (H2-Aa), mRNA [NM_010378]
0.023262324 down -2.630963 lincRNA:chr7:7074309-7076554 forward strand
0.027132124 down -2.612592 T-cell receptor alpha, variable 8 Gene [Source:MGI Symbol;Acc:MGI:98572] [ENSMUST00000103595]
0.01388815 down -2.6109252 lincRNA:chr3:70581406-70614856 forward strand
4.19E-04 down -2.6045172 Putative uncharacterized protein  [Source:UniProtKB/TrEMBL;Acc:Q3USM1] [ENSMUST00000100068]
0.008555005 down -2.6003883 Kcne1l Mus musculus potassium voltage-gated channel, Isk-related family, member 1-like, pseudogene (Kcne1l), mRNA [NM_021487]
0.01632718 down -2.5994704 lincRNA:chr5:22905597-22939154 reverse strand
0.042371582 down -2.5985231 lincRNA:chr1:40113912-40114565 reverse strand
0.004754094 down -2.5953007 Gm8005 PREDICTED: Mus musculus predicted gene, EG666253 (EG666253), mRNA [XM_982603]
0.03565778 down -2.5919802 lincRNA:chr2:67407510-67407845 reverse strand
0.003255898 down -2.5874841 Tmem88b Mus musculus transmembrane protein 88B (Tmem88b), mRNA [NM_001033394]
0.011873869 down -2.587198 lincRNA:chr1:63264155-63345773 reverse strand
0.044736933 down -2.5798922 lincRNA:chr12:53708656-53729799 forward strand
0.046892744 down -2.5780578 LOC100046350 PREDICTED: Mus musculus similar to immunoglobulin kappa chain (LOC100046350), mRNA [XM_001476057]
0.001538777 down -2.5765512 lincRNA:chr6:136440100-136450050 forward strand
2.42E-04 down -2.5730064 Scg2 Mus musculus secretogranin II (Scg2), mRNA [NM_009129]
0.02713636 down -2.5538616 Chrm3 Mus musculus cholinergic receptor, muscarinic 3, cardiac (Chrm3), mRNA [NM_033269]
0.034201648 down -2.5418255 Gm15234 PREDICTED: Mus musculus hypothetical protein LOC100042793 (LOC100042793), mRNA [XM_001478831]
0.024986293 down -2.5414574 Rgmb Mus musculus RGM domain family, member B (Rgmb), mRNA [NM_178615]
0.024078624 down -2.5289636 LOC100046275 PREDICTED: Mus musculus similar to Igha protein (LOC100046275), mRNA [XM_001475919]
1.61E-04 down -2.524352 Myog Mus musculus myogenin (Myog), mRNA [NM_031189]
0.04713852 down -2.52031 PREDICTED: Mus musculus similar to developmental pluripotency associated 5 (LOC100046088), mRNA [XM_001475553]
0.047203563 down -2.511821 Olfr912 Mus musculus olfactory receptor 912 (Olfr912), mRNA [NM_146810]
0.048330773 down -2.51035 lincRNA:chr12:33606225-33638225 reverse strand
0.017334627 down -2.4972074 lincRNA:chr15:99762797-99786472 reverse strand
0.003408436 down -2.4870849 Gm8122 PREDICTED: Mus musculus predicted gene, EG666471 (EG666471), mRNA [XM_984060]
1.82E-04 down -2.4813347 lincRNA:chr2:75492010-75492464 forward strand
0.04407372 down -2.4694932 Cpne8 Mus musculus copine VIII (Cpne8), transcript variant 2, mRNA [NM_001033851]
0.027031943 down -2.4585612 lincRNA:chr17:56791549-56803877 reverse strand
0.003398889 down -2.4528303 Dennd5b Mus musculus DENN/MADD domain containing 5B (Dennd5b), mRNA [NM_177192]
0.03556722 down -2.45209 2010015L04Rik Mus musculus RIKEN cDNA 2010015L04 gene (2010015L04Rik), transcript variant 1, mRNA [NM_177674]
0.046565693 down -2.4476736 Gm889 Mus musculus predicted gene 889 (Gm889), mRNA [NM_001033437]
0.018412622 down -2.4463785 Pramef17 Mus musculus XPRAME family member 17 (Pramef17), mRNA [NM_001085540]
0.003521734 down -2.4422457 lincRNA:chr5:23195569-23218551 reverse strand
0.005501596 down -2.4369717 Clec14a Mus musculus C-type lectin domain family 14, member a (Clec14a), mRNA [NM_025809]
0.031797912 down -2.431236 Plscr2 Mus musculus phospholipid scramblase 2 (Plscr2), mRNA [NM_008880]
0.003906689 down -2.4237776 lincRNA:chr8:91569369-91594119 forward strand
0.046453394 down -2.4222205 lincRNA:chr10:56151791-56184966 reverse strand
0.019034695 down -2.420759 Synm Mus musculus synemin, intermediate filament protein (Synm), transcript variant 1, mRNA [NM_201639]
0.012800788 down -2.4202602 Gm8232 PREDICTED: Mus musculus predicted gene, EG666678 (EG666678), mRNA [XM_985370]
0.008714957 down -2.4151423 lincRNA:chr13:114106455-114118105 reverse strand
7.90E-04 down -2.412914 lincRNA:chr4:90877414-90917198 reverse strand
0.007751404 down -2.4104824 AU016916 UI-M-HE0-cme-p-07-0-UI.r1 NIH_BMAP_HE0 Mus musculus cDNA clone IMAGE:30630030 5', mRNA sequence [CF747970]
0.009421228 down -2.408201 Unc93a Mus musculus unc-93 homolog A (C. elegans) (Unc93a), mRNA [NM_199252]
0.024528379 down -2.407491 lincRNA:chr12:33606225-33638225 reverse strand
0.046725135 down -2.4066412 Insm1 Mus musculus insulinoma-associated 1 (Insm1), mRNA [NM_016889]
9.31E-04 down -2.404702 lincRNA:chr4:101040523-101080248 forward strand
0.019702846 down -2.4025538 RIKEN cDNA 4930470H14 gene Gene [Source:MGI Symbol;Acc:MGI:1923065] [ENSMUST00000062637]
0.030913547 down -2.4022279 E030042O20RikPREDICTED: Mus musculus RIKEN cDNA E030042O20 gene (E030042O20Rik), mRNA [XM_001475569]
0.043483056 down -2.3915305 Olfr715 Mus musculus olfactory receptor 715 (Olfr715), mRNA [NM_146780]
0.022400815 down -2.3872209 H2-Eb1 Mus musculus histocompatibility 2, class II antigen E beta (H2-Eb1), mRNA [NM_010382]
0.03914856 down -2.3814428 Adam22 Mus musculus a disintegrin and metallopeptidase domain 22 (Adam22), transcript variant 3, mRNA [NM_001098225]
0.019416971 down -2.3749764 BC023105 PREDICTED: Mus musculus hypothetical LOC667597 (LOC667597), mRNA [XM_001471580]
0.011570687 down -2.3727005 Kdr Mus musculus kinase insert domain protein receptor (Kdr), mRNA [NM_010612]
0.02106082 down -2.3707187 lincRNA:chr15:32705156-32729116 reverse strand
0.008959818 down -2.369379 TRAV12-3 Fragment  [Source:UniProtKB/TrEMBL;Acc:Q5R1C7] [ENSMUST00000103657]
0.02810336 down -2.3689182 4930432N10Rik Mus musculus adult male testis cDNA, RIKEN full-length enriched library, clone:4930432N10 product:unclassifiable, full insert sequence. [AK015295]
4.40E-04 down -2.357078 lincRNA:chr10:110749845-110751384 forward strand
0.04423736 down -2.3570006 Gm7173 Mus musculus predicted gene 7173 (Gm7173), mRNA [NM_001099307]
0.044333216 down -2.3562446 Pou6f1 Mus musculus POU domain, class 6, transcription factor 1 (Pou6f1), mRNA [NM_010127]
0.005124209 down -2.3519533 PREDICTED: Mus musculus hypothetical LOC676390 (LOC676390), mRNA [XM_989725]
0.039078217 down -2.350685 lincRNA:chr6:136440100-136450050 forward strand
0.029202964 down -2.3321202 Pcdhb18 Mus musculus protocadherin beta 18 (Pcdhb18), mRNA [NM_053143]
0.022617005 down -2.3280177 Clic5 Mus musculus chloride intracellular channel 5 (Clic5), nuclear gene encoding mitochondrial protein, mRNA [NM_172621]
0.03076035 down -2.320389 Krt1 Mus musculus keratin 1 (Krt1), mRNA [NM_008473]
0.047066923 down -2.3066695 lincRNA:chr17:8088950-8106700 forward strand
0.017581325 down -2.296431 lincRNA:chr13:56286339-56298089 forward strand
0.02292247 down -2.2921531 Sox5 Mus musculus SRY-box containing gene 5 (Sox5), transcript variant 1, mRNA [NM_011444]
0.005593344 down -2.2914279 lincRNA:chr4:13536908-13593316 reverse strand
0.035465233 down -2.2896123 Cxcr1 Mus musculus chemokine (C-X-C motif) receptor 1 (Cxcr1), mRNA [NM_178241]
0.002009327 down -2.2830358 lincRNA:chr4:135136959-135139933 forward strand
0.007831177 down -2.2708342 Gm3389 PREDICTED: Mus musculus hypothetical protein LOC100046090 (LOC100046090), mRNA [XM_001475658]
2.96E-04 down -2.2666936 PREDICTED: Mus musculus predicted gene, EG666138 (EG666138), mRNA [XM_981856]
0.031185461 down -2.2636302 Pik3c2g Mus musculus phosphatidylinositol 3-kinase, C2 domain containing, gamma polypeptide (Pik3c2g), transcript variant 1, mRNA [NM_207683]
0.004668299 down -2.2555559 multimerin 1 Gene [Source:MGI (curated);Acc:MGI:1918195] [ENSMUST00000114267]
0.030975413 down -2.2550118 Fam181b Mus musculus family with sequence similarity 181, member B (Fam181b), mRNA [NM_021427]
0.017728237 down -2.2502282 Q8VF68 MOUSE (Q8VF68) Olfactory receptor MOR205-1, complete [TC1600521]
0.002975456 down -2.2442234 Dennd5b Mus musculus DENN/MADD domain containing 5B (Dennd5b), mRNA [NM_177192]
0.002361046 down -2.2379863 Olfr286 Mus musculus olfactory receptor 286 (Olfr286), mRNA [NM_001011779]
3.04E-05 down -2.2369878 Clec9a Mus musculus C-type lectin domain family 9, member a (Clec9a), mRNA [NM_172732]
0.008475517 down -2.236169 LOC674370 PREDICTED: Mus musculus similar to Histocompatibility 2, T region locus 3 (LOC674370), mRNA [XM_974183]
0.007403067 down -2.2274768 Cacna2d1 Mus musculus calcium channel, voltage-dependent, alpha2/delta subunit 1 (Cacna2d1), transcript variant a, mRNA [NM_001110843]
0.005807799 down -2.2159204 lincRNA:chr14:70483555-70484159 forward strand
0.008369488 down -2.2138164 HRAS-like suppressor family, member 5 Gene [Source:MGI (curated);Acc:MGI:1913977] [ENSMUST00000113313]
0.03661423 down -2.2123284 lincRNA:chr3:37612203-37612619 forward strand
0.009460452 down -2.2106175 Glt28d2 Mus musculus glycosyltransferase 28 domain containing 2 (Glt28d2), mRNA [NM_177130]
0.040873464 down -2.2009401 4930402D18Rik Mus musculus adult male testis cDNA, RIKEN full-length enriched library, clone:4930402D18 product:unclassifiable, full insert sequence. [AK015045]
0.017475078 down -2.1968029 Pramef12 Mus musculus PRAME family member 12 (Pramef12), mRNA [NM_029948]
0.03605714 down -2.1942027 Skint4 PREDICTED: Mus musculus hypothetical protein LOC100045107 (LOC100045107), mRNA [XM_001473685]
6.20E-04 down -2.1927018 lincRNA:chr14:99728359-99728958 forward strand
0.02798558 down -2.1910124 lincRNA:chr3:51990494-51991875 forward strand
0.030342124 down -2.1875122 lincRNA:chr1:167219841-167220505 forward strand
0.038377013 down -2.1870983 lincRNA:chr2:75481116-75481679 reverse strand
0.0366644 down -2.1831398 Gm5126 Mus musculus predicted pseudogene 5126 (Gm5126), non-coding RNA [NR_026596]
0.018678797 down -2.1817026 poliovirus receptor-related 3 Gene [Source:MGI (curated);Acc:MGI:1930171] [ENSMUST00000121803]
0.027619867 down -2.1796498 lincRNA:chr3:137736327-137752677 reverse strand
0.010750602 down -2.1687195 lincRNA:chr2:71585563-71588257 reverse strand
0.025067702 down -2.1665795 Sdc2 Mus musculus syndecan 2 (Sdc2), mRNA [NM_008304]
0.001022818 down -2.164921 lincRNA:chr2:75493715-75494227 reverse strand
0.015792994 down -2.1646893 Dixdc1 Mus musculus DIX domain containing 1 (Dixdc1), mRNA [NM_178118]
0.02952676 down -2.1645756 Kif6 Mus musculus kinesin family member 6 (Kif6), mRNA [NM_177052]
0.001905823 down -2.163324 Tmem30b Mus musculus transmembrane protein 30B (Tmem30b), mRNA [NM_178715]
0.021786967 down -2.1615465 junction adhesion molecule 2 Gene [Source:MGI (curated);Acc:MGI:1933820] [ENSMUST00000098407]
0.011449073 down -2.159949 lincRNA:chr12:15735906-15798506 reverse strand
2.53E-04 down -2.1591272 Spo11 Mus musculus sporulation protein, meiosis-specific, SPO11 homolog (S. cerevisiae) (Spo11), transcript variant 1, mRNA [NM_012046]
0.03477746 down -2.15505 lincRNA:chr19:21653968-21671718 forward strand
0.02770844 down -2.1430464 lincRNA:chr12:16873410-16873872 forward strand
0.018912973 down -2.1400049 lincRNA:chr2:104398943-104412968 forward strand
0.00739776 down -2.1386673 Neo1 Mus musculus neogenin (Neo1), transcript variant 1, mRNA [NM_008684]
0.009949248 down -2.137206 Cftr Mus musculus cystic fibrosis transmembrane conductance regulator homolog (Cftr), mRNA [NM_021050]
0.020501493 down -2.135301 Clec2d Mus musculus C-type lectin domain family 2, member d (Clec2d), mRNA [NM_053109]
0.03659509 down -2.131822 4930571B16Rik Mus musculus adult male testis cDNA, RIKEN full-length enriched library, clone:4930571B16 product:SAM domain, SH3 domain and nuclear localisation signals, 1, full insert sequence. [AK016268]
0.009591555 down -2.1274338 lincRNA:chr5:31856417-31916414 forward strand
0.006642493 down -2.1230462 lincRNA:chr15:5969454-5994540 forward strand
0.042138405 down -2.114473 Lyzl1 Mus musculus lysozyme-like 1 (Lyzl1), mRNA [NM_026092]
0.014020124 down -2.1110709 4930483J18Rik Mus musculus RIKEN cDNA 4930483J18 gene (4930483J18Rik), non-coding RNA [NR_015603]
1.72E-04 down -2.1064155 Glipr1l1 Mus musculus GLI pathogenesis-related 1 like 1 (Glipr1l1), mRNA [NM_027018]
0.019511387 down -2.1045275 lincRNA:chr17:88993214-89025839 forward strand
0.014800807 down -2.100788 lincRNA:chr3:108763862-108772151 forward strand
0.00181635 down -2.1004677 Phactr1 Mus musculus phosphatase and actin regulator 1 (Phactr1), transcript variant 3, mRNA [NM_001005748]
0.007747946 down -2.0980718 Cldn14 Mus musculus claudin 14 (Cldn14), transcript variant 1, mRNA [NM_019500]
0.006953039 down -2.097757 LOC100048689 PREDICTED: Mus musculus similar to natural killer cell receptor-P1, transcript variant 3 (LOC100048689), mRNA [XM_001480949]
0.039278377 down -2.093988 lincRNA:chr18:38776580-38841080 reverse strand
0.009309299 down -2.0798748 Rprm Mus musculus reprimo, TP53 dependent G2 arrest mediator candidate (Rprm), mRNA [NM_023396]
0.007994662 down -2.078953 Pbld Mus musculus phenazine biosynthesis-like protein domain containing (Pbld), mRNA [NM_026701]
0.04030174 down -2.0759645 Dnm3 Mus musculus dynamin 3 (Dnm3), transcript variant 1, mRNA [NM_001038619]
0.027741836 down -2.0728447 Olfr741 Mus musculus olfactory receptor 741 (Olfr741), mRNA [NM_207133]
0.024111805 down -2.0663557 Unc5a Mus musculus unc-5 homolog A (C. elegans) (Unc5a), mRNA [NM_153131]
0.010327232 down -2.064164 lincRNA:chr9:41422319-41425855 forward strand
0.006006947 down -2.0615156 LOC100036540 Mus musculus 13 days embryo heart cDNA, RIKEN full-length enriched library, clone:D330002C20 product:hypothetical protein, full insert sequence. [AK052165]
0.00937258 down -2.0599546 AW050198 NEONATAL_27_I15.x1 FH NEONATAL Mus musculus cDNA clone NEONATAL_27_I15 similar to Expressed sequence AW050198, mRNA sequence [DV065910]
0.003808046 down -2.0586975 4930527F14Rik Mus musculus adult male testis cDNA, RIKEN full-length enriched library, clone:4930527F14 product:unclassifiable, full insert sequence. [AK015914]
0.018606821 down -2.0561414 lincRNA:chr15:5446265-5544984 forward strand
0.03489278 down -2.0530276
0.005538682 down -2.0506186 lincRNA:chr14:65785477-65815777 forward strand
0.003403923 down -2.0488076 Tdrd6 Mus musculus tudor domain containing 6 (Tdrd6), transcript variant 2, mRNA [NM_198418]
0.049729194 down -2.0442464 lincRNA:chr15:32167516-32174417 reverse strand
0.012783631 down -2.037839 lincRNA:chr12:111287772-111333890 reverse strand
0.036405977 down -2.0365148 lincRNA:chr8:90000619-90061169 forward strand
0.01171654 down -2.03537 Vmn2r121 Mus musculus vomeronasal 2, receptor 121 (Vmn2r121), mRNA [NM_001100616]
0.026981687 down -2.0352573 Kcnmb1 Mus musculus potassium large conductance calcium-activated channel, subfamily M, beta member 1 (Kcnmb1), mRNA [NM 031169]
0.003053551 down -2.0348384 Olfr622 Mus musculus olfactory receptor 622 (Olfr622), mRNA [NM_147083]
0.003754432 down -2.032722 Gm2490 PREDICTED: Mus musculus similar to 4933409K07Rik protein (LOC100039909), mRNA [XM_001473759]
0.035923313 down -2.0310593 Cyp2c65 Mus musculus cytochrome P450, family 2, subfamily c, polypeptide 65 (Cyp2c65), mRNA [NM_028191]
0.020823495 down -2.030144 lincRNA:chr1:34734249-34786649 reverse strand
0.016619707 down -2.0296957 lincRNA:chr17:73335854-73336316 forward strand
8.12E-04 down -2.0288854 Hrh1 Mus musculus histamine receptor H1 (Hrh1), mRNA [NM 008285]
0.02246349 down -2.0281565 Gabrd Mus musculus gamma-aminobutyric acid (GABA) A receptor, subunit delta (Gabrd), mRNA [NM_008072]
0.002275112 down -2.0251787 Olfr910 Mus musculus olfactory receptor 910 (Olfr910), mRNA [NM_146811]
0.04960148 down -2.0245507 Defb46 Mus musculus defensin beta 46 (Defb46), mRNA [NM_001025351]
0.043677326 down -2.023902 Scrn1 secernin 1 Gene [Source:MGI (curated);Acc:MGI:1917188] [ENSMUST00000019268]
0.005235691 down -2.02331 Gulo Mus musculus gulonolactone (L-) oxidase (Gulo), mRNA [NM_178747]
0.025770968 down -2.0210783 lincRNA:chr7:133402766-133415516 reverse strand
0.002805648 down -2.0170434 Gm13298 Mus musculus predicted gene 13298 (Gm13298), mRNA [NM_001085530]
0.022016596 down -2.0169754 6230409E13Rik Mus musculus RIKEN cDNA 6230409E13 gene (6230409E13Rik), mRNA [NM_175234]
0.03716749 down -2.0164626 Gpr165 Mus musculus G protein-coupled receptor 165 (Gpr165), mRNA [NM_029536]
0.015886387 down -2.01364 Olfr535 Mus musculus olfactory receptor 535 (Olfr535), mRNA [NM_146954]
0.018069375 down -2.0082254 Olfr975 Mus musculus olfactory receptor 975 (Olfr975), mRNA [NM_146828]
0.007041506 down -2.0016358 Gm6401 PREDICTED: Mus musculus predicted gene, EG623168 (EG623168), mRNA [XM_891604]
0.002605108 down -1.9974836 lincRNA:chr8:113968152-113973727 reverse strand
0.036640346 down -1.9949766 lincRNA:chr14:65785477-65815777 forward strand
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The regenerative capacity of many stem cells declines functionally with age 
and, this decline triggers in part many age-related symptoms, and the 
development of certain diseases. Recent evidences have demonstrated the 
important roles of epigenetic in the maintenance of stemness, stay of 
differentiation and proliferation in HSCs, roles that are applicable to aging 
phenotype and cancer stem cells (CSCs). Understanding epigenetic changes in 
HSCs may provide a perspective on how these epigenetic changes contribute 
to the aging and cancer phenotype. In this sense, Polycomb group members 
(PcGs) are on the most responsible of these epigenetic changes and at the 
same time, Bmi1 in PRC1 and Ezh2 in PRC2 (and recently Ezh1) are important 
regulators of many important genes in the development of aging and cancer. It 
is demonstrated that Bmi1 and Ezh2 regulate some genes involve in aging and 
tumors suppressors such as p16Ink4a, p19ARF or p53. 
Their fine-tuning regulation of these Polycomb members are essential and the 
loss-of- function or gain-of-function in HSCs have been demonstrated that alter 
the normal homeostasis of HSCs. This loss of homeostasis can originated 
premature aging phenotypes or increases the possibilities of tumors. Try to 
understand this fine-tuning equilibrium is one of the most possibilities to 
increase the expected age and reduce cancer phenotypes because epigenetic 
are reversible changes, so, we can reverse to stay young and recover from 
cancer. 
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Fig. 1. Summary of the different roles and phenotype of Polycomb group member in HSCs. A) 
Normal aging of HSCs. B) Irregular aging of HSCs.  
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Discussion Chapter 1. Ectopic expression of the histone 
methyltransferase Ezh2 in haematopoietic stem cells causes 
myeloproliferative disease. 
 
In the last years, recent finding show the important role of Ezh2 in tumors, 
increase expression have been reported in many tumors but with the evolution 
of the deep-sequencing and new technologies, mutations in Ezh2 were 
described, some of these mutations have been describe such as lost-of-function 
and other with gain-of-function of Ezh2 (increasing trimethylation activity). With 
these data, one of the open questions is: Ezh2 is a tumors suppressors or 
oncogene?, Is dependent of tissues?, Is dependent of cell, stem cell, progenitor 
or differentiated cell?. But in the same way, the fine-tuning regulation of Ezh2 is 
clear. 
 
In this work, the knock-in model generated here, in which Ezh2 is expressed 
from the endogenous promoter of Rosa26 locus we report for the first time that 
the gain-of-function of Ezh2 in HSCs in mice models (with transgenic mice, not 
with retroviral infection of HSC in vitro), produce a myeloproliferative disorders 
(MPD), therefore Ezh2 is an oncogene such us others cancers.  
 
We demonstrated the oncogene role modulating the expression of Ezh2 with 
three different Cre-mice-models. One is a constituve cre system, vav-Cre, which 
remove stop cassette and increasing expression of Ezh2 in all hematopoietic 
cell, include HSCs, the second is LyzM-Cre, a constitutive cre system where the 
stop signal is removed only in myelod lineage and third is a conditional upon 
tamoxifen mice, where we remove the stop signal after birth. These different 
murine models have enabled us to characterize that the overexpression in the 
specific window of stem cell in hematopoietic system and not later in myeloid 
differentiation bias, is responsible of MPD. 
 
MPD is one of the most frequent hematopoietic malignancies, particularly in the 
elderly. In the majority of affected individuals, a cure for the disease cannot be 
achieved, and most die from severe cytopenias. MPD comprise a 
heterogeneous group of acquired clonal hematopoietic disorders characterized 
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by dysplasia of the myeloid, erythroid and/or megakaryocytic lineages. 
Identification of the cellular pools with capacity to start the neoplastic 
transformation underlying in MPD may promote proper classification and 
prognostication of disease and, eventually, the development of targeted 
therapy. In general, mouse models of MPD have had restricted success in 
recognizing the MPD-initiating cell population because of complexity in 
transplanting and reproducing the consequences of the primary disease. 
 
The knock-in model generated here, show an increasing in the proliferation rate, 
increasing the self-renewal in HSCs, leads to MPD and that is serially 
transplantable. We show that at least two distinct cellular sub-fractions, the 
Ezh2-KI LT- and ST-HSCs, are essential for MPD pathogenesis. In contrast, 
Ezh2-KI GMPs, although they are expanded in number and drive the disease 
phenotype in vivo, are unable to transplant the MPD. 
 
The molecular pathway was analysed in HSCs by arrays and methylation 
pattern. Genes, such as biglycan (Bgn) and Ntrk3, strongly correlate with the 
hematopoietic phenotype of Ezh2-KI mice and indicate that gene programs that 
are altered upon Ezh2 gain-of-function in LSK cells may prime these early 
hematopoietic progenitors to generate the myeloproliferative disorder developed 
in these mice. A possible explanation for our findings is that Ezh2 complexes 
coordinate the expression of genes that function to coordinate HSCs for 
differentiation to the myeloid lineage. Our working model proposes a molecular 
progression during tumorigenesis that starts with abnormal expansion of Ezh2-
expressing haematopoietic stem or myeloid progenitor cell compartments, in 
which genes such as ATF4 and NTRK3 undergo Ezh2-mediated gene silencing 
associated with progressive DNA methylation of their promoter CpG islands. 
 
H3K27 methylation is catalyzed by the SET domain of Ezh2 and plays a crucial 
role in the epigenetic control of proliferation and cellular differentiation, 
regarding hematologic malignancies; oncogenic activity of Ezh2 has also been 
described in MPD and in acute myeloid leukemia (AML) (Ernst et al., 2010), 
(Tanaka S, 2012), where it has been identified as a potential drug target (Fiskus 
et al., 2009), (Miranda et al., 2009). However, recent works has identified 
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acquired Ezh2 mutations in lymphoma and myeloid neoplasms (McCabe, 
2012), (Nikoloski et al., 2010), (Ernst et al., 2010). Although initially thought to 
reduce Ezh2 catalytic activity, the heterozygous Y641 missense mutation 
described in lymphomas works in conjunction with wild-type Ezh2 to increase 
levels of H3K27me3, and may be functionally equivalent to Ezh2 
overexpression. Unlike the mutation of a single residue and gain-of-function 
seen in lymphoma, missense and nonsense mutations associated with myeloid 
neoplasms are spread throughout the gene, resulting in loss of histone 
methyltransferase activity. 
 
Therapeutic suppression of MPN-inducing cells requires understanding of the 
molecular working of Ezh2-expressing stem cells. So far, Ezh2 levels are 
modulated by therapies primarily directed at DNA methylation or histone 
acetylation, rather than Ezh2-specific. Although the development of new clinical 
trials directed to inhibit the overactive Ezh2 function in hematologic 
malignancies, and solid tumors, is an area of great interest, it is important 
consider the inactivating mutations found in an important cohort of myeloid 
neoplasms for designing appropriated histone demethylating agents (Miranda et 
al., 2009). 
 
The results presented here provide the first experimental demonstration of 
altered hematopoietic stem cell function by overactive Ezh2 function, leading to 
myeloproliferative disorder. In about a third of patients, the MPD progresses to 
acute myeloid leukemia (AML), disease that can arise from hematopoietic stem 
cells or more mature progenitor cells, although the basis of these related 
syndromes remains poorly understood. The identification of Ezh2-activated LT- 
and ST-HSCs as potential leukemic stem cells (LSCs) for the Ezh2-induced 
MPD lends further support to the notion that leukemias and cancers may be 
sustained by rare LSCs or cancer stem cells. Indeed, our transplantation 
experiments demonstrate that the development of Ezh2-evoked MPD is cell 
autonomous, and Ezh2-activated LT- and ST-HSCs are uniquely able to 
transplant the MPD observed in primary Ezh2-KI donor mice. Since the only 
self-renewing capacity is sustained by the HSCs, we expect that only clones of 
Ezh2-expressing HSCs can induce and accumulate the epigenetic changes 
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required for the progression and development to further leukemia. Future 
investigation of stem cell-specific oncogenic role of Ezh2 in myeloid disorders 
should therefore provide a better molecular understanding of Ezh2-expressing 
HSCs acting with LSC functions, and may provide new insights into human 
MPD. 
 
Fig. 1. Schematic summary of phenotype in Ezh2-KI mice. In HSCs is increased the self-
renewal and proliferation. In the last differentiation steps produce an increase in the myeloid 
bias. 
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Discussion Chapter 2. Bmi1 is critical to prevent Ikaros-mediated 
lymphoid priming in hematopoietic stem cells. 
 
That Bmi1 is essential for the maintenance of HSCs pool was previously 
demonstrated in ubiquitous Bmi1-null mice. Here, we demonstrated that this 
role is cell autonomous of HSCs in a new mouse model conditional knock-out of 
Bmi1 where deletion of Bmi1 was specific of hematopoietic stem cell using the 
vavCre system. 
 
With this mouse we observe less HSC in KO-Bmi1 mice than in Wt in young 
and is exacerbated in adult mice. But it is not only a defect in the number of cell, 
it is a defect in the stemness of the HSCs, because these cells are unable to 
rescue irradiated hosts. Here we have demonstrated that Bmi1 is crucial for 
self-renewal of adult HSCs. In the same way, we observe that LT and ST cycled 
more rapidly but diminution of G0 phase. LSK KO-Bmi1 failed to maintain 
quiescence, another principal characteristic of the normal homeostasis 
maintenance of HSCs. 
 
In the other hand, in the differentiation, we observe significant loss of B and T 
lymphocytes in young animals and higher in old mice, smaller spleen and 
thymus and hypoplasia in bone marrow. So, Bmi1-null HSCs have a defect in 
the differentiation, and this defect is higher in lymphoid bias that in myeloid bias. 
We observe the same phenotype when we use the tamoxifen inducible mice. 
 
The molecular pathway was analysed in HSCs by arrays. Ikaros was one of the 
important gene of interest (Yoshida et al., 2006).  Ikaros displays crucial 
functions in the hematopoietic system and its loss of function has been linked to 
the development of lymphoid leukemia (Yoshida et al., 2010), (Nutt and Kee, 
2007) in particular, Ikaros has been found in recent years to be a major tumor 
suppressor involved in human B-cell acute lymphoblastic leukemia. In Bmi1-null 
mice, Ikaros is upregulated, Thus, given that lymphoid-lineage transcriptional 
priming is dependent on Ikaros, and that most of the upregulated factors in the 
absence of Bmi1 are known effectors of Ikaros-dependent lymphoid priming, we 
suggest that the priming and establishment of lymphoid- lineage potential in 
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HSCs requires the direct regulation by Bmi1 of Ikaros-dependent activation of a 
cascade of lymphoid gene expression. 
 
To rescue the phenotype of Bmi1-null mice, mir-92 have demonstrated to be a 
marker in B-cell malignancies, the expression of miR-92 into Bmi1-KO LSKs 
resulted in recovering the Bmi1-KO exhausted quiescent stem-cell pool, while 
the block in Bmi1-KO lymphoid-progenitor differentiation was rescued, allowing 
the development of mature lymphoid cells. 
 
Shows that Bmi1-mediated transcriptional repression is not only crucial for the 
regulation of the quiescent stem-cell pool, but also controls the expression of 
critical lymphoid-lineage priming genes in the HSC pool. The molecular studies 
described here reveal a dual role for the epigenetic regulator Bmi1 in stem-cell 
maintenance and the multilineage differentiation of the early hematopoietic 
hierarchy. 
 
The maintenance of HSC activity can be compromised by both by cell cycle 
blockade, preventing self-renewing divisions, or by cell cycle activation, leading 
to exhaustion of the HSC pool 
 
Bmi1-KO mutant HSCs revealed essential changes in the expression of genes 
associated with self-renewal and lineage priming, indicating a pivotal role of 
Bmi1 in their regulation. Bmi1 not only determines the proliferative capacity of 
normal stem cells, but also of leukemic stem cells. 
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Fig. 2. Schematic summary of phenotype of Bmi1-null mice. HSCs lose self-renewal potential, 
increasing cell cycle and differentiation. In the final steps of differentiation, lymphoid bias has a 
defect in the number and functionality while myeloid bias is less affected. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Discussion 
 
  
It is important to say, that the functionality of Ezh2 and Bmi1 in the context of 
PRC2 and PRC1 is equimolar, this meaning that Ezh2 and Bmi1 need the same 
number of the rest of the complex to the normal functionality of the complex, but 
is described that Ezh2 and Bmi1 can have different pathway and target genes 
by itself alone. We can use these mice models to try to elucidate these 
pathways and target genes. 
 
In summary, with these two different mice, we generate the possibilities to 
investigate Ezh2 and Bmi1 in other tissues such us heart (role in heart attack), 
brain (role in Parkinson, Alzheimer), bone marrow, their role in different cancers 
such us leukemias, breast cancer, colon cancer, and their role in different 
process such us stemness, differentiation, proliferation, IPS, reprograming or 
studies of rejuvenation. 
 
 
Fig. 3. Fine-tuning equilibrium of the expression of the different polycomb group member to 
maintain homeostasis. Over-expression of Ezh2 and Bmi1 have been demonstrated such us 
positive marker in tumors. In the case of Ezh2, have been describe some type of leukaemia with 
loss of function of Ezh2. Loss of Bmi1 has not been described with role in cancer at the 
moment.  
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1. Para comprender el papel de la histona methyltransfereasa Ezh2 en 
la progresión de las neoplasias hematológicas, hemos generado modelos de 
ratón que permiten ganancia de función de Ezh2 en el sistema 
hematopoyético de forma condicional (ratones Ezh2-KI).  
 
2. Hemos encontrado que la activación selectiva de Ezh2 durante la 
auto-renovación de HSCs compromete gravemente la función 
hematopoyética, dando lugar a la aparición de desórdenes mieloproliferativos 
(MPD) con un desenlace fatal, caracterizados por la expansión mieloide 
excesiva en la médula ósea y en el bazo, recuento elevado de glóbulos 
blancos y células mieloides maduras, y esplenomegalia.  
 
3. Animales letalmente irradiados y transplantados con HSCs 
sobrexpresando Ezh2 generaron importantes desórdenes mieloproliferativos, 
y no otras células de médula ósea transplantadas, indicando que son estas 
HSCs-Ezh2 el origen de estos desórdenes. 
 
4. Datos de expresión génica de HSCs procedentes de ratones Ezh2-
KI, en combinación con estudios de localización de marcas epigenéticas en 
numeros targets (p. ej. Evi-1, factor clave en leucemias mieloides y tumores 
sólidos) correlacionan fuertemente con el trastorno mieloproliferativo 
desarrollado en estos ratones.  
 
5. Hemos demonstrado que Ezh2 es una pieza clave en el control 
homeostático de las células madre hematopoyéticas (HSCs) con la 
implicación oncogénica en desórdenes mieloides.  
 
6. Para estudiar el papel Bmi1 durante las etapas iniciales de la 
hematopoyesis, hemos generado ratones condicionales knock-out para Bmi1 
y con delección específica en el sistema hematopoyético (ratones Bmi1-KO). 
Los ratones Bmi1-KO nacen con la frecuencia mendeliana esperada y eran 
fértiles, aunque el 93% mueren dentro de las 20-22 semanas, mientras que 
los hermanos de camada (ratones Bmi1-WT) tienen una esperanza de vida 
normal. 
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7. Hemos demostrado que las HSCs más primitivas (LT/ST-HSCs), y 
no otras células hematopoyéticas inmaduras presentes en médula ósea son 
capaces de “trasplantar” los defectos hematopoyéticos a ratones receptores, 
y con ello la muerte.  
 
8. Hemos analizado que la médula ósea de los animales Bmi1-KO no 
es capaz de llevar a cabo la diferenciación y maduración de linfocitos, 
mientras que no está alterado la maduración de las células mieloides.  
 
9. Para investigar cómo un mínimo número de HSCs funcionales en 
los ratones Bmi1-KO pueden dar lugar primero a una expansión excesiva de 
progenitores linfoides (CLPs), y posteriormente a escasos linfocitos maduros, 
hemos descifrado cuáles son los genes que pueden ser responsables de 
dicho fenómeno comparando los niveles de expresión génica de las HSCs 
mas primitivas de los ratones Bmi1-KO y Bmi1-WT.  
 
10. Nuestros resultados, tanto in vivo como in vitro, nos han permitido 
descifrar que Bmi1 regula directamente al factor de transcripción Ikaros, 
descrito extensivamente como una diana clave en la activación y maduración 
durante el linaje linfocitario.  
 
11. Demostramos así que Bmi1 no sólo es indespensable para una 
adecuada proliferación y mantenimiento de las HSCs, sino también que la vía 
se señalización Bmi1-Ikaros es esencial para una correcta diferenciación del 
linaje linfocitario. 
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Insights Into Stem Cell Aging 
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Spain 
1. Introduction 
The increase in average life expectancy in many developed countries is generating an aging 
society and an associated increase in age-related health problems. Mammalian aging occurs 
in part because of a decline in the restorative capacity of tissue stem cells. The use of stem 
cells in regenerative medicine promises to revolutionize the treatment of acute and chronic 
degenerative conditions, and stem cell research holds the key to the development of such 
therapies. The hallmark of adult stem cells is their ability to both self-renew and 
differentiate into multiple lineages. This demands a complex and still poorly understood 
network of molecular interactions between diverse cell-intrinsic regulators of self-renewal, 
such as certain Polycomb proteins and the tumor suppressor p16INK4a, both of which are 
absolutely required for the maintenance of certain stem cell population. Recent studies have 
begun to elucidate the molecular mechanisms underlying how stem cells decide between 
life and death, and highlight the importance of balance in their aging pathways. 
2. Aging and stem cells  
Recent advances in medicine research programs, and a better health care planning, have 
great influences in people living in many Western countries, increasing both quality of life 
and average lifespan. With the extension of lifetime, there is increasing interest in slowing or 
reversing the negative effects of aging. The fascinating discovery of tissue-resident adult 
stem and progenitor cells in recent years has led to an explosion of interest in the 
development of novel stem cell-based therapies to improve endogenous regenerative 
capacity or to repair damaged and diseased tissues. 
A major function of stem cells and their differentiation hierarchies may be to preserve 
the DNA integrity of the whole organism. When mutations occur despite certain error-
prevention capacities, potent tumor-suppressor mechanisms such as senescence and 
apoptosis eliminate the damaged stem cell, limiting its replicative expansion. However, 
when unrepaired genetic lesions in stem cells are passed on to their differentiated 
daughters, and accumulate with aging, it is required replacement of dead and non-
functional cells with newly differentiated cells derived from stem- and progenitor-cells. 
To date, the best-studied adult tissue stem cell type is the hematopoietic stem cell (HSC), 
which gives rise to all of the mature blood cells, throughout the life of the organism. 
Hematopoiesis in mammals occurs in distinct temporal waves shifting from the 
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extraembryonic yolk sac and fetal liver in embryos to bone marrow in adults. Primitive 
HSCs are the “true” stem cells, also termed the long-term repopulating HSCs (LT-HSCs), 
because they replenish the pool of blood cells by both maintaining the stem cells and 
allowing daughter cells to differentiate into the lymphoid, myeloid, and erythroid 
lineages. The daily replenishment of blood cells is achieved in large part by divisions and 
subsequent stepwise differentiation of cells descendants of LT-HSC pool, namely short 
term repopulating HSC (ST-HSC), and slightly more committed hematopoietic 
progenitor cells (MPP-HSC). The relative quiescence of LT-HSCs pool protects their 
genomic integrity by reducing the rounds of DNA replication and thus the probability of 
acquiring DNA damage that might compromise multilineage differentiation potential 
and/or render them malignant over time, though they appear to age with the host 
(Orkin and Zon, 2008). The rapid turnover of the hematopoietic system and the 
availability of advanced methods to study HSCs by different markers have led to this 
system being widely used as a model of the effects of aging on stem cell functionality 
(Figure 1). It is worthy to mention that although some aspects of aging may be shared by 
all somatic stem cell fractions, the mechanisms of aging are likely to differ between stem 
cell populations located in specific tissues (for example, intestine, muscle and bone 
marrow). 
 
Fig. 1. The hierarchically primitive cells of the hematopoietic system. Long-Term 
hematopoietic stem cells (LT-HSC) maintain hematopoiesis by coordinating self-renewal, 
and production of short-term HSC (ST-HSC), and subsequently, the multipotent progenitors 
(MPP), which have an incredible capacity to divide and make other types of cells as they 
mature, although a limited ability to self-renew. Ultimately, this generates an array of 
mature blood cells with different functions: lymphoid blood cells (the B-cells; T-cells; natural 
killer or NK cells; plasma cells; dendritic cells and others), and erythroid and myeloid blood 
cells (the erythrocytes or red blood cells; megakaryocytes or platelet producing cells; 
granulocytes such as neutrophils, eosinophils, and basophils; and monocytes which make 
macrophages). The stem and progenitor cells can be purified to near-homogeneity by 
surface markers. For example, LT-HSCs express low levels of lineage markers, high levels of 
Sca1 and CD117/c-KIT receptor, and low levels of CD34 (LSK CD34 lo). With limited 
renewal potential, the ST-HSC pool has a similar surface immunophenotype to LT-HSC 
except that it has higher levels of CD34 (LSK CD34 hi). As ST-HSC in turn proliferates to 
form more differentiated MPP, they increase expression of another surface marker, FLK2 
(LSK CD34 hi Flk2 hi).  
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3. The evidence for stem cell aging 
A growing body of evidence shows that the capacity of stem cells to maintain tissue 
homeostasis declines with age, and suggests that this decline may account for many age-
related phenotypes and diseases (Kirkwood and Austad, 2000). Significantly, 
engraftment of HSCs are capable of serial passages through a succession of mouse 
recipients, outliving the donor mouse (Ross et al., 1982; Siminovitch et al., 1964), though 
it is not possible to exceed up to five successful passages, and the recipients do not 
restore the hematopoietic system to the normal state (Gordon and Blackett, 1998). On the 
other hand, telomere length in blood cells of the transplanted recipient are 1-2 kb shorter 
than those in the donor, when evaluated several years following transplantation 
(Allsopp et al., 2003), which indicates that the level of telomerase is insufficient to 
prevent progressive telomere shortening in HSC. On the other hand, immunophenotypic 
characterization of hematopoietic stem- and progenitor-cell subsets diverges from 
function in old animals. The engraftment efficiency of immunophenotypically selected 
long-term HSCs from old mice approximately is threefold lower than that of the 
equivalent population from young mice (Morrison et al., 1997; Yilmaz et al., 2006). Also, 
age-related changes in stem-cell function include myeloid-biased differentiation and 
decreased homing ability (Liang et al., 2005). In conclusion, it has been extensively 
proved that the properties of HSCs change in several ways as they age, but still is poorly 
known which are the changes in the intrinsic and extrinsic factors involved that regulate 
the self-renewal and multilineage differentiation capacities of these regenerative cells 
(Huang et al., 2007).  
Although the stem- and progenitor-cell proliferation guarantees tissue repair, and thereby 
regeneration, it can also develop hyperproliferative diseases, like cancer, risk that is 
moderated by tumor-suppressors mechanisms. For example, while the increased expression 
of tumor suppressors with age (p53, p16INK4a) inhibits the development of cancer (inducing 
apoptosis or/and senescence) (Krishnamurthy et al., 2004; Ressler et al., 2006), over time it 
may have a negative effect on stem cell functionality, reducing capacity for self-renewal or 
differentiation, and ultimately leading to aging phenotypes (Beausejour and Campisi, 2006; 
Rodier et al., 2007). Thus, it is thought that many of the same mechanisms that contribute to 
cellular aging also act as suppressors of neoplastic growth (Campisi, 2005) (Figure 2). We 
will therefore need a better understanding of age-related changes in stem cell function by 
altering genetically the expression of tumor suppressors, which may improve effective 
longevity-promoting therapies. 
4. Self-renewal regulators in adult HSCs 
Stem cells are crucial for the homeostatic maintenance of mature, functional cells in many 
tissues throughout the lifetime of the animal, and this pool of stem cells must itself be 
maintained (Muller-Sieburg and Sieburg, 2008). This is achieved by self-renewal, a 
specialized cell division in which one or both daughter cells remain undifferentiated and 
retain essentially the same replication potential of the parent. The self-renewal program 
must involve the activity of dedicated regulatory genes (Gazit et al., 2008); but although the 
phenotypic and functional properties of HSCs have been characterized extensively, we have 
only just begun to understand how self-renewal is regulated. 
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Fig. 2. Potential stem cell stage: interplay between aging and cancer. During normal aging, 
stem cells accumulate DNA damage as the consequence of endogenous (telomere 
dysfunction, oxidative stress) or exogenous (oxidative stress, g-irradiation, UV light, and 
others) attacks. This provokes subsequent stress-dependent changes (for example, 
accumulation of the products from the INK4a/ARF locus or telomere shortening), which 
activates checkpoint responses that result in apoptosis or cellular senescence. If these events 
occur in stem/progenitor cells, there is a decrease in the overall number and/or 
functionality of both stem and progenitor cells, leading an alteration of tissue homeostasis 
and regenerative capacity–a phenomenon that might contribute to aging and aged-related 
pathologies. If, instead, DNA mutations that inactivate these checkpoint pathways 
accumulate (for instance, loss of p16INK4a or reactivation of telomerase), then cancer can 
arise. 
Polycomb complex in the maintenance of stemness. PcG proteins regulate self-renewal and 
lineage restriction in stem cells by inducing reversible chromatin modifications. PcG 
proteins have attracted increasing attention in stem cell and cancer stem cell research, given 
that it is now widely recognized that dynamic reprogramming of cells, for instance during 
differentiation, requires alterations to the epigenetic status of genes (Valk-Lingbeek et al., 
2004). These features makes them interesting subjects for stem cell research, since it is 
conceivable that dynamic reprogramming of cells, for instance during differentiation, 
requires alterations in the epigenetic state of gene expression programs. The two major 
multiprotein PcG complexes identified to date, PRC1 and PRC2, function in a cooperative 
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manner to maintain gene silencing (Pietersen et al., 2008) (Table 1). PRC2 initiates silencing, 
whereas PRC1 maintains and stabilizes gene repression. PRC2 contains histone 
methyltransferases (HMTs) that methylate lysines 9 and 27 on histone H3 and lysine 26 on 
histone H1. Deletion of PRC2 genes in mice results in early embryonic death, underscoring 
their importance in development. PRC1 recognizes the H3 lysine 27 methyl group added by 
PRC2 (Valk-Lingbeek et al., 2004), and subsequently the monoubiquityl-ligase activity of the 
PRC1 proteins Bmi1 or Ring1A/B toward histone H2A generates uH2AK119, which 
prevents access of the transcription machinery and facilitates chromatin compaction (Wang 
et al., 2004). Mouse mutants of most PRC1 members, in spite of displaying homeotic 
transformations, survive until birth as a result of partial functional redundancy provided by 
homologues, an exception being Ring1B-deficient mice (Voncken et al., 2003).  
PRC2 is recruited to target genes by the cofactor jARID2 (jumonji/ARID domain-containing 
2). Paradoxically, jARID2 also seems to inhibit PRC2 methyltransferase activity and may 
therefore regulate both the targeting and fine-tuning of PRC2 activity in stem cells and 
during differentiation (Panning, 2010). Once PRC1 recognizes and binds the H3K27me3 
mark added by PRC2, it recruits additional proteins to establish the repressed chromatin 
configuration (Jones and Baylin, 2007). Gene promoters marked with H3K27me3 in ESCs are 
significantly more likely than other promoters to become methylated in cancer (Schlesinger 
et al., 2007). Moreover, the PcG targets in normal prostate cells are the same as those that 
become methylated in prostate cancer (Gal-Yam et al., 2008). Thus, altered chromatin 
structure does not always result in changes in gene expression associated with disease. 
Rather, disease results from the replacement of PcG repressive histone marks with 
methylation directly on DNA, which locks the chromatin in an inactive state, a process 
called epigenetic switching (Gal-Yam et al., 2008). Although the mechanism underlying 
predisposition of PcG targets to DNA methylation is not fully understood, the PRC1 
component Cbx7 (chromobox homologue 7) was recently shown to interact directly with 
DNA (cytosine-5)-methyltransferase (DNMT)1 and DNMT3B at PcG target genes, 
establishing a link between histone and DNA methylation (Mohammad et al., 2009). 
Among PcG proteins, the PRC1 component Bmi1 is a fundamental self-renewal regulator, 
being required for self-renewal of all postnatal stem cell populations studied to date 
(Molofsky et al., 2003; Park et al., 2003; van der Lugt et al., 1994). Bmi1 was originally 
described as a proto-oncogene that induces B and T cell leukemias (van Lohuizen et al., 
1991), and is overexpressed in several human cancers, including mantle cell lymphoma, 
colorectal carcinoma, liver carcinomas, non-small-cell lung cancer, and cerebral tumors such 
as medulloblastomas (Martin-Perez et al., 2010). This evidence has strongly influenced 
cancer research, supporting the above-mentioned theory that cancer is essentially a stem cell 
disorder (Reya et al., 2001). The self-renewal function of Bmi1 in adult stem cells relies 
largely on the silencing of one of its targets, the locus encoding the p16INK4a and ARF 
tumor suppressors (Molofsky et al., 2006). Deletion of p16INK4a and/or ARF partially 
rescues the self-renewal defects observed in various stem cell populations from Bmi1-null 
mice. Nevertheless, as described by the authors, this rescue is incomplete and thus other 
major Bmi1 regulated genes must exist. Candidates for additional Bmi1 targets in the 
context of self renewal are the Hox (homeobox) genes. A subset of Hox genes has been 
implicated in mammalian brain development, and several of them are highly expressed in 
neurospheres formed in vitro from cultured neural stem cells of the subventricular zone of 
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Adapted from Takaaki Konuma et al. Develop. Growth Differ. (2010) 52, 505–516 
Table 1. Principcal components of the Polycomb Group Complexes and their hematopoietic 
defects in mutant mice. 
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Bmi-null mice (Molofsky et al., 2006). More recently, Bmi1 and Ring1A were shown to play 
essential roles in H2A ubiquitylation and Hox gene silencing. Knockout of Bmi1 results in 
significant loss of H2A ubiquitylation and an upregulation of HoxC13 expression, whereas 
Ezh2-mediated H3-K27 methylation is not affected (Cao et al., 2005). Similar findings have 
been described for the HoxC5 gene. However, considering that PcG proteins modify the 
chromatin of large sets of genes (Kirmizis et al., 2004), a great number of additional targets 
are likely to exist. For instance, both PRC2 and Bmi1 have recently been shown to play roles 
in the repression of E-cadherin expression (Yang et al., 2010). Interestingly, PcG genes have 
been shown to have a tumor suppressive function. In Drosophila, PcG proteins repress 
JAK/STAT and Notch signaling activity, whose activation drives disc cell overproliferation 
(Classen et al., 2009). Specifically, the Drosophila complex Psc (posterior sex combs), which 
includes Bmi1, and Suz12 (suppressor of zeste 12) play a tumor suppressive role mediated 
by Wnt repression in follicle stem cells(Li et al., 2010). In mammals, Eed (embryonic 
ectoderm development protein) displays tumor suppressive activity in the mouse 
hematopoietic system (Richie et al., 2002). Thus, PcG genes have been suggested to behave 
either as proto-oncogenes or as tumor suppressors depending on the tissue, cell context, 
developmental stage and gene dosage. 
Bmi1 is regulated by Sonic Hedgehog, providing a direct connection between PcG and a 
major stem cell-specific pathway (Leung et al., 2004). Furthermore, activation of either 
Hedgehog or Notch signaling has been shown to increase Bmi1 expression, whereas siRNA 
knockdown of Bmi1 abrogates the effects of Hedgehog or Notch signaling on sphere 
formation, a functional readout of stemness. Thus the effects of Hedgehog and Notch 
signaling on stem cell self-renewal appear to be largely dependent on Bmi1. A complex 
regulation of Bmi1 is suggested by the fact that distinct Bmi1 regulators have been found in 
different types of cancer, for example Twist1 in head and neck squamous cell carcinoma and 
the Zeb1 (zinc finger E-box binding homeobox 1) – miR-200 pathway in pancreatic cancers 
(Wellner et al., 2009). Furthermore, a single PcG function can be regulated by multiple 
factors, for example Snail1 regulates E-cadherin silencing by PRC2, whereas the action of 
PRC1 on this target is regulated by Twist1 (Yang et al., 2010). 
In summary, PcG proteins, in particular Bmi1, are essential for self-renewal and proliferative 
potential, which are crucial for the maintenance of stemness, acting as a critical failsafe 
mechanism against loss of stem cells in response to senescence signals. In turn, Bmi1 must 
be finely-regulated to prevent uncontrolled replicative expansion and tumor induction. 
Despite the importance of PcG proteins, we are only beginning to unravel how these master 
regulators are themselves regulated to achieve an appropriate balance between ensuring 
stem cell longevity and preventing tumorigenesis. 
The tumor suppressors p16INK4a and ARF. Cell-cycle regulators such as the INK4/ARF locus 
appear to play an important role in the reaction of adult stem cells to stress and aging. The 
INK4/ARF locus plays a central role in tumor suppression, reflected in its inactivation in 
almost 50% of human cancers (Sharpless, 2005). Indeed, this locus is regarded as one of the 
most important anti-oncogenic defenses of the mammalian genome, comparable in 
importance only to p53. The remarkable feature of the INK4/ARF locus is that it encodes 
three tumor suppressors in a genomic segment of about 50 kb: p16INK4a, its related family 
member p15INK4b, and ARF (called p19ARF in mice and p14ARF in humans). The actions of 
p16INK4a, p15INK4b and ARF are well understood. Both p16INK4a and p15INK4b inhibit the kinase 
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activity of CDK4/6-cycD complexes, thus contributing to the maintenance of the active, 
growth-suppressive form of the retinoblastoma (Rb) family of proteins. ARF contributes to 
the stability of p53 by inhibiting the p53-degrading activity of MDM2. Through the 
activation of Rb and p53, the INK4/ARF locus is able to induce cell senescence and cell death 
(Gil and Peters, 2006; Lowe and Sherr, 2003). These tumor suppressors have taken on 
additional importance given recent evidence that at least one product of the locus, p16INK4a, 
also contributes to the decline in the replication potential of self-renewing cells during the 
aging of stem cells. The expression of p16INK4a is relatively low in the HSCs of young mice, 
but is upregulated with age or in response to cellular stresses (Janzen et al., 2006). Although 
the number of immunophenotypic HSCs increases with age in wild-type animals, HSC 
functionality is impaired. In particular, the HSC compartment of old animals is more rapidly 
exhausted by serial transplantation than that of young animals. In contrast, aging has the 
opposite effect on p16INK4a-/- HSCs, with p16INK4a-/- HSCs from old animals substantially 
outperforming young p16INK4a-/- HSCs in serial transplantation assays (Janzen et al., 2006). 
In fact, old p16INK4a-/- HSCs perform as well as young wild-type HSCs in this assay. Thus 
p16INK4a compromises HSC functionality in older mice. Similar results were obtained in 
studies of p16INK4a-/- neuronal stem cells and pancreatic islets (Krishnamurthy et al., 2006; 
Molofsky et al., 2006), revealing a general role for p16INK4a in the regulation of stem cell and 
progenitor cell aging. Therefore, on one face of this coin, p16INK4a acts as a potent tumor 
suppressor that promotes longevity by suppressing the development of cancer, while on the 
flipside, the increase of p16INK4a levels with age impairs the proliferation of stem or 
progenitor cells, ultimately reducing longevity. Thus, p16INK4a seems to balance an 
equilibrium reducing cancer incidence, but also contributing to aging by decreasing stem 
cell self-renewal and proliferation. These observations suggest the provocative but as yet 
unproven notion that mammalian aging results in part from the beneficial effects of tumor 
suppressor proteins (Figure 2). 
The transcription factor p53. Besides p16INK4a tumor suppressor, p53 is also a tumor 
suppressor that influences stem cell self-renewal, tissue regenerative capacity, age-related 
disease, and cancer, which activity is lost in nearly half of all human cancers(Toledo and 
Wahl, 2006). The p53 protein is normally inactive, due in part to its rapid degradation by the 
specific ubiquitin ligase Mdm2. A multitude of stresses converge on p53 through complex, 
and partially understood, signaling pathways that stabilize and modify p53. The analysis of 
the effect of p53 in aging has revealed a dual role that seems to depend on the intensity of 
p53 activity. Overexpression of short isoforms of p53 in mice have greater protection against 
tumor development than wild-type mice, while at the same time they show signs of 
premature aging (Maier et al., 2004; Tyner et al., 2002). However, mouse models of increased 
wild-type p53 activity do not present premature aging. In particular, bacterial artificial 
chromosome transgenic mice that bear a third copy of the p53 locus show a decreased 
cancer incidence but normal longevity and normal onset of aging phenotypes (Garcia-Cao et 
al., 2002; Matheu et al., 2007; Matheu et al., 2004). An additional mouse model, the super-
INK4a/ARF mice, with an extra copy of the entire INK4a/ARF locus (being ARF an activator 
of p53), show a significantly reduced incidence of cancer, although the mice aged normally 
(Matheu et al., 2004). To investigate whether the concomitant expression of both tumor 
suppressors had a synergistic effect, mice that bear a third copy of the p53 locus and a third 
copy of the INK4/ARF locus show increased longevity and delayed aging in a manner that 
cannot be explained by their reduced incidence of cancer (Matheu et al., 2007). Therefore, 
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and though the effects of p53 and INK4/ARF locus expression in aging are context and 
dosage dependent, these results suggest that under physiological aging (labeled by 
moderate increase of still regulated p53 activity), the damaged cells are eliminated by either 
triggering their self-destruction (by apoptosis) or by pulling them out of the proliferative 
pool (by inducing senescence). In contrast, by massive DNA damage, the presence of 
uncontrolled activity of p53 results in excessive elimination of cells by p53 that exhausts the 
capacity of tissue regeneration leading to premature aging.  
The INK4/ARF locus and age-associated phenotypes. p16INK4a and ARF may also be broadly 
important to diseases of aging beyond their function in stem cells. Specifically, three 
research consortia that undertook genome-wide association studies across large, carefully 
annotated patient samples have reported an association between single nucleotide 
polymorphisms (SNPs) near to INK4a/ARF locus and frailty (Melzer et al., 2007), 
atherosclerotic heart disease (ASHD)(Helgadottir et al., 2007) (McPherson et al., 2007), and 
type-2 diabetes (Saxena et al., 2007; Zeggini et al., 2008) in large human cohorts. However, 
few of the associated SNPs near the locus, and associated with these phenotypes, are not in 
linkage disequilibrium with each other, which suggests that more than one polymorphism 
near the locus influences these aging phenotypes. Therefore, although these studies do not 
pinpoint specific polymorphisms that affect the risks of age-related diseases, there are only 
four genes in the vicinity of the mapped polymorphisms: p16INK4a, ARF, p15INK4b, and 
ANRIL (a noncoding RNA). More relative data suggest specific links: p16INK4a expression 
increases with age in pancreatic β cells, and p16INK4a deficiency increases β-cell regenerative 
capacity(Krishnamurthy et al., 2006), providing a mechanism by which polymorphisms that 
affect p16INK4a expression or activity might affect risk for type-2 diabetes. It remains unclear 
whether these polymorphisms influence the risk of frailty and heart disease through their 
effects on tissue regenerative capacity or by mechanisms that are completely independent of 
stem/progenitor cells. Nevertheless, in light of the murine genetic studies that link 
INK4a/ARF locus and stem cell function, proteins encoded by the locus are the strongest 
candidates to mediate the effects of these polymorphisms on the incidence of these common 
diseases that are associated with aging.  
5. Conclusions 
The regenerative capacity of many stem cells declines functionally with age and, this decline 
triggers in part many age-related symptoms, and the development of certain diseases. 
Recent evidences have demonstrated that certain tumor suppressors, like p16INK4a, also 
suppresses the proliferation of stem or progenitor cells in the bone marrow, pancreas and 
brain. Thus, p16INK4a seems to balance equilibrium reducing cancer incidence, which 
promotes longevity, but also decreasing stem cell self-renewal and proliferation, 
compromising tissue regeneration and repair, which are likely to reduce longevity. These 
observations allow us to suggest the provocative but unproved hypothesis that mammalian 
aging results in part from the beneficial efforts of tumor suppressor proteins to interdict 
cancer. In this stage, characterization of how stem cells age, such as the characterization of 
reliable biomarkers, deregulated signaling pathways, loss of self-renewal or acquisition of 
defects in differentiation of stem cells, will contribute to understand the age-associated 
pathophysiological decline. Likewise, it is also essential to figure out the cellular and 
molecular components of stem cell niches, how the niche changes during aging, and 
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whether senescent stem or support cells alter the niche. In summary, the rescue, treatment, 
or replacement of aged and dysfunctional adult stem and progenitor cells may provide 
novel avenues to treat diverse devastating premature aging and age-related disorders 
including hematopoietic and immune disorders, heart failure and cardiovascular diseases, 
neurodegenerative, muscular and gastrointestinal diseases, atherosclerosis and aggressive 
and lethal cancers. 
6. Acknowledgement  
This work was supported by the Human Frontiers Science Program Organization, the 
Spanish Ministries of Science and Innovation (SAF2010-15386) and Health (FIS PI06/0627). 
We thank Simon Bartlett for editing assistance. The CNIC is supported by the Ministry of 
Science and Innovation and the Pro-CNIC Foundation. 
7. Abbreviatons 
PcG, Polycomb Group, PRC1, Polycomb repressive complex 1, PRC2, polycomb repressive 
complex 2. 
8. References 
Allsopp, R.C., Morin, G.B., DePinho, R., Harley, C.B., and Weissman, I.L. (2003). Telomerase 
is required to slow telomere shortening and extend replicative lifespan of HSCs 
during serial transplantation. Blood 102, 517-520. 
Beausejour, C.M., and Campisi, J. (2006). Ageing: balancing regeneration and cancer. Nature 
443, 404-405. 
Campisi, J. (2005). Senescent cells, tumor suppression, and organismal aging: good citizens, 
bad neighbors. Cell 120, 513-522. 
Cao, R., Tsukada, Y., and Zhang, Y. (2005). Role of Bmi-1 and Ring1A in H2A ubiquitylation 
and Hox gene silencing. Mol Cell 20, 845-854. 
Classen, A.K., Bunker, B.D., Harvey, K.F., Vaccari, T., and Bilder, D. (2009). A tumor 
suppressor activity of Drosophila Polycomb genes mediated by JAK-STAT 
signaling. Nat Genet 41, 1150-1155. 
Gal-Yam, E.N., Egger, G., Iniguez, L., Holster, H., Einarsson, S., Zhang, X., Lin, J.C., Liang, 
G., Jones, P.A., and Tanay, A. (2008). Frequent switching of Polycomb repressive 
marks and DNA hypermethylation in the PC3 prostate cancer cell line. Proc Natl 
Acad Sci U S A 105, 12979-12984. 
Garcia-Cao, I., Garcia-Cao, M., Martin-Caballero, J., Criado, L.M., Klatt, P., Flores, J.M., 
Weill, J.C., Blasco, M.A., and Serrano, M. (2002). "Super p53" mice exhibit enhanced 
DNA damage response, are tumor resistant and age normally. Embo J 21, 6225-
6235. 
Gazit, R., Weissman, I.L., and Rossi, D.J. (2008). Hematopoietic stem cells and the aging 
hematopoietic system. Semin Hematol 45, 218-224. 
Gil, J., and Peters, G. (2006). Regulation of the INK4b-ARF-INK4a tumour suppressor locus: 
all for one or one for all. Nat Rev Mol Cell Biol 7, 667-677. 
 
Insights Into Stem Cell Aging 
 
257 
Gordon, M.Y., and Blackett, N.M. (1998). Reconstruction of the hematopoietic system after 
stem cell transplantation. Cell Transplant 7, 339-344. 
Helgadottir, A., Thorleifsson, G., Manolescu, A., Gretarsdottir, S., Blondal, T., Jonasdottir, 
A., Sigurdsson, A., Baker, A., Palsson, A., Masson, G., et al. (2007). A common 
variant on chromosome 9p21 affects the risk of myocardial infarction. Science 316, 
1491-1493. 
Huang, X., Cho, S., and Spangrude, G.J. (2007). Hematopoietic stem cells: generation and 
self-renewal. Cell Death Differ 14, 1851-1859. 
Janzen, V., Forkert, R., Fleming, H.E., Saito, Y., Waring, M.T., Dombkowski, D.M., Cheng, T., 
DePinho, R.A., Sharpless, N.E., and Scadden, D.T. (2006). Stem-cell ageing 
modified by the cyclin-dependent kinase inhibitor p16INK4a. Nature 443, 421-426. 
Jones, P.A., and Baylin, S.B. (2007). The epigenomics of cancer. Cell 128, 683-692. 
Kirkwood, T.B., and Austad, S.N. (2000). Why do we age? Nature 408, 233-238. 
Kirmizis, A., Bartley, S.M., Kuzmichev, A., Margueron, R., Reinberg, D., Green, R., and 
Farnham, P.J. (2004). Silencing of human polycomb target genes is associated with 
methylation of histone H3 Lys 27. Genes Dev 18, 1592-1605. 
Krishnamurthy, J., Ramsey, M.R., Ligon, K.L., Torrice, C., Koh, A., Bonner-Weir, S., and 
Sharpless, N.E. (2006). p16INK4a induces an age-dependent decline in islet 
regenerative potential. Nature 443, 453-457. 
Krishnamurthy, J., Torrice, C., Ramsey, M.R., Kovalev, G.I., Al-Regaiey, K., Su, L., and 
Sharpless, N.E. (2004). Ink4a/Arf expression is a biomarker of aging. J Clin Invest 
114, 1299-1307. 
Leung, C., Lingbeek, M., Shakhova, O., Liu, J., Tanger, E., Saremaslani, P., Van Lohuizen, 
M., and Marino, S. (2004). Bmi1 is essential for cerebellar development and is 
overexpressed in human medulloblastomas. Nature 428, 337-341. 
Li, X., Han, Y., and Xi, R. (2010). Polycomb group genes Psc and Su(z)2 restrict follicle stem 
cell self-renewal and extrusion by controlling canonical and noncanonical Wnt 
signaling. Genes Dev 24, 933-946. 
Liang, Y., Van Zant, G., and Szilvassy, S.J. (2005). Effects of aging on the homing and 
engraftment of murine hematopoietic stem and progenitor cells. Blood 106, 1479-
1487. 
Lowe, S.W., and Sherr, C.J. (2003). Tumor suppression by Ink4a-Arf: progress and puzzles. 
Curr Opin Genet Dev 13, 77-83. 
Maier, B., Gluba, W., Bernier, B., Turner, T., Mohammad, K., Guise, T., Sutherland, A., 
Thorner, M., and Scrable, H. (2004). Modulation of mammalian life span by the 
short isoform of p53. Genes Dev 18, 306-319. 
Martin-Perez, D., Piris, M.A., and Sanchez-Beato, M. (2010). Polycomb proteins in 
hematologic malignancies. Blood 116, 5465-5475. 
Matheu, A., Maraver, A., Klatt, P., Flores, I., Garcia-Cao, I., Borras, C., Flores, J.M., Viña, J., 
Blasco, M.A., and Serrano, M. (2007). Delayed aging through damage protection by 
the Arf/p53 pathway. Nature in press. 
Matheu, A., Pantoja, C., Efeyan, A., Criado, L.M., Martin-Caballero, J., Flores, J.M., Klatt, P., 
and Serrano, M. (2004). Increased gene dosage of Ink4a/Arf results in cancer 
resistance and normal aging. Genes Dev 18, 2736-2746. 
 
Advances in Hematopoietic Stem Cell Research 
 
258 
McPherson, R., Pertsemlidis, A., Kavaslar, N., Stewart, A., Roberts, R., Cox, D.R., Hinds, 
D.A., Pennacchio, L.A., Tybjaerg-Hansen, A., Folsom, A.R., et al. (2007). A common 
allele on chromosome 9 associated with coronary heart disease. Science 316, 1488-
1491. 
Melzer, D., Frayling, T.M., Murray, A., Hurst, A.J., Harries, L.W., Song, H., Khaw, K., Luben, 
R., Surtees, P.G., Bandinelli, S.S., et al. (2007). A common variant of the p16(INK4a) 
genetic region is associated with physical function in older people. Mech Ageing 
Dev 128, 370-377. 
Mohammad, H.P., Cai, Y., McGarvey, K.M., Easwaran, H., Van Neste, L., Ohm, J.E., 
O'Hagan, H.M., and Baylin, S.B. (2009). Polycomb CBX7 promotes initiation of 
heritable repression of genes frequently silenced with cancer-specific DNA 
hypermethylation. Cancer Res 69, 6322-6330. 
Molofsky, A.V., Pardal, R., Iwashita, T., Park, I.K., Clarke, M.F., and Morrison, S.J. (2003). 
Bmi-1 dependence distinguishes neural stem cell self-renewal from progenitor 
proliferation. Nature 425, 962-967. 
Molofsky, A.V., Slutsky, S.G., Joseph, N.M., He, S., Pardal, R., Krishnamurthy, J., Sharpless, 
N.E., and Morrison, S.J. (2006). Increasing p16INK4a expression decreases forebrain 
progenitors and neurogenesis during ageing. Nature 443, 448-452. 
Morrison, S.J., Wright, D.E., Cheshier, S.H., and Weissman, I.L. (1997). Hematopoietic stem 
cells: challenges to expectations. Curr Opin Immunol 9, 216-221. 
Muller-Sieburg, C., and Sieburg, H.B. (2008). Stem cell aging: survival of the laziest? Cell 
Cycle 7, 3798-3804. 
Orkin, S.H., and Zon, L.I. (2008). Hematopoiesis: an evolving paradigm for stem cell 
biology. Cell 132, 631-644. 
Panning, B. (2010). Fine-tuning silencing. Cell Stem Cell 6, 3-4. 
Park, I.K., Qian, D., Kiel, M., Becker, M.W., Pihalja, M., Weissman, I.L., Morrison, S.J., and 
Clarke, M.F. (2003). Bmi-1 is required for maintenance of adult self-renewing 
haematopoietic stem cells. Nature 423, 302-305. 
Pietersen, A.M., Evers, B., Prasad, A.A., Tanger, E., Cornelissen-Steijger, P., Jonkers, J., and 
van Lohuizen, M. (2008). Bmi1 regulates stem cells and proliferation and 
differentiation of committed cells in mammary epithelium. Curr Biol 18, 1094-1099. 
Ressler, S., Bartkova, J., Niederegger, H., Bartek, J., Scharffetter-Kochanek, K., Jansen-Durr, 
P., and Wlaschek, M. (2006). p16INK4A is a robust in vivo biomarker of cellular 
aging in human skin. Aging Cell 5, 379-389. 
Reya, T., Morrison, S.J., Clarke, M.F., and Weissman, I.L. (2001). Stem cells, cancer, and 
cancer stem cells. Nature 414, 105-111. 
Richie, E.R., Schumacher, A., Angel, J.M., Holloway, M., Rinchik, E.M., and Magnuson, T. 
(2002). The Polycomb-group gene eed regulates thymocyte differentiation and 
suppresses the development of carcinogen-induced T-cell lymphomas. Oncogene 
21, 299-306. 
Rodier, F., Campisi, J., and Bhaumik, D. (2007). Two faces of p53: aging and tumor 
suppression. Nucleic Acids Res 35, 7475-7484. 
 
Insights Into Stem Cell Aging 
 
259 
Ross, E.A., Anderson, N., and Micklem, H.S. (1982). Serial depletion and regeneration of the 
murine hematopoietic system. Implications for hematopoietic organization and the 
study of cellular aging. J Exp Med 155, 432-444. 
Saxena, V., Ondr, J.K., Magnusen, A.F., Munn, D.H., and Katz, J.D. (2007). The 
countervailing actions of myeloid and plasmacytoid dendritic cells control 
autoimmune diabetes in the nonobese diabetic mouse. J Immunol 179, 5041-5053. 
Schlesinger, Y., Straussman, R., Keshet, I., Farkash, S., Hecht, M., Zimmerman, J., Eden, E., 
Yakhini, Z., Ben-Shushan, E., Reubinoff, B.E., et al. (2007). Polycomb-mediated 
methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in 
cancer. Nat Genet 39, 232-236. 
Sharpless, N.E. (2005). INK4a/ARF: a multifunctional tumor suppressor locus. Mutat Res 
576, 22-38. 
Siminovitch, L., Till, J.E., and McCulloch, E.A. (1964). Decline in Colony-Forming Ability of 
Marrow Cells Subjected to Serial Transplantation into Irradiated Mice. J Cell 
Physiol 64, 23-31. 
Toledo, F., and Wahl, G.M. (2006). Regulating the p53 pathway: in vitro hypotheses, in vivo 
veritas. Nat Rev Cancer 6, 909-923. 
Tyner, S.D., Venkatachalam, S., Choi, J., Jones, S., Ghebranious, N., Igelmann, H., Lu, X., 
Soron, G., Cooper, B., Brayton, C., et al. (2002). p53 mutant mice that display early 
ageing-associated phenotypes. Nature 415, 45-53. 
Valk-Lingbeek, M.E., Bruggeman, S.W., and van Lohuizen, M. (2004). Stem cells and cancer; 
the polycomb connection. Cell 118, 409-418. 
van der Lugt, N.M., Domen, J., Linders, K., van Roon, M., Robanus-Maandag, E., te Riele, 
H., van der Valk, M., Deschamps, J., Sofroniew, M., van Lohuizen, M., et al. (1994). 
Posterior transformation, neurological abnormalities, and severe hematopoietic 
defects in mice with a targeted deletion of the bmi-1 proto-oncogene. Genes Dev 8, 
757-769. 
van Lohuizen, M., Verbeek, S., Scheijen, B., Wientjens, E., van der Gulden, H., and Berns, A. 
(1991). Identification of cooperating oncogenes in E mu-myc transgenic mice by 
provirus tagging. Cell 65, 737-752. 
Voncken, J.W., Roelen, B.A., Roefs, M., de Vries, S., Verhoeven, E., Marino, S., Deschamps, J., 
and van Lohuizen, M. (2003). Rnf2 (Ring1b) deficiency causes gastrulation arrest 
and cell cycle inhibition. Proc Natl Acad Sci U S A 100, 2468-2473. 
Wang, L., Brown, J.L., Cao, R., Zhang, Y., Kassis, J.A., and Jones, R.S. (2004). Hierarchical 
recruitment of polycomb group silencing complexes. Mol Cell 14, 637-646. 
Wellner, U., Schubert, J., Burk, U.C., Schmalhofer, O., Zhu, F., Sonntag, A., Waldvogel, B., 
Vannier, C., Darling, D., zur Hausen, A., et al. (2009). The EMT-activator ZEB1 
promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell 
Biol 11, 1487-1495. 
Yang, M.H., Hsu, D.S., Wang, H.W., Wang, H.J., Lan, H.Y., Yang, W.H., Huang, C.H., Kao, 
S.Y., Tzeng, C.H., Tai, S.K., et al. (2010). Bmi1 is essential in Twist1-induced 
epithelial-mesenchymal transition. Nat Cell Biol 12, 982-992. 
 
Advances in Hematopoietic Stem Cell Research 
 
260 
Yilmaz, O.H., Kiel, M.J., and Morrison, S.J. (2006). SLAM family markers are conserved 
among hematopoietic stem cells from old and reconstituted mice and markedly 
increase their purity. Blood 107, 924-930. 
Zeggini, E., Scott, L.J., Saxena, R., Voight, B.F., Marchini, J.L., Hu, T., de Bakker, P.I., 
Abecasis, G.R., Almgren, P., Andersen, G., et al. (2008). Meta-analysis of genome-
wide association data and large-scale replication identifies additional susceptibility 
loci for type 2 diabetes. Nat Genet 40, 638-645. 
 
Artículos que no forman parte de la tesis 
 
 
126
 
 
www.landesbioscience.com Cell Cycle 3277
Cell Cycle 9:16, 3277-3285; August 15, 2010; © 2010 Landes Bioscience
 RepoRt RepoRt
*Correspondence to: Susana Gonzalez; Email: sgonzalez@cnic.es
Submitted: 06/01/10; Accepted: 06/02/10
Previously published online: www.landesbioscience.com/journals/cc/article/12598
DOI: 10.4161/cc.9.16.12598
Introduction
Adult stem cells have the capacity both to produce more stem 
cells of the same type (self-renewal), and to give rise to multi-
potent progenitors that in turn differentiate into a defined set of 
mature differentiated progeny to maintain or repair their host 
tissue.1 The best-characterized adult stem cells are the hema-
topoietic stem cells (HSCs),2 whose self-renewal capacity is 
commonly measured by lifelong reconstitution of all blood-cell 
lineages after transplantation into lethally irradiated recipients.3 
Knowledge of the mechanisms that control HSC self-renewal is 
essential for the accurate predication and cure of hematopoietic 
disorders.
Hematopoietic cell differentiation, proliferation and activ-
ity are modulated by microRNAs (miRNAs),4 evolutionarily 
conserved ~22 nt non-protein coding RNAs that regulate gene 
expression. miRNAs target specific mRNAs by perfect or imper-
fect base pairing with motifs mostly present in the 3' untrans-
lated regions (3'UTR). Targeted mRNAs are then degraded or 
their translation inhibited. However, the mechanism and precise 
targets of miRNA function in HSCs are unknown.
HSC self-renewal is impaired by mutation of the tumor sup-
pressor p53 or alterations to p53 signaling,5 and altered p53 
function is an important index in the progression of hematologic 
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malignancies.6 The importance of p53 in the prevention of can-
cer is demonstrated by the fact that 50% of human cancers, 
irrespective of tumor type or patient age, involve loss of p53 
function.7 In response to various stress conditions, p53 rapidly 
accumulates and functions as a sequence-specific DNA-binding 
transcription factor, promoting the transcription of genes that 
induce cell cycle arrest, apoptosis and senescence, essential phys-
iological responses to cancer-related stresses.8
Studies in genetically engineered mouse models suggest 
that, in addition to its anti-tumor action, p53 may directly 
regulate aging.5,9-15 Deletion of both p53 alleles in the mouse 
germline shortens lifespan considerably. While this is clearly 
related to the development of tumors, these mice remarkably 
have an increased HSC pool and show enhanced HSC self-
renewal,10,16 which could also influence the premature aging of 
these mice. In contrast, p53 hypermorphic (p53+/m) mice, which 
have constitute p53 activity, are resistant to spontaneous can-
cers, and display a number of accelerated aging phenotypes.9,11 
Transplantation assays have demonstrated that the constitutively 
high p53 activity induces a decreased HSC self-renewal capac-
ity,15 which may thus contribute to accelerated aging.9 However, 
mice with one extra copy of genomic p53 (“super-p53,” here-
after sp53) age normally, despite showing enhanced responses 
to DNA damage and being more resistant to spontaneous and 
3278 Cell Cycle Volume 9 Issue 16 
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HSC function in sp53 mice. Although mutation of p53 itself or 
alterations within the p53 signaling pathway regulates HSC self-
renewal,5 it is still unknown whether the p53 functional activity 
of mice with an increased gene dosage of p53 may alter either 
HSCs frequency or their HSCs self-renewal capacity. Initial char-
acterization of HSCs activity in the sp53 transgenic mice showed 
that the abundance of immunophenotypically enriched long-
term repopulating HSCs (LT-HSC), as defined according immu-
nophenotypic markers (Lin-Sca-1+c-kit+CD34lowFlk-2low),17,18 was 
slightly reduced compared to wild-type (wt) mice, while p53-
null mice showed the expected increase in HSC pool size10,16 
(Suppl. Fig. S1A). This reduction in the HSC numbers in sp53 
mice could be caused by an apoptotic effect, and assays of cell 
carcinogen-induced tumors.13 It remains unclear if the elevated 
p53 activity in these mice alters HSC frequency or self-renewal 
capacity.
In this study, we report that in sp53 mice the hematopoietic-
specific miRNA, miR-33, is significantly downregulated in the 
sp53 HSCs but highly expressed in more-differentiated progeni-
tor subpopulations. Remarkably, bone marrow transplantation 
of sp53 HSC/progenitors overexpressing miR-33 significantly 
increased the HSC self-renewal capacity. We further show that 
miR-33 is a potent repressor of p53 through binding to conserved 
motifs in their mRNAs 3'UTRs. We conclude that HSCs self-
renewal is promoted by miR-33-mediated downregulation of 
p53.
Figure 1. HSC functional ability of sp53 mice. (A) Fluorescence-activated cell sorting (FACS) plots are gated on AnnexinV+/pI- LSK cells from wild-type 
(wt), sp53 and p53-/- mice and the numbers indicate the percentage of subpopulations of an individual representative experiment. In the right, data 
shown are the mean percentage (±SD) of Annexin-V+/pI- in the LSK cells (p < 0.05, n = 7). (B) Competitive repopulating capacity of sp53 LSK cells. 
Lethally irradiated recipient mice (CD45.1) were transplanted with the indicated numbers of cells from wild type (wt), sp53 and p53-/- mice (CD45.2) and 
competitor cells (CD45.1). percent chimerism of donor cells 4 and 12 weeks after transplantation is presented as mean ± SD (p < 0.05).
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To confirm and define this above data, the functional impli-
cation of miR-33 in the hematopoietic system was studied in 
vivo by competitive repopulation assays. Mouse bone marrow 
cells enriched for HSC/progenitor cells (LSK) from wt, sp53 
and p53-/- mice were transduced with miR-33 or empty control 
MSCV-based retrovirus. The miR-33 appropriate processing 
into transduced LSK cells led to a substantial reduction in the 
p53 mRNA expression (Suppl. Fig. S2). Transduced cells were 
transplanted into lethally irradiated recipients B6.SJL recipient 
mice (CD45.1) along with a constant dose of competitor marrow 
cells (CD45.1). Flow cytometric analysis of the peripheral blood 
in stably engrafted chimeric mice showed significant increasing 
levels of sp53 donor-derived (CD45.2) LSK cells overexpress-
ing miR-33 relative to the controls (p < 0.05). Accordingly, the 
transplantation efficiency was slightly upregulated in wild-type 
mice, while HSC engraftment ability using p53-/- miR-33-LSK 
cells was unaltered (Fig. 2B). This effect was specific to miR-33, 
as neither control retrovirus nor retroviruses expressing miR-207 
or miR-27 significantly affected engraftment levels or lineage 
output when transduced into mouse HSC/committed progeni-
tors (data not shown). The increased repopulating capacity of 
miR-33 expressing sp53 LSK cells reduced survival of recipients 
from 100% (four of four) to 60% (six of ten) at five moths after 
transplantation; in contrast, miR-33 expression in p53-/- donor 
cells had no effect on survival compared with vector. Together, 
our findings provide evidence indicating that the miR-33 plays 
a critical role in the sp53 HSC repopulating capacity, through a 
likely regulation of p53.
miR-33 represses endogenous p53. Based on the conse-
quences of ectopic miR-33 in HSC self-renewal, we hypoth-
esized the possibility of p53 regulation by miR-33. As a first 
approach to evaluate this, we searched for potential miR-33 
binding sites in the p53 mRNA sequence. Alignment of the 
3'UTRs of human and mouse p53 mRNA revealed the pres-
ence of two conserved motifs with predicted miR-33 bind-
ing capability (Fig. 3A). The motifs span ~200 bp each and 
are more than 50% identical between human and mouse, and 
both motifs show minimal complementation to miR-33 seed-
sequence (Fig. 3A). To determine whether hsa-miR-33a down-
regulates p53 expression by targeting these 3'UTR motifs, we 
constructed sensor vectors containing the Renilla luciferase 
coding region upstream of wt, or mutant versions of the human 
p53 3'UTR ; the vectors included a firefly luciferase cassette to 
normalize for internal luciferase activity. The presence of miR-
33a suppressed p53-3'UTR luciferase activity by about two-
fold compared with mutant p53-3'UTR constructs (p < 0.01) 
(Fig. 3B). The same suppressive effect was achieved by co-
transfection with mimic miR-33a toward human p53-3'UTR 
(p < 0.01) (Fig. 3B). Consistent with the luciferase reporter 
assay, ectopic expression of mmu-miR-33 in primary wt mouse 
embryonic fibroblasts (MEFs) importantly dropped p53 protein 
expression (Fig. 3C), and a similar suppression was seen with the 
validated p53 suppressor miR-125b21 (p < 0.01; Suppl. Fig. S3A). 
PCR analysis showed that miR-33 decreased the expression of 
p53 mRNA (p < 0.05) (Fig. 3C) and of the well-characterized 
p53-target genes p21 and bax (p < 0.05) (Suppl. Fig. 3B). These 
survival indicated significant differences in the number of apop-
totic (AnnexinV+/PI-) Lin-Sca-1+c-kit+ (LSK) cells from sp53 mice 
compared with wt and p53-/- mice (p < 0.05, Fig. 1A); moreover, 
these mice showed enhanced activation of p21 mRNA expres-
sion (Suppl. Fig. S1B), consistent with the enhanced response 
of sp53 mice to DNA damage.13 Therefore, the sp53 LSK cells 
exhibited an improved apoptotic response that likely correlated 
with a decrease in the HSCs number, fact could influence in the 
HSC self-renewal in sp53 mice.
To examine whether the enhanced apoptotic response of sp53 
mice contributes to the HSC behavior in these animals, we tested 
the ability of LSK cells of each genotype (wild-type, s-p53 and 
p53-/-) to competitively repopulate lethally irradiated mice. The 
LSK cells (CD45.2 expressing) were transplanted into lethally 
irradiated recipients of the congenic B6.SJL (CD45.1 express-
ing) strain, together with a fixed number of competitor (CD45.1) 
bone marrow cells, and peripheral blood populations were ana-
lyzed by flow cytometry at 4 and 12 weeks. The repopulating 
capacity of sp53 LSK cells showed a mild increase in repopulating 
capacity compared with wt cells (Fig. 1B), while p53-/- cells was 
three- or four folds higher (p < 0.05), in line with their previ-
ously characterized high HSC self-renewal capacity10 (Fig. 1B). 
These findings were reflected in survival rates after five months: 
ten of eleven recipients (90%) transplanted with competitor plus 
sp53 donor LSK cells survived, compared with three of ten (33%) 
that received competitor plus p53 null donor LSK cells. Together, 
these observations suggest that the increased of LSKs apoptotic 
in sp53 mice does not account for the relatively low self-renewal 
potential of sp53 HSCs.
miR-33 expression upregulates the repopulating ability of 
HSCs. Based on the observation that certain miRNA regulates 
immature hematopoietic cell function, as the miR-29 does dur-
ing early hematopoiesis,19 we wonder whether the divergences 
on HSC self-renewal from mice with different p53 activities 
could be done by specific miRNAs. In this manner, we exam-
ined the miRNAs expression profiles by array analysis of sorted 
multipotent progenitors (MPP: immunophenotypically defined 
as Lin-Kit+Sca1+CD34+Flk-2+, respectively), lineage-committed 
progenitors (Lin+) and highly enriched repopulating HSCs pop-
ulations (with both long- and short-term repopulation abilities, 
defined immunophenotypically as Lin-Kit+Sca1+CD34lowFlk-
2low and Lin-Kit+Sca1+CD34lowFlk-2+) isolated from sp53 and wt 
mice. In this manner, we have identified several putative miR-
NAs differentially expressed (by 2-way Anova analysis with a 
stringent cutoff of 5% FDR for multi-testing correction) (data 
not shown). Expression of 25 mature candidate miRNAs was 
validated by stem-loop RT followed by TaqMan PCR analysis,20 
and normalized against an endogenous small RNA (sno-R2)19 
(data no shown). Two miRNAs, miR-33 and miR-207, drew 
our attention because of their differing expression in the studied 
subpopulations. Of these, miR-33 was expressed at significantly 
lower level in sp53 HSCs compared with wt (p < 0.05) but was 
highly expressed in the sp53 MPP population, while its expression 
in the wt subpopulations showed the inverse pattern (Fig. 2A). 
Overall, it seems that the miR-33 had a possible involvement in 
the HSC function.
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mimic miR-33a into the DB, Ramos and U2932 lymphoma cell 
lines, which have low endogenous miR-33 expression (Suppl. 
Fig. S4A). Overexpression of hsa-miR-33a strongly suppressed 
protein and mRNA expression of p53 in these cells (p < 0.01) 
and also significantly reduced the level of dauxorubicin-induced 
apoptosis (p < 0.01) (Suppl. Fig. S5B). These observations show 
that miR-33 modifies the expression and the activity of p53, 
suppressing p53-induced apoptosis and the response of tumor-
derived cell lines to DNA damage.
miR-33 induces tumorigenesis. To verify and extend the 
above data, we reasoned that downregulation of p53 by miR-33 
should replicate the neoplastic transformation capacity of p53-
null control MEFs.23 To test this, we retrovirally transduced 
wt MEFs with the miR-33 gene, and subsequently transduced 
these cells with oncogenic Ras (RasV12) or control vector. 
Among other miRNAs tested (data not shown), miR-33 sig-
nificantly increased the formation of neoplastically transformed 
foci when co-expressed with RasV12 (p < 0.05), mimicking the 
immortalization and neoplastic transformation phenotypes of 
results indicate that the p53-3'UTR contains putative binding 
sites for miR-33a that mediate the p53 repression.
miR-33 decreases p53-mediated apoptosis. Under physiologi-
cal conditions, the short half-life of p53 keeps its levels relatively 
low. DNA damage or multiple physiological stresses induces 
rapid accumulation of p53 through post-transcriptional mecha-
nisms, activating its potential as a transcriptional activator.7 To 
examine the biological consequences of high levels of miR-33 
levels on the response to DNA damage, parental HCT116 cells 
were treated with cisplatin (30 umol/L) and then transfected 
with mimic hsa-miR-33a. Ectopic miR-33a expression signifi-
cantly suppressed cisplatin-induced apoptosis (~40%; p < 0.01), 
as quantified by Annexin V staining. Subsequent knockdown 
of the ectopic miR-33a by co-expression of miR-33a antisense 
oligonucleotide (antagomiR-33a) rescued the apoptotic response 
(p < 0.01) (Fig. 3D). miR-33a is among a small group of miR-
NAs highly expressed in human B cell chronic lymphocytic leu-
kemia (CLL), which also includes miR-190 and miR-19a.22 To 
investigate the role of miR-33 in lymphoma cells, we transfected 
Figure 2. effect of miR-33 on the self-renewal capacity of sp53 HSCs. (A) Relative normalized expression levels of both miR-33 and miR-207 in FACS-
purified wt, sp53 and p53-/- HSC, Mpp and lineage committed progenitors (Lin+) cells. Data shown are the mean percentage (±SD) (p < 0.05, n = 5). 
(B) Competitive repopulation capacity of sp53 LSK cells transduced with miR-33. Lethally irradiated recipient mice (CD45.1) were transplanted with the 
indicated numbers of cells from wild-type (wt), sp53 and p53-/- mice (CD45.2) and competitor cells (CD45.1). percent chimerism of donor cells 4 and 12 
weeks after transplantation is presented as mean ± SD (p < 0.05).
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Figure 3. Specificity of p53 suppression by miR-33. (A) Schematic representation of the sequence alignment between the mature miR-33 and the 
3'UTR-p53. the miR-33 response elements matching are shown with Watson-Crick base-pairing (in red, identical sequences), and are located into the 
two conserved p53-3'UTR. (B) Reporter experiments were performed in HeLa cells cotransfected with either hsa-miR-33a retroviral vector or miR-33a 
miRNA duplexes, as miR-33a mimic, along with wild-type or mutated versions of the miR-33 putative binding sites in the human p53-3'UTR. the lucifer-
ase ratio between the Firefly and Renilla of the control sample was adjusted to 1. A summary of three independent experiments is shown. Data shown 
are the mean percentage (±SD) (p < 0.01, n = 4). (C) miR-33 dowregulates both mRNA and p53 protein expression. primary wt MeFs were transduced 
with control or miR-33 retroviral expressing vectors and drug-selected for three days; expression levels of both murine p53 and miR-33 were quanti-
fied by qRt-pCR. Data shown are the mean percentage (±SD) (p < 0.01, n = 3). Immunoblot analysis shows the corresponding levels of protein p53. the 
experiment was performed three independent times and a representative result displayed. (D) percentage of apoptotic HCt116 cells upon treatment 
with cisplatin (30 umol/L) for 24 hours and further transfection with either mimic miR-33a alone or mimic miR-33a follow by antagomiR-33a. percent-
age of apoptotic cells was determined after AnnexinV-pI (see details in Materials and Methods). Data shown are the mean percentage (±SD)  
(p < 0.01, n = 6).
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Figure 4. oncogenic activity of miR-33. (A) Foci formation assays on wild-type and INK4a/ARF-/- MeFs (106 cells) retrovirally-transduced with miR-33 or 
an empty vector (control), and subsequently infected with a plasmid encoding oncogenic Ras (RasV12). Foci were scored after 3 weeks before scoring 
the total number of neoplastic foci. Data shown are the mean percentage (±SD) (p < 0.05, n = 6). (B) Colony-formation in soft-agar and tumorigenesis 
assays. Clones (3 x 105 cells) from Ras/miR-33-transformed wtMeFs or Ras/miR-33-transformed INK4a/ARF-/- MeFs were plated on soft-agar for two 
weeks. the figure shows representative fields. For the tumor formation assay, the above-mentioned cells were injected subcutaneously into nude 
mice and the growth of tumors was scored after 21 days. All the data shown in parts (A and B) are representative of a minimum of two independent 
assays. (C) Reciprocal relationship between p53 and miR-33 levels in murine tumors. Representative immunohistochemistry for p53 protein levels and 
qRt-pCR of miR-33 from murine tumors that overexpressed miR-33, after 4 weeks of inoculation. original magnifications, 400x.
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when cells enriched with the miR-33 improved the engraftment 
assays and shorten the survival of recipients. Overall, our data 
indicate that miR-33 plays an important role in the earliest stages 
of hematopoietic development, and that ectopic expression of a 
single miRNA is sufficient to alter hematopoietic self-renewal 
and ultimately aging. We specifically selected the p53-null mice 
as control for the study because the HSC function is upregu-
lated, which could cause the early recipient death.10 Functional 
analysis of the primitive hematopoietic cellular fractions (LSK 
cells) in sp53 and wt mice exhibited small differences in num-
ber and similar competitive reconstitution ability. As a control, 
p53-deficient animals showed increases in both LSK cells in bone 
marrow and LT-HSC, as well as an enforced self-renewal capac-
ity consistent with early studies.10 We also assessed HSC apop-
totic levels in the various p53 genotype categories. Interestingly, 
Annexin/PI staining indicated that HSC fractions from sp53 
showed an important high level of apoptosis, what likely account 
for the slightly reduction in the long-term repopulation HSC 
fractions (LT-HSCs), whereas wt and p53-/- HSCs showed simi-
lar rates of reduced apoptosis. Overall, the improved apoptotic 
response of the sp53 LSK cells, which likely correlated with a 
reduction in the HSCs number, did not account for changes in 
the sp53 HSC self-renewal capacity. Accordingly, a variety of 
tumor types are associated with inappropriate miRNA expres-
sion or structural alterations to miRNA genes, demonstrating 
the oncogenic or tumor-suppressive potential of specific miR-
NAs,26,27 like the miR-33. However, further experiments will be 
required to completely exclude other possible explanations for 
the improved engraftment of miR-33-expressing LSK cells from 
the sp53 mice.
Although numerous protein factors that control p53 have been 
identified as central to many cellular stress responses, few studies 
have addressed the downregulation of p53. miR-125b, the first 
miRNA shown to directly regulate p53, was recently shown to 
play a protective role during development and stress responses.21 
Fornari and colleagues showed that miR-122, by modulating 
cyclin G
1
, influences p53 protein stability and transcriptional 
activity and reduces the invasive capability of hepatocellular 
carcinoma-derived cell lines.28 In addition, recent studies showed 
that p53 binds directly to the miR-34 promoter and activates 
miR-34 transcription in response to DNA damage and oncogenic 
stress, demonstrating that miRNAs can participate in signaling 
downstream of p53.29
The demonstration here of an action of miR-33 upstream of 
p53 extends current understanding of the role of miRNAs in the 
regulation of the p53 pathway. In fact, the importance of miR-
NAs in tumorigenesis is demonstrated in our study when the 
miR-33 can replace p53-loss in the classic oncogenic coopera-
tion assay with oncogenic Ras. It is becoming increasingly clear 
that most miRNAs target multiple genes with related functions, 
and thereby exert strong effects on a particular regulatory path-
way. miR-33 is a good example of this, functioning to influence 
tumor-suppressor networks by suppressing p53, essential regula-
tors of cell survival. Analysis of HSC behavior in miR-33-defi-
cient mice will further define the role of miR-33 in fetal and/or 
adult hematopoiesis, what will help to develop new treatments 
p53-null control MEFs (Fig. 4A). Analysis of miR-33 expres-
sion by real-time PCR confirmed that miR-33 was significantly 
upregulated in Ras/miR-33-transformed wt MEFs, as well 
MEFs transduced with miR-33 alone, relative to its expression 
in control MEFs (p < 0.01; Suppl. Fig. S5). Individual foci from 
Ras/miR-33-transformed wt MEFs were capable of anchorage-
independent growth in soft-agar, a characteristic of oncogenic 
transformation, additionally supported by foci from p53-/- MEF 
cultures, which does not express the miR-33. Ras/miR-33-trans-
formed wt MEFs from the soft agar assays were also able to form 
subcutaneous tumors when injected into nude mice (Fig. 4B), 
supporting the proposed role of miR-33-mediated p53 repression 
in this transformation. To determine the relevance of the above 
findings in vivo, we studied whether there was an inverse correla-
tion between both the protein levels of p53, and the miR-33 levels 
in these murine tumors. In this manner, among the tumors that 
were p53 (n=12) negative, the majority had high levels of miR-33 
(50 to 70%) (Fig. 4C). All together, these remarks indicate that 
the RasV12-associated neoplastic transformation capacity of 
miR-33 is dependent on its repression of p53 and confers onco-
genic potential.
Discussion
It has been demonstrated that changes in p53 status can have 
important effects on cancer incidence, longevity and stem-cell 
function facts that have been demonstrated by different p53 
murine models.5 One of the first direct linkage of p53 with aging 
process was reported by Tyner and colleagues.9 The p53 hyper-
morphic (p53+/m) mice display higher p53 activity than sp53 mice, 
a decrease HSC self-renewal capability in transplantation assays 
and premature aging.9 Thus, alteration of p53 activity appears 
to affect both HSC frequency and self-renewal, allowing a sim-
ple relationship between high p53 activity equals more cancer 
resistance and reduced longevity. However, super-p53 mice that 
have three copies of p53 showed an enhanced p53 response to 
DNA damage and more resistant to spontaneous and carcinogen-
induced tumors than normal mice.24 Importantly, the sp53 mice 
have a normal lifespan and show no evidence of early aging,24 but 
it is still unknown whether the p53 functional activity of these 
mice may alter either HSCs frequency or their HSCs self-renewal 
capacity. Using a variety of in vitro and in vivo assays, our data 
are compatible with a mechanistic model by which the miR-33 
modifies HSC repopulating efficiency of sp53 mice by impairing 
the p53 function.
Although several miRNAs have been shown to regulate the 
differentiation of hematopoietic lineages, there is little informa-
tion available regarding their functional roles in the most imma-
ture hematopoietic cells, HSC and committed progenitors.25 In 
essence, our miRNA profiling of hematopoietic stem cells from 
murine models with different p53 activities provides clues of 
miRNAs, significantly the miR-33 that may be important for 
HSC self-renewal. The functional implications of the miR-33 
were further validated by its ectopic expression in immature 
mouse hematopoietic cells (i.e., LSK). In fact, we have verified 
that HSC from sp53 mice are truly functionally advantageous 
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10% FCS. For miRNAs transduction, retroviral supernatants 
were produced by transient transfection of HEK293T cells with 
pCL-Eco (Imgenex) and retroviral constructs (pMSCV-GFP) 
expressing pre-miRNA mmu-miR-33, for mice and hsa-miR-
33a, for humans (hereafter miR-33 and miR-33a respectively) 
using lipofectamine 2000 (Invitrogen). Primary MEFs were 
transduced with retroviral supernatants for 20 h in the presence 
of 4 ug/ml polybrene (Sigma-Aldrich) and cells were analyzed 
after puromicine selection. miRNA duplexes and antisense oli-
gonucleotides for miR-33a, antagomiR-33a and miRNA mimic 
negative control (Ambion) were transfected at a final concentra-
tion of 100 nM into HCT116 cells using a MEF Nucleofector Kit 
(Amaxa). To generate the wt and mutant Luc-miR-33-promoter 
constructs, a 1.2 kb fragment harboring the miR-33 promoter 
was inserted between the SmaI and SacI sites of the pGL2 lucif-
erase reporter plasmid (Promega). The full-length murine p53 
cDNA was cloned into the pcDNA3-1 vector, downstream of 
the CMV promoter and was transfected into HEK293T cells 
using lipofectamine 2000. The 3'UTRs of both mouse and 
human p53 were amplified from genomic DNA and individu-
ally cloned into the psiCHECK vector (Promega) immediately 
3 downstream of the Renilla luciferase gene. Seed regions were 
mutated to remove complementarity to miR-33 nucleotides 2–7 
with the QuickchangeXL Mutagenesis Kit (Stratagene). Primers 
sequences and amplifications conditions are available from the 
authors on request. The resulting plasmids were confirmed both 
by restriction enzyme digestion and DNA sequencing.
miRNA analysis. Total RNA was prepared from sorted sub-
populations as indicated with Trizol reagent (Invitrogen) and sub-
sequently column-purified with the RNeasy Mini Kit (Qiagen). 
TaqMan MicroRNA assays were used to quantify the level of 
mature miRNAs by TaqMan Reverse Transcription Reagents 
(Applied Biosystems). For qRT-PCR of mRNAs, cDNAs were 
synthesised from 1 mg total RNA. Real-time PCR was carried 
out in triplicate using the SYBR green PCR Master Mix (Applied 
Biosystems) in an ABI PRISM 7700 thermocycler (Applied 
Biosystems). b-actin or sno-R2 were used as endogenous normal-
ization controls. Sequence Detector software was used for data 
analysis and relative fold induction was determined by the com-
parative threshold cycle method.
Mature miR-33 expression was measured using the mirVana 
qRT-PCR miRNA detection kit (Ambion). In brief, total RNA 
was isolated using Trizon (Invitrogen). Complementary DNA 
(cDNA) was synthesized using U6- or miR-33-specific RT 
primer sets, followed by application with their respective PCR 
primer. Expression levels were normalized to endogenous expres-
sion of U6 small nuclear RNA.
Luciferase assays. HeLa cells were co-transfected with the 
indicated reporter constructs and the miR-33 retroviral vector 
(200 ng) using lipofectamine 2000. Cell extracts were obtained 
after 48 h and firefly and Renilla luciferase activities were mea-
sured with the Dual-Luciferase reporter system (Promega) 
according to the manufacturer’s instructions.
Foci formation and tumorigenesis assays. Foci formation 
assays were performed with wt and INK4/ARF-/- MEFs (106 cells) 
co-expressing oncogenic Ras and pre-miRNA retroviral vectors 
that enhance donor HSC engraftment and reduce transplanta-
tion-related complications.
Because p53 is frequently downregulated in cancers in which 
the p53 gene itself is not mutated. From a clinical perspective, it 
will be interesting to investigate whether miR-33-p53 dysregu-
lation represents a novel mechanism for cellular transformation 
in certain types of cancers, and also to determine the poten-
tial of restoring p53 functionality with antagomiR-33 as a new 
approach to cancer therapy.
Materials and Methods
Mice. C57BL/6 wild-type (wt; CD45.2), C57BL6/SJL (CD45.1), 
p53-/- (C57BL/6, CD45.2) and super-p53 (sp53; C57BL/6, 
CD45.2) mice were bred in-house in a pathogen-free environ-
ment, and were provided with standard care and nutrition 
according to institutional guidelines and animal study proposals 
approved by the CNIC. C57BL6/SJL (CD45.1) mice were pur-
chased from The Jackson Laboratories.
Flow cytometric analysis. Murine hematopoietic stem and 
progenitor cells were evaluated by flow cytometry and obtained 
by flushing the femurs and tibias with washing medium (DMEM, 
2% FBS, 10 mM Hepes pH 7.2). A single-cell suspension was 
filtering through a 70 mm nylon cell strainer and stained with 
a lineage (Lin) cocktail of biotinylated antibodies to CD11b, 
Gr-1, Ter119, CD3e and CD45R/B220 (BD Biosciences). For 
detection and sorting, we used streptavidin conjugated-PE or 
Cy7, Sca1-PE/Cy5.5, c-Kit-APC (CD117), Flk-2-PE (CD135) 
and CD34-FITC (all from BD Biosciences). For the apoptosis 
assay, we used PI (Molecular Probes) and AnnexinV-APC (BD 
Biosciences).
Repopulation assay. Transplants were performed into the con-
genic CD45.1+ B6.SJL mouse strain and monitored for CD45.2+ 
donor-derived cells. Transplants were discontinued when sur-
vival was below 50%. For the competitive repopulation assay, we 
injected 2000 LSK from wild type, sp53 and p53-/- mice (CD45.2) 
together with 5 x 105 competitor cells (CD45.1) into lethally 
irradiated B6.SJL mice (CD45.1). For retroviral transduction of 
miRNAs, LSK cells (5 x 105) isolated from wt, p53-/- and sp53 
mice were infected with miRNA retroviruses (at least 106 cfu/ml) 
by spinoculation (at 1,600x g and at 37°C). Following 24 hours 
of culture in medium containing 10 ng/ml IL-3, 10 ng/ml IL-6 
and 100 ng/ml stem cell factor, a second round of spinoculation 
was performed, followed by an additional 24 hours of culture. 
Then 2.5 x 104 infected cells were mixed with 4 x 105 “support-
ive” B6/SJL bone marrow cells and injected, via the retro-orbital 
route, into lethally irradiated C57/Bl6J (11 Gy) recipient mice. 
Peripheral blood cell counts were obtained by tail vein nicking 4 
and 12 weeks post-transplantation, red blood cells were lysed with 
NH
4
Cl and the remaining cells were stained with either APC-
anti-CD45.2 (eBioscience), FITC-anti-CD45.1 (eBioscience).
Cells and gene transfer. HEK-293T, HeLa and HCT116 
cells were grown under standard conditions in DMEM supple-
mented with 10% FCS at 37°C. Isolation, culture and assays 
with MEFs were done as described.30 The DB, Ramos and U2932 
lymphoma cell lines were cultured in RPMI supplemented with 
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1% H
2
O
2
, immersed in boiling 1 mM EDTA buffer for 2 min 
and incubated in 10% normal horse serum for 30 min at RT. 
Anti-p53 (M-156; Santa Cruz) antibodies were used. Samples 
were then incubated with biotinylated anti-mouse IgG followed 
by avidin-biotin peroxidase complexes (Vector Lab.) for 30 min. 
Diaminobenzidine was used as the chromogen and hematoxylin 
as the nuclear counterstain.
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or empty vector (control). After 3 weeks, transfected plates were 
scored for the total number of neoplastic foci by visual inspec-
tion and under the microscope. For the tumorigenesis assay, 
cells from neoplastic foci were harvested and resuspended in 
PBS. Cells (5 x 105) were mixed with Matrigel Matrix (150 ml) 
(BD Bioscience) and injected subcutaneously into both flanks 
of nude mice. Tumor volumes were estimated from caliper 
measurements.
Protein analysis and immunohistochemistry. Immunoblots 
were performed following standard procedures. For detection of 
murine p53, we used polyclonal antibody M-156 (Santa Cruz); 
for human p53, monoclonal antibody 1801 (Cell Signaling); and 
for b-actin, monoclonal antibody AC-15 (Sigma). Secondary 
antibodies were either HRP-linked anti-rabbit IgG (Amersham) 
or HRP-linked anti-mouse IgG (DAKO). Signals were detected 
by enhanced chemiluminescence (GE lifesicences). Regarding 
murine tumors, twenty-seven samples were analyzed by immu-
nohistochemistry. Sections were deparaffinized, treated with 
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Abstract: The ability of cancer cells to divide indefinitely whilst supporting tumor growth, metastasis and invasiveness 
resembles the behavior of stem cells. Here, we overview the role of Polycomb (PcG)-dependent epigenetic silencing 
mechanisms in stem cell biology and cancer, focusing on two major PcG components, Ezh2 and Bmi1. In a recent patent, 
stem cell PcG targets were shown to be more prone to cancer-specific promoter DNA methylation than non-targets, indi-
cating that reversible PcG-mediated gene repression becomes replaced by permanent silencing. This epigenetic switching 
keeps the cell in a sustained state of self-renewal, predisposing it to tumorigenic transformation. These findings might 
provide the means of identifying the stem-cell epigenetic signatures associated with the origin of specific types of cancer. 
Based on the reversibility of epigenetic histone modifications, PcG proteins have become established targets in clinical 
practice for the treatment of a variety of cancers, notably treatments with histone deacetylase and methyltransferase in-
hibitors. A number of reports and patents highlight the potential of alternative approaches to targeting PcG for cancer 
therapy, including micro-RNA expression and the use of Hedgehog signaling pathway antagonists. The major shortcom-
ing of current approaches is their lack of specificity. The identification of tumorigenic epigenetic alterations together with 
the development of inhibitors to target them promises to open the way toward personalized cancer treatment. 
Keywords: Bmi1, cancer, epigenetic reprogramming, epigenetic switching, Ezh2, histone deacetylase inhibitors, histone meth-
yltransferase inhibitors, polycomb, stem cells. 
INTRODUCTION 
Stem Cells and Cancer 
 Stem cells provide the source for replenishing mature 
cells in the organism throughout its life while also maintain-
ing the stem-cell pool itself [1]. This maintenance is 
achieved by self-renewal, a specialized cell division in which 
one or both daughter cells remain in the undifferentiated 
state, retaining essentially the same replication potential of 
the parent cell. The self-renewal program is achieved 
through a finely-tuned network of regulatory genes which 
are only just beginning to be decoded [2]. In response to 
DNA mutations, stem cells must suppress self-renewal, and 
the damaged cells must be eliminated to prevent their repli-
cative expansion. This is achieved through the activation of 
tumor-suppressor mechanisms leading to senescence and/or 
apoptosis. There is a clear resemblance between stem cells 
and the ability of certain cancer cells to divide indefinitely 
while simultaneously supporting tumor growth, metastasis 
and invasiveness [3]. Indeed, alterations involving these 
regulatory pathways can potentially give rise to so-called 
cancer stem cells, which, according to the cancer stem cell 
hypothesis, underlie the origin of most cancers [4]. Cancers 
contain different cell types, but a variety of observations 
indicate that tumors are driven and sustained by this rare 
population of cancer stem cells that both self-renew and give 
rise to non-stem cancer cells [5]. This suggests that the same 
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genes are likely to regulate self-renewal in normal stem cells 
and cancer stem cells, and emphasizes the importance of 
identifying and understanding these genes for the develop-
ment of efficient anti-cancer strategies.  
 The immortality of cancer cells might originate through 
the activation of stem-cell-specific pathways that are essen-
tial for self renewal, such as Wnt (wingless and int), Sonic 
Hedgehog or Notch [6, 7]. Genomic analysis reveals a strong 
correlation between the transcriptomes of stem cells and the 
most undifferentiated and proliferative tumor cells, associ-
ated with poor prognosis [8-12]. For instance, the oncogene 
Myc can reactivate an embryonic stem cell (ESC)-like pro-
gram in normal and cancer cells [12]. This action of Myc is 
independent of its canonical transcription factor activity [13], 
and involves Myc-induced epigenetic regulation through 
histone hyperacetylation [14, 15]. Furthermore, promoter 
occupation by Myc correlates strongly with a histone H3 
lysine 4 trimethylation (H3K4me3) signature and correlates 
inversely with H3K27me3 [16]. Other chromatin conforma-
tion similarities between ESCs and the most undifferentiated 
cancer cells include loss of heterochromatin markers such as 
heterochromatin protein 1? (HP1?) [17, 18] and of H3 di-
methylation on lysine 9 (H3K9me2) [19]. In ESCs, many 
tumor suppressor and pro-differentiation genes are epige-
netically silenced by marking with bivalent domains, while 
cancer cells, in addition to these marks, further acquire 
methylation on H3K9 and DNA [5]. These additional repres-
sive marks have been suggested to contribute to a higher-
order chromatin organization that permanently silences tu-
mor suppressor and pro-differentiation factor genes [20]. 
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 One of the best-characterized mediators of epigenetic 
silencing is the Polycomb group (PcG) of proteins. Recent 
work shows that PcG target genes in ESCs are more likely to 
become methylated in cancer [10, 11, 21], supporting an 
important role for PcG-mediated gene silencing via aberrant 
DNA methylation in oncogenesis [22] Fig. (1). Permanent 
gene silencing in cancer cells is related to altered expression 
of the PcG components Bmi1 (B lymphoma Mo-MLV inser-
tion region), a component of Polycomb repressive complex 
(PRC)-1, and Ezh2 (enhancer of zeste homologue 2), the 
histone-methylating component of PRC2 [23, 24]. Impor-
tantly, Bmi1 is regulated by Sonic Hedgehog in certain stem 
cell populations, providing evidence of a direct connection 
between PcG and a major stem cell-specific pathway [25]. 
ROLE OF POLYCOMB SILENCING MECHANISMS 
IN THE MAINTENANCE OF STEMNESS  
 PcG proteins regulate self-renewal and lineage restriction 
in stem cells by inducing reversible chromatin modifications. 
PcG proteins have attracted increasing attention in stem cell 
and cancer stem cell research, given that it is now widely 
recognized that dynamic reprogramming of cells, for in-
stance during differentiation, requires alterations to the epi-
genetic status of genes [26] Fig. (1).  
 The two major multiprotein PcG complexes identified to 
date, PRC1 and PRC2, function in a cooperative manner to 
maintain gene silencing Table 1. PRC2 initiates silencing, 
whereas PRC1 maintains and stabilizes gene repression. 
PRC2 contains histone methyltransferases (HMTs) that 
methylate lysines 9 and 27 on histone H3 and lysine 26 on 
histone H1. Deletion of PRC2 genes in mice results in early 
embryonic death, underscoring their importance in develop-
ment. PRC1 recognizes the H3 lysine 27 methyl group added 
by PRC2 [26], and subsequently the monoubiquityl-ligase 
activity of the PRC1 proteins Bmi1 or Ring1A/B toward 
histone H2A generates uH2AK119, which prevents access of 
the transcription machinery and facilitates chromatin com-
paction [27]. Mouse mutants of most PRC1 members, in 
spite of displaying homeotic transformations, survive until 
birth as a result of partial functional redundancy provided by 
homologues, an exception being Ring1B-deficient mice [28].  
 PRC2 is recruited to target genes by the cofactor jARID2 
(jumonji/ARID domain-containing 2). Paradoxically, 
jARID2 also seems to inhibit PRC2 methyltransferase activ-
ity and may therefore regulate both the targeting and fine-
tuning of PRC2 activity in stem cells and during differentia-
tion [29-31]. Once PRC1 recognizes and binds the 
H3K27me3 mark added by PRC2, it recruits additional pro-
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Epigenetic switching from Polycomb-mediated histone methylation to aberrant DNA methylation. Tumor supressor genes are 
expressed in normal cells and become silenced in cancer. This can occur by Polycomb reprogramming through Ezh2-mediated methylation 
of H3K27. Polycomb-mediated repression is reversible and can be targeted by different strategies, such as histone methylase inhibitors 
(DZNep) and other nucleoside analogues, histone deacetylase inhibitors, Hedgehog signaling pathway antagonists (cyclopamine), and the 
induction of miRNAs (miR-101, miR-200c, miR-15a, miR-16). Polycomb-silenced targets in normal stem and progenitor cells are prone to 
DNA methylation, which replaces reversible gene repression with permanent silencing, locking the cell into a perpetual state of self-renewal 
and predisposition to subsequent malignant transformation, a process called epigenetic switching. It is not yet clear whether DNA methyl-
transferase inhibitors can reverse epigenetic switching to restore the Polycomb-repressed state, whereas combination of these compounds 
with histone deacetylase inhibitors has recently been shown to reactivate PcG targets. Red arrows represent Polycomb-related epigenetic 
alterations during transformation; green arrows represent reversion of these alterations by Polycomb-targeted epigenetic therapy.  
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teins to establish the repressed chromatin configuration [23]. 
Gene promoters marked with H3K27me3 in ESCs are sig-
nificantly more likely than other promoters to become meth-
ylated in cancer [10, 11, 21]. Moreover, the PcG targets in 
normal prostate cells are the same as those that become 
methylated in prostate cancer [32]. Thus, altered chromatin 
structure does not always result in changes in gene expres-
sion associated with disease. Rather, disease results from the 
replacement of PcG repressive histone marks with methyla-
tion directly on DNA, which locks the chromatin in an inac-
tive state, a process called epigenetic switching [32] Fig. (1). 
Although the mechanism underlying predisposition of PcG 
targets to DNA methylation is not fully understood, the 
PRC1 component Cbx7 (chromobox homologue 7) was 
recently shown to interact directly with DNA (cytosine-5)-
methyltransferase (DNMT)1 and DNMT3B at PcG target 
genes, establishing a link between histone and DNA methy-
lation [33]. 
 Among PcG proteins, the PRC1 component Bmi1 is a 
fundamental self-renewal regulator, being required for the 
self-renewal of all postnatal stem cell populations studied to 
date [34-36]. Bmi1 was originally described as a proto-
oncogene that induces B and T cell leukemias [37, 38], and 
is overexpressed in several human cancers, including mantle 
cell lymphoma, colorectal carcinoma, liver carcinomas, non-
small-cell lung cancer, and cerebral tumors such as medul-
loblastomas [39-43]. This evidence has strongly influenced 
cancer research, supporting the above-mentioned theory that 
cancer is essentially a stem cell disorder [7]. The self-
renewal function of Bmi1 in adult stem cells relies largely on 
the silencing of one of its targets, the locus encoding the 
p16INK4a and ARF tumor suppressors [36, 44]. Deletion of 
p16INK4a and/or ARF partially rescues the self-renewal 
defects observed in various stem cell populations from 
Bmi1-null mice [45-47]. Nevertheless, as described by the 
authors, this rescue is incomplete and thus other major Bmi1 
regulated genes must exist [47]. Candidates for additional 
Bmi1 targets in the context of self renewal are the Hox (ho-
meobox) genes. A subset of Hox genes has been implicated 
in mammalian brain development, and several of them are 
highly expressed in neurospheres formed in vitro from cul-
Table 1. Major Polycomb Group Proteins. 
Drosophila Melanogaster Human Mouse 
PRC2 / Initiation complex 
ESC EED EED 
E(Z) EZH1  
EZH2 
EZH1/ENX2  
EZH2/ENX1 
SU(Z)12 SUZ12 SUZ12 
PRC1 / Maintenance complex 
PC CBX2/HPC1 CBX2/M33 
 CBX4/HPC2 CBX4/MPC2 
 CBX8/HPC3 CBX8/PC3 
 CBX7 CBX7 
PH EDR1/HPH1 EDR1/MPH1/RAE28 
 EDR2/HPH2 EDR2/MPH2 
 EDR3/HPH3 EDR3 
RING RING1/RNF1/RING1A RING1/RING1A 
 RNF2/RING1B RNF2/RING1B 
PSC BMI1 BMI1 
 RNF110/ZFP144/PCGF2 RNF110/ZFP144/MEL18 
 ZNF134 ZNF134 
PHO YY1 YY1 
PHO-like 
SCM 
SCML1 SCMH1 
 SCML2 SCMH2 
PCL PHF1 PHF1/PCL1 
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tured neural stem cells of the subventricular zone of Bmi-
null mice [36]. More recently, Bmi1 and Ring1A were 
shown to play essential roles in H2A ubiquitylation and Hox 
gene silencing. Knockout of Bmi1 results in significant loss 
of H2A ubiquitylation and an upregulation of HoxC13 ex-
pression, whereas Ezh2-mediated H3-K27 methylation is not 
affected [48]. Similar findings have been described for the 
HoxC5 gene. Bmi1 stimulates the H2A ubiquitin ligase ac-
tivity of Ring1A/B, which is required for HoxC5 silencing 
and cell growth in HeLa cells [49]. However, considering 
that PcG proteins modify the chromatin of large sets of genes 
[50], a great number of additional targets are likely to exist. 
For instance, both PRC2 and Bmi1 have recently been 
shown to play roles in the repression of E-cadherin expres-
sion [51, 52]. Interestingly, PcG genes have been shown to 
have a tumor suppressive function. In Drosophila, PcG pro-
teins repress JAK/STAT and Notch signaling activity, whose 
activation drives disc cell overproliferation [53]. Specifi-
cally, the Drosophila complex Psc (posterior sex combs), 
which includes Bmi1, and Suz12 (suppressor of zeste 12) 
play a tumor suppressive role mediated by Wnt repression in 
follicle stem cells [54]. In mammals, Eed (embryonic ecto-
derm development protein) displays tumor suppressive activ-
ity in the mouse hematopoietic system [55]. Thus, PcG genes 
have been suggested to behave either as proto-oncogenes or 
as tumor suppressors depending on the tissue, cell context, 
developmental stage and gene dosage [56]. 
 Bmi1 is regulated by Sonic Hedgehog, providing a direct 
connection between PcG and a major stem cell-specific 
pathway [25]. Furthermore, activation of either Hedgehog or 
Notch signaling has been shown to increase Bmi1 expres-
sion, whereas siRNA knockdown of Bmi1 abrogates the 
effects of Hedgehog or Notch signaling on sphere formation, 
a functional readout of stemness. Thus the effects of Hedge-
hog and Notch signaling on stem cell self-renewal appear to 
be largely dependent on Bmi1 [57]. A complex regulation of 
Bmi1 is suggested by the fact that distinct Bmi1 regulators 
have been found in different types of cancer, for example 
Twist1 in head and neck squamous cell carcinoma and the 
Zeb1 (zinc finger E-box binding homeobox 1) – miR-200 
pathway in pancreatic cancers [52, 58]. Furthermore, a single 
PcG function can be regulated by multiple factors, for exam-
ple Snail1 regulates E-cadherin silencing by PRC2, whereas 
the action of PRC1 on this target is regulated by Twist1 [51, 
52]. 
 In summary, PcG proteins, in particular Bmi1, are essen-
tial for self-renewal and proliferative potential, which are 
crucial for the maintenance of stemness, acting as a critical 
failsafe mechanism against loss of stem cells in response to 
senescence signals. In turn, Bmi1 must be finely-regulated to 
prevent uncontrolled replicative expansion and tumor induc-
tion. Despite the importance of PcG proteins, we are only 
beginning to unravel how these master regulators are them-
selves regulated to achieve an appropriate balance between 
ensuring stem cell longevity and preventing tumorigenesis. 
A POLYCOMB-MEDIATED EPIGENETIC STEM 
CELL SIGNATURE IN CANCER 
 The targets of PcG suppression in stem cells have re-
cently been shown to be up to twelve times more likely to 
show cancer-specific promoter DNA methylation than non-
targets, indicating a stem cell origin for cancer in which 
reversible gene repression is replaced by permanent silencing 
that results in perpetual self-renewal [10] Fig. (1). Laird and 
Widschwendter [10] have described and patented a method 
for identifying preferred DNA methylation signatures for 
specific cancers. The procedure is based on identifying PcG 
proteins and PcG target loci in a precursor cell population, 
and subsequently determining the characteristic methylation 
status of at least one CpG dinucleotide within these loci in 
the cancer cells. Cancer-specific hypermethylated CpG 
dinucleotides occur more frequently in developmental re-
pressor loci occupied by the PRC2 components Suz12 and 
Eed and the H3K27me3 silencing mark. The definition of the 
stem cell signature is improved if the cancer cells also ex-
press at least one of the transcription factors OCT4 (octamer-
binding transcription factor 4), SOX2 (sex determining re-
gion Y-box 2) or Nanog [10]. In a previous report the same 
authors studied the DNA methylation of 195 gene promoters 
in ten primary human colorectal tumors and matched normal 
mucosae [59]. They subsequently identified and correlated 
cancer-associated DNA methylation with the occupancy of 
Suz12 and Eed and the H3K27Me3 status in stem cells [60]. 
This association was independently confirmed for genes 
methylated specifically in ovarian or breast cancer [10]. In 
independent microarray experiments, Hatada et al. [61] 
showed that a high percentage of hypermethylated genes in 
lung cancer cells had at least one PRC2 mark.  
 The predisposition of ESC PRC2 targets to cancer-
specific DNA hypermethylation indicates crosstalk between 
PRC2 and DNMTs in early precursor cells with a PRC2 
distribution similar to that of ESCs [10]. ESCs and other 
stem and embryonic cell types display a similar profile of 
PRC2 targets, whereas the set of PRC2 targets in cancer cell 
lines is markedly different [62], confirming that the crosstalk 
leading to predisposition to DNA methylation occurs early in 
oncogenesis. Moreover, not all cancer-specifically methy-
lated genes are ESC PRC2 targets, and thus PRC2 targets in 
other stem or progenitor cells contribute to the diversity of 
DNA methylation targets observed in different types of can-
cer [10]. Additionally, PRC1 Cbx7 has been shown to inter-
act directly with DNMT1 and DNMT3B at PcG target genes 
[33]. 
 DNA methylation is also observed in adult stem cell 
populations, such as CD34-positive hematopoietic progenitor 
cells. In CD34-positive cells, DNA methylation was twice as 
frequent in genes containing at least two of the PRC2 marks 
than in genes lacking these marks [10]. The authors proposed 
that aberrant PRC2-DNMT crosstalk occurs at low frequency 
in stem cells, and does not disrupt normal differentiation if 
the silencing affects only a small number of PRC2 targets 
that are not essential for differentiation. However, if a suffi-
cient number of a particular subset is affected, then the re-
sulting DNA methylation prevents proper differentiation, and 
predisposes the cell to further malignant development. 
 Screening for promoter DNA hypermethylation in PRC2 
targets has substantial potential for therapeutic applications, 
including the transplantation of precursor cells derived from 
cloned or cultured ESCs [63]. To date, the potential of undif-
ferentiated precursors to expand after host engraftment pre-
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sented a major hurdle for their use in regenerative therapy, 
since they might ultimately lead to tumor formation. It is 
now possible to use the DNA hypermethylation markers to 
identify, screen, select or enrich for a precursor cell popula-
tion and separate it from those cells with a developmental 
predisposition to cancer [10]. Further understanding of the 
mechanisms underlying epigenetic switching might suggest 
ways to epigenetically reprogram abnormal tissue in order to 
regain a differentiated fate and recover normal cell function.  
POLYCOMB COMPLEXES AS THERAPEUTIC 
TARGETS IN CANCER 
 The reversibility of epigenetic modifications makes them 
especially attractive targets in cancer therapy Fig. (1). For 
instance, targeting PcG Bmi1 by small, noncoding microR-
NAs (miRNAs) such as miR-128 results in cell proliferation 
arrest and loss of self-renewal in human glioma neurosphere 
cultures [64]. However, we currently lack sufficient under-
standing of the regulatory mechanisms of epigenetic silenc-
ing and the appropriate ways to target PcG proteins. 
 Drugs that target histone methylases have shown the 
most promising results, although more work is needed to 
define their specificities and characterize the stability of their 
effects. For instance, in preclinical studies, DZNep (S-adeno-
sylhomocysteine hydrolase inhibitor 3-deazaneplanocin A) 
depleted the levels of the core PRC2 components Ezh2, Eed 
and Suz12. Consequently, H3K27me3 levels declined, lead-
ing to apoptosis of cancer cells but not normal cells [65, 66]. 
This drug is an effective treatment for cancers characterized 
by high Ezh2 expression, such as prostate and breast cancer 
[67]. Interestingly, DZNep strongly impairs the self-renewal 
of glioblastoma multiforme cancer stem cells in vitro and 
their tumor-initiating capacity in vivo. Expression of c-Myc, 
which is essential for glioblastoma multiforme cancer stem 
cells, is strongly repressed upon DZNep-induced depletion 
of Ezh2 [68]. However, DZNep has subsequently been found 
to also decrease the levels of H4K20me3, demonstrating its 
lack of specificity [69]. 
 Ezh2 is also degraded upon treatment with other nucleo-
side analogues such as decitabine (2’-deoxy-5-azacytidine) 
and cytarabine (1?-arabinofuranosylcytosine) [70]. These 
DNMT inhibitors (DNMTI) are effective treatments for 
myeloid leukaemias, a group of diseases characterized by a 
differentiation block of precursor cells [71]. Unlike DZNep, 
decitabine and cytarabine induce differentiation by triggering 
the caspase-dependent degradation of Nanog and OCT4 [70]. 
The patterns of demethylation induced by azacytidine and 
decitabine in colon cancer and leukemia cell lines are highly 
specific, non-random and reproducible, demonstrating tar-
geted demethylation of specific loci [72]. Demethylation 
occurs preferentially at CG dinucleotides within CG islands, 
indicating a role for DNA sequence context. However, a 
subset of genes is never demethylated by treatment with 
these drugs, and these genes are enriched for PRC2 compo-
nents in ESCs [72]. Thus, DNMTIs alone do not reactivate 
PcG targets, at least in the two independent cancer cell lines 
that have been investigated. 
 Bmi1 expression in cultured cells can be targeted by 
treatment with sodium butyrate (NaB), a histone deacetylase 
inhibitor (HDACI). This provides a possible novel explana-
tion for the anti-cancer actions of HDACIs against many 
hematologic malignancies and some solid tumors. Inhibition 
of PcG proteins by NaB in breast cancer cell lines leads to 
the induction of growth-inhibitory genes such as p21WAF1 
and p57KIP2, and to cell death via premature senescence and 
apoptosis. The transcriptional repression of Bmi1 by NaB is 
independent of c-Myc, which was previously shown to be 
necessary for Bmi1 expression, and it remains unknown 
what factor or factors link the HDACI action of NaB to 
downregulation of Bmi1 [73]. Another HDACI, panobi-
nostat, enhances DZNep-mediated reduction in Ezh2 expres-
sion, leading to increased expression of p16, p21, p27 and 
FBX032, and apoptosis, in cultured acute myeloblastic leu-
kemic cells and mouse models [74]. More recently, com-
bined treatment with the HDACI entinostat and the demethy-
lating agent vidaza was found to strongly inhibit growth of 
engrafted K-ras/p53 mutant lung adenocarcinomas in nude 
rats by targeting and ablating pleomorphic cells that occu-
pied 75% of the tumor masses [75]. The same combination 
therapy causes a similar reduction in tumor burden in ortho-
topically growing K-Ras or EGFR mutant tumors. Re-
expression of PcG-regulated genes such as p16 and others 
coding for transcription factor binding proteins was observed 
in the treated tumors, together with increased expression of 
proapoptotic genes and the cyclin-dependent kinase (CDK) 
inhibitor p21 [75]. Thus, combination of HDACIs with 
DNMTIs may allow reactivation of PcG targets. 
 PcG activity is regulated by signaling pathways, and 
these may serve as viable therapeutic targets for the inhibi-
tion of PcG-driven tumorigenicity. For instance, Ezh2 gene 
transcription is negatively regulated by the tumor suppresor 
protein RB (retinoblastoma protein) [76]. AKT phosphory-
lates Ezh2 at Ser21, suppressing its methyltransferase activ-
ity and thereby reducing the levels of H3K27me3. The phos-
phorylated-Ezh2 complex can target non-histone substrates 
that are important for tumorigenicity, providing an explana-
tion of why overexpressed Ezh2 has less methyltransferase 
activity toward histone H3 in certain cancers [77]. In these 
cases, the frequency of H3K27 trimethylation can be restored 
by treating with LY294002, an inhibitor of the phosphatidy-
linositol-3-kinase/AKT signaling pathway. Additionally, 
CDK1 and CDK2 phosphorylate Ezh2 at Thr350 under 
physiological conditions. CDK-mediated phosphorylation 
improves Ezh2 recruitment and maintains H3K27me3 levels 
at PcG-target loci, and is essential for Ezh2-driven prolifera-
tion and migration of prostate cancer cells [78]. In contrast, 
phosphorylation of Ezh2 by CDK1 at Thr487 inhibits Ezh2 
target binding and HMT activity through disruption of the 
PRC2 complex. Accordingly, treatment of cancer cell lines 
with the CDK1 inhibitor CGP74514A increases H3K27me3 
levels [79]. In prostate cancer, Ezh2 activity is also regulated 
by the oncogenic transcription factor ERG (E-twenty-six 
related gene). ERG binds to the Ezh2 promoter and can in-
duce Ezh2 overexpression, and thus pharmacological inhibi-
tion of ERG activity has the potential to reduce the elevated 
Ezh2 levels associated with some prostate cancers, as shown 
in published and patented work [80, 81]. As mentioned 
above, Bmi1 is regulated by interactions between the Sonic 
Hedgehog and Notch pathways, and mediates the effects of 
these pathways on mammary stem cell self-renewal. The 
recent patent of Wicha and colleagues describes how Bmi1 
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activity in breast tumor cells can be reduced by treatment 
with Hedgehog signaling pathway antagonists such as cyclo-
pamine or analogues [57]. Another recent patent indicates 
that retinoic acid treatment of NTERA2 cells, an embryonic 
carcinoma cell line, significantly reduces expression of Bmi1 
by targeting the upstream zinc finger transcription factor 
SALL4 [82]. 
 A number of published studies and patents show a corre-
lation between PcG alterations in cancer and dysregulated 
expression of miRNAs [67, 83-88]. For example, miR-101 
targets Ezh2 for degradation and is downregulated in several 
types of cancer, leading to increased Ezh2 levels and de-
creased expression of tumor suppressor genes. Restoring 
expression of miR-101 reduces H3K27me3 levels and inhib-
its colony formation and cell proliferation, for instance in 
prostate cancer [67, 84, 85]. miR-200c, which is downregu-
lated in human breast cancer stem cells, inhibits the in vitro 
clonal expansion of breast cancer cells and in vivo tumor 
formation driven by human breast cancer stem cells. An 
effect of miR-200c on Bmi1 expression has been suggested 
as a plausible mechanism for these effects [85-87]. In ovar-
ian cancer patients and cell lines, miR-15a and miR-16 are 
underexpressed, which correlates inversely with Bmi1 pro-
tein levels. In vitro, these miRNAs directly target the Bmi1 
3’ untranslated region, and subsequently Bmi1 protein levels 
are downregulated, leading to a significant reduction in ovar-
ian cancer cell proliferation and clonal growth [88]. 
 Furthermore, Bmi1 has recently been shown to influence 
the response of tumors to chemotherapy [89,90]. Bmi1 si-
lencing enhances docetaxel chemotherapy activity and im-
pairs Bmi1-driven antioxidant responses in prostate cancer 
cell lines [89]. In the same report, examination of clinical 
datasets revealed a positive correlation between Bmi1 and 
antioxidant gene expression, predictive of poor prognosis in 
pancreatic cancer patients. Thus, Bmi1 enhances antioxidant 
responses, and thereby might allow pancreatic cancer cells to 
survive docetaxel-based chemotherapy [89]. Similarly, Bmi1 
silencing reduces intracellular glutathione levels and exacer-
bates ROS production in response to chemotherapeutics such 
as cisplatin, leading to apoptosis of chemoresistant ovarian 
cancer cells. In an in vivo orthopic mouse model of chemore-
sistant ovarian cancer, knockdown of Bmi1 by nanoliposo-
mal delivery of Bmi1 siRNA significantly inhibits tumor 
growth. Importantly, combination of Bmi1 knockdown with 
cisplatin therapy almost completely abrogated tumor growth 
[90].  
 Thus, PcG proteins, as master molecular regulators of the 
cellular epigenetic landscape, are currently established in 
clinical practice as effective targets for the successful treat-
ment of a variety of cancers, particularly through inhibition 
of histone methylases and deacetylases. The mechanisms 
underlying the therapeutic benefit of these compunds are not 
yet clear, but ongoing work combining genomic sequencing 
and expression data may provide the answers. 
CURRENT & FUTURE DEVELOPMENTS 
 PcG proteins play a crucial role in maintaining stemness 
and thus must be finely regulated to prevent uncontrolled 
replicative expansion and tumor induction. We are just be-
ginning to decipher the complex regulatory networks con-
trolling PcG master regulators, which include major stem 
cell-specific pathways such as Hedgehog and Notch. Simi-
larly, PcG proteins appear to target a large variety of genes 
in addition to tumor supressors, including the Hox genes. A 
complete picture of the regulatory mechanisms underlying 
PcG silencing and their downstream targets is absolutely 
required for the development of appropriate and specific 
means to target PcG proteins. 
 Recent evidence demonstrates that stem cell PcG target 
genes are much more prone to promoter DNA methylation 
than other genes. This switch from histone methylation to 
DNA methylation, called epigenetic switching, replaces 
reversible gene repression by permanent silencing, leading to 
persistent self-renewal and predisposition to malignant trans-
formation [10] Fig. (1). Screening for DNA hypermethyla-
tion of PcG target promoters has great therapeutic potential, 
and could be used for instance to remove cells with devel-
opmental predisposition to cancer before transplantation of 
precursor cells derived from cloned or cultured ESCs [63]. 
 The reversibility of PcG reprogramming makes PcG 
proteins attractive targets in cancer therapy Fig. (1). A num-
ber of clinical and preclinical studies show the benefits of 
therapies that inhibit PcG, such as inhibitors of histone 
methylases and deacetylases; however, more work is needed 
to develop inhibitors that target specific epigenetic altera-
tions and thus minimize side effects. High-throughput tech-
nologies such as genome-wide sequencing combined with 
RNA profiling and chromatin immunoprecipitation are gen-
erating a great amount of data that is being used to identify 
epigenetic alterations underlying the origin of cancer. Char-
acterization of the PcG-mediated epigenetic stem cell signa-
ture, unique to each type of cancer [10], has enormous poten-
tial to improve diagnosis and intervention. The combination 
of these approaches holds the promise of making personal-
ized cancer treatment a reality. 
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SUMMARY
Polycomb group (PcG) proteins are key epigenetic
regulators of hematopietic stem cell (HSC) fate. The
PcGmembers Ezh2 and Ezh1 are important determi-
nants of embryonic stem cell identity, and the tran-
script levels of these histone methyltransferases
are inversely correlated during development. How-
ever, the role of Ezh1 in somatic stem cells is largely
unknown. Herewe show that Ezh1maintains repopu-
lating HSCs in a slow-cycling, undifferentiated state,
protecting them from senescence. Ezh1 ablation
induces significant loss of adult HSCs, with concom-
itant impairment of their self-renewal capacity due
to a potent senescence response. Epigenomic and
gene expression changes induced by Ezh1 deletion
in senesced HSCs demonstrated that Ezh1-medi-
ated PRC2 activity catalyzes monomethylation and
dimethylation of H3K27. Deletion of Cdkn2a on the
Ezh1 null background rescued HSC proliferation
and survival. Our results suggest that Ezh1 is an
important histonemethyltransferase for HSCmainte-
nance.
INTRODUCTION
Epigenetic regulation of chromatin structure is thought to con-
trol cell memory, and Polycomb group (PcG) proteins are impor-
tant components of diverse epigenetic phenomena, including
genomic imprinting, cell fate determination, stem-cell plasticity
and renewal, and cancer development (Goldberg et al., 2007).
PcG-mediated epigenetic alteration of hematopoietic stem cells
(HSCs) is considered a driving force behind many age-related
HSC changes and is often dysregulated in human malignancies
(Sauvageau and Sauvageau, 2010). Protection of the transcrip-
tional ‘‘stemness’’ network is thus essential for the maintenance
of a healthy HSC compartment throughout life. However, little is
known about how epigenetic mechanisms dictate the activities
of Polycomb factors to ensure blood homeostasis.
PcG proteins assemble in multimeric complexes and induce
transcriptional repression of target genes through chromatin
changes such as methylation of lysine 27 on histone 3 (H3K27).
Biochemical analysis revealed that PcG proteins assemble in at
least two complexes, Polycomb repressive complexes 1 and 2
(PRC1 and PRC2). Studies of mouse mutants showed that these
factors are essential for normal development, with deletion of
Polycomb genes resulting in prenatal or early postnatal death,
depending on inactivated gene and how the inactivation is
achieved (Sauvageau andSauvageau, 2010). ThePRC2complex
contains one of two homologous enhancer of zeste (Ez) pro-
teins (Ezh1 or Ezh2), which contain near identical catalytic SET
domains (Laible et al., 1997). Ezh1 andEzh2 are chromatin-modi-
fying histone lysine methyltransferases (Margueron and Rein-
berg, 2011). Most research on H3K27 has focused on the
trimethylated form (H3K27me3), while the monomethylated and
dimethylated forms (H3K27me1 and H3K27me2, respectively)
remain poorly characterized (Margueron and Reinberg, 2011).
Although Ezh2 knockout in embryonic stem cells (ESCs) reduces
H3K27 dimethylation and trimethylation, H3K27 methylation at
PcG target promoters is not abolished. This has been attributed
to the activity of Ezh1, which forms an alternative PRC2 com-
plex (Shen et al., 2008) and has distinct chromatin-binding prop-
erties (Margueron et al., 2008). The importance of the H3K27me3
mark has been characterized through conditional targeting of
Ezh2 in somatic stem cells in the brain, pancreas, epidermis,
and hematopoietic system (Chen et al., 2009; Ezhkova et al.,
2009; Mochizuki-Kashio et al., 2011; Pereira et al., 2010; Su
et al., 2003). Double knockout of Ezh1 and Ezh2 in mouse skin
abolishes the H3K27me3 modification and severely compro-
mises formation and maintenance of hair follicles (Ezhkova
et al., 2011). However, the role of PRC2-Ezh1 in themaintenance
of HSCs is unknown.
Cell senescence is a permanent cell-cycle arrest that is re-
fractory to growth factors and other proliferation signals. Un-
like apoptotic cells, which rapidly disintegrate, senescent cells
remain viable in long-term culture and are found with increasing
frequency in aged tissues and at sites of age-related pathology,
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Figure 1. Characterization of Primitive Hematopoietic Populations in Ezh1-KO Mice
(A) Expression of total Ezh2 and Ezh1 mRNA was measured by qRT-PCR in sorted bone marrow (BM) subpopulations from young (8-week-old) and aged
(50-week-old) WT mice: lineage negative (Lin); Lin, Sca1+, c-Kit+ (LSK); long-term repopulating HSCs (LSKCD34lowFlk-2low; LT-HSCs), myeloid progenitors
(LinKit+Sca1; MPs), and common lymphoid progenitors (LinKitlowSca1lowCD127+; CLPs). Results are standardized to b-actin and are expressed as the fold
change of the indicated subpopulations from aged mice compared with the same gated subpopulations from young mice (means ± SD; n = 12, *p < 0.05).
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including preneoplastic lesions. Cells senesce in response to
many potentially oncogenic stressors, including severe DNA
damage, dysfunctional telomeres, chromatin alterations, oxida-
tive stress, and strong mitogenic signals such as those delivered
by some oncogenes (Collado et al., 2007). Induction of the
senescence program normally requires activation of tumor sup-
pressor pathways, including the p19ARF (p14ARF in humans), p53,
and RB-p16INK4a signaling cascades, and the senescence pro-
gram is now regarded as a potent cell-autonomous barrier to
tumorigenesis (Prieur and Peeper, 2008). Accordingly, loss of
the senescence response increases the incidence of cancer in
humans and mice (Nardella et al., 2011). Moreover, cell se-
nescence also entails increased secretion of proinflammatory
proteins, inducing the senescence-associated (SA) secretory
phenotype (SASP), and might contribute significantly to chronic
inflammation (Freund et al., 2010).
Epigenetic mechanisms play an important role in senescence.
In senescing human fibroblasts, heterochromatic regions con-
dense to form senescence-associated heterochromatic foci
that limit the DNA damage response (Di Micco et al., 2011; Narita
et al., 2003). Expression of Jhdm1b, a demethylase specific for
the H3K36me2 modification, causes cell immortalization or
leukemic transformation depending on its demethylase activity
on p15INK4b, and its knockdown results in cell senescence (He
et al., 2008). In human and mouse fibroblasts, the Cdkn2a region
(encoding p16INK4a and ARF) is repressed by PcG-mediated
H3K27me3, and the repressive mark is lost during oncogene-
induced senescence, resulting in Cdkn2a expression (Bracken
et al., 2007).
The incomplete loss of H3K27me3 in Ezh2/ ESCs, the rela-
tively mild phenotypes of tissues lacking Ezh2, and the inverse
expression patterns of Ezh1 and Ezh2 during development
together suggest that Ezh1- and Ezh2-mediated H3K27 methyl-
ation are differentially coordinated during tissue development
and homeostasis. It is therefore important to determine the role
of Ezh1-containing PRC2 complexes in HSC maintenance. We
report here that Ezh1 is essential for adult hematopoiesis through
the regulation of histone H3K27methylation. Our results indicate
that Ezh1 promotes a slow cycling state in primitive HSCs and
prevents differentiation and senescence of adult HSCs.
RESULTS
Expression of the Histone Methyltransferase Ezh1
Increases during HSC Aging
Since expression of several PcG genes involved in chromatin
organization becomes dysregulated during the aging of HSCs
(Chambers et al., 2007b), we hypothesized that histone methyl-
transferase activity might be coordinately distributed between
Ezh1 and Ezh2 in young and old HSC populations. Ezh1 and
Ezh2 mRNAs were detected in primitive long-term HSCs (LT-
HSCs) isolated from the bone marrow (BM) of young (8-week-
old) wild-type C57BL/6 mice; but while levels of Ezh1 mRNA
were 3-fold higher in LT-HSCs isolated from BM of 50-week-
old mice, Ezh2 transcript levels did not change with age (p <
0.05; Figure 1A). A similar divergence was seen with protein
expression (Figure 1B), as noted in other studies on human
and mouse HSCs (Mochizuki-Kashio et al., 2011; Wagner
et al., 2009) and mouse kidney (Margueron et al., 2008). Protein
levels of the other PRC2 components, Suz12 and Eed, did not
change with age (Figure 1B). Given this pattern of Ezh1 expres-
sion in repopulating HSCs, we hypothesized that Ezh1 might act
primarily as a homeostatic regulator of HSCs.
To test this, we generated a conditional knockout Ezh1 allele in
which exons encoding the SET catalytic domain were flanked
with loxP sequences (ckoEzh1fl/fl) (Figure 1C). To induce spe-
cific Ezh1 deletion in the hematopoietic system, we crossed
ckoEzh1fl/fl mice with vavCre transgenic mice. From here on,
Ezh1fl/fl-vavCretg/+ knockout mice and their Ezh1fl/fl-vavCre+/+
wild-type (WT) littermates are referred to as Ezh1-KO and
Control. Analysis of primitive HSCs (LSKCD150+CD48; 20-
week-old) showed that complete Ezh1 deletion correlated with
increased expression of p16INK4a, ARF, and p15INK4b (p <
0.001), whereas expression of Ezh2 was unaffected (Figure 1D).
(B) Representative western blots (WBs) showing the expression of Ezh1, Ezh2, Suz12, Eed, and b-actin in HSCs (LSK cells) from young (8-week-old) and aged
(50-week-old) WT mice.
(C) Top: Ezh1 genomic locus and the Ezh1-targeted locus before and after Cre-mediated recombination. Red arrows mark the loxP sequences. The restriction
enzyme-digested DNA fragments recognized by the 30and 50 probes are indicated. Bottom: Southern blots show HindIII-digested genomic DNA isolated from
both ckoEzh1+/+ and ckoEzh1fl/+ ESCs hybridized with the 30and 50 probes (left panels). Genomic PCR analysis of ckoEzh1+/+, ckoEzh1fl/fl, and ckoEzh1fl/+ mice
are shown in the right panels. See also Table S1.
(D) qRT-PCR analysis of the mRNA expression of Ezh1, p16INK4a, ARF, and Ezh2 in HSCs (LSKCD150+CD48) from Ezh1-KO and Control mice. Data are
standardized to b-actin levels, and are expressed as the fold change of the indicated subpopulation from Ezh1-KO mice relative to Control mice (means ± SD;
n = 12, **p < 0.001, *p < 0.05). See also Table S2.
(E) Representative WBs showing the protein levels of Ezh1, Ezh2, H3K27me3, H3K27me2, H3K27me1, and histone3 (H3) in HSCs (LSKCD150+CD48) from
Ezh1-KO and Control mice.
(F) Histological and immunostaining characterization of paraffin-embedded BM sections from Ezh1-KO mice and Control littermates, using hematoxylin and
eosin staining (H&E), and anti-Ki67 and anti-Ezh1 antibodies. Scale bars represent 500 and 50 mm for H&E and 100 mm for immunohistochemistry.
(G) Representative FACS profiles of BM cells from Ezh1-KOmice and Control littermates. BM cells were immunostained with antibodies to hematopoietic lineage
markers, c-Kit and Sca1. FACS plots were gated on the LSK supopulation (orange gate), which was subclassified for expression of CD34 and CD135 to give the
percentages of MPPs, LT-HSCs, and ST-HSCs, and for expression of CD150+ and CD48 to give the percentage of the LSK-SLAM population. The CLP fraction
(green gate) was gated on LKlowSlowCD127+. Myeloid progenitors, defined as the LK+S (LKS) population (MP, blue gate), were subclassified into common
myeloid progenitors (CMPs), granulocytic macrophage progenitors (GMPs), and megakaryocytic-erythroid progenitors (MEPs) based on CD16/32 and CD34
expression. At least five mice per genotype were tested, over at least two separate experiments. Numbers indicate percentages of the total nucleated BM cell
population, except for the subclassification of LSK cells, where numbers indicate the percentage of the total LSK subpopulation.
(H and I) Absolute numbers per femur of LSK, LT, ST, MPP, and LSK-SLAM primitive populations (H), and CLP, CMP, MEP, and GMP subpopulations (I) (as
described in Figure 1G) in BM from Control and Ezh1-KO mice.
Data are means ± SD (n = 10, *p < 0.05, **p < 0.001). See also Figure S1.
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Figure 2. Ezh1 Deletion Induces Cellular Senescence
(A and B) Average chimerism in posttransplant competitive recipients transplanted with 1:1 ratios of donor and competitor cells, analyzed by the contribution of
donor-derived (CD45.2) cells to peripheral blood (PB) cells (A), and the indicated subclassified LSK populations (B). FACS plots show a representative experi-
ment. The bar graphs show the percentages of the indicated populations 12 weeks posttransplant. Data are means ± SD (n = 8, *p < 0.05, **p < 0.001). See also
Figure S2.
(C) Percentage of early apoptotic cells (annexinV-Hoechst staining) in the indicated populations. Data are means ± SD (n = 6, *p < 0.05).
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The overall level of H3K27me3 was not altered in Ezh1-KO
mice; however, the levels of H3K27me2 and H3K27me1 were
markedly lower (Figure 1E).
Ezh1 Deletion Causes BM Failure
We next examined the effect of Ezh1 deficiency on primitive
HSC subpopulations in BM. Immunostaining for Ezh1 in BM
sections revealed specific vavCre-mediated Ezh1 deletion in
hematopoietic cells, while fibrovascular stroma (sinusoid endo-
thelial cells and fibroblasts) remained positive, a finding also
reflected in weak Ezh1 protein expression in whole Ezh1-KO
BM (Figure 1F; data not shown). Histological analysis detected
severe femoral hypoplasia in BM of adult Ezh1-KO mice (Fig-
ure 1F), reflecting a 2-fold lower BM cellularity than in Controls
(p < 0.001; Figure S1A available online). Nonlymphoid tissues
showed no significant differences in Ezh1 staining between
genotypes (Figure S1B). Furthermore, adult Ezh1-KO animals
had a smaller HSC-enriched LSK pool than Controls (p <
0.05; Figures 1G and 1H). Analysis of LSK subfractions in
Ezh1-KO mice showed significantly lower frequencies (p <
0.001) and absolute numbers (p < 0.001) of all three primi-
tive repopulating LSK populations: LT-HSCs, short-term HSCs
(ST-HSCs), and multipotent progenitors (MPPs) (Figures 1G
and 1H). Further enrichment of the LSK population with SLAM
markers (CD48 and CD150+) confirmed reduction of the
LSK-SLAM population in Ezh1-KO BM (p < 0.001; Figures 1G
and 1H).
The more mature lymphoid progenitor pool was also signifi-
cantly smaller in KO mice (p < 0.05; Figures 1G and 1I), while
frequencies and numbers of myeloid progenitors and colony-
forming cells (CFCs) were unaffected (Figure 1I and Figure S1C).
Moreover, pyrorin Y staining of LSK CD34low cells showed a
smaller pool of quiescent (G0) HSCs in Ezh1-KO mice (p <
0.05; Figure S1D). Analysis of BM cells for the side popula-
tion (SP) phenotype, a marker of quiescent HSCs in adult BM,
revealed 2-fold fewer SP cells in Ezh1-KO mice (p < 0.05;
Figure S1E).
To determine the long-term reconstitution capacity of Ezh1-
deficient BM cells, we crossed the ckoEzh1fl/fl line with
Rosa26Cre-ERT2 mice to generate Rosa26Cre-ERtg/tg;Ezh1fl/fl
(Ezh1-KO-ER) and Rosa26Cre-ERtg/tg;Ezh1+/+ (Control-ER)
mice. After tamoxifen induction of Cre-mediated Ezh1 deletion,
BM cells from these mice were used in competitive transplanta-
tion experiments, thus excluding influence from the Ezh1-defi-
cient BM microenvironment on hematopoiesis. Donor-derived
(CD45.2) Ezh1-KO-ER BM cells did not contribute significantly
to peripheral blood (PB) at 12 weeks posttransplant (wpt; p <
0.05; Figure 2A) or LSKs in BM at 16 wpt (p < 0.001; Figure 2B).
Moreover, KO donor cells contributed weakly to lymphoid pro-
genitors in BM (p < 0.05; Figure S2A). These results are consis-
tent with a requirement for Ezh1 in the self-renewal and mainte-
nance of adult HSCs.
HSC Senescence Is Increased in Ezh1-KO BM
Analysis of freshly isolated primitive stem- and progenitor-cell
BM populations revealed no difference between genotypes in
the frequency of annexinV+/Hoechst cells, indicating that pro-
grammed cell death does not underlie the disappearance of
Ezh1-KO LSK HSCs from the BM or their inability to compete
with WT cells in transplantation experiments (Figure 2C). We
therefore analyzed whether Ezh1 deletion affects the prolifera-
tion of primitive hematopoietic cells in vivo. Examination of
cell-cycle status by BrdU incorporation, normalized for total
numbers, showed that the LT- and ST-HSC/MPP Ezh1-KO pop-
ulations cycled less than corresponding Controls (p < 0.05; Fig-
ure 2D and data not shown).
Given that hematopoietic-specific Ezh1 inactivation trig-
gered accumulation of transcripts for p16INK4a and ARF (Fig-
ure 1D), which are critical activators of the senescence pro-
gram (Lowe et al., 2004), we tested whether Ezh1 deletion
triggered cellular senescence in HSCs. Consistent with the anti-
senescence role of other Polycomb proteins such as Bmi1
(Jacobs et al., 1999), depletion of endogenous Ezh1 in isolated
mouse embryonic fibroblasts (MEFs) resulted in increased tran-
script and protein expression of p16INK4a and ARF (p < 0.001;
Figure S2B), as well as increased activity of senescence-
associated SA-b-galactosidase (SA-b-gal) (Figure S2C). Con-
versely, reexpression of Ezh1 should recapitulate the immortal-
ization phenotype of p16INK4a/ARF null MEFs (Gonzalez et al.,
2006). Evaluation of this in colony-formation assays in Ezh1-
deleted MEFs confirmed that Ezh1 reexpression immortalizes
fibroblasts by downregulating expression of p16INK4a and ARF
(Figure S2C).
These in vitro results suggested that adult Ezh1-KO BM might
have a senescent phenotype. To test this in vivo, we first
measured SA-b-gal activity in primitive HSC subpopulations
by FACS-based assay using the fluorogenic substrate C12FDG
(Debacq-Chainiaux et al., 2009). Approximately 34% of Ezh1-
KO LT-HSCs were positive for SA-b-gal, comparable to Ras-
induced MEF senescence (Kuilman et al., 2010), while fewer
than 7% of HSCs from Control littermates stained positive (p <
0.001) (Figure 2E and Figure S2D). In contrast, the frequency
of MPP senescence was similar in WT and Ezh1-KO BM (Fig-
ure 2E). We also examined SA-b-gal activity and DNA damage
by immunohistochemistry in BM sections. Immunostaining for
gH2AX DNA repair foci revealed activation of the DNA-damage
response in Ezh1-BM mice (Figure 2F), consistent with recent
evidence linking DNA damage to cellular senescence (Di Micco
et al., 2011). Immunostaining also revealed greater expression
of Dcr2, p15INK4b, and p16INK4a in Ezh1-KO BM, whereas
(D) Proliferation rate of LSK, MP, and CLP subpopulations measured by in vivo BrdU incorporation over 24 hr. Data are means ± SD (n = 5, *p < 0.05).
(E) Left: Percentage of senescence-associated b-gal (SA-b-gal) positive cells determined by flow cytometry in LSK, LT, ST, and MPP primitive populations in
Control and Ezh1-KOmice. Fluorescence histograms for C12-fluorescein show the relative levels of b-gal in LSK subpopulations; the values above the peaks are
the median fluorescence intensities of the respective populations. Right: Percentage of SA-b-gal-positive cells in LSK, LT, ST, and MPP populations. Data are
means ± SD (n = 6, *p < 0.05, **p < 0.001). See also Figure S2.
(F) Cytochemical staining of SA-b-gal activity in paraffin sections of BM from Control and Ezh1-KO mice, and accompanying panels showing representative
paraffin-embedded BM sections from Control and Ezh1-KO mice immunostained with the indicated antibodies.
Scale bars, 50 mm. See also Figure S2.
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expression of Bmi1 and Ezh2 was the same in Control and
Ezh1-KO BM (Figure 2F). RT-PCR analysis confirmed greater
expression of the senescence markers Dcr2, p15INK4b, and
Dec1 (Collado and Serrano, 2006) in Ezh1-KO LSKCD150+
cells (Figure S2E). To confirm the role of Ezh1 in hematopoie-
sis, we retrovirally reexpressed Ezh1 in Ezh1-KO-ER HSCs
(LSKCD150+) and examined the ability of these cells to res-
cue hematopoiesis in competitive transplantation experiments.
Ezh1 overexpression substantially decreased p16INK4a expres-
sion in LSKCD150+ cells but had no effect on Ezh2 levels (Fig-
ure S2F). In the transplantation experiments, restored Ezh1
expression rescued the capacity of donor Ezh1-KO cells to
engraft (Figure S2G). Moreover, mice engrafted with these cells
were protected from the accumulation of senescent LSK
cells observed in recipients of vector-overexpressing Ezh1-KO
cells (p < 0.05; Figure S2H). These results suggest a primary func-
tion of Ezh1 in the protection of adult HSCs from senescence.
Ezh1 Is Not Required for Fetal Hematopoiesis
Ezh2 appears to be required only in fetal HSCs, since its deletion
does not compromise adult hematopoiesis except for lympho-
poiesis (Mochizuki-Kashio et al., 2011; Su et al., 2003). To inves-
tigate the requirement of Ezh1 during fetal hematopoiesis, we
first tested the specificity of vavCre activity in fetal liver (FL) by
crossing vavCretg/+ mice with Rosa26-eYFPtg/ mice. Consistent
with previous studies (Stadtfeld and Graf, 2005), immunohisto-
chemistry revealed constitutive vav-promoter-driven Cre ex-
pression in hematopietic cells from E9.5, mostly restricted to
FL (Figure 3A). Total FL cell numbers in mutant mice were indis-
tinguishable from those of Control littermates (Figure 3B). How-
ever, FL of mutant mice contained lower proportions of all
primitive FL-LSK cells (p < 0.05; Figure 3C). In repopulation
experiments, Ezh1-deficient and Control FL cells showed only
a slight difference in the ability to reconstitute the lymphoid-con-
taining (B220) population in PB (Figure 3D). Analysis of SA-b-gal
SA-β-gal
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Figure 3. Characterization of Primitive
Hematopoietic Populations in Ezh1-KO
Mice
(A) vavCre expression in a sagittal section of
an E11.5 Rosa26-eYFPtg/+/vavCretg/+ embryo.
Expression is detected in most hematopoietic
cells and organs. YFP-positive cells are brown
and sections were hematoxylin counterstained.
The right panel shows an enlarged view of the
fetal liver (FL) area.
(B) Absolute cell numbers in whole FLs from
Control and Ezh1-KO mice at E11.5 (n = 12).
(C) Left: Representative FACS profiles of FL cells
from Ezh1-KO mice and Control littermates were
gated on the LSK subpopulation; the CLP fraction
was gated on LKlowSlowCD127+, and myeloid
progenitors were defined as the LKS population
(MP). Numbers indicate percentages of the
total nucleated BM cell subpopulations. At least
eight mice per genotype were tested, over at
least two separate experiments. Right: Absolute
numbers per FL of LSK, MP, and CLP primitive
populations are indicated. Data are means ± SD
(n = 16, *p < 0.05).
(D) Recipient mice were injected with pooled FL
cells from Ezh1-KO mice or Control littermates
(CD45.2). Average chimerism in posttransplant
recipients: values on the right panels are the
mean percentages of donor-derived (CD45.2)
lymphoid (B220) cells 8 weeks after secondary
transplant. FACS plots show a representative
experiment (n = 6).
(E) SA-b-gal-positive cell content in transplanted
chimeras harboring FL cells from Control or Ezh1-
KO mice, determined by flow cytometry of LSK,
CLP, and MP primitive populations. Top: C12-
fluorescein fluorescence histograms show the
relative levels of b-gal in LSK subpopulations;
values above the peaks are the median fluores-
cence intensities of the respective populations
(n = 6). Bottom: Percentages of SA-b-gal-positive
cells in LSK, MP, and CLP populations. Data are
means ± SD (n = 6; bottom panel).
(F) Representative cytochemical staining of SA-
b-gal-positive cells on BM paraffin sections.
Scale bars, 50 mm.
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expression in E12.5 FL by FACS and cytochemical staining did
not show accumulation of senescent FL cells of either genotype
(Figures 3E and 3F). These data thus suggest that while Ezh1
deletion in FL influences HSC number, Ezh1 is not required for
maintenance of fetal hematopoiesis.
Ezh1 Deficiency Impairs B Cell Development
Given the differences in primitive subpopulations in Ezh1-KO
mice, we analyzed whether specific Ezh1 deletion affects adult
hematopoiesis in vivo. PB cell counts and flow cytometry of
spleen and thymus in Ezh1-KO animals revealed marked and
significant loss of B lymphocytes (p < 0.05) and a slight drop
in myeloid cells (Figures 4A–4C). Ezh1-KO spleens were about
half the size of spleens from Control littermates (p < 0.05; Fig-
ure 4B), consistent with the reduced proportion of mature
lymphoid cells (p < 0.05; Figure 4B). Histopathological analysis
of Ezh1-KO spleen mice was consistent with this phenotype
(Figure 4D). Hematoxylin and eosin staining showed manifest
white and red pulp hypoplasia and an absence of germinal
centers in Ezh1-KO spleen, accompanied by lymphoid cell
depletion. Analysis of Ezh1-deficient BM cells showed altered
development of pro-B cells (IgMB220+CD43+), pre-B cells
(IgMB220+CD43), and immature B cells (IgM+B220+CD43),
with a concomitantly reduced proportion of recirculating lym-
phoid cells (IgM+B220highCD43) (p < 0.05; Figure 4E). The
alterations in B cell development indicate that Ezh1 is required
for proper differentiation of HSCs into lymphoid progeny, and
raise the possibility that PRC2-Ezh1 restricts certain HSC/pro-
genitor activities, similar to the impaired B cell maturation from
pro-B to pre-B cells observed in mice lacking Ezh2 (Su et al.,
2003).
BM Failure upon Loss of Ezh1 Is Hematopoietic Cell
Autonomous
To define the impact of Ezh1 on the maintenance of the stem cell
pool, we performed sequential BM transplantations. BM from
Ezh1-KO or WT littermate mice (CD45.2) was injected into irradi-
ated CD45.1 hosts, which were monitored for reconstitution of
PB, spleen, and BM. Ezh1-KO cells showed significantly weaker
PB chimerism at 4 wpt (p < 0.05; Figure S3A), as well as less
engraftment of primitive HSCs at 16 wpt (p < 0.05; Figure S3B).
PB lymphoid cell counts were significantly lower in Ezh1-KO-in-
jected hosts than in control-injected counterparts (p < 0.05; Fig-
ure 5A). Donor-derived CD45.2+ BM cells were then purified and
injected into secondary recipients. Spleens of secondary recipi-
ents showed a consistent decrease in the lymphoid-containing
(B220) population (p < 0.05; Figure 5B). Moreover, the senes-
cence phenotype was far more marked in secondary recipients
of Ezh1-KO cells than in secondary recipients of Control BMcells
(Figure 5C). Strikingly, Ezh1/ HSCs were unable to engraft ter-
tiary recipients, while recipients of Control cells survived (data
not shown).
Ezh1 Deletion Results in Homing Defects in BM Cells
To evaluate the mechanism of action of Ezh1 loss on HSC
engraftment, we assessed the homing capacity of CFSE-labeled
Ezh1-KO and Control HSCs in transplantation assays. CFSE+
Ezh1-KO LSK cells homed to the BM of recipient mice at a lower
frequency than cells from Control mice (p < 0.05; Figure 5D).
Comparable results were obtained by injecting tamoxifen-
treated Ezh1-KO-ER HSCs (CD45.2) into CD45.1 hosts (p <
0.05; Figure S3C). The retention of Ezh1-deficient HSCs in
the BM niche was examined by reciprocal transplant experi-
ments in which WT donor BM cells (CD45.1) were transplanted
into tamoxifen-treated Control-ER or Ezh1-KO-ER recipients
(CD45.2). Analysis of recipient PB and immunohistochemical
staining of paraffin BM sections revealed no differences in
engraftment between the genotypes (Figures 5E and 5F), indi-
cating that an Ezh1-deficient microenvironment does not affect
HSC engraftment. Together, our transplantation experiments
demonstrate that the development of Ezh1/-induced senes-
cence is hematopoietic cell autonomous, with defective migra-
tion of HSCs to the BM that likely compromises their self-
renewal.
Regulation of Multipotency Genes by Ezh1
To investigate the mechanism by which Ezh1 deletion impairs
HSC activity, we profiled gene expression in highly enriched re-
populating HSCs (LSKCD150+CD48) isolated from Ezh1-KO
and Control mice. Stringent gene array analysis identified 788
differentially expressed genes in Ezh1-KOHSCs (297 downregu-
lated and 491 upregulated; Table S4). A complete list of these
genes has been deposited in the Gene Expression Omnibus,
accession number GSE36288. The downregulated genes in-
cluded many crucial for HSC function, such as Gata3, Runx1,
Meis1, Myb, Pten, Foxo3a, Thy1.1, Abcg2, Srgap2, Pbx1, and
Cdkn1a (Chambers et al., 2007a; Forsberg et al., 2010). Also
downregulated were genes for essential lymphoid differentiation
factors (Ng et al., 2009; Oguro et al., 2010), such as Dntt, Flk2,
Igh6, Ikaros, Sfpi1, and Mef2c, and cell-cycle related genes
such as Cdc6, Cdk1, andMcm5, suggesting growth arrest (Kuil-
man et al., 2010) (Figures S4A and S4B). The set of upregulated
genes included genes related to secreted proteins and differen-
tiation/development (e.g., Bmp2 and Igfbp3), consistent with the
central role of secreted factors in senescence (Kang et al., 2011).
Moreover, there was robust upregulation of genes encoding
proinflammatory factors associated with SASP, including IL-6,
IL-7, granulocyte macrophage colony-stimulating factor (GM-
CSF), and certain insulin-like growth factor (IGF)-binding pro-
teins (Coppe´ et al., 2010) (Figures 6B and 6C). These findings
suggest that Ezh1 controls the secretome by repressing secre-
tion of key senescence factors. Furthermore, we detected
altered expression of genes regulated by other Polycomb
members, including upregulated expression of Dkk2, Cyp1b1,
Vsnl1, and Il6R, and downregulated expression of H2Afx,
Gmnn, and Foxc1 (Bracken et al., 2006; Majewski et al., 2008)
(Figures 6B and 6C). The genes differentially regulated in Ezh1-
depleted cells were objectively classified by Gene Ontology
analysis (Figure 6A). Changes in expression for several genes
from each category were validated by real-time PCR using
sorted HSCs (LSKCD150+CD48 cells) from Ezh1-KO and
Control mice (Figure 6B), confirming the array analysis.
We next conducted chromatin immunoprecipitation (ChIP)
experiments on sorted Ezh1-KO and WT HSCs (LSKCD150+
cells) to detect the effect of Ezh1 deletion on H3K27 methyla-
tion and the specific binding of Ezh1, Ezh2, and Bmi1 to the
promoter regions of Ezh1 target genes. Lack of Ezh1 increased
the amount of bound H3K27me2 in the promoter regions of the
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Figure 4. Lymphoid Differentiation Defects in Ezh1-KO Hematopoiesis
(A) Peripheral blood counts in 20- to 22-week-old Ezh1-KO and Control mice. WBC, white blood cells; LYM, lymphocytes; MID, monocytes; GRA, granulocytes;
RBC, red blood cells; PLT, platelets. Data are means ± SD (n = 8, *p < 0.05).
(B) Top: Representative FACS plots showing the percentages of lymphoid (B220) andmyeloid (Ly6G and F4/80) positive cells in the Ezh1-KO andControl spleens.
Bottom: Bar charts show absolute numbers of total spleen, lymphoid, andmyeloid cell populations in the spleens of Ezh1-KO and Control mice; data aremeans ±
SD (n = 11, *p < 0.05). The photograph shows representative spleens from Ezh1-KO and Control mice.
(C) Left: Representative FACS plots showing the percentages of CD4-positive, CD4+CD8-positive, and CD8-positive cells in the thymus of Ezh1-KO and Control
animals. Right: The photograph shows thymus from Ezh1-KO andControl mice, and the bar charts show thymus cell populations and absolute numbers ofmature
lymphoid (CD4, CD4+CD8, and CD8) cells. Data are means ± SD (n = 10).
(D) Histological (H&E) and immunostaining (anti-Ki67 antibody) characterization of representative spleen sections from Ezh1-KO mice and Control littermates.
Scale bars, 1,000 mm (upper panels) and 200 mm (magnified views in lower panels).
(E) Left: Representative FACS plots showing the percentages of pro-B cells (IgMB220+CD43+), pre-B cells (IgMB220+CD43), immature B cells (IgM+
B220+CD43), and recirculating cells (IgM+B220highCD43) in Ezh1-KO and Control BM. Right: Absolute numbers per femur of mature lymphoid cell populations
in Ezh1-KO and Control mice. Data are means ± SD (n = 12, *p < 0.05).
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downregulated genes Cdc6, Runx1, and Mef2c, but not in the
promoters of p16INK4a, Bmp2, and Igfbp3 (Figure S4A). Interest-
ingly, the entire promoter regions of Cdc6, Runx, and Mef2c
were enriched for the H3K27me1 signal in Ezh1-KO cells,
whereas this signal was absent from the p16INK4a, Bmp2, and
Igfbp3 promoters. In contrast, the levels of H3K27me3 and
A 
C 
E 
S
A
-
-gal
Control Ezh1-KO 
 Control 
 Ezh1-KO 
D
on
or
-d
er
iv
ed
 c
el
ls
 (%
) 
( s
ec
on
da
ry
 re
ci
pi
en
ts
) 
0
15
30
45
60
0
2
4
6
8
* * 
CD3 CD4 CD8 B220 Mac-1+/Gr-1 LY6G F4-80
D 
CFSE 
C
ou
nt
 
0.17% 
 Control 
 Ezh1-KO 
0
  0.1 
  0.2
  0.3
  0.4
  0.5 
%
 o
f C
FS
E
 +
  c
el
ls
 
62 % 
B 
 Control 
Ezh1-KO 
B220 
S
S
C
 
37% 
0
  2
  4
  6
  8
  10 
Control   Ezh1-KO
 Control 
 Ezh1-KO 
B
22
0 
ce
lls
 (x
10
6 )
 
CD45.1 
0.3 
CD45.2 
98.8 
CD45.1 
0.5 
CD45.2 
99 
 Monocytes 
D
on
or
-d
er
iv
ed
 c
el
ls
 (%
) 
0 
15 
30 
45 
60 
    WBC  Lymphocytes  Neutrophils 
H
&
E
 
K
i6
7 
Control-ER  Ezh1-KO-ER F 
 Control 
0.35% 
Ezh1-KO 
 Control-ER 
 Ezh1-KO-ER
Figure 5. Ezh1 Function in Hematopoiesis Is Cell Autonomous
(A) Average chimerism in posttransplant secondary recipients (separated by a 10-week reconstitution period) analyzed for the contribution of donor-derived
(CD45.2) cells to circulating mature myeloid cells (Mac-1/Gr-1), macrophages (F4-80), granulocytes (LY6G), and lymphoid subfractions (CD3, CD4, CD8, and
B220). Data are means ± SD (n = 8; *p < 0.05). See also Figure S3.
(B) Subpopulation profiles of B cells (B220; CD45.1/CD45.2) in spleens of secondary recipient mice transplanted with BM cells from Ezh1-KO mice or Control
littermates. The bar chart shows the percentages (mean ± SD) of the indicated populations (n = 8; *p < 0.05).
(C) Cytochemical staining of SA-b-gal-positive cells in paraffin-fixed BM sections of recipient mice transplanted with BM cells from Ezh1-KO mice or Control
littermates. Scale bars, 50 mm.
(D) Representative FACS plots of BM cells in recipient mice 24 hr after injection with CFSE-labeled Control or Ezh1-KO LSK cells. The bar chart shows themean ±
SD of two independent experiments with four mice per experiment (n = 8; *p < 0.05). See also Figure S3.
(E) H&E and anti-Ki67 staining of BM sections of Control-ER and Ezh1-KO-ER recipient mice injected with WT BM cells. Scale bars, 500 mm and 50 mm.
(F) Average chimerism in posttransplant Control-ER and Ezh1-KO-ER recipients analyzed by the contribution of donor-derived (CD45.1) cells to PB populations
(WBC, white blood cells). Data are means ± SD (n = 9).
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bound Ezh2 and Bmi1 in the Cdc6, Runx, and Mef2c pro-
moters were not affected by the absence of Ezh1 (Figure S4A).
Furthermore, whereas Control HSCs showed site-specific
binding of Ezh1, Ezh2, and Bmi1 to the promoter regions of
p16INK4a (Bracken et al., 2007), Bmp2, and Igfbp3, binding
was absent from these upregulated genes in Ezh1-KO cells.
Comparable results were observed with the upregulated Ezh1-
target genes IL-6, Cdkn1a, and Zmat3 (data not shown). These
data support the view that the actions of Ezh2 and Bmi1 likely
require the presence of Ezh1, and that Ezh1-dependent repres-
sion induces monomethylation of H3K27 as the primary product
of the PRC2-Ezh1 reaction, with subsequent dimethylation. The
gene expression data thus correlate strongly with the hemato-
poietic phenotype of Ezh1-KO mice and suggest a mechanism
by which the histone methytansferase Ezh1 protects against
senescence.
A 
Cell-To-Cell Signaling and Interaction 
Hematological System Development and Function 
Immune Cell Trafficking 
Inflammatory Response 
Cell Cycle, and Cellular Organization 
Cellular  Movement  
Hematological Disease  
Cellular Function and Maintenance 
0 2.0
Percentage 
 changed 
4.0 6.0 8.0 10.0
32.4 
48.3 
55.2 
47.4 
38.2 
58.2 
42.4 
42.2 
 R
el
at
iv
e 
ex
pr
es
si
on
 le
ve
l  
B 
M
T3
 
M
A
P3
K
6 
C
A
LC
B
 
LY
6a
 
C
D
19
 
C
XC
L1
2 
C
A
M
P 
C
FH
 
FA
SL
G
 
C
YB
R
 
K
D
R
 
IL
6 
C
dc
2 
C
dk
n1
a 
C
dk
n2
a 
IT
G
A
7 
JA
M
2 
R
A
P1
A 
PT
PN
11
 
G
M
-C
SF
 
ST
AT
5 
SN
R
PN
 
G
LD
C
 
EW
SR
1 
HSCs (LSKCD150+CD48-)
C
el
l-t
o-
C
el
l  
S
ig
na
lin
g
H
em
at
ol
og
ic
al
S
ys
te
m
 
Im
m
un
e 
C
el
l 
Tr
af
fic
ki
ng
 
In
fla
m
m
at
or
y 
 
R
es
po
ns
e 
C
el
l C
yc
le
 
C
el
lu
la
r O
rg
an
iz
. 
C
el
lu
la
r 
M
ov
em
en
t 
H
em
at
ol
og
ic
al
 D
is
ea
se
 
C
el
lu
la
r  
 
M
ai
nt
en
an
ce
 
3 1 0 -1 -3
Relative expression
(log2 scale)
Sfpi1
Flk2
Mef2c
Control Ezh1-KO
Polycomb-
related
Senescence- 
associated
Lymphoid 
development  
Foxc1
Gmnn
Il6R
Dkk2
Bmp2
IGF-BP1
GM-CSF
C 
Genes downregulated
in Ezh1-KO HSCsD 
Lymphoid development
regulator genes
Polycomb-related
genes
297
 71
29
297
161
42
Polycomb-related
genes
491
75
 18
Senescence-associated
genes
491
51
 9
Genes upregulated
in Ezh1-KO HSCs
Figure 6. Ezh1 Maintains BM Homeostasis
(A) Enrichment scores for GO categories in the set of genes differentially expressed in Ezh1-deficient HSCs identified high percentage changes in genes
regulating HSC maintenance.
(B) Relative expression levels of selected transcripts (horizontal axis) from each GOcategory (A) measured by qRT-PCR in sorted HSCs (LSKCD150+CD48) from
Ezh1-KO and Control mice. Data are means ± SD from three replicates in Ezh1 null HSCs normalized to expression in Control HSCs (dashed line).
(C) Representative heat maps show the expression of genes with lymphoid-development, senescence-associated, and Polycomb-related functional annotations
that are significantly downregulated and upregulated in Ezh1 mutant LSKCD150+CD48 cells. The rows correspond to genes and the columns to samples. Gene
expression values (relative to the mean expression in Control cells) are indicated on a log2 scale according to the color scheme shown.
(D) Venn diagram illustrating the overlap between genes downregulated and upregulated in these cells and genes with senescence-, lymphoid- and Polycomb-
related functional annotations according to the studies cited in the main manuscript.
See also Figure S4 and Table S2.
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Ezh1 Limits the HSC Senescence Response by
Repressing Cdkn2a
To test whether repression of Cdkn2a by Ezh1 is essential for its
antisenescence function, we generated Ezh1/Cdkn2a triple-
knockout (TKO) mice (Ezh1fl/fl;p16INK4a-ARFfl/fl;vavCretg/+) and
Control-TKO mice (Ezh1fl/fl;p16INK4a-ARFfl/fl;vavCre+/+) to condi-
tionally eliminate hematopoietic Cdkn2a expression in the Ezh1-
KO background (Figure 7A). Complete deletion of Ezh1 and
p16INK4a/ARF was not accompanied by significant compensa-
tory upregulation of other Polycomb members (p < 0.05; Fig-
ure 7A; data not shown). We also observed altered HSC expres-
sion of the Ezh1 targets Runx1 and Cdc6 (Figure 7A). Total cell
numbers in BM, thymus, and spleen of Ezh1/Cdkn2a-TKO
mice were similar to numbers in Control-TKO littermates (Fig-
ure 7B), and mutant and Control mice also had similar propor-
tions of all major BM populations, including LSK, common
lymphoid progenitor (CLP), andMP stem/progenitor populations
(Figure 7C). The deletion of p16INK4a and ARF in Ezh1-KO HSCs
A B 
C D 
E 
Figure 7. Recovery of Defective Hematopoiesis in Ezh1/Cdkn2a-TKO Mice
(A) qRT-PCR analysis of the expression of Ezh1, p16INK4a, ARF, Runx1, and Cdc6 mRNA in total HSCs (LSKCD150+CD48) from Ezh1/Cdkn2a-TKO mice
(Ezh1fl/fl;p16INK4a-ARFfl/fl;vavCretg/+). Results are standardized to b-actin and expressed relative to littermate Control-TKO mice (Ezh1fl/fl;p16INK4a-ARFfl/fl;
vavCre+/+). Data are means ± SD; n = 10, **p < 0.001, *p < 0.05).
(B) Absolute numbers of mature lymphoid (B220 and CD4/CD8) cells and total cellularity in spleen, thymus, and BM of Ezh1/Cdkn2a-TKO and Control-TKOmice.
Data are means ± SD (n = 5).
(C) Left: Representative FACS plots of BM cells, indicating mean percentages of the LSK populations, in Ezh1/Cdkn2a-TKO mice and Control-TKO littermates.
Right: Absolute numbers per femur of the LSK (LS+K+), CLP (LKlowSlowCD127+), and MP (LK+S) subpopulations. Data are means ± SD (n = 8).
(D) C12-fluorescein fluorescence histograms showing the relative levels of b-gal in LSK subpopulations from Control-TKO and Ezh1/Cdkn2a-TKO mice. The
values above the peaks are the median fluorescence intensities of the respective populations (n = 6).
(E) Contribution of donor-derived (CD45.2) cells from Ezh1/Cdkn2a-TKO and Control-TKOmice to PB populations in recipients at 4 weeks posttransplant (WBC,
white blood cells). Data are means ± SD (n = 7).
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led to a near complete bypass of the senescence pathway
as determined by the decrease in the proportion of LSK cells ex-
hibiting SA-b-gal activity (4%–7% SA-b-gal+ cells, compared
with 5% in Control-TKO mice) (Figure 7D). To test the function-
ality of Ezh1/Cdkn2a-TKO HSCs, we generated competitive
chimeras. Remarkably, flow cytometry of PB in stably engrafted
chimeric mice showed that donor contribution to lymphocytes
declined slightly after 8 weeks without affecting PBmyeloid cells
(Figure 7E). In summary, these data suggest that removal of
p16INK4a and ARF from the Ezh1 null background rescues hema-
topoiesis by increasing proliferation and alleviating senescence
in the Ezh1-KO BM.
DISCUSSION
Chromatin modifiers such as the PcG proteins determine the
transmission of genetic information and regulate cell differentia-
tion. Disruption of PcG function prevents differentiation of ESCs
and correct embryonic development. The PRC2 methyltrans-
ferase Ezh2 was thought to be unique and essential for all
H3K27me3 marks in ESCs (Bernstein et al., 2006; Boyer et al.,
2006). However, its homolog Ezh1 is also indispensable for the
establishment of pluripotent cells and for the maintenance of
ESC self-renewal (Margueron et al., 2008; Shen et al., 2008).
Here we show that this dual requirement also holds true for
at least one population of somatic stem cells, the HSCs. The
extreme sensitivity of hematopoietic cells to Ezh1 inactivation
is remarkable when compared with the weaker impact of inacti-
vating its homolog Ezh2 in a similar system (Mochizuki-Kashio
et al., 2011; Su et al., 2003). Ezh1 deficiency severely reduces
the size of the adult HSC fraction and impairs the capacity of
HSCs for self-renewal and quiescence, effects not observed in
mice lacking Ezh2 (Mochizuki-Kashio et al., 2011). We thus
conclude that Ezh1 plays a dominant role among histone meth-
yltransferases in the maintenance of adult HSCs.
We show that in the hematopoietic system, where stem cell
activation is a transitory state that requires self-renewal coupled
with the prevention of differentiation and senescence, Ezh1
plays an unanticipated and critical role. Ezh1 protects primitive
hematopoietic cells from senescence by keeping them in a
slow-cycling state through its PRC2-associated Polycomb func-
tion. Deletion of Ezh1 profoundly compromises BM hematopoi-
esis, but not the self-renewal capacity of HSCs in FL. This
reflects the specialized function of Ezh1, which is mediated
through monomethylation and dimethylation of H3K27, thereby
preventing proliferation and repressing pathways required for
terminal differentiation and senescence of adult HSCs. Our
data suggest that Ezh1-deficient cells exhibit delayed lympho-
cyte differentiation at specific stages of hematopoiesis, and it
may be that this effect arises from the reduced size of the prim-
itive HSC population.
Epigenetic mechanisms, including DNA methylation and his-
tone modification, are important regulators of gene expression
in senescence. The initial challenge in revealing Ezh1-mediated
regulation of gene expression was to determine what Ezh1 target
genes do. Through genome-wide array analyses combined with
quantitative ChIP assays, we have examined epigenomic and
gene expression changes induced by Ezh1 deletion in senesced
HSCs. Our results identify a coordinated methylation of the
repressive H3K27 mark, which activates the master senescence
regulator Bmp2 (Kaneda et al., 2011) and selectively represses
expression of Runx1 and Cdc6, which regulate critical hemato-
poietic processes (Swiers et al., 2010). Our results reveal dy-
namic and harmonized H3K27me1 and H3K27me2 alterations,
repression of Runx1 without gain of H3K27me3, and selective
activation of downstream target genes, such as Smad1, that
may contribute to growth arrest (Kaneda et al., 2011). Despite
this broad association of H3K27me1 H3K27me2 with silenced
genes in different tissue lineages, loss of Ezh1-mediated repres-
sion reduces the proliferation of these lineages by upregulating
the Cdkn2a locus, and tempers acquisition of the senescence
barrier. Indeed, deletion of the p16INK4a/p19ARF locus rescues
the HSC defects in these mice. Our findings underline the
importance of epigenetic changes in the regulation of the criti-
cal physiological barrier to inducing the senescence that blocks
oncogenic transformation. Further understanding of how PRC2-
Ezh1 maintains specific gene-expression patterns may come
from consideration of overall chromatin structure, an essential
issue that has garnered attention in the context of ESC differen-
tiation (Margueron and Reinberg, 2011).
Ezh1 and Ezh2 proteins are implicated in H3K27 monomethy-
lation, dimethylation, and trimethylation, with each methylated
form likely to be functionally distinct. The regulation of the level
of H3K27 methylation is, however, unknown. The answer may
lie in the particular protein composition of PRC2 complexes.
For example, Suz12 has been found to be essential for
H3K27me3, but dispensable for H3K27me1 (Pasini et al., 2004).
Similarly, the mammalian protein PHF1, a Drosophila PCL
homolog, associates with PRC2 components and stimulates
formation of H3K27me3 in vitro and in vivo (Cao et al., 2008).
Our work suggests that H3K27me1 plays a critical role in main-
taining heterochromatin condensation and gene silencing, a
mechanism reminiscent of the silencing imposed by two Arabi-
dopsis histone methyltransferase genes, ATXR5 and ATXR6
(Jacob et al., 2010). It remains unknown, however, how this
histone modification signals such events. One possibility is
that H3K27me1 simply recruits an H3K27me1-binding protein.
Alternatively, monomethylation of H3K27 (and possibly further
H3K27me2 and H3K27me3 modifications) may act in a negative
manner, either by preventing unmethylated H3K27-interacting
proteins from binding chromatin or by blocking alternative his-
tone modifications to H3K27. We thus suggest that H3K27me1
is an important intermediary PRC2-Ezh1 product, since it not
only constitutes the substrate for subsequent H3K27me2, but
also prevents H3K27 acetylation. In fact, our results, while vali-
dating only a small proportion of Ezh1-regulated transcripts,
shed light on this matter, and demonstrate the binding of Ezh1,
Ezh2, and Bmi1 to upregulated Igfbp3, IL-6, Cdkn1a, Zmat3,
Bmp2, and p16INK4a transcripts in WT HSCs (Bracken et al.,
2007). The action of Ezh1 might thus involve other chromatin
targets, such as Bmi1 or Ezh2, enabling fine regulation of cell
specification processes. These data provide a starting point for
further studies to uncover the underlying mechanisms of Ezh1-
mediated hematopoiesis.
Our results imply that Ezh1-regulated senescence ability is a
limiting factor in the maintenance of functional HSC reserves.
It thus seems plausible that some of the decline in HSC re-
constituting potential associated with defective self-renewal in
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Ezh1-KOmice could be due to senescence, rather than genomic
damage or telomere erosion. Loss of HSC potential might be
mediated by activation of senescence or cytostatic tumor
suppressor pathways at cell-cycle checkpoints, leading to dele-
tion or growth arrest of defective progenitor clones.
On the basis of our results, we propose that Ezh1 regulates
the balance between HSC maintenance and a protective senes-
cence response to prevent uncontrolled proliferation. Abundant
evidence indicates that cell senescence is a natural physio-
logical protection against tumor development, and therapeutic
engagement of senescence may present a valuable treatment
strategy for cancer. Targeting the PRC2-Ezh1 complex is an
attractive approach to the manipulation of these intrinsic senes-
cence pathways. The ability to promote senescence induction
upstream of Cdkn2a is likely to have a substantial therapeutic
effect, especially given the frequent mutations that inactivate
these pathways. Understanding molecular mechanisms by
which Ezh1 affects stem cell fate will provide new insights into
HSC biology and will also increase understanding of leukemic
transformation, with the potential to facilitate eradication of
leukemic stem cells.
EXPERIMENTAL PROCEDURES
Mice
Generation and analysis of ckoEzh1fl/+ mice is detailed in the Supplemental
Information. The vavCre and Rosa26-Cre-ERT2 mouse lines were maintained
after backcrossing to C57BL/6 over two generations, and were crossed with
ckoEzh1fl/fl mice to generate Ezh1-KO (Ezh1fl/fl/vavCretg/+), Control (Ezh1fl/fl/
vavCre+/+), Ezh1-KO-ER (Ezh1fl/fl-CreERtg/tg) and Control-ER (Ezh1+/+-
CreERtg/tg) mice. All genotyping primers are listed in Table S1. ckop16INK4a/
ARFfl/fl mice, kindly provided by Anton Berns, were crossed with Ezh1-KO
mice to generate Ezh1/Cdkn2a-TKO and Control-TKOmice. Additional details
are provided in the Supplemental Experimental Procedures.
Transplantation Assays
Cells were transplanted (via retro-orbital injection) into the congenic CD45.1+
B6.SJL mouse strain, and hosts were monitored for the presence of CD45.2+
donor-derived cells. Engraftment efficiency in recipients was monitored by
FACS analysis of the contribution of donor CD45.1-positive cells to PB popu-
lations at 8 weeks posttransplant. Additional details are provided in the
Supplemental Experimental Procedures.
Flow Cytometry, Cell Sorting, ChIP Assays, Protein Analysis, and
Immunohistochemistry
Details are described in the Supplemental Experimental Procedures.
Statistical analysis
Computational processing of experimental data is described in the Supple-
mental Information. All data are expressed as means ± SD. Statistical signifi-
cance of differences was measured by unpaired two-tailed Student’s t test;
*p < 0.05, or **p < 0.001.
ACCESSION NUMBERS
A complete list of the differentially expressed genes in Ezh1-KO HSCs has
been deposited in the Gene Expression Omnibus under accession number
GSE36288.
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Figure S1. Conditional inactivation of Ezh1 mice. 
(A) Total BM cellularity (femurs) in control and Ezh1-KO mice. Data are expressed as 
means ± SD, n = 8 per genotype (** p<0.001). 
(B) Brain and liver sections from Ezh1-KO mice and control littermates stained with 
hematoxylin and eosin (H&E) and anti-Ezh1 antibodies.  
(C) Colony formation assay using BM cells from control and Ezh1-KO mice. Data are the 
numbers of live colonies (>30 cells) formed after 12 days culture on methylcellulose. 
Values are means ± SD (n = 10). 
(D) FACS analysis of LSKCD34- cells in the quiescent, G0 phase of the cell cycle. 
Representative plots show Hoechst 33342 and PyroninY staining in control and Ezh1-KO 
mice. Numbers indicate the percentage of cells in G0 from at least three independent 
experiments (*p < 0.05). 
(E) Side population (SP) of BM cells in control and Ezh1-KO mice, identified by Hoechst 
33342 staining and the use of blue and red filters. A representative experiment is shown. 
Numbers indicate the percentage of SP cells from three independent experiments (*p < 
0.05). Related to Figure 1. 
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Figure S2. Ezh1 deletion impairs bone marrow cell function. 
(A) Contribution of donor-derived (CD45.2) cells to circulating CLP, CMP, MEP and GMP 
progenitors in posttransplant recipients. Values are means ± SD (* p<0.05; n = 9).  
(B) qRT-PCR analysis of the mRNA expression of Ezh1, ARF, p16INK4a, and Ezh2 in mouse 
embryonic fibroblasts (MEFs) from Ezh1-KO and Control mice retrovirally-transduced 
with Cre recombinase. Results are standardized to βactin levels and are expressed as the 
fold change relative to MEFs from control mice (means ±SD; n=10, ** p<0.001). 
(C) Top: Senescence-associated β-galactosidase (SA-β-gal) activity in Cre-expressing 
control and Ezh1-KO MEFs. Bottom: Colony-formation assay with primary Ezh1-KO 
MEFs retrovirally-transduced with Ezh1 or empty vector (control). INK4a/ARF-/- MEFs 
were also tested. 10000 cells were seeded per plate and cultured for 3 weeks before staining 
with crystal violet. 
(D) Flow cytometry detection of SA-β-gal-positive primary wild-type MEFs retrovirally-
transduced with RasV12 or empty vector (control). Fluorescence histograms for C12-
fluorescein show the relative levels of βgal in MEFs-expressing RasV12 and control; the 
values above the peaks are the median fluorescence intensities of the corresponding 
populations.  
(E) qRT-PCR analysis of mRNA expression of senescence markers in LSKCD150+ cells 
from Ezh1-KO mice. Results are standardized to βactin levels and are expressed as the fold 
change relative to control BM cells (means ±SD; n=10, ** p<0.001; * p<0.05).  
(F) Relative normalized expression levels of Ezh1, p16INK4a, p15INKb, ARF and Ezh2 
transcripts in sorted Ezh1-KO-ER HSCs (LSKCD150+) transduced with either Ezh1 or 
empty vector MSCV-based retrovirus. Results are standardized to βactin levels and are 
expressed as the fold change of the indicated subpopulation from mutant relative to control 
cells (means ±SD; n=10, *p<0.05, ** p<0.001). 
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(G) Competitive repopulating capacity of Control-ER and Ezh1-KO-ER LSKCD150+ cells 
transduced with either Ezh1 or empty-vector MSCV-based retrovirus. The figure shows the 
average chimerism in posttransplant competitive recipients transplanted with 1:1 ratios of 
donor and competitor cells, analyzed for the contribution of donor-derived (CD45.2) cells 
to peripheral blood (PB). FACS plots show a representative experiment. The bar graphs 
show the percentages (mean ± SD) of the indicated populations in PB 8 weeks 
posttransplant (n = 5; * p<0.05). 
(H) SA-β-gal-positive cell content in transplanted chimeras injected with Control-ER and 
Ezh1-KO-ER LSKCD150+ cells transduced with Ezh1 or empty-vector MSCV-based 
retrovirus. Data are the numbers of C12-fluorescein fluorescence-positive cells as a 
percentage of the LSK, MP and CLP populations. Values are means ± SD (n=5). Related to 
Figure 2. 
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Figure S3. Ezh1 function in hematopoiesis is cell autonomous.  
(A) Recipient mice were injected with BM cells from Ezh1-KO mice or control littermates, 
and peripheral blood (PB) was analyzed for contribution by donor-derived cells (CD45.2) 
at 12 weeks posttransplant. Values are means ± SD (n = 12, *p < 0.05).  
(B) Contribution of donor-derived cells (CD45.2) to BM subpopulations (LSK, MP, and 
CLP) in primary recipient mice 16 weeks posttransplant with BM cells from Ezh1-KO mice 
or control littermates. The bar chart shows the percentages (mean ± SD) of the indicated 
populations in PB (n = 6; *p < 0.05). Similar results were obtained in a second experiment.  
(C) Representative FACS plots showing the contribution of Control-ER and Ezh1-KO-ER 
donor BM cells (CD45.2) to BM populations in irradiated wild-type CD45.1 recipients 24 h 
posttransplant. Data represent at least three independent experiments. The bar chart shows 
the percentage contribution of donor-derived Ezh1-KO-ER or Control-ER cells (CD45.2), 
where values are means ± SD (n=5, *p < 0.05). Related to Figure 5. 
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Figure S4. Ezh1 maintains bone marrow homeostasis.  
(A) Representative heat maps show the expression of genes with lymphoid-development, 
senescence-associated and Polycomb-related functional annotations that are significantly 
down- and upregulated in Ezh1 mutant LSKCD150+CD48- cells. The rows correspond to 
genes and the columns to samples. Gene expression values (relative to the mean expression 
in control cells) are indicated on a log2 scale according to a color scheme shown.  
(B) The Venn diagram illustrates the overlap between genes down- and up-regulated in 
these cells and genes with senescence-, lymphoid- and Polycomb-related functional 
annotations according to the literature indicated in the main manuscript. 
(C) Top: Diagrams illustrating the genomic context of the IL6, Cdk1, Cdkn1a, Foxa1, 
Zmat3, and Abcg2 promoter loci. The x axis shows the calculated percent identity between 
the human and mouse sequences over a window of 200-nucleotides at each base pair (dark 
blue indicates the coding region and light blue the 5´UTR region). Three regions amplified 
in the ChIP studies by site-specific quantitative PCR are indicated by bars (1-3 promoter 
targeted regions and 4 as non-promoter amplified regions). Bottom: ChIP analysis the 
promoter regions of the indicated genes in LSKCD150+ cells from control and Ezh1-KO 
mice. Chromatin-bound DNA was probed with antibodies to Ezh1, Ezh2, and Bmi1. IgG 
was used as an isotype control. Percentages of input DNA are shown as the means ± SD of 
triplicate independent experiments (* p<0.05). Related to Figure 6. 
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Table S1: Primer sequences used for genotyping 
cko-Ezh1fl/fl mice 
Fw LOXP1 Ezh1 GGCAAGCACTTTCCCTCTGG 
Rv LOXP1 Ezh1 GGGAGGCAAGCCTTAGATGC 
 
p16INK4a-ARFfl/fl mice 
FW LOX P1 CCTGACTATGGTAGTAAAGTGG 
FW LOX P2 ACGTGTATGCCACCCTGACC 
 
vav-Cre mice 
Fw Vavcre AGATGCCAGGACATCAGGAACCTG 
Rv Vavcre ATCAGCCACACCAGACACAGAGATC 
Fw int-pos control CTAGGCCACAGAATTGAAAGATCT 
Rv int-pos control GTAGGTGGAAATTCTAGCATCATCC 
 
Rosa26Cre-ERT2 mice 
Fw RNA3 NEW CAGTACACATACAGACTTTTGG 
Rv POL GAGCGAACAGGGCGAAGAGC 
Rv ERT2 TCCATGGAGCACCCAGTGAA 
  
 
Table S2: Primer and probe sequences used in qRT-PCR 
Fw Ezh1 cDNA E17 ACCTGCTGCTGGCCCCTTC 
Rv Ezh1 cDNA E17.b GACTCCTTGATGAAGGTGCCC 
Fw Ezh2 GCCCACCTCGGAAATTTCCTGC 
Rv Ezh2 CAGAGCACCTGGGAGCTGCTG 
Fw mBMI1 int CAGCAATGACTGTGATGC 
Rv mBMI1 int CTCCAGCATTCGTCAGTC 
Fw p16 E1 CGAACTCTTTCGGTCGTACCC 
Rv p16 E2 TTGAGCAGAAGAGCTGCTACG 
Fw1 mp15 qPCR AGATCCCAACGCCCTGAACCG 
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SUPPLEMENTAL EXPERIMENTAL PROCEDURES  
Mice. The conditional knock-out Ezh1 (cko-Ezh1fl/fl) ckoEzh1fl/+ mice were generated by 
introducing the targeting vector into R1 embryonic stem cells. 20 μg of linearized target 
vector was electroporated into 107 R1 mouse ES cells using 500 μF and 250 V settings on 
Gene Pulser (Bio-Rad). After 24 h, the cells were plated in medium containing G418 (170 
μg/ml) and selected for neomycin resistance in for 8 days. The neomycin-resistant colonies 
were picked, expanded and split into 96-well plates. To detect the Ezh1-targeted exons, 
genomic DNA was isolated from the ES cells, digested with HindIII (for the 5´probe) and 
ScaI (for the 3´probe), and the fragments separated on 0.7% and 0.8% agarose gels, 
respectively. Excision of Ezh1 DNA, the loss of Ezh1 RNA, and the loss of Ezh1 protein 
were confirmed by Southern blotting, western blotting, PCR and sequence analysis, 
according to standard protocols. Chimeric mice were crossed to the C57BL/6 background 
over at least 6 generations. For further genotyping, a PCR-based strategy was developed to 
distinguish between the floxed and the Cre-excised Ezh1 alleles (primers are listed in Table 
S1).  
In Ezh1-KO-ER and control-ER mice, Cre was induced by injections on five consecutive 
days with 1 mg tamoxifen (Sigma) in corn coil. Wild-type C57BL/6 (CD45.2+) and 
C57BL6/SJL (CD45.1+) mice were purchased from The Jackson Laboratory. Ezh1-KO, 
Control, Ezh1-KO-ER, Control-ER, Ezh1/Cdkn2a-TKO and Control-TKO mice (used at 20 
weeks old unless indicated) were all on the C57BL/6 (CD45.2) background. All mice, 
including Rosa26-eYFPtg/ and vavCretg/+, were bred in-house. Peripheral blood samples 
(~50 µL) were collected by tail bleeding into tubes containing EDTA. All mice were 
maintained in a pathogen-free environment. Animal studies were approved by the local 
ethics committee. All animal procedures conformed to EU Directive 86/609/EEC and 
Recommendation 2007/526/EC regarding the protection of animals used for experimental 
and other scientific purposes, enforced in Spanish law under Real Decreto 1201/2005. 
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Cells and gene transfer. All cells used in this study were grown under standard conditions 
in DMEM medium supplemented with 10% fetal calf serum at 37°C Isolation, culture, and 
assays with MEFs were as described (Palmero and Serrano, 2001). For Cre recombinase 
expression, retroviral supernatants were produced by transiently transfecting HEK293T 
cells (Lipofectamine 2000; Invitrogen) with pCL-Eco (Imgenex) and retroviral constructs 
(pMSCV-GFP) encoding Cre. Primary MEFs were transduced with retroviral supernatants 
for 20h in the presence of 4ug/ml polybrene (Sigma-Aldrich), and cells were analyzed after 
puromycin selection. For retroviral transduction, LSKCD150+ cells (5 x105) isolated from 
Ezh1-KO and Control mice were infected with Ezh1-encoding of empty retroviral vectors 
(at least 106 cfu/ml) by spinoculation (at 1,600 × g and 37°C). After 24 h culture in medium 
containing 10 ng/ml IL-3, 10 ng/ml IL-6, and 100 ng/ml stem-cell factor, a second round of 
spinoculation was performed, followed by an additional 24 h culture. Infected cells (5 x 
105) were then mixed with 5 x 105 “supportive” B6/SJL bone marrow cells and injected, via 
the retro-orbital route, into lethally-irradiated B6.SJL (11 Gy) recipient mice. Peripheral 
blood cell counts were obtained by tail vein nicking 4 and 12 weeks post-transplantation. 
 
Transplantation assays. For competitive transplants, 5 x 105 BM cells from individual 
Ezh1-KO-ER or littermate mice (CD45.2) were transplanted together with 5 x 105 
competitor cells (CD45.1) into lethally-irradiated (10Gy) 8-week-old B6.SJL mice 
(CD45.1). Repopulation was assessed at 4 and 16 weeks by FACS analysis of PB. 
Noncompetitive serial transplants were initiated by transplanting 2 x 106 whole BM cells, 
or fetal liver cells, pooled from three control or Ezh1-KO donors (CD45.2) into each 
irradiated recipient (CD45.1). For homing experiments, we isolated lineage-negative cells 
from BM, labeled with carboxyfluorescein diacetate succinimidyl ester (CFSE, Molecular 
Probes), and 2 × 106 washed cells were injected retro-orbitally into CD45.1+ lethally-
irradiated B6.SJL mice. Recipient mice were sacrificed 24h later and CFSE+ cells detected 
by FACS analysis of BM cells. For reciprocal transplant experiments, 1 x 106 BM cells 
from wild-type mice (CD45.1) were transplanted into lethally-irradiated (10Gy) 8-week-old 
Ezh1-KO-ER or littermate mice (CD45.2). After one week of stable reconstitution, the 
recipients were treated with tamoxifen by injections on five consecutive days with 1 mg 
tamoxifen (Sigma) in corn coil. 
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Flow cytometry and cell sorting. Single-cell suspensions were prepared from BM, fetal 
livers removed from embryos 11.5-13.5 d postcoitus, PB or spleen, and red cells were lysed 
with ACK buffer (NH4Cl/KHCO3). Cells were analyzed with a cocktail of biotinylated anti-
mouse antibodies to Gr-1 (Ly-6G), F4-80, CD3var epsilon, CD4, CD8a (Ly-2), and B220 
(CD45R) (BD Biosciences). Cells were detected and sorted using streptavidin conjugated 
to Alexa647, APC/Alexa750, Q-dot605, 405 (Invitrogen), or R/PE (BD Biosciences). 
Directly conjugated antibodies used were as follows: cKit-PerCP/Cy5.5, cKit-PE, cKit-
APC (CD117) and Flk2-PE (CD135) (BD Biosciences); Sca1-PE/Cy7, Sca1-APC, Sca1-PE 
(Ly 6A/E, Caltag); and CD34-Alexa647, CD127-PE, CD48-PE, CD150-APC and 
CD16/32-Alexa700 (BD Biosciences). For PB cell counts, PB was obtained by tail vein 
nicking, red blood cells were lysed with NH4Cl, and the remaining cells were stained with 
either APC-anti-CD45.2 (eBioscience) or PE/Cy5.5-anti-CD45.1 (eBioscience) and the 
following lineage surface markers: CD3e-Biotin-ST-405, PE-anti-CD4 (GK1.5), and APC-
anti-CD8 (53-6.7) for T cells; Alexa647 anti-B220 (RA3-6B2; eBioscience) for B cells; 
F4/80-PB for monocytes; and PE-anti-Gr-1 for granulocytes (RB6-8C5; eBioscience). For 
the cell-cycle analysis, BrdU incorporation was analyzed with the APC-BrdU Flow Kit 
(BD Biosciences). BM was assayed 24 h after a single intraperitoneal injection of BrdU 
(100 μl of a 10 mg/ml solution). Surface staining for lineage markers was performed as 
above with antibodies to Lin-APC-Alexa750, Sca1-Biotin-Qdot605, cKit-PerCP/Cy5.5, 
CD135-APC, and CD34-FITC (GFP is lost after fixing; data not shown). For the apoptosis 
assay, BM cells were stained with lineage, stem, and progenitor markers, followed by 
staining with Hoechst 33342 and AnnexinV–APC (BD Biosciences). To detect quiescent 
HSCs or side population (SP) cells, unmanipulated BM cells were incubated with 10 ug/ml 
Hoechst 33342 for 90 min at 37°C. Cells were washed and stained with antibodies to c-Kit, 
Sca1, and Lin. The cells were fixed in 5% PFA, and incubated with the RNA dye pyronin 
Y (PY, 1 μg/ml) prior to flow cytometry. The proportion of cells in G0 (PYlow, Hoechstlow) 
was measured in the LK+S+CD34low or CLP gated populations. For fluorescence detection 
of SA-β-gal activity, cells (107cell/ml) were incubated with C12FDG (33 µM; Sigma), a β-
galactosidase substrate that generates a fluorescent product upon cleavage, for 60 min at 
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37°C (Debacq-Chainiaux et al., 2009). Senescent cells were detected in fixed tissues with 
the Senescence β-Galactosidase Staining Kit (Cell Signaling). 
 
Protein analysis and immunohistochemistry. Immunoblots were performed as described 
(Gonzalez et al., 2006). Antibodies used for western blots were anti-Ezh1 (Abcam), anti-
Bmi1 (Millipore), anti-EZH2 (Active Motif), anti-Eed (Millipore), anti-Suz12 (Abcam), 
anti-H3K27me3 (Upstate), anti-H3K27me2 (Abcam), anti-H3K27me1 (Millipore), and 
anti-β-actin (monoclonal antibody AC-15; Sigma). Secondary antibody was HRP-linked 
anti-mouse IgG (DAKO). Signals were detected by enhanced chemiluminescence (GE 
Lifesciences). For histopathology, femurs were fixed in formaldehyde, decalcified, and 
paraffin embedded. Spleens were treated similarly, with the omission of decalcification. 
Sections (4.5 µm) were cut and stained with hematoxylin and eosin (H&E) or processed for 
immunohistochemistry (IHC). Sections for IHC were stained with anti-Ezh1, anti-Bmi1, 
anti-p16Ink4a, anti-p19, anti-Dcr2, anti-Ezh2, anti-p15Ink4b, and anti-Ki67 (Ab-2; Neo-
Markers). Samples were then incubated with biotinylated anti-mouse IgG followed by 
development with avidin-biotin peroxidase complexes (Vector Lab.).  
 
Chromatin immunoprecipitation assays (ChIP). ChIP assays were conducted as 
described (Gonzalez et al., 2008). Antibodies used for immunoprecipitation were anti-Ezh1 
(Abcam), anti-Bmi1 (Millipore), anti-EZH2 (Active Motif), anti-H3K27me3 (Upstate), 
anti-H3K27me2 (Abcam), anti-H3K27me1 (Millipore) and anti-H2K4me3 (Abcam). DNA 
from precipitated complexes was amplified by RT-PCR. RT-PCR amplifications were 
performed in triplicate with multiple dilutions, and primer sequences are listed in 
Supplementary Table S3.  
 
Gene expression and qRT-PCR. Total RNA was isolated from peripheral blood, bone 
marrow, spleen, and other tissues with Trizol reagent (Invitrogen), and treated essentially as 
described (Gonzalez et al., 2008). Primer sequences are listed in Supplementary Table S2. 
Gene expression assays were performed using the Agilent Whole Mouse Gene Expression 
Microarray (60K format) with labeled RNAs isolated from control and Ezh1-KO 
LSKCD150+CD48- cells. Single color Agilent microarrays (design 028005) were used to 
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compare gene expression levels between knockout and wild type. Agilent’s Feature 
Extraction software was used to translate the microarray images into data sets. The Agilent 
“processed signal” column was extracted from the data sets. This column is the result of 
Agilent’s within-array normalization procedure. Robust Multiarray Average (RMA) was 
applied to normalize intensities between arrays. The resulting dataset was filtered by 
applying two quality control tests in GeneSpring GX (Agilent Technologies). Genes whose 
expression level was greater than the 20 percentile of the data range for at least one 
condition were retained. The Limma package (Bioconductor) was used to assess genes 
showing significant differences between the two conditions. The Benjamini-Hochberg 
method was used to control for false discovery rate. Genes were considered to be 
differentially expressed between Ezh1-KO and control HSCs when the fold-change >1.50 
and the adjusted p-value <0.05.  
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